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5α-reductases (5αRs) catalyse reduction of 4-pregnene steroids, most notably the 
androgen testosterone to its more potent metabolite dihydrotestosterone (DHT). 
Well-characterised isozymes of 5αR are designated 5αR1 and 5αR2. Inhibitors of 
5αR, finasteride (a 5αR2 inhibitor) and dutasteride (a dual 5αR1 and 5αR2 
inhibitor), are utilised in conditions where a reduction in androgen action is 
desired, including benign prostatic hyperplasia. Although 5αR2 is 
predominantly expressed in reproductive tissues, both isozymes, but 
particularly 5αR1, are expressed in metabolic tissues including liver and adipose 
and both metabolise glucocorticoids as well as androgens; therefore inhibition of 
5αR may have consequences for metabolic health. This thesis addresses the 
hypotheses that 5αR1 inhibition with dutasteride decreases insulin sensitivity 
and causes dysregulation of the HPA axis in humans.  
 
Metabolism and the HPA axis were studied in men prior to and following 3 
months of dutasteride (0.5 mg daily; n=16), finasteride (5 mg daily; n=16) or 
control (tamsulosin MR; 0.4 mg daily; n=14). Glucose disposal during 
hyperinsulinaemia was the primary endpoint, measured during a 
hyperinsulinaemic euglycaemic clamp, with d2-glucose and d5-glycerol tracers. 




decreased with dutasteride versus both finasteride and control, while hepatic 
insulin sensitivity was preserved. Body fat increased with dutasteride, though 
was not accompanied by changes in metabolic or inflammatory gene transcript 
abundance in subcutaneous adipose biopsies, nor any differences in abdominal 
adipose depots on post-treatment MRI. Subtle dysregulation of the HPA axis 
was evident with both 5αR inhibitors, though to a greater degree with 
dutasteride and changes were largely compensated for.  
 
In support of this study, this thesis also describes the development, validation 
and application of two novel liquid chromatography tandem mass spectrometry 
assays; establishing compliance by measuring serum drug levels, and 
demonstrating effects of 5αR inhibitors on androgen metabolism and adrenal 
steroidogenesis by measurement of testosterone, DHT and androstenedione.  
 
In conclusion, 5αR1 inhibition with dutasteride, but not finasteride, induces 
peripheral insulin resistance and increases body fat. Findings presented may 
have important implications for patients prescribed dutasteride for benign 
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1.1 5α-Reductases  
5α-Reductases (3-oxo-5α-steroid 4 dehydrogenase, E.C. 1.3.99.5)  are enzymes 
catalysing one of the principal routes of metabolism for steroids with 3-keto-
enol functional groups in the A ring (Figure 1.1). Most notably, 5α-reductases 
(5αRs) catalyse the conversion of the androgen testosterone to its more 
potent metabolite dihydrotestosterone. Of particular relevance to this thesis, 
in addition to testosterone, 5αRs also catalyse the irreversible and rate-
limiting step of glucocorticoid metabolism (in humans, the metabolism of 
cortisol to 5α-dihydrocortisol), thus potentially playing a key role in 
regulating tissue exposure to glucocorticoids.  
 
Three isozymes of 5α-reductase (5αR) have been identified to date, with 
types 1 and 2 the best characterised at present. 5αRs are widely expressed; 
5αR2 is predominantly expressed in the reproductive tract, while both 5αR1 
and 5αR2 are expressed in non-reproductive sites, including metabolic 
tissues such as the liver. 5αRs are the target of pharmaceutical inhibitors 
used in the treatment of androgen-dependent disorders including benign 
prostatic hyperplasia, prostate cancer and polycystic ovarian syndrome; 
5αR2 is inhibited by finasteride and dual 5αR1 and 5αR2 isozyme inhibition 
is achieved with dutasteride. This thesis will focus on the effects of 5αR 
inhibition on glucocorticoid metabolism and consequences for fuel 
homeostasis and the stress response.   
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5αR enzymes were initially described and characterised in the 1950s and 
1960s. Early rodent work revealed the presence of an enzyme, most 
abundantly present in liver, which catalysed the 5α-reduction of steroids 
(Forchielli et al., 1958, Schneider, 1952, Schneider and Horstmann, 1951). The 
1935 isolation of the ‘male’ steroid hormone, testosterone (Butenandt and 
Hanisch, 1935, Ruzicka et al., 1935) sparked a flurry of research into 
androgen synthesis, action, metabolism, and related therapeutic applications 
(Freeman et al., 2001) – this interest continues unabated today. Initially felt to 
be an inactive metabolite, 5α-dihydrotestosterone (referred to as DHT 
throughout this thesis), the 5α-reduced metabolite of testosterone, was later 

















A A A B B B 
Figure 1.1 Generic schematic of principal metabolic pathways for steroids with 
3-keto-enol functional groups in the steroid A ring. R, Reductase; OHase, 
hydroxylase.  
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the enzyme catalysing its formation) was illustrated via two main 
investigative pathways (Russell and Wilson, 1994). Firstly, the demonstration 
that DHT was formed in androgen target tissues such as the prostate 
(Bruchovsky and Wilson, 1968a). Secondly, showing that DHT is crucial to 
normal virilisation in the developing embryo. Lack of 5αR activity causing a 
disorder of sexual development was described in the 1970s (Fisher et al., 
1978, Imperato-McGinley et al., 1974, Walsh et al., 1974). This condition, now 
termed 5αR deficiency, occurs in chromosomally 46 XY individuals and is 
characterised by lack of, or reduction in virilisation at birth, followed by 
development of a male phenotype at puberty, though without associated 
prostatic growth. 
 
Russell and colleagues have led much of the research towards characterising 
the 5αRs. The first cDNA clone of 5αR (Andersson and Russell, 1990) was 
followed by the finding that, in fact, individuals with 5αR deficiency had 
normal levels of the only gene known at the time encoding for 5αR (Jenkins 
et al., 1992). This isozyme was designated to be 5α-reductase type 1 (5αR1), 
and provided the impetus to pursue the identity of what must be another 
isozyme influencing androgen action in man. Further work (Andersson et al., 
1991) identified the 5αR isozyme most abundant and physiologically 
significant in the male genital tract, now known as 5α-reductase type 2 
(5αR2). Those deficient in this isozyme have a phenotype of 
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pseudohermaphroditism (Andersson et al., 1991) and while a rat model with 
inhibition of 5αR2 has been shown to be a phenocopy (George and Peterson, 
1988), a transgenic model in mice lacking 5αR2 had only smaller prostates 
and seminal vesicles, but otherwise normal external genitalia and fertility 
(Mahendroo et al., 2001).  
 
The discovery of at least two isozymes of 5αR has had significant 
implications for understanding of steroid physiology and metabolism, and 
has been key in the therapeutic approach to many androgen target tissue 
disorders, particularly benign prostatic hypertrophy and androgenic 
alopecia. The identification of a third 5αR isozyme has led to further 
diversification of 5αR research. While expression (Godoy et al., 2011, Uemura 
et al., 2008) and pharmacological inhibition (Kazutoshi et al., 2008, Mohler et 
al., 2011) of 5αR3 have been described, at present there is very limited 
understanding of this isozyme, its substrates and its products. This thesis 
will focus on the roles of 5αR1 and 5αR2, and implications of inhibiting these 
isozymes in humans.  
 
1.1.2 Biochemistry  
5αRs are hydrophobic, membrane-bound enzymes with predicted molecular 
weights of approximately 28-29 kDa (Russell and Wilson, 1994). Human 
5αR1 is a 259 amino acid protein, while human 5αR2 is a 254 amino acid 
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protein. In human and rat tissues the pH optima allows biochemical 
differentiation between these two isozymes, with 5αR1 having a pH optima 
spanning pH 6 - 8.5 and 5αR2 having a pH optima around 5 (Russell and 
Wilson, 1994). However, the biochemical properties of the type 2 isozyme are 
not fully defined for all conditions and all species, and it may well function 
at a neutral pH within the cell (Russell and Wilson, 1994) as this is what is 
suggested in cell lysate experiments. The location of both 5αR1 and 5αR2 
varies by species and tissue, with rat prostate (type 1) and human prostate 
(type 2) in a perinuclear location, and rat liver (type 1) and human liver (type 
2) located in endoplasmic reticulum (Russell and Wilson, 1994). Half-lives of 
both enzymes are in the order of 20-30 hours (Russell and Wilson, 1994).  
 
1.1.3 Genetics  
In humans, 5αR1 is encoded for on chromosome 5 (SRD5A1) (Jenkins et al., 
1991) and 5αR2 on chromosome 2 (SRD5A2)  (Labrie et al., 1992). Both 
isozymes have five exons and four introns, and retain a high degree of 
homology between isozymes and species, suggestive of  a common origin 
(Russell and Wilson, 1994). There is also an apparently non-functioning 
pseudogene mapped to the X chromosome (Jenkins et al., 1991). Genetic 
abnormalities in 5αR have been the initial driving focus of much of the 
research around 5αRs. Details of genetic mutations causing 
pseudohermaphroditism have been reviewed (Russell and Wilson, 1994).  
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Additional genetic variants have also been described in diseases with 
metabolic and hormonal dyshomeostasis. In polycystic ovarian syndrome 
(PCOS), SNPs in both 5αR genes are associated; a variant in SRD5A2 is 
protective against PCOS, while several different variants in SRD5A1 are 
associated with presence, and increased severity, of hirsutism (Goodarzi et 
al., 2006).  In benign prostatic hyperplasia,  single nucleotide polymorphisms 
(SNPs) in SRD5A1 (though not SRD5A2) are associated with disease severity 
(Klotsman et al., 2004), however implications of this are not well understood 
at present. An increased risk of developing the metabolic syndrome is 
associated with a SNP in SRD5A2 in those previously treated for testicular 
cancer (Boer et al., 2011). Peripheral arterial disease has been associated with 
two SNPs in SRD5A1, though not with SRD5A2 (Signorelli et al., 2008); given 
the previous association of these SNPs with decreased conversion of 
testosterone to DHT, it was concluded that decreased local metabolism of 
testosterone associated with the SRD5A1 SNPs may confer increased risk of 
peripheral arterial disease. In a study of 57 males with type 2 diabetes, a SNP 
associated with increased 5αR1 activity (seen as an increase in 
DHT/testosterone ratio) has been identified, however no genetic 
polymorphisms in either SRD5A1 or SRD5A2 were associated with the 
diabetic phenotype (Ellis et al., 2005).   
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While several SNPs in both SRD5A1 and SRD5A2 have  been identified, and 
in future may provide further understanding of disease mechanisms and 
exciting opportunities for targeted therapeutics, these findings have not yet 
been translated into clinical practice.  
 
1.1.4 Tissue distribution  
5αR1 and 5αR2 are widely expressed in many species (summarised for 
human, mouse and rat in Table 1-1), and an understanding of expression 
patterns for both isozymes is paramount to understanding enzyme function. 
Research pertaining to 5αRs has been predominantly conducted in rodent 
models, however there are important inter-species differences in the tissue 
distribution of the 5αR isozymes. These differences are relevant to 
interpretation of which tissues will be affected by genetic manipulation 
(animal models), genetic defects (humans) and consequences of 
pharmacological inhibition. In humans, 5αR1 exists primarily in non-genital 
skin, whereas 5αR2 is found primarily in the reproductive tract including 
prostate, seminal vesicles, epididymis and genital skin (Russell and Wilson, 
1994). Both isozymes are found in liver (Russell and Wilson, 1994) and while 
hepatic 5αR1 is thought to be the key enzyme in glucocorticoid metabolism, 
at this stage the differential role played by 5αR1 versus 5αR2 in human liver 
is not well defined.  In mouse prostate 5αR2 predominates, in contrast to rat 
prostate where both isozymes can be detected (Russell and Wilson, 1994). In 
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contrast to human, where both isozymes are expressed, hepatic 5αR 
expression in rats is solely type 1, with female rats expressing 10-20 times 
that of male rats (Russell and Wilson, 1994). Otherwise, 5αR expression is 
similar in males and females. As well as the liver and reproductive tract, 
5αRs are also widely expressed in the central nervous system in mammalian, 
aquatic and avian species (Lephart, 1993a, Rego et al., 2009).  Both mRNA 
and protein have been demonstrated for 5αR3 in several tissues in humans 
including skin, skeletal muscle, liver, kidney, colon and pancreas, as well as 
in several malignant tissues (Godoy et al., 2011, Uemura et al., 2008). 
However, the implications of 5αR3 action are not well understood at present.  
 
Table 1-1 (below): Tissue distribution of 5α-reductases types 1 and 2 in human 
(H), rat (R) and mouse (M). In cases of differing evidence, those demonstrating 
expression are shown. 5αR1, 5α-reductase type 1; 5αR2, 5α-reductase type 2; , 
present; , absent; ±, very low levels; IC,  either immunocytochemistry or 
immunohistochemistry; vasc., vasculature; G, gamma aminobutyric acid; g, 
glutaminergic neurons; PN, peripheral nerves. Activity
a
, demonstration of 
substrate → product in conditions designed for optimal isozyme action.  
Activity
b
, ex vivo or in vivo demonstration of substrate 5α-reduction . *mRNA 
identified but isozyme not specified. For many organs expression/activity varies 
considerably depending on component of tissue tested – details are within 
referenced papers. An earlier version of this table has been published previously 
(Nixon et al., 2012).  
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Liver H; R; 
M 
H; R R H; R; 
M 
H; R  H (Russell and Wilson, 1994) (Normington and Russell, 
1992) (Mahendroo et al., 1997) (Livingstone et al., 2000a) 
(Seo et al., 2009) (Houston et al., 1987) 
Adipose H; R; 
M 
  H; M   H; R (Zyirek et al., 1987) (Wake et al., 2007) (MacKenzie et al., 
2008) (Livingstone et al., 2009b) (Drake et al., 2005) 
(Longcope and Fineberg, 1985) 
Skeletal Muscle H; R H; R  H±; R H  H± (Thigpen et al., 1993) (Longcope and Fineberg, 1985, 
Aizawa et al., 2010, Pollanen et al., 2011) 
Heart/ vasc. R   R   H; R (Normington and Russell, 1992) (Lephart, 1993b) (Blom et 
al., 2001) (Milewich et al., 1987) 
Pancreas       H (Iqbal et al., 1983) 
Kidney H; R H H H; R H H M± (Russell and Wilson, 1994) (Thigpen et al., 1993) 
(Mowszowi.I and Bardin, 1974) 
Adrenal H; R; 
M± 
H; R H H; R; 
M 
H H R (Russell and Wilson, 1994) (Thigpen et al., 1993) (Yokoi et 
al., 1998b) (Luu-The et al., 2005) (Colby and Kitay, 1972) 
Lung H; R; 
M 
H H H; R H   (Normington and Russell, 1992) (Provost and Tremblay, 
2007) (Provost et al., 2002) (Kimura et al., 2003) 
IMMUNE 
Spleen R   R    (Normington and Russell, 1992) 
Monocytes/ 
Macrophages 
H; M   H±; M   H; R; M (Milewich et al., 1983) (Hammer et al., 2005) (Lofthus et 
al., 1984) (Araneo et al., 1991) (Yang et al., 2011) 
Lymphocytes H  H H±   M (Zhou et al., 1998) (Samy et al., 2001) 
Thymus R*   R*    (Borlak et al., 2004) 
SKIN & BONE 
Genital Skin H H  H H  H; R (Russell and Wilson, 1994) (Thiele et al., 2005) (Pinsky et 
al., 1978) (Dube et al., 1975) 
Non-Genital 
Skin 
H H  H± H  H; R (Russell and Wilson, 1994) (Luuthe et al., 1994) (Takayasu 
et al., 1980) (Eicheler et al., 1995) (Randall et al., 1982) 
(Dube et al., 1975) 
Hair follicle H H  H H  H (Eicheler et al., 1998) (Eicheler et al., 1995) (Sawaya and 
Price, 1997) 
Sweat gland H       (Sato et al., 1998) 
Cartilage R  R:♂,♀ R    (Raz et al., 2005) 
Bone H  H H  H± R (Turner et al., 1990) (Issa et al., 2002) 
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SENSORY 





    R (Agis-Balboa et al., 2006) (Kiyokage et al., 2005) (Li et al., 
1997) 
Eyes  H   H   H (Weinstein et al., 1991) (Rocha et al., 2000) 
NEUROLOGICAL 
Hypothalamus H; R; 
M 
H; R R H; R H  R (Karolczak et al., 1998) (Russell and Wilson, 1994) 
(Thigpen et al., 1993) (Pelletier et al., 1994) (Lephart, 
1993b) (Li et al., 1997) 
Pituitary H; R H; R R H; R H  R (Russell and Wilson, 1994) (Nowak, 2002) (Lephart, 
1993b) (Yokoi et al., 1996) 
Thalamus M(G, g) R; 
M(G,g) 







 H   R (Agis-Balboa et al., 2006) (Pelletier et al., 1994) (Li et al., 
1997) (Stoffel-Wagner et al., 2000) (Melcangi et al., 1988) 






H H; R H  R (Agis-Balboa et al., 2006) (Pelletier et al., 1994) (Torres 
and Ortega, 2006) (Li et al., 1997) (Stoffel-Wagner et al., 
1998) (Steckelbroeck et al., 2001) (Melcangi et al., 1988) 
Medulla 
oblongata 
H H  H H  R (Thigpen et al., 1993) (Li et al., 1997) 
Pons H H  H H  R (Russell and Wilson, 1994) (Thigpen et al., 1993) (Li et al., 
1997) (Melcangi et al., 1988) 
Amygdala M(g) M(g)     R (Agis-Balboa et al., 2006) (Li et al., 1997) 
Corpus 
Collosum 
M M     R (Agis-Balboa et al., 2006) (Melcangi et al., 1988) 






 H H  R (Russell and Wilson, 1994) (Thigpen et al., 1993) (Agis-
Balboa et al., 2006) (Li et al., 1997) (Melcangi et al., 1988) 
Spinal cord R R  R R  R; M (Pozzi et al., 2003) (Patte-Mensah et al., 2004) (Maclusky 
et al., 1987) (Hauser et al., 1987) 
PN / 
paraganglia 
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Prostate H; R  H; R  H; R; 
M± 
H; R H; R R;M H (Shirakawa et al., 2004) (Russell and Wilson, 1994) 
(Normington and Russell, 1992) (Mahendroo et al., 2001) 
(Houston et al., 1987) 
Testes H; R H M H; R H M M (Russell and Wilson, 1994) (Mahendroo et al., 2004) 
(Sheffield and Oshaughnessy, 1988) 
Epididymis H; R; 
M 
H; R R; M H; R; 
M 
H; R R; M H (Thigpen et al., 1993) (Mahony et al., 1998) (Delarminat et 
al., 1980) (Viger and Robaire, 1994) (Normington and 
Russell, 1992) (Mahendroo et al., 2001) 
Vas Deferens R   R   H; R; M (Russell and Wilson, 1994) (Seethalakshmi et al., 1982) 
(Dupuy et al., 1979) (Jeanfaucher et al., 1986) 
Seminal 
Vesicles 
H; R H; R M H; R H; R M  (Pratis et al., 2000) (Russell and Wilson, 1994) 
(Mahendroo et al., 2001) 
Ovary H; R; 
M 
H H H; R; 
M 
H H  (Russell and Wilson, 1994) (Normington and Russell, 
1992) (Thigpen et al., 1993) (Jakimiuk et al., 1999) 
(Backstrom et al., 1986) (Milewich et al., 1995) (Luu-The 
et al., 2005) 
Vagina H; M   H; M   R (Berman et al., 2003) (Blom et al., 2001) (George, 1993) 
(Luu-The et al., 2005) 
Uterus H;M H; M  H; M± H  R (Mahendroo et al., 1997) (Blom et al., 2001) (Luu-The et 
al., 2005) (Ito et al., 2002) 
Placenta M H; M H  H H R (Milewich et al., 1979) (Dombroski et al., 1997) (Vu et al., 
2009) (Mahendroo et al., 1997) (Chan and Leathem, 1975) 
Breast H H  H H  H; R; M (Lloyd, 1979) (Wiebe et al., 2000) (Suzuki et al., 2001) 
(Mori et al., 1978) (Abulhajj and Kiang, 1982) 
GASTRO-INTESTINAL 
Stomach R   R    (Normington and Russell, 1992) 
Intestine R   R   H; R (Normington and Russell, 1992) (Nienstedt et al., 1980b) 
(Nienstedt et al., 1980a) (Eiknes et al., 1983) 
 
Chapter 1: Introduction 
                                                                                                             13 
 
1.1.5 Substrates and products  
Known substrates of 5αR are steroid hormones with a double bond between 
carbons 4-5 of the A-ring (Figure 1.2).  
 
Figure 1.2 Schematic of basic steroidal structure. Steroids have three 
cyclohexane rings (denoted, by convention, A, B and C) and one cyclopentane 
ring (denoted D). Individual carbon atoms within the steroid molecule are 
denoted by numbers. Carbons 4 and 5 of the A ring are the site of 5α-reductase 
enzyme activity, where a double bond in this position is reduced to form the 5α-
dihydrosteroid.    
 
5α-reductases catalyse the irreversible reaction:  
 
3-oxo-δ4-steroid + 2NADPH        →   3-oxo-5α-steroid + 2NADP+  
 
The consequence for the substrate is the reduction of the carbon 4-5 double 
bond, with NADPH acting as cofactor. 5αR has an absolute requirement for 
NADPH in order to catalyse the A-ring reduction of its steroid substrates, 
and is unable to utilise NADH as an alternative (Frederiksen and Wilson, 
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1971). In vitro studies suggest it is the denaturing of the 5αR enzyme which 
leads to the cessation of its reductase actions, rather than paucity of substrate 
or NADPH (Frederiksen and Wilson, 1971). However, this is in contrast to 
the findings in other studies, suggesting substrate depletion is responsible for 
any cessation of 5αR activity (Larsen, 2002).  
 
The metabolic pathway of 3-oxo-δ4-steroids via 5αR generally follows the 
pattern: 
 
3-oxo-δ4-steroid → 5α-dihydrosteroid → 3α (or β), 5α-tetrahydrosteroid 
 
The initial reaction is catalysed by 5αRs and is irreversible, while the latter is 
catalysed by 3α- or 3β- hydroxysteroid dehydrogenase and is reversible 
(Figure 1.3). 3αHSDs make up the aldo-keto reductase (AKR) 1C enzyme 
family, of which there are four known isozymes. AKR1C1, AKR1C2, and 
AKR1C3 all have a role in the metabolism of androgens and progesterones, 
with one or more of these detected in liver, prostate, breast, uterus and brain 
(Penning et al., 2000). AKR1C4 is liver specific and acts together with the 5α 
and 5β-reductases (Penning et al., 2000). 3αHSD versus 3βHSD metabolite 
formation varies greatly in an isoform and tissue dependent manner; ratios 
of 3α:3β HSD metabolites are 1:4 (AKR1C1:3βHSD), 20:1 (AKR1C2:3βHSD), 
1.5:1 (AKR1C3:3βHSD), and 3.6:1 (AKR1C4:3βHSD), (Steckelbroeck et al., 
2004).  
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Many hormonally active steroids, other than oestrogens, have the δ4-3-oxo 
group in the A ring, and tetra-hydro reduction of the A ring was traditionally 
thought to inactivate these steroids prior to excretion (Makin et al., 2010), 
rendering them more susceptible to conjugation.  Prior to the identification of 
5αR2, in vitro investigations characterised substrate nature and reaction rates 
for a number of 3-oxo-δ4-steroids. McGuire and colleagues (McGuire et al., 
1960) demonstrated the many substrates of 5αR in rat liver, but also 
indicated some 3-oxo-δ4-steroids which were not 5α-reduced. These were 
















Figure 1.3. Generic metabolic pathways for 3-oxo-δ
4
-steroids metabolised by 
5α-reductase. Enzymes indicated in interrupted boxes. R, reductase; HSD, 
hydroxysteroid dehydrogenase.  
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(McGuire et al., 1960). Another study characterised 5αR substrate specificity 
of a variety of 3-oxo-δ4-steroids in rat prostate, and demonstrated the 
likelihood of a single 5αR isozyme in prostate as compared to liver 
(Frederiksen and Wilson, 1971).  
 
In humans, the most biologically significant substrates of 5αR are 
testosterone, progesterone, aldosterone and cortisol (Figure 1.4). Human 5αR 
(prior to isozyme identification) has been shown to act with differing 
efficiencies on its key substrates; Km values for testosterone (3.6 µM), 
androstenedione (1.7 µM) and progesterone (0.8 µM) demonstrate this 
(Andersson and Russell, 1990). While catabolic activity with 
mineralocorticoids and glucocorticoids has been demonstrated (Frederiksen 
and Wilson, 1971, Andersson and Russell, 1990), their comparative Km values 
were unable to be determined.  Due to the known biological activity of their 
metabolites, testosterone and progesterone are certainly the most researched 
substrates of 5αR, however it is now increasingly evident that the 5α-reduced 
metabolites of cortisol may also have physiologically relevant effects 
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                   17, 20 Lyase 
Figure 1.4 Classical pathway of steroid synthesis; substrates of 5α-reductase indicated with stars. All steroid hormones (in solid 
boxes) are formed from their common precursor cholesterol. Enzymes (in interrupted boxes) catalyse conversion reactions. 3βHSD, 
3β-hydroxysteroid dehydrogenase; 21OHase, 21α-hydroxylase; 11βOHase, 11β-hydroxylase; Aldo synthase, aldosterone synthase; 
17βHSD, 17β-hydroxysteroid dehydrogenase; 5αR, 5α-reductase.  
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1.1.5.1 Androgens 
Androgens (discussed further in Section 1.21.2) are steroid hormones 
instrumental in the establishment and maintenance of the male phenotype, 
and are also key players in many aspects of health (and disease) in both men 
and women. The conversion of the androgen testosterone to its more potent 
metabolite 5α-dihydrotestosterone (DHT) is the best characterised, most 
clinically significant and pharmacologically targeted reaction catalysed by 
5αR.  5.6% of plasma testosterone in men, and 3.5% in women is irreversibly 
converted to DHT (Ito and Horton, 1971). Free DHT levels in men peak 
during their 20s, with levels slowly declining thereafter (Starka et al., 2009). 
DHT production patterns in women do vary from men, with the key 
differences being a reduced amount of testosterone as substrate, and the fact 
that their DHT is primarily sourced from androstenedione rather than 
testosterone (Ito and Horton, 1971). The majority of DHT exists as a result of 
peripheral conversion from testosterone, principally in prostate and skin, 
rather than direct secretion (Ito and Horton, 1971), however non-classical 
‘backdoor’ pathways of DHT synthesis do exist and are discussed further in 
Section 1.2.1.    
 
The relative importance of DHT in the developing male is seen both pre- and 
post-natally. The human placenta is known to express both isozymes of 5αR, 
and when compared with female fetuses, male fetuses show significantly 
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greater expression of 5αR1, and a trend towards a greater expression of 5αR2 
(Vu et al., 2009). Post-natal significance of DHT is reflected in the peak ratio 
of DHT to testosterone, which is maximal in infancy and childhood, with 
rates dropping until approximately age 20 years after which they remain 
steady into old age (Starka et al., 2009).  
 
Patients with a complete 5αR2 deletion can have normal serum DHT 
concentrations and present with variable degrees of masculinisation 
(Imperato-Mcginley et al., 1991, Thigpen et al., 1993), revealing the ability of 
5R1 to deputise for 5R2. Prior to the identification of the different 
isozymes, in 5αR mutations leaving very low levels of 5αR activity, 
administration of exogenous testosterone was shown to increase DHT 
concentrations from low normal to within the normal range (Price et al., 
1984). These observations support the notion of DHT acting as an endocrine 
hormone, as well as in an autocrine and paracrine manner as was 
traditionally thought. This also adds weight to the concept of inhibiting both 
5αR1 and 5αR2 for disorders such as benign prostatic hypertrophy, as DHT 
formed in extra-prostatic tissues may be acting in an endocrine manner to 
drive prostatic growth. Pharmacological 5αR inhibition now forms a key part 
of the medical armamentarium in treatment of benign prostatic hyperplasia, 
and is discussed further in Section 1.3.2.  
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Additional androgen substrates of 5αR are epitestosterone and 
androstenedione. Epitestosterone, an epimer of testosterone, is a naturally 
occurring steroid hormone. While presumed to act via both the androgen 
receptor, as well as non-genomic routes, mechanisms of epitestosterone 
action are not confirmed (Starka, 2003).  In vitro radioactive experiments 
show epitestosterone to be a better 5αR substrate than testosterone, with Km 
values approximately 3 times lower (Frederiksen and Wilson, 1971), and it is 
also able to serve as a competitive inhibitor of testosterone reduction in 
prostatic nuclei (Frederiksen and Wilson, 1971, Starka, 2003). Less than 5% of 
epitestosterone is converted to its 5α- (and then 3α-) reduced metabolite, 5α-
androstane-3α,17α-diol, prior to urinary excretion (Starka, 2003) and the 
physiological properties of these metabolites are unknown. Androstenedione 
can be formed from the peripheral metabolism of DHEA. It is then reduced 
by either 5αR or 5βR (in equal proportions), followed by 3αHSD reduction to 
form androsterone and etiocholanolone respectively (Auchus, 2009). In rat 
prostate, androstenedione was demonstrated to be approximately equal to 
testosterone in its substrate specificity for 5αR (Frederiksen and Wilson, 
1971). The properties of androstenedione’s 5α-reduced metabolite are 
unknown. Androsterone is readily converted into DHT (though is not 
amenable to aromatisation) (Auchus, 2009), and while briefly of interest in 
conditions such as hirsutism, it has been shown to be of limited clinical 
utility at present (Zwicker and Rittmaster, 1993). Both epitestosterone (Piper 
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et al., 2009) and androsterone (Aguilera et al., 2009) are now most commonly 
measured as part of doping control efforts in professional sport. 
 
1.1.5.2 Glucocorticoids 
Glucocorticoids (discussed further in Section 1.4), steroid hormones 
synthesised by the adrenal glands, are vital to many aspects of health 
including glucose regulation and response to stress. The action of 5αR on 
glucocorticoids is the rate limiting and irreversible step in their degradative 
pathway (Figure 1.7, Section 1.4.1). As with other 5αR substrates, 
glucocorticoids are metabolised to their 5α-dihydro and 5α-tetrahydro 
metabolites. While several glucocorticoids are 5αR substrates, the most 
significant in humans is cortisol.  
 
Cortisol is reduced to 5α-dihydrocortisol via hepatic 5αR, and is then further 
reduced prior to urinary excretion, with 5α-tetrahydrocortisol forming 
between 11-25% urinary cortisol metabolites (Shamim et al., 2000, Andrew et 
al., 1998, Best and Walker, 1997). While 5αR action on glucocorticoids is 
predominantly hepatic (Baudrand et al., 2011), it is also thought to 
metabolise glucocorticoids in adipose (Wake et al., 2007, MacKenzie et al., 
2008), possibly the brain (Thigpen et al., 1993), but not in the prostate 
(Frederiksen and Wilson, 1971). In rodents, corticosterone (B) is the most 
significant glucocorticoid, owing to a lack of adrenal 17α-hydroxylase, and is 
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reduced by 5αR to form 5α-dihydrocorticosterone (5αDHB) which is further 
reduced to 5α-tetrahydrocorticosterone (5αTHB).  
 
Two other glucocorticoids, namely cortisone and 11-deoxycortisol, have been 
shown to act as 5αR substrates, however have not yet been shown to be of 
clinical significance. Cortisol can be interconverted with its biologically 
inactive metabolite cortisone by the actions of the 11βHSD enzymes. While 
C4-5 reduction of cortisone is predominantly catalysed via 5β-reductase 
(5βR), it can also be reduced by 5αR to form 5α-dihydrocortisone in vitro in 
microsomal rat liver fractions (McGuire and Tomkins, 1960), though not in 
rat prostate (Frederiksen and Wilson, 1971). Humans are not known to 
excrete a urinary 5α-metabolite of cortisone (Bush and Mahesh, 1959). 11-
Deoxycortisol is usually converted to cortisol via the actions of the enzyme 
11β-hydroxylase. It is known to be approximately as good a substrate as 
testosterone for 5αR (Frederiksen and Wilson, 1971) and in vitro studies in rat 
liver homogenates (Forchielli et al., 1955) confirm this. There is very little 
known about the site(s) and nature of in vivo 11-deoxycortisol metabolism in 
humans. A study with tritiated 11-deoxycortisol in 6 healthy human 
volunteers (Dehertogh et al., 1964) showed it disappears rapidly from 
plasma, with only 3% of initial IV dose remaining after 5 minutes, 0.08% 
remaining after 90 minutes, and 70% excreted in urine within 24 hours, 
however the relative contribution of 5αR in this metabolism is not defined. 
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However, the in vivo actions of the 5α-reduced metabolites of 11-
deoxycortisol remain unknown. 
 
While thought to lack metabolic effects, 5α-reduced glucocorticoids have 
anti-inflammatory effects and are discussed further in Section 1.4.1.  
 
1.1.5.3  Progesterones  
Progesterone is a steroid hormone synthesised by the ovaries and adrenal 
cortex, classically known for its role in normal and abnormal female 
reproductive physiology. 40-60% of plasma progesterone is metabolised to 
5α-dihydroprogesterone (5αDHP) principally in corpus luteum (Dombroski 
et al., 1993), placenta (Milewich et al., 1979), liver and brain. Approximately 
90% of synthesis and subsequent metabolism of 5αDHP occurs in extra-
hepatic sites (Dombroski et al., 1993). Prior to excretion, metabolism 
preferentially follows a pattern of 3β- (rather than 3α-) reduction, followed 
by 6α-hydroxylation, to finally be excreted in urine in the form of 3β,6α-
dihydroxy-5α-pregnan-20-one (Chantilis et al., 1996).   
 
Recent interest in the 5α-reduction of progesterone has primarily been in the 
field of psychiatric and neurological research.  Progesterone is present at a 
greater concentrations in the brain (as compared to testosterone), and its 
kinetic properties potentially make it a more favourable substrate for 5αR 
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(Lephart, 1993a). 5αR1 is present in substantially larger amounts than 5αR2 
in rat, mouse and human brain (Rego et al., 2009), thus is thought to be the 
most important 5αR isozyme in neurological steroid metabolism.  
 
5αDHP can bind to the progesterone receptor (Dong et al., 2001) and function 
as a neurosteroid. In male rats, 5αDHP has been shown to be a potent anti-
convulsant in a model of complex partial seizures with secondary 
generalisation (Lonsdale et al., 2006), and shows greater effect than either 
progesterone or 5αTHP. 5αDHP (along with progesterone and 
allopregnanolone) can promote Schwann cell proliferation through 
interaction with other transcription factors, and plays a part in the regulation 
of myelin formation (Brinton et al., 2008).  
 
There is a substantial body of evidence indicating that the 3αHSD metabolite 
of 5αDHP, allopregnanolone, is active as a modulator of the GABAergic 
neurotransmission system, likely via non genomic mechanisms (Purdy et al., 
1990). It is the 3α, and not the 3β, metabolites of 5αDHP that have this 
capability (Purdy et al., 1990). In a murine model, protracted social isolation 
stress was associated with a substantial decrease in 5αR1 activity, with 
subsequent reduction in both 5αDHP and allopregnanolone levels (Dong et 
al., 2001).  
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While reduced activity of 5αR1 is associated with some negative phenotypes 
(Dong et al., 2001), the use of 5αR inhibitors in rodent models has 
demonstrated an ability to reduce potentially distressing phenotypes 
including compulsive (Bini et al., 2009) and psychotic behaviours (Bortolato 
et al., 2008). Given the many substrates of 5αR1 and its regional and inter-
species variations in brain expression, dissecting the contribution of different 
5αR substrates and metabolites is difficult; it is likely that pathways 
influencing cognition, mood and behaviour are modulated by multiple 5α-
reduced neuroactive steroids.   
 
In addition to progesterone, two other progesterones are known to be 5αR 
substrates, namely 20α-dihydroprogesterone (20αDHP) and 17α-
hydroxyprogesterone (17αOHP). 10% of plasma progesterone is converted to 
20αDHP (Dombroski et al., 1993), and this can then be converted by 5αR to 
20α-hydroxy-5α-pregnan-3-one. In female rats 5αR action on 20αDHP is 
prominent in the anterior pituitary and medial basal hypothalamus, with 
metabolite action likely mediated via non-genomic routes due to low affinity 
for the progesterone receptor (Nowak, 2002).  5α-Reduced metabolites of 
20αDHP are hypothesised, though not confirmed, to have a biologically 
significant role as neurosteroids. 17αOHP is a glucocorticoid precursor, and 
while ex vivo work in human fetal small intestine (Nienstedt et al., 1980b) 
demonstrated that 17OHP could be 5α-reduced, it was 5β- metabolites which 
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predominated. While this early work demonstrates intestinal 5α-reducing 
capacity, these findings have not extended into further published research.  
 
1.1.5.4  Mineralocorticoids 
Aldosterone is a substrate for 5αR in the rat kidney, with 5α- and 5β- 
metabolites formed in approximately equal amounts. Of interest is that the 
5α- and 3α,5α- metabolites of aldosterone retain significant mineralocorticoid 
activity, and though their relative potency is less than aldosterone itself, they 
may still be biologically relevant (McDermott et al., 1983). These metabolites 
have been shown to cause hypertension in adrenalectomised spontaneously 
hypertensive rats, and when compared to 3β, 5α- or 3α,5β- aldosterone, the 
5α- or 3α,5α- aldosterone metabolites have a greater propensity to cause 
hypertension and suppress plasma renin activity (Gorsline et al., 1986).  
 
Another mineralocorticoid, 11-deoxycorticosterone, is a substrate for 5αR 
(Frederiksen and Wilson, 1971). Both 11-deoxycorticosterone and its 5α-
reduced metabolite, 5α-dihydro-11-deoxycorticosterone, show 
mineralocorticoid activity, though the latter to a lesser degree (Sekihara et al., 
1978).  5α-dihydro-11-deoxycorticosterone has also been shown to act as an 
antagonist to more potent mineralocorticoids (Sekihara and Yazaki, 1993). 
The physiological relevance of the 5α-reduced mineralocorticoids in humans 
is unknown. 
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1.2 Androgens 
1.2.1 Significance, Synthesis and Metabolism 
Androgens are steroid hormones which play an integral role in development 
and maintenance of gender phenotypes, and are also key players in other 
organ systems including bone and metabolism. Androgen production occurs 
principally in reproductive tissues in males and both the adrenal glands and 
ovaries in females. The main adrenal androgens are dehydroepiandrosterone 
(DHEA) and androstenedione, while the main androgens synthesised in 
extra-adrenal sites are testosterone and dihydrotestosterone (DHT).   
 
The sulfated derivative of dehydroepiandrosterone (DHEAS) is the 
quantitatively most significant androgen in adult humans (El Kihel, 2012), 
however while altered concentrations of DHEA and DHEAS are associated 
with different health conditions, their role and mechanism of action is yet to 
be well described. Androstenedione is important as a precursor to the extra-
adrenal synthesis of testosterone. Synthesis of testosterone and its 
subsequent metabolism are summarised in Figure 1.5. Testosterone and its 
more potent metabolite dihydrotestosterone are biologically the most 
significant androgens and are the focus of androgen discussion in this thesis.   
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Products of testosterone metabolism include androgens, principally 
dihydrotestosterone (catalysed by 5αR) and oestrogens (catalysed by 
aromatase). While ovarian steroid production is the main source of 
oestrogens in pre-menopausal women, peripheral conversion of androgens 
to oestrogens is the predominant source in men and post-menopausal 
women; therefore this pathway provides another important avenue of 
androgen action, and modulation of any aspects of androgen or oestrogen 
physiology cannot be viewed in complete isolation.  Along with all 5α-
reduced androgens, dihydrotestosterone cannot serve as an aromatase 
substrate as A ring reduction prevents this (Larsen, 2002).  
 
Daily production rates of DHT in men are between 280 µg (Mahoudeau et al., 
1971) and 400 μg, with testosterone production being ~5 mg per day (Murray 
RK, 2006).  Approximately 85% of DHT production is from testosterone, with 
the remainder from androstenedione (Mahoudeau et al., 1971), and the 
amount of testosterone available to serve as substrate is the key determinant 
of DHT production rates (Larsen, 2002). Sites of testosterone conversion to 
DHT mirror sites of 5αR expression (Table 1-1), with principal sites of DHT 
production being reproductive organs, skin and liver. There is a small 
amount of DHT produced in adipose (Longcope and Fineberg, 1985); in 
contrast, skeletal muscle can metabolise DHT, however is not considered a 
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significant site of its synthesis (Thigpen et al., 1993, Longcope and Fineberg, 
1985) .  
 
While its synthesis is irreversible, DHT metabolism is reversible, therefore 
actions of metabolising enzymes contribute to regulation of tissue exposure 
to DHT. As with other 5α-reduced steroids, DHT is metabolised by 3α- and 
3β- HSDs, with subsequent formation of glucuronic acid conjugates prior to 
excretion in urine (Pirog and Collins, 1999, Belanger et al., 2003). 3αHSD 
reductase activity is approximately 5 times greater than 3βHSD reductase 
activity, both in vitro (Pirog and Collins, 1999) and in vivo (Mahoudeau et al., 
1971), and forms the major pathway for DHT metabolism. In contrast to rat 
models, no significant differences attributable to age or sex have been 
observed in this ratio in human liver (Pirog and Collins, 1999). The 
importance of local DHT metabolism is highlighted in both normal and 
abnormal tissues. In genital skin from both males and females, DHT is 
synthesised (by 5αR from testosterone, and by 3αHSD from 3αDiol) at a 
significantly greater rate than non-genital skin, though its degradation is 
comparable (Morimoto et al., 1991). In pathological processes such as benign 
prostatic hyperplasia, an increase in prostatic DHT concentration does not 
just reflect an increase in 5αR activity, but also a corresponding decrease in 
DHT metabolism via 3αHSD, 3βHSD and 17βHSD (Isaacs et al., 1983).  In 
contrast, an increase in DHT inactivation is seen in visceral (but not 
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subcutaneous) adipose in abdominally obese women, perhaps reflecting a 
compensatory phenomena whereby already metabolically compromised 
adipose is protected from exposure to excess androgens (Blouin et al., 2003). 
The final metabolites of DHT prior to excretion are glucuronic acid 
conjugates; while this stage of DHT metabolism is less well understood, 
levels of these metabolites (and thus activity of these enzymes) have been 
shown to correlate with metabolic risk factors and proposed as potential 
future markers of metabolic disease (Vandenput et al., 2007, Miljkovic et al., 
2011).  
 
The most well recognised pathway of DHT synthesis is via 5αR action on 
testosterone. However, there are also so-called “backdoor” pathways (i.e. 
pathways independent of DHEA, androstenedione and testosterone) to DHT 
synthesis, which are increasingly recognised, particularly in prostate cancer 
research, and are summarised in Figure 1.6. This pathway stems from the 3α, 
5α- HSD metabolite of 17-hydroxyprogesterone which can be metabolised to 
androsterone, and in turn can be metabolised via the actions of 17βHSD and 
3αHSD enzymes to form DHT. The significance of these pathways is twofold. 
Firstly, these pathways may provide an important route of androgen 
production in castration resistant prostate cancer. Secondly, there are 
potential differences in the way these “backdoor pathways” are targeted by 
5αR inhibitor drugs (discussed further in Section 1.3.2); it has been 
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suggested, though not well clarified, that dutasteride (a dual 5αR isozyme 
inhibitor), but not finasteride (a 5αR2 inhibitor), inhibits the backdoor 
pathway (Mohler et al., 2011).  
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Figure 1.5 Principal pathways for synthesis and metabolism of testosterone and 
dihydrotestosterone. OH, hydroxy; HSD; hydroxysteroid dehydrogenase; 
DHEA, dehydroepiandrosterone; R, reductase; DHT, dihydrotestosterone; 
UDP-GT, Uridine diphosphate glucuronyl transferase (reverse reaction 
catalysed by β-glucuronidase); 3αDiol: 5α-androstan-3α, 17β-diol; 3βDiol: 5α-
androstan-3β, 17β-diol.  
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Figure 1.6 “Backdoor” pathway to dihydrotestosterone (DHT) synthesis. DHT can also be synthesised via pathways 
independent of dehydroepiandrosterone (DHEA), androstenedione and testosterone. Principal “backdoor pathway” 
intermediates are shown in italics, and enzymes catalysing formation of these intermediates are shown (boxed). OH, hydroxy; 
HSD, hydroxysteroid dehydrogenase; DH, dihydro; P, progesterone. 
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1.2.2 Mechanism of action 
Androgens exert their effects through binding of the androgen receptor (AR); 
the two androgens able to bind with subsequent physiological effect are 
testosterone and dihydrotestosterone. AR is a member of the steroid 
hormone receptor family, with a structure highly conserved through 
evolution. It is encoded for on the X chromosome (Xq11-12), with eight 
exons; the first exon encodes the N-terminal domain, exons 2-3 the central 
DNA binding domain, and exons 4-8 encode the C-terminal ligand binding 
domain (Gelmann, 2002).  AR is essentially ubiquitously expressed, with all 
tissues other than the spleen showing some AR expression (Gelmann, 2002).   
 
Binding of AR triggers a chain of events similar to that described in detail 
later for glucocorticoids (Figure 1.8, Section 1.4.2), terminating in either 
activation or repression of gene expression. AR is located primarily in the 
cytoplasm (Bennett et al., 2010). Upon binding of testosterone or DHT to the 
cytoplasmic AR there is a release of heat shock proteins, conformational 
change exposing the activation function 2 (AF-2) binding surface and 
translocation to the nucleus. The AR-ligand complex can then bind specific 
androgen response elements on DNA (Gobinet et al., 2002), and either 
transactivation or transrepression of gene transcription then follow.  DHT 
acts via the same pathway as testosterone, but does so with greater receptor 
affinity and subsequent effect (Bruchovsky and Wilson, 1968b, Askew et al., 
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2007), with a dissociation constant (Kd) in prostate from AR of 3.4 x 10-10 M 
for dihydrotestosterone, compared with 0.49 nM for testosterone (Wilson and 
French, 1976).   
 
Testosterone and its androgen metabolites do not solely bind AR. DHT and 
its 3β- reduced metabolite 5-androstane-3,17-diol have been shown to exert 
effects via the oestrogen β receptor in neuronal cell lines (Pak et al., 2007), 
and the latter can modulate the stress response and behavioural phenotypes 
in in vitro and in vivo models (Handa et al., 2008). Androgens are also ligands 
for other receptors including the steroid X receptor (Zhou et al., 2009), 
however all alternate receptor pathways are not as well understood as those 
mediated via the androgen receptor.  
 
In addition to genomic mechanisms of action, androgens also have non-
genomic signalling actions. The term ‘non-genomic’ describes modes of 
androgen action that are rapid (seconds to minutes), are membrane 
mediated, and do not involve (at least initially) transcription or translation 
(Foradori et al., 2008). These mechanisms may play a role in reproductive 
physiology and animal behaviour, however at this stage are not well 
understood (Foradori et al., 2008).  
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Non-classical pathways for androgen action can be demonstrated in animal 
models. An example is in the demonstration that testosterone exerts its 
effects on atherogenesis in both an AR dependent and independent manner;  
in an Apo-E deficient model of predisposition to atherosclerotic disease, AR 
knockout mice respond favourably to testosterone therapy, but to a lesser 
degree than their wild-type counterparts (Bourghardt et al., 2010).   
 
Understanding androgen action is imperative for the understanding and 
treatment of androgen-dependent disorders. Disorders characterised by a 
decrease in androgen action (such as hypogonadism) can be treated with 
synthetic androgens. The long-term potential for adverse effects temper the 
use of androgen replacement therapies, and monitoring for occult prostate 
cancer is considered a mandatory aspect of therapeutic monitoring (Rhoden 
and Morgentaler, 2004), though in the absence of adequate trial data this has 
largely been recommended due to hypothetical risks and increased prostate 
cancer risk may not be seen in practice (Marks et al., 2006, Page et al., 2011b). 
In order to alleviate potential for long-term harm, the use of selective 
androgen receptor modulators (SARMs) are the subject of ongoing research, 
with the aim to give positive tissue-specific effects on muscle and bone, while 
sparing the prostate (Haendler and Cleve, 2012). The inability for the 
enzymes 5αR and aromatase to convert SARM molecules to their 5α-reduced 
and aromatised metabolites respectively likely affords them some of their 
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tissue specificity (Haendler and Cleve, 2012). Conditions where excess or 
abnormal androgen action are deleterious can be treated with anti-androgen 
therapies (usually used in advanced prostate cancer) or with drugs targeting 
androgen synthesis or metabolism, such as 5αR inhibitors (discussed in 
Section 1.3.2).   
 
1.2.3 Androgens in health and disease 
Androgens play an important role in health in both sexes, with the 
importance of androgens in male physiology being the focus of this section. 
Androgens are critical in pre-natal sexual differentiation (Cunha et al., 1992) 
and remain vitally important throughout post-natal life particularly in 
establishment of secondary sexual characteristics at puberty (Imperato-
McGinley et al., 1979) and maintenance of this male phenotype thereafter. In 
addition, androgens play an essential part in spermatogenesis and fertility 
(Dohle et al., 2003).  
 
In addition to the pivotal role played in sexual function and reproduction, 
androgens are also important in other organ systems. Androgens influence 
bone growth both directly as androgens, and indirectly following 
aromatisation and formation of oestrogens. Overall androgens preserve bone 
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density principally through maintenance of cancellous bone 
(Vanderschueren et al., 2004).  
 
Body composition is influenced by androgens, principally testosterone. 
Muscle mass is increased by testosterone; a finding largely seen in studies of 
testosterone therapy in hypogonadal men where an increase in muscle mass 
is seen (Brodsky et al., 1996, Schroeder et al., 2005) resulting from an increase 
in muscle protein synthesis (Brodsky et al., 1996). Decreased testosterone is 
associated with increased fat mass (Mammi et al., 2012), and treatment with 
synthetic androgens decreases visceral adiposity (Wang et al., 2000, 
Schroeder et al., 2004) or prevents its accumulation (Allan et al., 2008).   
 
Just as androgens are of such importance to health in all stages of life, 
aberrations in androgen physiology can have pathological consequences. In 
adulthood principal pathological processes include those where a decline in 
androgen concentrations is seen, such as hypogonadism, and those where 
excess androgen action is implicated in diseases such as prostate cancer, 
androgenic alopecia and benign prostatic hyperplasia.  
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1.3 Benign prostatic hyperplasia 
1.3.1 Overview of benign prostatic hyperplasia 
Benign prostatic hyperplasia (BPH) is a condition characterised by a non-
cancerous increase in cell number within the prostate gland. As the prostate 
surrounds the urethra, clinically BPH manifests as a constellation of 
symptoms, often described by the umbrella term ‘lower urinary tract 
symptoms’ (LUTS), which can include urinary frequency, hesitancy, 
nocturia, and incomplete bladder emptying. BPH is the most common 
prostate condition, histologically present in approximately 50% of men at 50 
years, rising to 80% at 80 years (Guess et al., 1990). On a population basis 
these figures are highly comparable to those who are symptomatic of BPH, 
though it has been consistently found that these findings are not necessarily 
true on an individual basis (Guess et al., 1990). Studies also report weak 
correlations between sonographically determined prostate transition zone 
volumes and reported symptoms (Franciosi et al., 2007). It follows, that the 
pathophysiology of benign prostatic hyperplasia is complex.  
 
The prostate is a male exocrine gland composed of both glandular epithelium 
and stromal tissues, all contained within the prostatic capsule. Glandular 
epithelial cells produce important components of semen which aid in sperm 
motility and thus function. Stromal structures include sphincters, the 
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neurovascular bundle and prostatic capsule. Glandular regions of the 
prostate are anatomically divided into central, peripheral and transition 
zones. In the normal prostate the peripheral zone comprises 70% of 
glandular prostate mass, the central zone 25%, and the transition zone 5% 
(McNeal, 1988). The peripheral zone is affected by the vast majority of 
inflammatory and malignant disorders of the prostate. A smaller number 
occur in the transition zone, while the central zone is resistant to these 
conditions. In contrast, BPH affects primarily the transition zone, with some 
cases affecting the central peri-urethral zone (McNeal, 1988). Glandular 
architecture in BPH is normal.  
 
Both epithelial and stromal tissues express the androgen receptor, and while 
the former directly mediates androgen effects on prostate growth, the latter 
does so indirectly through androgen stimulation of stromal growth factors 
which in turn stimulate prostatic epithelial proliferation (Schalken, 2005). 
Prostate size is determined through a complex and delicate balance of 
androgen-mediated growth and apoptosis (Isaacs, 1996, Mirone et al., 2006). 
There are important differences in the response of different prostatic cell 
types to androgens, whereby AR in epithelial cells functions to suppress 
growth, whereas in stromal cells functions to stimulate proliferation 
(Bauman et al., 2006, Niu et al., 2008a, Niu et al., 2008b); these regional 
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differences are important not only in health but also in understanding 
prostate disease and designing new therapeutic approaches.  
 
While testosterone was previously considered the main ‘male’ sex hormone, 
the discovery that it is DHT that exerts intra-prostatic androgen effects 
provided a key breakthrough in androgen and prostate research (Marks et 
al., 2008). The growth of the prostate follows the trajectory of serum 
testosterone at puberty (Cunningham, 1996) and androgens are at least 
permissive players in prostatic growth. This understanding stems from the 
fact that prepubertal orchidectomy prevents prostate cancer, and 
orchidectomy is employed as an effective therapeutic modality in advanced 
prostate cancer (Isaacs, 1996). Despite the importance of androgens in 
prostatic growth, both testosterone and DHT concentrations decline with 
age, making it unlikely that BPH is solely an androgen-dependent disorder 
(Starka et al., 2009). It is also recognised however that circulating 
concentrations of androgens do not necessarily reflect the intra-prostatic 
environment (Marks et al., 2008). In BPH intra-prostatic DHT concentrations 
are not elevated, however this is the context of declining plasma testosterone 
levels with age, therefore may be considered to be relatively increased 
(Bartsch et al., 2002).  
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Whilst not negating the importance and direct influence of androgens on 
prostatic size and BPH, a broadening of research interests has been seen in 
recent years. In particular establishing other causative factors in BPH has 
been a key focus, with an aim to improving current therapeutic options. 
Prominent amongst recent research publications has been in establishing the 
link between BPH and the metabolic syndrome. While both BPH and the 
metabolic syndrome increase in prevalence as men age, an aetiological link 
between these two conditions was hypothesised following epidemiological 
studies. Multiple cohort studies have found associations with insulin 
resistance, obesity and low levels of physical activity with an increased 
incidence of BPH (Moul and McVary, 2010, Parsons et al., 2006), and 
increasing physical activity has been shown to reduce the risk of BPH 
(Parsons and Kashefi, 2008). The underlying mechanism for this observed 
association has not been established. Proposed theories include trophic 
effects of insulin in hyperinsulinaemic individuals (Hammarsten and Peeker, 
2011), inflammation as suggested by both a significant increase in C-reactive 
protein levels seen amongst patients with lower urinary tract symptoms 
(Kupelian et al., 2009), and a weak but significant relationship between 
histological inflammation on prostate biopsy and lower urinary tract 
symptoms (Nickel et al., 2008). Serum concentrations of cortisol do not differ 
between BPH patients and age-matched controls (Tan et al., 2003). In 
response to a stressful task, measurement of salivary cortisol shows no 
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correlation with objective measures of BPH severity, however there is a 
significant correlation with subjective measures in terms of higher bother and 
impact scores (Ullrich et al., 2007). More detailed measures of the link 
between glucocorticoids and BPH have not been reported in published 
literature. Much remains to be understood regarding the aetiology of BPH, 
however aberrations in level and function of several hormones, particularly 
androgens and insulin, are likely to be contributing factors, and are the 
subject of ongoing research.     
 
1.3.2 Treatment of benign prostatic hyperplasia, focusing on 
5α-reductase inhibitors 
Treatment modalities in BPH include observation, lifestyle modifications, 
medical or surgical therapy; the latter is usually reserved for those in whom 
medical therapy has failed. Medical treatments fall into two main categories, 
namely alpha adrenergic blockers and 5αR inhibitors. The aim is to improve 
symptoms and reduce complications such as urinary retention. 
Characteristics of commonly used medications are listed in Table 1-2.  
Monotherapy is generally commenced with an alpha blocker, which in the 
first year of treatment are more effective than 5αR inhibitors (Wilt and 
N'Dow, 2008). The mode of action of α blockers has traditionally been 
described as relaxation of prostate smooth muscle as α1 receptors are 
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abundant in prostate (Lepor, 2009), though this simplistic view is disputed 
(Lepor, 2007, Lepor, 2009).  Alpha 1 (α1) receptors are widely distributed 
throughout the body, and are currently categorised into three subtypes – 
α1A, α1B, and α1D (2009). Tamsulosin is selective for α1A and α1D receptors, 
with 10 fold greater affinity than for α1B, though this affords it no additional 
clinical benefit (Lepor, 2007). The main reason why tamsulosin is often 
selected over other α blockers is that no dose titration is needed due to lack 
of a significant first-dose hypotensive effect.  
 
Many compounds, broadly classified as steroidal and non-steroidal drugs, 
have been investigated as potential 5αR inhibitors, and have been 
comprehensively reviewed (Aggarwal et al., 2010). The only two 5αR 
inhibitors licensed for use in humans are finasteride and dutasteride; both 
steroidal compounds. Finasteride was licensed for use in BPH in 1992, and 
dutasteride followed a decade later in 2002. The main difference between 
these two drugs can be expressed as their in vitro potency against 5αR, 
measured as the amount of drug required to inhibit enzyme action by 50% 
(half maximal inhibitory concentration, IC50). Against human 5αR2, 
finasteride and dutasteride have IC50 values of <0.1 nM and 0.5 nM 
respectively. In contrast, a marked difference between these compounds is 
seen in their activity against human 5αR1, where finasteride has an IC50 of 52 
nM, compared with the more potent dutasteride with an IC50 of 2.4 nM 
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(Aggarwal et al., 2010).  At concentrations used in vivo, finasteride in humans 
acts to inhibit 5αR2 alone (Tian, 1996), compared with dutasteride which acts 
to inhibit both 5αR1 and 5αR2 (Frye, 2006).  
 
Another important consideration with 5αR inhibitor drugs is their selectivity 
towards 5αR; the main consideration being that they do not cause a decrease 
in synthesis of 5αR substrates, nor inhibit other enzymes metabolising 5αR 
substrates, particularly 5βR. Several 3-oxo-4-azasteroid compounds tested 
have been shown to have significant inhibitory activity against 3βHSD 
(Brandt and Levy, 1989); the exact mechanism of this inhibition has not been 
established. However, at clinically relevant doses, there is no significant 
inhibition of 3βHSD by finasteride (Brandt and Levy, 1989) or dutasteride 
(Frye, 2006). While known to be a competitive inhibitor, at clinical doses 
there is not thought to be effective inhibition of 5βR by finasteride (Drury et 
al., 2009). The inhibitory activity of dutasteride against 5βR is not described. 
Dutasteride inhibits 5αR3, while finasteride is not thought to (Mohler et al., 
2011), however consequences of drug inhibition of 5αR3 are not well 
understood.  
 
After three months of treatment, dutasteride leads to a >90% reduction in 
both serum and intra-prostatic DHT concentrations (Wurzel et al., 2007). This 
is associated with an increase in testosterone, however these testosterone 
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concentrations are not significantly different from concentrations in placebo-
treated men. Finasteride also lowers serum DHT , though to a lesser degree 
at approximately 70% suppression (Andriole and Kirby, 2003, Clark et al., 
2004). Both have demonstrated effect in those with moderate to severe 
disease (Gravas and Oelke, 2010), and while dutasteride lowers circulating 
and prostatic DHT concentrations to a greater degree, this has not been 
shown to result in clinically significant differences in efficacy (Andriole and 
Kirby, 2003, Marihart et al., 2005). The evidence behind the efficacy of dual 
therapy (i.e. α blocker + 5αR inhibitor) suggests an overall benefit (Montorsi 
et al., 2010), though findings are not consistent (Gravas and Oelke, 2010) and 
practice does vary between centres. Improvements in longterm outcomes 
with dutasteride therapy may not be in BPH itself, but may be due to a 
hypothesised reduction in prostate cancer risk (Goldenberg et al., 2009), 
however the role of 5αR inhibitors in prostate cancer is still unclear (Nacusi 
and Tindall, 2011) and at this stage are not used in this context outside of 
clinical trial settings.  
 
5αR inhibitors are not just utilised in treatment of prostate disease. 
Finasteride is used in androgenic alopecia treatment with moderate evidence 
for clinical efficacy (Mella et al., 2010), though in this context is given at a 
lower dose (1 mg daily) than is used in BPH. In women with hirsutism, 
finasteride is utilised as an anti-androgen (Escobar-Morreale et al., 2012), and 
 
Chapter 1: Introduction 
                                                                                                             47 
 
is effective in doses of 2.5 - 5 mg daily (Bayram et al., 2002). Although 5αR1 is 
highly expressed in skin and hair follicles (Eicheler et al., 1995), dutasteride is 
not licensed for treatment of alopecia or hirsutism.  
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Drug Class α Blocker 5αR Inhibitor 5αR Inhibitor 
Target α1A and α1D receptors 5αR1 and 5αR2 5αR2 
Usual dose 
(BPH) 
0.4 mg po daily 0.5 mg po daily 5 mg po daily 
Bioavailability >90%  60% 80% 
Tmax 4-5 hours 2-3 hours 1-2 hours 
T1/2 14-15 hours (modified 
release formulation) 
3-5 weeks 6-8 hours 
Protein 
binding  
94-99% 99.5% 90% 
Serum DHT 
suppression 
Unknown 94.7% 70.8% 
Prostate DHT 
suppression 
Unknown 93-95% 80-90% 
Metabolism Hepatic:  





Table 1-2 Drug Characteristics. Tmax, time to maximum concentration; T1/2, elimination half 
life; BPH, benign prostatic hyperplasia; DHT,  dihydrotestosterone; 5αR, 5α-reductase; po, 
oral administration Sources: Finasteride and dutasteride (Gravas and Oelke, 2010, Marks et 
al., 2008); tamsulosin [Merck drug information sheet]. 
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While 5αR inhibitors are clinically used for their anti-androgen properties, 
they could also have clinically relevant effects on other substrates of 5αR. 
This thesis will focus on the metabolic and hypothalamic-pituitary-adrenal 
axis effects of 5αR inhibition, which are not only be influenced by 




1.4.1 Significance, synthesis and metabolism 
Glucocorticoids are steroid hormones produced by the zona fasiculata of the 
adrenal cortex under control of the hypothalamic-pituitary-adrenal (HPA) 
axis. Corticotrophin releasing hormone (CRH) produced by the 
hypothalamus stimulates the anterior pituitary to produce and secrete 
adrenocorticotrophic hormone (ACTH). ACTH in turn stimulates adrenal 
glucocorticoid synthesis and cortisol acts to negatively feedback and regulate 
its own production. Glucocorticoid effects are predominantly initiated by 
binding to the intra-cellular glucocorticoid receptor (GR), with the resultant 
cascade influencing gene expression. Glucocorticoids play a key role in many 
essential biological processes, whether for basal homeostasis or stress-related 
responses. These actions are varied and involve growth, development, 
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regulation of glucose metabolism, and responses to stress, infection, and 
inflammation.  
 
The quantitatively most abundant and physiologically most relevant 
endogenous glucocorticoids are considered to be cortisol and corticosterone. 
Cortisol is the main glucocorticoid in humans, accounting for approximately 
30% of adrenocortical hormone synthesis (Barrett KE, 2010), and circulating 
concentrations of cortisol are 10-20 times greater than those of corticosterone 
(Hariharan et al., 1992), largely a reflection of the fact that production rates of 
corticosterone are approximately one third that of cortisol (Barrett KE, 2010).  
Rodents lack adrenal 17α-hydroxylase, and thus utilise corticosterone as their 
main glucocorticoid (Laplante et al., 1964).  
 
Variations in glucocorticoid concentration or action influence many, and 
cause some, pathological processes. Glucocorticoid excess is seen clinically in 
Cushing’s syndrome, with multi-system consequences including insulin 
resistance, obesity, dyslipidaemia and depression. Glucocorticoid deficiency, 
as seen in Addison’s disease, can be potentially fatal in the face of injury or 
illness that would typically be overcome via a response mounted by 
endogenous glucocorticoids. It is not only aberrant glucocorticoid production 
that can manifest clinically, but also pathological entities involving impaired 
glucocorticoid action. Glucocorticoid resistance is associated with a range of 
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underlying abnormalities including GR receptor mutations, defective GR 
binding, translocation or transactivation (processes described in 1.4.2) 
(Barnes, 2010). Clinically this can manifest as patients with poor 
glucocorticoid response in usually glucocorticoid responsive disease states 
such as asthma or rheumatoid arthritis.  
 
Control of both circulating and intracellular cortisol concentrations are vital 
to health. Intracellular regulation of glucocorticoids is influenced by the 
activity of glucocorticoid regenerating and degrading enzymes. While the 
contribution of the adrenals to cortisol synthesis is vital, several studies have 
demonstrated the considerable importance of tissue glucocorticoid 
production (Andrew et al., 2002, Stimson et al., 2009, Basu et al., 2004). 
Glucocorticoid metabolism within tissues occurs reversibly via the 11β-
hydroxysteroid dehydrogenases (11βHSD), and irreversibly via the 5α- and 
5β-reductases (Figure 1.7). The 11βHSD enzymes catalyse the reaction 
between active cortisol with inactive cortisone, corresponding to a 
biologically significant structural change of a carbon 11 hydroxyl to keto 
group. 11βHSD has two known isozymes. 11βHSD1 acts predominantly as a 
reductase in vivo, catalysing the formation of cortisol from cortisone. 
11βHSD2 acts in the opposite direction and inactivates cortisol. 
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Morbidity is associated with abnormal glucocorticoid metabolism. In the rare 
autosomal recessive disorder Syndrome of Apparent Mineralocorticoid 
Excess (SAME), a lack of 11βHSD2 means cortisol is not inactivated in 
mineralocorticoid target tissues, and is therefore able to act as a 
mineralocorticoid receptor agonist with resulting hypertension and 
hypokalaemia (Wilson et al., 2001). Research characterising the role of 
11βHSD1 in glucocorticoid regulation perhaps best exemplifies the ability of 
tissue glucocorticoids to affect metabolism without altering circulating 
cortisol concentrations. In the context of normal or near-normal plasma 
cortisol concentrations in metabolic disease, tissue-specific dysregulation of 
cortisol regeneration by 11βHSD1 has been demonstrated in adipose (Rask et 
al., 2002) and liver (Baudrand et al., 2010, Baudrand et al., 2011). Importantly, 
alterations in tissue glucocorticoid concentrations have been shown to affect 
insulin sensitivity (Masuzaki et al., 2001, Morton et al., 2001). The 
pharmacological inhibition of 11βHSD1 remains an area of intense research 
interest with an attempt to develop inhibitors selective to only the 
detrimental effects of elevated intra-tissue glucocorticoid effects (Hughes et 
al., 2008, Morton, 2010). 
 
Enzymatic regulation of cortisol metabolism also impacts on circulating 
cortisol  concentrations. Enhanced peripheral glucocorticoid clearance results 
in less negative feedback inhibition of ACTH-dependent steroids. This is 
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seen in conditions such as PCOS (Rodin et al., 1994) and possibly during 
growth hormone treatment (Isidori et al., 2003) where enhanced cortisol 
clearance, associated with decreased 11βHSD1 activity, is thought to 
contribute to activation of the HPA axis with (as a byproduct of attempts to 
increase cortisol secretion) an increase in adrenal androgens (Rodin et al., 
1994). These features are particularly apparent in the rare Apparent 
Cortisone Reductase Deficiency (Jamieson et al., 1999). While targeting 
metabolic disease, the potential for activation of the HPA axis in response to 
reduced negative feedback following 11βHSD1 inhibition is the subject of 
ongoing research (Harno, 2010). Conversely, decreased peripheral 
glucocorticoid clearance is also associated with pathology; with decreased 
activation of the HPA axis from reduced peripheral clearance potentially 
rendering individuals less able to adapt to stressful stimuli (Yehuda and 
Seckl, 2011).   
 
The influence exerted by 11βHSDs demonstrates the importance of 
enzymatic regulation in glucocorticoid physiology. Additional enzymatic 
control of glucocorticoids is in the initial, rate-limiting, step in glucocorticoid 
metabolism: the reduction of the carbon 4-5 double bond by 5αR or 5βR. The 
action of 5αR and 5βR in inactivating cortisol occurs principally in the liver 
(Gold, 1961). The formation of dihydrocortisol (DHF) or dihydrocortisone 
(DHE) is followed by further reduction to tetrahydrocortisol (THF) or 
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tetrahydrocortisone (THE) respectively. These are then conjugated and 
excreted mostly in urine with around 15% excreted in faeces (Barrett KE, 
2010). Approximately 50% of secreted cortisol is excreted as βTHF, αTHF and 
THE, 25% as cortols/cortolones, 10% as C19 steroids, and 10% as 
cortolic/cortolonic acids, with the remaining being free unconjugated 
steroids (Tomlinson et al., 2004). Alternate pathways for excretion exist, with 
either 6β-hydroxylation, or (for 10% of secreted cortisol and cortisone) 
conversion to 17-ketosteroid or 20-hydroxy derivatives which are then 
conjugated and excreted in urine (Barrett KE, 2010). 
 
The irreversible reduction of the carbon 4-5 double bond can be catalysed by 
either 5α- or 5β-reductase; normally 5α:5β metabolites are formed in a 1:2 
ratio (Tomlinson et al., 2004), however this ratio is altered in several disease 
states. It is significantly higher in hyperthyroidism, significantly lower in 
hypothyroidism (Hoshiro et al., 2006), and in both cases this is due to 
differences in 5αR rather than 5βR activity. As described above, the aetiology 
of PCOS may be related to increased glucocorticoid metabolism, with a 
subsequent decrease in negative feedback causing increased ACTH 
stimulation of adrenal androgens (Stewart et al., 1990, Tsilchorozidou et al., 
2003). In lean women with PCOS, there is a significant increase in 5αR 
activity, with the 5αTHF:5βTHF ratio rising to approximately 0.7 
(Tsilchorozidou et al., 2003). This finding has been reiterated in a study 
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showing increased 5αR activity in both obese and non-obese PCOS patients 
(Vassiliadi et al., 2009). The pathophysiology of obesity and fatty liver is still 
unclear, but altered glucocorticoid metabolism is thought to play a 
significant role (Roberge et al., 2007). In obese Zucker rats, an increase in 
hepatic 5αR activity was seen, with a much greater proportion of 5α:5β 
corticosterone metabolites formed (Livingstone et al., 2000a). In humans, 
obesity and female gender are associated with increased 5αR activity 
(Andrew et al., 1998, Fraser et al., 1999, Reynolds et al., 2001), and in men 
with fatty liver an increase in 5βR is seen (Westerbacka et al., 2003).      
 
5αR transcript abundance in adipose is lower in women than men, however 
does not correlate with either generalised or central obesity (Wake et al., 
2007). A positive correlation has been demonstrated between hepatic 5αR 
mRNA expression and hyperinsulinaemia in obese patients – hypothesised 
to be an adaptive response aiming to preserve hepatic insulin sensitivity in 
the face of raised glucocorticoid concentrations (Baudrand et al., 2011). In 
two  very rare cases of 5αR deficiency, a lower 5α-reduction of cortisol (as 
well as testosterone) is reported (Fisher et al., 1978), however clinical 
consequences of this were not described.   
 
Alterations in 5αR activity are studied in animal models of human disease, 
where variations in activity are also seen. Hepatic 5α-reduction of 
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corticosterone in rats is increased in obesity (Livingstone et al., 2000a, 
Livingstone et al., 2005) and obesity is, at least partially, related to 
glucocorticoid concentrations as adrenalectomy attenuates weight gain, and 
normalises omental fat 11βHSD1 activity (Livingstone et al., 2000b). This 
increased 5αR activity is thought to be independent of androgens, as 
gonadectomy does not alter the relative difference in 5αR expression 
between lean and obese animals (Barat et al., 2007).  
 
It is not only the substrates of 5αR that have biological relevance; metabolites 
5αDHB and 5αTHB can also bind GR (McInnes et al., 2004). Upon binding 
GR, 5αTHB can activate mRNA expression from glucocorticoid responsive 
genes, and contribute to central negative feedback (McInnes et al., 2004). 
5αTHB also displays both in vitro and in vivo anti-inflammatory effects, 
without metabolic toxicity (Yang et al., 2011). 5αDHB does not have any 
mineralocorticoid activity (Sekihara et al., 1978), however the 
mineralocorticoid activity of 5αTHB is unknown. 5αDHB binding to the SXR 
has been demonstrated (Blumberg et al., 1998), though it remains unknown 
how physiologically relevant this pathway is.  
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5βDHF 5αDHF 5βDHE 
Figure 1.7: Principal pathways of glucocorticoid metabolism. OHase, hydroxylase; HSD, hydroxysteroid dehydrogenase; 
R, reductase; DHF, dihydrocortisol; DHE, dihydrocortisone; THF, tetrahydrocortisol; THE, tetrahydrocortisone. 
Metabolism of 5α- and 5β- metabolites also occurs via 3βHSD.  
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1.4.2 Mechanisms of glucocorticoid action 
Following adrenocortical synthesis, glucocorticoids are released into the 
systemic circulation. Corticosteroid-binding globulin (CBG) binds the 
majority of glucocorticoids, rendering them biologically unavailable. 
Albumin also binds glucocorticoids with low affinity but high capacity (van 
der Laan and Meijer, 2008).  Lipophilic in nature, glucocorticoid molecules 
are thought to diffuse through the cell membrane (Zhou and Cidlowski, 
2005), however there is evidence of steroid transporters such as the 
multidrug resistant P-glycoprotein at the blood-brain barrier (Karssen et al., 
2001), the organic anion transporter 3 in adrenocortical cells (Asif et al., 2005), 
and the glucocorticoid importer demonstrated in rat liver (Lackner et al., 
1998). Once inside the cell, glucocorticoids bind their intra-cellular receptors, 
including GR. With such a wide array of glucocorticoid actions, it is not 
surprising that the glucocorticoid receptor is essentially ubiquitously 
expressed.  
 
The human glucocorticoid receptor (hGR) gene comprises 9 exons and is 
situated on chromosome 5. Two homologous receptor isoforms, designated α 
and β, occur as a result of exon 9 splicing (Nicolaides et al., 2010). There is 
further complexity in GR function due to translation of both α and β 
transcripts into two distinct proteins, named hGR-A and hGR-B, with the 
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latter demonstrating greater efficacy in transactivation, though similar in 
other respects (Zhou and Cidlowski, 2005). In addition, hGR is subject to 
post-translational modification, though the physiological relevance of this is 
not well understood (Zhou and Cidlowski, 2005). hGRβ isoform exists in 
human and zebrafish, though was traditionally thought not to be present in 
rodents (Kino et al., 2009). The presence of GRβ mRNA and protein in 
murine cells and tissues has been shown, with reportedly similar properties 
to hGRβ (Hinds et al., 2010). hGR isoforms are structurally identical until 
amino acid 727, after which hGRα has 50, and hGRβ 15, distinct amino acids 
(Nicolaides et al., 2010). These structural differences correspond to a unique 
ligand-binding domain; with N-terminal domain and DNA binding domain 
preserved between isoforms (Kino et al., 2009).  α and β isoforms of hGR 
have distinct functional properties. hGRα undergoes the classical 
conformational changes described below, is bound by glucocorticoids (both 
natural and synthetic) and influences gene transcription via binding to 
glucocorticoid response elements (GRE) (Nicolaides et al., 2010).  In contrast, 
hGRβ does not bind glucocorticoid agonists (as its structural configuration 
renders the formation of a ligand binding pocket impossible), but rather 
exerts a dominant negative effect on the transcriptional activity of hGRα 
(Kino et al., 2009, Lewis-Tuffin and Cidlowski, 2006). hGRβ can however 
bind the ligand RU486, a glucocorticoid antagonist, which results in 
cytoplasm to nucleus translocation, and both up and down-regulation of 
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gene expression (Lewis-Tuffin et al., 2007); though the physiological 
relevance of this is yet to be clarified. hGRβ has been implicated in 
glucocorticoid-resistant rheumatoid arthritis where its expression is 
increased (Kozaci et al., 2007), as well as other inflammatory diseases where 
there is an enhancement of its dominant negative inhibition of hGRα (Barnes, 
2010, Lewis-Tuffin and Cidlowski, 2006). However, the exact nature and 
importance of hGRβ is still unclear. Given that hGRβ cannot bind GR 
agonists, it is presumed, though not confirmed, to lack a direct role in the 
function of glucocorticoids and their metabolites.  
 
Prior to ligand binding GR resides as part of a cytoplasmic polyprotein 
complex. GR is a ligand dependent transcription factor, and remains inactive 
in its unbound state. Ligand binding leads to conformational changes, 
unravelling of the polyprotein complex, and exposure of nuclear localisation 
signals. Upon glucocorticoid binding, GR is transported into the nucleus and, 
following homodimerisation, binds to glucocorticoid response elements 
(GREs) on target genes (Zhou and Cidlowski, 2005). In addition to 
homodimers, glucocorticoid action can also be mediated via monomers 
(Schacke et al., 2002) and multimers (Adams et al., 2003). The key 
glucocorticoid actions are categorised as transactivation and transrepression. 
Transactivation leads to activation of gene expression, as seen in the 
activation of tyrosine aminotransferase and phosphoenolpyruvate 
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carboxykinase (PEPCK), both enzymes involved in gluconeogenesis (Schacke 
et al., 2002). Transrepression is the inhibition of a transcription factor 
responsible for up-regulation of gene expression, with the net effect being 
down-regulation of gene expression.  This can either occur via GR binding to 
negative GREs or through interaction with further transcription factors. 
Binding to negative GREs is seen in osteoblasts with resulting decrease in 
transcription of the bone protein osteocalcin (Stromstedt et al., 1991); which 
contributes to some of the long-term osteopenic consequences of 
glucocorticoid therapy (Schacke et al., 2002). Repression of pro-
opiomelanocortion (POMC) gene transcription by glucocorticoids is also 
mediated via a negative GRE (Drouin et al., 1989). Transrepression without 
GR binding to DNA is seen when GR binds to a transcription factor that 
usually induces transcription of pro-inflammatory proteins. NF-ĸB and 
activating protein (AP)-1 are examples of proteins whose actions are 
inhibited when bound by GR (De Bosscher and Haegeman, 2009) (Figure 
1.8).  
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Figure 1.8: Mechanisms of glucocorticoid actions 
Glucocorticoids (spotted circle) when bound to the glucocorticoid receptor (GR- 
solid black) alter gene transcription through three main pathways (1, 2 or 3): 
(adapted from (Schacke et al., 2002)) 1. Transactivation involves binding of the 
homodimer to the glucocorticoid response element (GRE) on a target gene and 
activation of gene transcription. 2. Transrepression occurs via binding of a 
monomer to a negative GRE and repressing gene transcription. 3. Repression of 
gene transcription can also occur via the interaction of a monomeric ligand bound 
GR with a transcription factor (TF), which then inhibits the activation of gene 
transcription by these transcription factors.  
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Although many of the biological properties of glucocorticoids are mediated 
via GR, at least two other classes of receptor bind with glucocorticoids, 
namely the mineralocorticoid receptor (MR) and the steroid and xenobiotic 
receptor (SXR). The latter is synonymous with the pregnane activated 
receptor (PAR) and in rodents the pregnane X receptor (PXR).  
 
The mineralocorticoid receptor was cloned in 1987 by Arriza and colleagues 
(Arriza et al., 1987), revealing a 984 amino acid protein encoded on 
chromosome 4. When comparing human MR with human GR, there is 94% 
homology with the DNA binding domain and 57% with the ligand binding 
domain.  In terms of ligand affinity, the mineralocorticoid receptor is 
certainly not exclusively bound by mineralocorticoids. The affinities for 
steroidal ligands are approximately deoxycorticosterone = corticosterone ≥ 
aldosterone = cortisol (Funder, 2005) and circulating concentrations of 
glucocorticoids are at least 100-1000 times greater than circulating 
aldosterone (Yang and Young, 2009). The fact that aldosterone is able to exert 
any physiological effect at all is largely explained by the co-expression of the 
enzyme 11β-hydroxysteroid dehydrogenase type 2 (11βHSD2) in MR 
expressing cells (Edwards et al., 1988, Funder et al., 1988). 11βHSD2 converts 
cortisol into receptor-inactive cortisone, thereby preventing MR activation by 
glucocorticoids. Myocardium and hippocampus are amongst the most 
notable tissues lacking significant 11βHSD2 activity, where cortisol (or 
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corticosterone) is the most significant MR ligand rather than aldosterone 
(Yang and Young, 2009). It is worth noting that while glucocorticoids bind 
MR, mineralocorticoids such as aldosterone are not known to bind GR (Yang 
and Young, 2009).  
 
SXR is a nuclear receptor most prominently expressed in liver and intestine, 
which plays a key role in transcriptional regulation of CYP3A4 (Zhou et al., 
2009). SXR has a wide range of ligands ranging from glucocorticoids to drugs 
such as the antituberculous drug rifampicin. While traditionally considered 
an ‘orphan’ receptor, increasing bodies of evidence suggest a greater role for 
SXR in endogenous glucocorticoid metabolism than previously thought. In 
vitro studies demonstrate dexamethasone to be a weak activator of human 
and mouse SXR (Moore et al., 2000). More convincing evidence still comes 
via gene knockout models, where traditional inducers such as 
dexamethasone fail to cause Cyp3a4 gene activation (Zhou et al., 2009). The 
role of SXR in glucocorticoid and mineralocorticoid homeostasis in 
transgenic mice was investigated by Zhai et.al. (Zhai et al., 2007), showing 
activation of SXR causes an increase in corticosterone concentrations, and an 
increase in adrenal enzymes involving in steroid synthesis. These alterations 
happen independently of the HPA axis, so that hypercortisolism co-exists 
with a normal response to a dexamethasone suppression test.   
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In addition to receptor mediated effects, glucocorticoids also act via non-
genomic routes. These actions are rapid and do not directly involve effects on 
gene transcription classically associated with glucocorticoid activity. Non-
genomic effects of glucocorticoids are widespread and are now considered 
important mediators of effect for both endogenous and synthetic 
glucocorticoids (Borski, 2000, Stahn et al., 2007).  
 
1.4.3 Glucocorticoids in health 
Glucocorticoids are vital to many aspects of health, particularly immunity 
and macronutrient metabolism. In essence, glucocorticoids act to promote 
synthesis and mobilisation of energy substrates such as glucose and fatty 
acids, and are particularly important in times of stress, inflammation and 
infection.  
 
Glucocorticoids influence glucose homeostasis in a counter-regulatory 
manner to insulin; they increase plasma glucose concentrations by increasing 
gluconeogenesis and decreasing peripheral glucose uptake. Glucocorticoids 
stimulate gluconeogenesis by increasing gene expression of key enzymes 
involved in glucose production, including tyrosine aminotransferase (TAT) 
(Jantzen et al., 1987), phosphoenolpyruvate carboxykinase (PEPCK) (Hanson 
and Reshef, 1997) and glucose-6-phosphatase (Van Schaftingen and Gerin, 
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2002). In skeletal muscle glucose uptake is decreased, glycogen synthesis 
reduced and proteolysis induced to mobilise amino acids for use as 
gluconeogenic substrates (Vegiopoulos and Herzig, 2007). Effects of 
glucocorticoids on adipose tissue are complex and not completely 
understood, though they are known to exert effects which likely differ by 
time, adipose depot and prandial state (and corresponding changes in insulin 
and catecholamine concentrations), with an overall effect of increasing 
lipolysis when energy substrates are needed and promoting lipid storage 
when insulin concentrations are elevated (Macfarlane et al., 2008, Coppack et 
al., 1994, Lundgren et al., 2004). Effects of glucocorticoids on glycogen 
turnover are more akin to effects mediated by insulin, whereby both 
synthesis and lysis are promoted, perhaps in preparation for glucose release 
(Andrews and Walker, 1999, Macfarlane et al., 2008).  
 
Both acute and chronic blood pressure regulation is influenced by 
glucocorticoids. While co-expression of 11βHSD2 in sites of MR expression 
such as kidney prevent excessive MR-mediated glucocorticoid activity 
(Edwards et al., 1988), glucocorticoids are able to increase blood pressure by 
enhancing angiotensin II-mediated effects and promoting sodium retention 
(Brem, 2001). Peripherally, glucocorticoids increase vascular tone both by 
potentiating the effects of vasoconstrictors such as catecholamines, and via 
direct effects on vascular smooth muscle cells increasing vascular tone and 
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thus peripheral vascular resistance (Ullian, 1999). While the role of 
glucocorticoids in a normotensive population has not been clearly 
demonstrated (Fraser et al., 1999), importance in hypertension, and in those 
at risk of hypertension, has been shown in terms of increased cortisol 
secretion and increased dermal sensitivity to synthetic glucocorticoids 
(Walker et al., 1998).    
 
As key modulators of the immune system, glucocorticoids are vital in 
response to infection and inflammation, and act to inhibit production of pro-
inflammatory molecules, influence recruitment of cells involved in the 
immune response, and induce transcription of anti-inflammatory genes 
(McEwen et al., 1997). Glucocorticoids also modulate bone turnover through 
a number of mechanisms (Schacke et al., 2002) resulting in decreased 
osteoblast and increased osteoclast activity, and circadian cortisol variation is 
reponsible for circadian variations seen in osteocalcin, a marker of osteoblast 
activity (Heshmati et al., 1998).  
 
1.4.4 Glucocorticoids in disease and therapeutics  
Aberrations in glucocorticoid concentrations and metabolism are detrimental 
to health, and these effects are principally seen as an impaired response to 
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stress and infection, increased fracture risk and increased metabolic and 
cardiovascular risk; the latter forming the focus of discussion in this section.  
 
Addison’s disease, a condition characterised by insufficient production of 
adrenal steroids, including glucocorticoids, is associated with an increased 
risk of cardiovascular disease (Bergthorsdottir et al., 2006). In addition, those 
with excess circulating glucocorticoid concentrations, such as patients with 
Cushing’s syndrome, there is an increase in both cardiovascular morbidity 
and mortality when compared with the general population (Etxabe and 
Vazquez, 1994, Mancini et al., 2004). These risks are largely reversible upon 
treatment, however persistence of increased risk is seen long-term, 
particularly in those with pituitary Cushing’s syndrome (Cushing’s disease) 
(Colao et al., 1999, Giordano et al., 2011, Graversen et al., 2012). Common 
features between the adverse metabolic phenotype seen in Cushing’s 
syndrome and those seen in the metabolic syndrome have led to the 
hypothesis that excess glucocorticoids may play a key role in the 
pathogenesis of the metabolic syndrome, and may therefore also provide a 
therapeutic target (Walker, 2006).  In particular, there is an activation of the 
HPA axis seen in patients with the metabolic syndrome, of unconfirmed and 
likely multi-factorial aetiology, including effects of early life programming, 
chronic stress and abnormal tissue cortisol metabolism (Anagnostis et al., 
2009).   
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The metabolic syndrome, comprised of obesity (particularly abdominal), 
hypertension, diabetes and dyslipidaemia, is the cluster of disorders most 
influential in the development and progression of cardiovascular diseases. 
The term is synonymous with the previously entitled ‘syndrome X’ or 
‘metabolic syndrome X’. The concept of the metabolic syndrome arose in the 
late 1980s (Reaven, 1988) with the observation that insulin resistance was 
associated, perhaps causally, with this constellation of diagnoses. Insulin 
resistance was characterised as a decrease in insulin-mediated glucose 
uptake, and reduction in insulin suppression of free fatty acid release from 
adipose, with resulting hyperglycaemia and hyperinsulinaemia.  
 
Definitions of the metabolic syndrome have evolved over the years and do 
still vary by country and professional body. The current definition adopted 
by the Scottish Intercollegiate Guidelines Network (SIGN, 2007) is any three 
of the following: 
 Increased waist circumference (≥102 cm in men, ≥88 cm in women; or 
≥90 cm in Asian men, ≥80 cm in Asian women) 
 Elevated triglyceride (≥1.7 mmol/L) 
 Decreased high density lipoprotein (HDL) cholesterol (<1.03 mmol/L 
in men, <1.29 mmol/L in women) 
 Blood pressure >130/85 mmHg or active treatment for hypertension 
 Fasting glucose >5.6 mmol/L or active treatment for hyperglycaemia 
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Other features of the metabolic syndrome can include increased levels of 
small and atherogenic low density lipoprotein (LDL) molecules. In addition, 
there are many other chronic diseases which have been associated with the 
metabolic syndrome, including obstructive sleep apnoea and benign 
prostatic hyperplasia, though these are currently defined as parallel 
diagnoses. There is no specific treatment for the metabolic syndrome per se, 
rather the therapeutic approach lies in optimising lifestyle, promoting weight 
loss, and management of hypertension and diabetes as appropriate (SIGN, 
2007).  
 
Multiple studies demonstrate that each component of the metabolic 
syndrome has been linked with increased risk of cardiovascular 
complications, including abdominal obesity (Ibrahim, 2010), hypertension 
(Kannel, 1996), and dyslipidaemia (Catapano et al., 2011). Fasting glucose 
and simple measures of impaired glucose tolerance are useful measures on a 
population basis where time and resources are limited, though more 
detailed, sensitive and precise measures are more appropriate in a research 
context (Antuna-Puente et al., 2011). The concept of the metabolic syndrome 
is attractive in the holistic nature of its definition, however this approach has 
been criticised as it arguably does not add to strength of risk prediction that 
is afforded by viewing risk factors in isolation (Sattar et al., 2008), albeit most 
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studies do show a significant increase in cardiovascular risk associated with 
the metabolic syndrome (Cornier et al., 2008).  
 
While insulin resistance appears to be at the heart of the pathophysiology of 
the metabolic syndrome (and its individual components), its underlying 
cause remains unknown. The role of aberrant intra-tissue metabolism of 
other hormones including glucocorticoids in inducing or worsening insulin 
resistance is a key research focus.   
 
Additional evidence for the potential role of glucocorticoids in the metabolic 
syndrome is seen in the side effect profile of synthetic glucocorticoids. 
Therapeutics in a number of disease processes have utilised synthetic 
glucocorticoids for over half a century. Indications for glucocorticoid use 
vary greatly, and include asthma, inflammatory bowel disease, rheumatoid 
arthritis, peritumour oedema and prevention of transplant rejection. Dose, 
duration of therapy and route of administration are all adapted to clinical 
indication and patient characteristics. While being very effective, 
glucocorticoid therapy is perennially plagued by the relatively high risk of 
adverse effects, often in vulnerable patient populations.  
 
In a dose-dependent manner, glucocorticoid therapy induces insulin 
resistance, with increased glucose and insulin concentrations, increased 
 
Chapter 1: Introduction 
                                                                                                             72 
 
proteolysis and decreased insulin-mediated peripheral glucose uptake and 
lipolysis suppression (van Raalte et al., 2011). The challenge of finding 
synthetic glucocorticoids with specificity and potency, but without 
significant adverse events, has led the drive to develop dissociated GR 
ligands – that is ligands which differentially induce transrepression rather 
than transactivation. Transrepression is thought to account for the majority 
of beneficial effects of glucocorticoid therapy (mainly anti-inflammatory 
effects), while transactivation is associated with adverse effects (e.g. elevated 
blood glucose levels), however the reality is by no means so clear-cut 
(Schacke et al., 2002). Multiple pre-clinical compounds are currently under 
investigation in animal models (De Bosscher, 2010), though the complexity of 
these physiological and biochemical pathways means that many potential 
synthetic ligands can no longer be considered as either agonists or 
antagonists, but rather may have cell or organ specific effects (van der Laan 
and Meijer, 2008).   
 
1.5 Effects of modulating 5α-reductase on 
metabolism and the HPA axis.  
Against the background above, it is apparent that 5αR is a key enzyme 
involved in the metabolism of many steroid hormones, including androgens 
and glucocorticoids. There are several strands of evidence which suggest a 
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potential link between 5αRs and metabolism, including metabolic effects of 
enzyme substrates and perhaps products, associations of SNPs in 5αR 
encoding genes with metabolic disease, and demonstrated alteration of 5αR 
activity in a range of disease processes. Inhibition of 5αR is a therapeutic 
approach commonly employed in the treatment of androgen dependent 
disorders such as benign prostatic hyperplasia. However, reflective of the 
importance of 5αR in a wide array of processes in health and disease, 
including glucocorticoid metabolism, there is a potential for ‘off-target’ 
effects on metabolic health as a result of 5αR inhibition.   
 
Effects of 5αR inhibitors on extra-prostatic tissues may arise either due to a 
reduction in 5α-reduced metabolite concentration, an increase in 5αR 
substrate concentration, or indirect effects as a result of altered clearance and 
compensatory changes in HPA or hypothalamic-pituitary-gonadal axes. 
Observations in those with genetic disorders involving 5αR, and in those on 
drugs inhibiting 5αR are the two investigational modalities in human 
studies. The former is a very rare scenario, while the latter very common. 
Genetic defects of 5αR are associated with impaired metabolism of multiple 
steroid hormones (Fisher et al., 1978, Russell and Wilson, 1994), however  
metabolic consequences are not described.   
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1.5.1 Evidence from human studies 
The metabolic effects of 5αR inhibitors have been investigated to a limited 
degree in clinical studies. A meta-analysis investigating the safety of 
dutasteride (Andriole and Kirby, 2003), showed that there were no 
significant differences in glucose concentrations or liver function tests after a 
year of therapy, whether compared with placebo or finasteride. The effect of 
1 year of dutasteride treatment on BMI was investigated in a Korean 
population (Hong et al., 2010). This was a randomised controlled trial with 
three study arms - tamsulosin alone, dutasteride alone, and combination of 
tamsulosin and dutasteride. The only measures made were serum 
testosterone level and BMI. They concluded that, only in those with a lower 
baseline testosterone level, treatment with dutasteride (whether as 
monotherapy or in combination) significantly reduced BMI by 
approximately 0.2 kg/m2. An underlying mechanism for this finding was not 
hypothesised.    
 
The effect of finasteride on HDL and lipoprotein lipase levels was 
investigated in a study of 28 patients with mild BPH (Denti et al., 2000) who 
were randomised to either placebo or finasteride for 6 months. A significant 
increase in HDL and lipoprotein lipase levels was seen in the finasteride 
group, however this did not correlate with DHT concentrations, and the 
underlying mechanism was not explained. A larger RCT with both 
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finasteride and dutasteride (Amory et al., 2008) found no difference in lipid 
profiles after a year of treatment. Overall, while there have been several 
studies looking at extra-prostatic effects of 5αR inhibitors in humans, 
detailed assessments of metabolism, and insulin sensitivity in particular, are 
lacking.  
 
Effects of finasteride on glucocorticoid concentrations and regulation have 
been explored by some groups. Given the structural similarity of finasteride 
with endogenous steroids, it has been hypothesised (Rittmaster et al., 1994) 
that finasteride treatment could alter adrenal steroidogenesis. 10 healthy 
volunteers were given 28 days of finasteride, with baseline and post-
treatment measures. There was no difference in basal or ACTH (250 µg) 
stimulated cortisol concentrations.  Other studies also report no difference in 
basal cortisol concentrations after 10 days (Lewis et al., 1997) or 6 months 
(Uygur et al., 1998) of finasteride treatment. A study investigating endocrine 
effects of finasteride in hirsute women (Fruzzetti et al., 1994) found that basal 
cortisol decreased significantly after one month of treatment, though this 
significance was lost after three months. There was also a significant 
dampening of the response to 250 µg of synthetic ACTH. While these levels 
and responses were decreased, cortisol values remained within the normal 
range. The authors hypothesised that perhaps alterations in free versus 
bound cortisol (and its metabolites) may be taking place, however this was 
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not investigated further. Effects of dutasteride on the HPA axis are not 
known, though are the subject of ongoing clinical trials in different areas of 
research including alcoholism (Covault, 2012) and menstruation related 
mood disorders (Martinez, 2012).  
 
1.5.2 Evidence from animal models  
The role of 5αR1 in rodents can be specifically investigated via genetic 
manipulation. In comparison to their wild-type counterparts, high-fat fed 
male mice with targeted disruption of 5αR1 (5αR1 -/-) show significant 
weight gain, both fasting and post-glucose hyperinsulinaemia and increased 
liver triglycerides (Livingstone et al., 2008). These changes were not seen in 
5αR1 knockout males on a control diet, however were seen in female mice 
regardless of diet. 11βHSD1 and 5βR, the two other key glucocorticoid 
metabolising enzymes, did not show an increase in activity, suggesting that 
the lack of 5αR activity was not compensated for by other enzymes. In 
contrast to findings of liver fat accumulation and insulin resistance, adipose 
insulin sensitivity was preserved with appropriate suppression of non-
esterified fatty acids with high-dose insulin (Livingstone et al., 2009a). 
 
The administration of finasteride or placebo, with and without gonadectomy, 
was used to demonstrate both the effects of pharmacological inhibition, as 
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well as differentiate the relative effects of androgens and glucocorticoids. In 
obese Zucker rats finasteride (a dual isozyme inhibitor in rats) induced 
insulin resistance and increased liver triglycerides. Weight and plasma 
triglycerides remained unchanged, again highlighting the importance of 
circulating versus intra-tissue metabolic profiles. Changes persisted with or 
without gonadectomy, supporting the hypothesis of glucocorticoid-mediated 
changes (Livingstone et al., 2009a). 
 
5αR1-/- male mice have reduced bone mass and decreased forearm muscle 
grip strength (Windahl et al., 2011), however effects of 5αR1 targeted 
disruption on muscle insulin sensitivity are unknown.  
 
Basal corticosterone concentrations were unchanged in male 5αR1 knockout 
mice, however clearance of corticosterone was impaired, after both an acute 
bolus and chronic infusion of corticosterone in adrenalectomised mice 
(Livingstone et al., 2010). In the acute setting, a significantly increased level 
of corticosterone was seen 30 and 60 minutes post-bolus. Chronic infusion 
was followed by a 2.3 fold increase in plasma corticosterone concentrations. 
While it could be hypothesised that other steroid metabolising enzymes may 
compensate for aberrations in 5αR, this was not seen. Activity assays 
indicated hepatic and gonadal 11βHSD1 and hepatic 5βR were unaltered in 
5αR1 knockout mice. In finasteride treated obese Zucker rats, there was no 
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difference in plasma corticosterone concentrations. Response to suppression 
or stimulation of corticosterone synthesis was not assessed in response to 
finasteride treatment.  
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1.6 Global Hypothesis 
 
Inhibition of 5α-reductase type 1 with the dual isozyme inhibitor dutasteride 
adversely affects fuel metabolism and causes dysregulation of the 
hypothalamic-pituitary-adrenal axis.   
 
1.7 Global Aims 
 
To investigate the effects of 5α-reductase inhibitor drugs on metabolism and 
on the hypothalamic-pituitary-adrenal axis, specifically: 
 To establish whether pharmacological inhibition of 5α-reductases has 
an adverse effect on insulin sensitivity.  
 To establish whether metabolic sequelae of 5α-reductase inhibition are 
more pronounced with inhibition of 5α-reductase type 1 and 2 (with 
dutasteride), compared to inhibition of 5α-reductase type 2 alone (with 
finasteride).  
 To establish whether inhibition of 5α-reductases causes dysregulation 
of the hypothalamic-pituitary-adrenal axis.   
 In support of these studies, to develop and validate laboratory assays 
for the measurement of androgens, dutasteride, finasteride and tamsulosin 
via liquid chromatography tandem mass spectrometry (LC-MS/MS).  
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2.1 Introduction 
Laboratory methods described in this chapter were used in the analysis of 
samples collected as part of the clinical study described in Chapters 5 and 6. 
Two novel liquid chromatography tandem mass spectrometry (LC-MS/MS) 
methods developed and validated are described separately in Chapters 3 and 
4. Clinical methods are described in Chapters 5 and 6. Room temperature 
(RT) is defined as a temperature between 18 - 22 °C.  
 
2.2 Equipment 
a) Plate shaker (mass spectrometry and adipokine assays) 
IKA® KS 260 Basic shaker (Staufen, Germany) 
b) Plate shaker (used in ELISA assays described in Sections 2.3 and 2.4) 
Thermo iEMS™ incubator/ shaker (UK) 
c) Plate washer (used in ELISA assays described in Sections 2.3 and 2.4) 
Anthos Labtec aw1 microplate washer (Salzburg, Austria) 
d) Plate reader (used in ELISA assays described in Sections 2.3 and 2.4) 
Dynatech Laboratories MRX microplate reader (Berkshire, UK) 
e) Centrifuge 
Eppendorf 5810R (Hamburg, Germany) 
f) Micro-centrifuge 
Eppendorf 5415R (Hamburg, Germany) 
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g) Centrifuge (for 384 well PCR plates) 
Grant-bio LMC-3000 (Grant Instruments Ltd., Shepreth, UK)  
h) Nitrogen dry-block (for use with individual glass tubes) 
Techne Dri-Block® DB3A sample concentrator (Staffordshire, UK) 
i) Nitrogen dry-block (for use with plates in 96 well configuration) 
SPE Dry™ 96 Dual (Biotage, Uppsala, Sweden) 
j) Thermal cycler 
Techne TC-512 (Staffordshire, UK) 
k) Real-Time-PCR System 
LightCycler® 480 (Roche Diagnostics Ltd., Burgess Hill, UK), operated 
with LightCycler® 480 software version 1.5 
l) Balance (used for weighing adipose prior to assay in Section 2.10.4, 
and for weighing charcoal used to strip serum in Chapter 3) 
Mettler HK60 (Mettler Instrumente Ag, Zürich, Switzerland) 
m) Balance  
Mettler Toledo MT5 microbalance (Mettler Instrumente Ag, Zürich, 
Switzerland) 
n) Vortex 
Hook and Tucker Instruments rotamixer (Croydon, UK) 
o) Sonicator 
Decon® FS-minor sonicator (Ultrasonics Ltd., Sussex, UK) 
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p) Magnetic stirrer 
SM1 magnetic stirrer (Stuart Scientific Co. Ltd, Surrey, UK) 
q) Waterbath (for RIAs) 
Grant Sub14 waterbath (C&M Scientific, Livingston, UK) 
r) Homogeniser 
Pro200 homogeniser (PRO Scientific, Oxford, USA) 
s) pH meter 
Hanna Instruments pH 210 microprocessor pH meter (Bedfordshire, 
UK) 
t) 1470 Wizard™ Automatic Gamma Counter (Wallac, now Perkin 
Elmer, Seer Green, UK) 
u) 96-Well vacuum manifold 
IST VacMaster®-96 (Biotage, Uppsala, Sweden) 
v) 96-Well collecting plates  
96-Well Masterblock® (Greiner Bio One, Frickenhausen, Germany)  
 
2.3 Quantitation of plasma insulin by enzyme-linked 
immunosorbent assay (ELISA)   
Plasma insulin was quantified by a ultrasensitive insulin ELISA kit (DRG®, 
Mountainside, New Jersey, USA). The manufacturer's limit of detection was 
0.07 mU/L. Cross-reactivity with proinsulin and C-peptide was reported as  
< 0.01%. 
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Samples assayed were clamp samples (Chapter 5.3.5.6) at timepoints 
(minutes): +75, +90, +165, +180, +255 and +270. This represented two 
samples during each steady state phase of the clamp (pre-insulin, low dose 
hyperinsulinaemia, high dose hyperinsulinaemia). Samples from both 
clamps for each volunteer were assayed together.  
 
Standards (supplied in the kit) represented a concentration range of 0.15 
mU/L – 20 mU/L. Samples were prepared as either neat (baseline, +75, +90); 
1:4 in calibrator 0 solution (+165, +180), or 1:8 in calibrator 0 solution (+255, 
+270).  Standards (duplicate; 25 µL) and samples (duplicate; 25 µL) were 
added to wells already pre-coated with mouse anti-human insulin 
antibodies. Enzyme conjugate in enzyme conjugate buffer (100 µL; 1:11) was 
added to each well. After incubation (60 minutes; RT), the plate was washed 
seven times (300 µL) in wash buffer supplied (diluted 1 in 21 in distilled 
water) to remove unbound excess conjugate. Tetramethylbenzidine solution 
was added (200 µL) to each well, the plate was incubated in the dark (30 
minutes; RT) before addition of sulphuric acid stop solution (50 µL) to stop 
the reaction. The absorbance at 450 nm was measured 
spectrophotometrically. A standard curve was constructed (semi-log power 
fit with tails standard curve) and sample concentration calculated by 
interpolation. Acceptable r2 value of the standard curve was considered to be 
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> 0.99. Duplicates of standards and samples were deemed acceptable if the 
relative standard deviation (RSD, calculated as standard 
deviation/mean*100) was < 20%. 
 
2.4 Quantitation of salivary cortisol by ELISA  
Salivary cortisol was quantified by a high sensitivity salivary cortisol ELISA 
kit (Salimetrics®, State College, Pennsylvania, USA). Standards (supplied in 
the kit) represented a concentration range of 0.33 - 82.77 nmol/L, with a 
reported limit of detection of 0.08 nmol/L. Standards (duplicate; 25 µL) and 
samples (duplicate; 25 µL) were added to wells already pre-coated with 
monoclonal mouse anti-cortisol antibodies. High (27.3 nmol/L; duplicate; 25 
µL) and low (2.9 nmol/L; duplicate; 25 µL) controls were added to separate 
control wells. Assay diluent (phosphate buffered solution provided with kit) 
was added (duplicate; 25 µL) to zero and non-specific binding wells. Enzyme 
conjugate in assay diluent (200 µL; 1:1600) was added to each well. After 
incubation (60 minutes; RT), the plate was washed four times in wash buffer 
supplied (diluted 1 in 10 in distilled water) to remove unbound excess 
conjugate. Tetramethylbenzidine solution was added (200 µL) to each well, 
the plate was incubated in the dark (30 minutes; RT) before addition of 
sulphuric acid stop solution (50 µL) to stop the reaction. The difference in 
absorbance between 630 nm and 450 nm was measured 
spectrophotometrically. A standard curve was constructed (Sigmoidal semi-
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log curve) and sample concentration calculated by interpolation. Acceptable 
r2 of standard curve was considered to be > 0.99. Duplicates of standards and 
samples were deemed acceptable if the RSD was < 20%.  
  
2.5 Quantitation of plasma dehydroepiandrosterone 
sulphate (DHEAS) by radioimmunoassay (RIA) 
DHEAS was quantified using an 125I-DHEAS RIA kit (Siemens, Surrey, UK). 
The manufacturer reported a limit of detection of 0.03 µmol/L, and 
recommended a standard curve range was 0.14 – 1000 µmol/L. They 
reported an intra-assay precision of < 6% and inter-assay precision of ≤ 12%. 
Cross-reactivity with other steroids included: DHEA 0.57%, androstenedione 
1.21%, testosterone 0.37%, DHT 0.09%.  
 
Zero calibrator (50 µL; duplicate) was added to the non-specific binding and 
maximum binding tubes. Remaining calibrators, controls and samples (50 
µL; duplicate) were added to DHEAS-Ab coated tubes. 125I-DHEAS (1 mL; 
1.345 kBq) was added to each well. Following vortex mixing, tubes were 
incubated in a water bath (37 °C, 30 minutes). Tube contents were decanted, 
and tubes counted (1 minute) in gamma counter calibrated for 125I. A 
standard curve was constructed (logit-log curve) and sample concentration 
calculated by interpolation. Duplicates of standards and samples were 
deemed acceptable if the RSD was < 20%. 
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2.6 Quantitation of plasma cortisol by RIA 
Plasma cortisol was quantified using a 125I RIA kit (MP Biomedicals, Brussels, 
Belgium), with samples measured at baseline (fasting sample prior to clamp), 
following low dose (0.25 mg) dexamethasone suppression (Chapter 5.3.4.5), 
and at +20, +30, +40 and +60 minutes following IV Synacthen (1 µg, Chapter 
5.3.4.5).  
 
Standards (supplied in the kit) represented a concentration range of 0 – 
2758.6 nmol/L. The manufacturer reported intra-assay precision was < 9%, 
inter-assay precision < 10%, and limit of detection 4.7 nmol/L. Volunteers 
were not receiving synthetic glucocorticoids which may cross-react with the 
assay, other than prescribed dexamethasone as part of the dexamethasone 
suppression test; cross-reactivity with dexamethasone was reported to be < 
0.1%. Standards, control and samples (duplicate; 25 µL) were added to tubes 
pre-coated with monoclonal rabbit anti-cortisol antibodies. Cortisol-125I (1 
mL; 1.009 kBq) was added to each tube, and vortex mixed prior to incubation 
(45 minutes, 37 °C). Tube contents were decanted, and tubes counted for 180 
seconds in a gamma counter calibrated for 125I. A standard curve was 
constructed (spline smoothed) and sample concentration calculated by 
interpolation. Duplicates of standards and samples were deemed acceptable 
if the RSD was < 20%. 
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2.7 Quantitation of cortisol binding globulin (CBG) by 
RIA 
Plasma CBG was quantified using a 125I RIA kit (DIAsource ImmunoAssays 
S.A., Louvain-la-Neuve, Belgium) with samples measured at baseline (fasting 
sample prior to clamp, Chapter 5.3.4.4).  
 
Standards (supplied in the kit) represented a concentration range of 0 – 0.15 
µmol/L. The manufacturer reported intra-assay precision was 3.9%, inter-
assay precision 4.8%, and limit of detection 0.005 µmol/L. Samples 
(singlicate; 100 µL) were diluted in dilution buffer provided (2.4 mL). 
Standards and controls provided in the kit were reconstituted in distilled 
water. Standards, controls and diluted samples (singlicate; 100 µL) were 
added to CBG-antibody (goat anti-mouse) pre-coated tubes. CBG-125I (100 µL; 
0.85 kBq) was added to each tube. CBG anti-serum (100 µL) was added to 
each tube, tubes were gently mixed prior to incubation (2 hours, RT, shaking 
at 400 rpm). Tube contents were decanted, and tubes were washed (2 mL) 
with wash solution provided. Wash solution was carefully aspirated and 
tubes counted for 60 seconds in a gamma counter calibrated for 125I. A 
standard curve was constructed (sigmoidal) and sample concentration 
calculated by interpolation.  
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2.8 Quantitation of plasma Non-Esterified Fatty Acids 
(NEFAs) by coupled enzyme reaction assay 
Plasma NEFAs were quantified by a coupled enzyme reaction assay (Zen-
Bio, Inc., Research Triangle Park, USA). Standards, dilution buffer and 
reagents A and B were provided by the manufacturer. Reagents A and B 
were reconstituted in manufacturer supplied reagent diluent on the day of 
the assay. Standards represented a concentration range of 0 – 333 µmol/L. 
Standards (singlicate; 5 µL, made up to 50 µL with dilution buffer) and serum 
samples (singlicate; 5 µL) were added to wells. Dilution buffer (supplied in 
kit; 45 µL) was added to each sample well to result in 1:10 dilution of sample. 
Reagent A (100 µL) and then reagent B (50 µL) were added to all wells. After 
gentle shaking the plate was incubated (10 minutes; 37 °C) before being 
allowed to re-equilibrate (5 minutes; RT). Any bubbles visible in wells were 
pierced with a needle prior to optical density measurement at 540 nm. A 
linear standard curve was constructed and sample concentration calculated 
by interpolation. Acceptable r2 of standard curve was considered to be > 0.99. 
 
2.9 Measurement of adipokines by multiplex 
immunoassay 
Adipose derived peptides are referred to as adipokines throughout this 
thesis. Adipokines were measured by Milliplex™, an immunoassay 
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conducted on the surface of fluorescent-coded magnetic beads. Beads 
contained two fluorescent dyes; the precise concentration of these dyes was 
specific to a group of analytes (designated a “panel”), and analyte-specific 
“capture” antibodies on the surface of the beads conferred analyte specificity 
and allowed quantitation of multiple analytes simultaneously. The analytes 
quantified from serum were captured by the appropriate beads, with 
subsequent addition of a biotinylated detection antibody and a Streptavidin-
Phycoerythrin reporter molecule allowing quantitation. Two manufacturer 
defined “panels” were used, with one assay to measure leptin, MCP-1, and 
IL-8, and another to measure adiponectin and resistin. Kits and 
instrumentation were supplied by Merck Millipore (Watford, UK). 
 
2.9.1 Instrumentation 
Multiplex assays were performed on a MagPix® system operated with 
xPONENT® software, version 4.1. The MagPix® system comprised two 
lasers; the first laser was used to excite internal fluorescent dyes to identify 
analytes of interest, and the second laser was used to excite the fluorescent 
reporter molecule. The latter signal was used to quantify the immunoassay 
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2.9.2 Leptin, MCP-1, IL-8 
Samples were analysed according to the protocol in the manufacturer 
supplied kit.  Standards (supplied in the kit) represented a concentration 
range of 38 – 600000 pg/mL for leptin, 1.3 - 20000 pg/L for MCP-1, and 0.64 - 
10000 pg/mL for IL-8. Limits of detection, intra-assay precision, and inter-
assay precision reported by the manufacturer were: leptin 19 pg/mL, 5%, 
13%; MCP-1 1.2 pg/mL, 2%, 11%; IL-8 0.3 pg/mL, 3%, 14%.  
 
Assay buffer (200 µL) was added to each well. The plate was sealed and 
incubated on a plate shaker (10 minutes; RT), before removal of assay buffer. 
Standards or controls (25 µL) were added to appropriate wells, in duplicate. 
Assay buffer (25 µL) was added to background and sample wells. Serum 
matrix (lyophilised serum matrix reconstituted in 1 mL deionised water, 25 
µL) was added to background, standard and control wells. Samples (25 µL) 
were added to appropriate sample wells, in duplicate. A suspension of 
antibody (anti-human) immobilised beads were sonicated (30 seconds) and 
vortexed (1 minute). 150 µL of each antibody bead vial (one per analyte) was 
added to mixing bottle, and mixture was diluted up to 3 mL with bead 
diluent. Prepared magnetic beads (25 µL) were added to each well, the plate 
was sealed, wrapped in foil and incubated on plate shaker (18 hours; 4 °C). 
Decanting of well contents in any subsequent steps were performed with 
assay plate on a magnetic plate. The plate was washed three times with wash 
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buffer supplied (diluted 1:10 in deionised water, 200 µL/well). Detection 
antibodies (50 µL) were added to each well. The plate was sealed, covered in 
foil and incubated on a plate shaker (1 hour, RT). Streptavidin-Phycoerythrin 
(50 µL) was added to each well. The plate was sealed, covered in foil and 
incubated on a plate shaker (30 minutes, RT). Well contents were removed, 
and the plate washed (200 µL, three times). Assays were resuspended in 
Drive Fluid (100 µL) prior to analysis. A standard curve (logistic 5 point 
weighted) was constructed and sample concentration calculated by 
interpolation. Acceptable r2 of standard curve was considered to be > 0.99. 
 
2.9.3 Adiponectin (total) and Resistin 
The method used was identical to that described in Section 2.9.2, with the 
following exceptions: samples were added at a 1:400 or 1:800 dilution, and no 
serum matrix was added to background, standard or control wells. 
Standards (supplied in the kit) represented a concentration range of 0.01 – 
160 µg/mL  for adiponectin, and 2.56 - 40000 ng/mL for resistin. Limits of 
detection, intra-assay precision, and inter-assay precision reported by the 
manufacturer were: adiponectin 145.4 pg/mL, 5.6%, 15%; resistin 6.7 pg/mL, 
6%, 13%.  
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2.10 Quantifying abundance of mRNAs of genes of 
interest from subcutaneous adipose tissue 
 
2.10.1 Equipment 
All kits for RNA extraction and reverse transcription were from Qiagen, 
West Sussex, UK.  
 
2.10.2 Buffers and Solutions 
a) DEPC water  
Diethylpyrocarbonate (DEPC; 10 drops) was added to distilled water (1 L). 
This was mixed, allowed to stand (RT) for 24 hours prior to autoclaving. 
Storage was at RT.  
b) 10x TBE 
Tris base (0.89 M), boric acid (0.89 M) and EDTA (0.5 M, 40 mL) were 
dissolved in distilled water (800 mL). pH was adjusted to 8.0 with the 
addition of NaOH (1 M), then volume adjusted to 1 L with distilled water. 
Storage was at RT.  
c) 0.5x TBE 
10x TBE (50 mL) was diluted with distilled water (950 mL) and stored at 
RT.   
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2.10.3 Tissue collection 
A biopsy of subcutaneous abdominal adipose was taken with informed, 
written consent, as per the clinical study protocol (Chapter 5.3.5.10). Samples 
were frozen immediately on dry ice and stored at -80 °C until analysis. 
Biopsies were performed pre-treatment and post-treatment for each 
volunteer.   
 
2.10.4 RNA extraction from subcutaneous adipose 
Adipose tissue (~100 mg) was homogenised in Qiazol Lysis Reagent (1 mL, 
Qiagen) and incubated (5 minutes, RT). Chloroform (200 µL) was added, 
mixed and incubated (3 minutes, RT) before centrifugation (12,000 g; 15 
minutes; 4 °C). The supernatant (600 µL) was removed, and an equal volume 
of ethanol (70%, v/v) added and mixed by pipetting. The solution was placed 
in an RNeasy spin column and the eluate discarded after centrifugation 
(10,000 g; 30 seconds; RT). The column was washed with Buffer RW1 (700 
µL) and Buffer RPE (500 µL) sequentially. In each step the eluate was 
discarded following centrifugation (10,000 g; 30 seconds; RT). Buffer RPE 
(500 µL) was added to wash the membrane, followed by a further 
centrifugation step (10,000 g; 2 minutes; RT). The RNeasy spin column was 
then placed in a fresh collecting tube (2 mL) and remaining Buffer RPE 
removed by centrifugation (16,000 g; 1 minute; RT). The RNeasy spin column 
was placed in a fresh Eppendorf (1.5 mL). RNase-free water (40 µL) was 
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added, incubated (10 minutes, RT) and RNA eluted by centrifugation (10,000 
g; 1 minute; RT). The eluate was then added back to the RNeasy spin column, 
incubated (10 minutes, RT) and RNA re-eluted by centrifugation (10,000 g; 1 
minute; RT). Eluted RNA was stored at -80 °C.  
 
2.10.5 RNA quantitation 
RNA was quantified using a Nanodrop Spectrophotometer (Thermo Fisher, 
West Sussex, UK). Concentration was determined by the absorbance at 260 
nm wavelength (A260), and the purity assessed by the ratio of RNA/DNA 
(A260/A280), which was deemed acceptable if between 1.9 and 2.1.  
 
2.10.6 RNA quality 
RNA quality was assessed by electrophoresis on a denaturing agarose 
(Lonza, Berkshire, UK) gel (1.2% w/v in 0.5 x TBE). Samples (2 - 3 µL) were 
prepared by adding loading dye (Promega, WI, USA; 1 in 5 dilution in 
distilled water; 10 µL). Prepared samples (10 µL) were electrophoresed on the 
gel (100 V, 1 hr) and RNA integrity assessed on the basis of 28S and 18S 
ribosomal RNA (rRNA) bands. RNA integrity was deemed satisfactory if 
clear 28S and 18S bands were present without smearing, and if the 28S rRNA 
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2.10.7 Reverse Transcription 
Total RNA (0.5 µg) was reverse transcribed using the QuantiTect Reverse 
Transcription kit. Where insufficient RNA was extracted to allow reverse 
transcription of 0.5 µg (3 volunteers) the maximum possible (319.2 ng; 394.8 
ng; 418.4 ng) RNA was used, and the same amount was reverse transcribed 
from the volunteer’s other sample. RNA (12 µL) was added to gDNA 
wipeout buffer (2 µL) and incubated (42 °C, 2 minutes) to eliminate any 
contaminating genomic DNA. To each sample, Quantiscript RT buffer (4 µL), 
RT primer mix (1 µL) and Quantiscript Reverse Transcriptase (1 µL) were 
added. Two negative controls were prepared as above, one without reverse 
transcriptase to detect presence of contamination by genomic DNA (denoted 
“-RT control”), and one with water instead of RNA to detect any 
contamination with RNA of reagents used (denoted “water control”). 
Samples were incubated (42 °C, 15 minutes; then 95 °C, 3 minutes) in PCR 
thermal cycler, before being cooled at 4 °C. Resultant cDNA was stored at -20 
°C.  
 
2.10.8 Real-Time Polymerase Chain Reaction (RT-PCR) 
mRNA was quantified using real-time PCR. Intron-spanning primers (shown 
in Table 2-1 for genes of interest, and Table 2-2 for housekeeping genes, 
Invitrogen Ltd., Paisley, UK) were designed to match probes within the 
Roche Universal Probe Library. Aliquots from all samples being analysed 
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were pooled and prepared as standard curve by serial dilution in PCR grade 
water at concentrations of: 1:4, 1:8, 1:16, 1:32, 1:64, 1:128; 1:256; 1:512. A 
Mastermix (8 µL) was prepared consisting of Probe Master (5 µL), PCR grade 
water (2.7 µL), forward primer (0.1 µL), reverse primer (0.1 µL) and probe 
(0.1 µL), and was added to each well. Where Applied Biosystems (TaqMan®) 
assay was used instead (Table 2.3), Mastermix (8 µL) was prepared consisting 
of Probe Master (5 µL), PCR grade water (2.5 µL), primer-probe mix (0.5 µL). 
cDNA was diluted (1:20) with PCR grade water. A –RT control and water 
control sample from each batch of reverse transcription was also analysed on 
every plate. Diluted cDNA (2 µL) was then added to each well. All samples 
and standards were assessed in triplicate. One gene was quantified for all 
samples on one plate. The plate was covered and centrifuged (4214 g, 2 
minutes, RT) before being run on the PCR system.   
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Gene: Name 
Gene accession number 
Primer sequence 
Forward, 5’ → 3’; Reverse, 3’ → 5’ 
UPL Probe 
 
ACACA: Acetyl-Coenzyme A carboxylase α isoform 1 
NM_198834.1 
Forward GATGTGGATGATGGGCTACA 73 
Reverse TGAGGCCTTGATCATTACTGG 
PLIN2: Adipocyte differentiation-related protein (Perilipin 2) 
NM_001122.2 




Forward GGTGAGAAGGGTGAGAAAGGA 85 
Reverse TTTCACCGATGTCTCCCTTAG 
AKR1C2: Aldo-keto reductase family 1, member C2  
NM_001354.4 
Forward CCATACAGAAACTTCTTTTCCACA 34 
Reverse AACCAATGGCATGTGAGAGG 
AR: Androgen receptor 
NM_000044.2 
Forward GCCTTGCTCTCTAGCCTCAA 14 
Reverse GTCGTCCACGTGTAAGTTGC 
DGAT2: Diacylglycerol O-acyltransferase homolog 2  
NM_032564.3 
Forward GAGGGGTCTGGGAGATGG 55 
Reverse TTGAGCCAGGTGACAGAGAA 
ESR1: Estrogen receptor α 
NM_000125.3 
Forward TTACTGACCAACCTGGCAGA 24 
Reverse ATCATGGAGGGTCAAATCCA 
ESR2: Estrogen receptor β 
NM_001040275.1 
Forward TGGGTGATTGCCAAGAGC 52 
Reverse GTTTGAGAGGCCTTTTCTGC 
FASN: Fatty acid synthase  
NM_004104.4 
Forward CAGGCACACACGATGGAC 11 
Reverse CGGAGTGAATCTGGGTTGAT  
GPD2: Glycerol-3-phosphate dehydrogenase 2 (mitochondrial) 
NM_000408.3 
Forward TCGCGCGTGAGGATCTAT 25 
Reverse AGTCCTAAAACAGTTGCAAGAGC 
GR: Glucocorticoid receptor 
NM_000176.2, NM_001018074.1, NM_001018075.1, NM_001018076.1, 
and NM_001018077.1 
Forward TTCAAAAGAGCAGTGGAAGGA 11 
Reverse TTTCTTCGAATTTTATCGATGATG 
LIPE: Hormone sensitive lipase  
NM_005357.2 




Forward TTGTCACCAGGATCAATGACA 25 
Reverse GTCCAAACCGGTGACTTTCT 
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LPL: Lipoprotein lipase  
NM_000237.2 
Forward ATGTGGCCCGGTTTATCA 25 
Reverse CTGTATCCCAAGAGATGGACATT 
HSD11B1: 11β-Hydroxysteroid dehydrogenase type 1 (11β HSD1) 
NM_005525.2 
Forward CAATGGAAGCATTGTTGTCG 20 
Reverse GGCAGCAACCATTGGATAAG 
GPAM: Glycerol-3-phosphate acyltransferase 1 (mitochondrial) 
NM_020918.4 
Forward GGAAAGTTTATCCAGTATGGCATT 59 
Reverse TGATATCTTCCTGGTCATCGTG 
MCP1: Monocyte chemotactic protein 1  
NM_002982.3 
Forward TTCTGTGCCTGCTGCTCAT 83 
Reverse GGGGCATTGATTGCATCT 
PPARG: Peroxisome proliferator-activated receptor γ (PPARγ) 
NM_005037.5 
Forward TGACAGGAAAGACAACAGACAAAT 7 
Reverse GGGTGATGTGTTTGAACTTGATT 
PPARGC1A: PPARγ coactivator 1α 
NM_013261.3 
Forward TGAGAGGGCCAAGCAAAG 13 
Reverse ATAAATCACACGGCGCTCTT 
SRD5A1: 5α-Reductase type 1 (5αR1) 
NM_001047.2 
Forward TTGGAGAAATCATGGAGTGGT 37 
Reverse ACTCTTCAAATTTCCGGAGGTA 
SRD5A2: 5α-Reductase type 2 (5αR2)† 
NM_000348.3 
Forward TATATTGCGCCAGCTCAGG 80 
Reverse AAACATACGTAAACAAGCCACCT 
SRD5A2: 5α-Reductase type 2 (5αR2)† 
NM_000348.3 
Forward CACCTGGGACGGTACTTCTG 29 
Reverse GCAGTGAGTACACAAATGTCCTG 
SRD5A2: 5α-Reductase type 2 (5αR2)† 
NM_000348.3  
Forward CAGCTACAGGATTCCACAAGG 50 
Reverse TCAATGATCTCACCGAGGAA 
SREBF1: Sterol regulatory element binding transcription factor 1  
NM_001005291.1 
Forward CGCTCCTCCATCAATGACA 77 
Reverse TGCGCAAGACAGCAGATTTA 
SREBF2: Sterol regulatory element-binding transcription factor 2 
NM_004599.2 
Forward ATCTGGATCTCGCCAGAGG 74 
Reverse CCAGGCAGGTTTGTAGGTTG 
UCP 2: Uncoupling protein 2  
NM_003355.2 
Forward TGAAAGCCAACCTCATGACA 29 
Reverse GATGACAGTGGTGCAGAAGC 
Table 2-1 Primers used for genes of interest analysed by real-time polymerase chain reaction with Roche Universal Probe 
Library (UPL). † SRD5A2 attempted three times with different primers.  
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Gene: Name 
Gene accession number 
Primer sequence 
Forward, 5’ → 3’; Reverse, 3’ → 5’ 
UPL Probe 
 
PPIA: Peptidylprolyl isomerase A (cyclophilin A) 
NM_021130.3 
Forward ATGCTGGACCCAACACAAAT 48 
Reverse TCTTTCACTTTGCCAAACACC 
RPL32: Ribosomal protein L32 
NM_000994.3 
Forward GAAGTTCCTGGTCCACAACG 17 
Reverse ATGGCTTTGCGGTTCTTG 
TBP: TATA-binding protein  
NM_001172085.1 
Forward GAACATCATGGATCAGAACAACA 87 
Reverse ATAGGGATTCCGGGAGTCAT 
GAPDH: Glyceraldehyde-3-phosphate dehydrogenase 
NM_002046.3 
Forward AGCCACATCGCTCAGACAC 60 
Reverse GCCCAATACGACCAAATCC 
Table 2-2 Primers tested as housekeeping genes in real-time polymerase chain reaction with Roche Universal Probe Library 
(UPL).  
 
Gene: Name TaqMan ABI catalogue number 
CYP19A1: Aromatase Hs00903413_m1 
Table 2-3 TaqMan® Applied Biosystems (ABI) assay was used for aromatase.    
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Samples were denatured by heating (95 °C, 5 minutes), then underwent 50 
cycles of PCR amplification, comprising denaturation (95 °C, 10 seconds), 
annealing (60 °C, 30 seconds), and elongation (72 °C, 1 second). Samples 
were then cooled (40 °C, 30 seconds). Amplification curves were plotted (x 
axis: cycle number; y axis: fluorescence intensity). Excitation was at 483 nm 
and detection at 533 nm. Triplicates were acceptable if standard deviation of 
the crossing point was < 0.4 cycles. Standard curve generated from pooled 
and diluted samples was fitted with a straight line and acceptable if reaction 
efficiency was between 1.7 and 2.2.  
 
mRNA abundances were quantified and normalised against the mean of the 
transcript levels of a combination (PPIA + TBP + GAPDH) of house-keeping 
genes (those tested are summarised in Table 2-2).  
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2.11 Quantitation of glucose, glycerol, d2-glucose 
and d5-glycerol by gas chromatography mass 
spectrometry (GC-MS) 
 
2.11.1 Reagents and standards 
HPLC grade water was from Fisher Scientific (Loughborough, UK). HPLC 
grade acetonitrile was from VWR (Lutterworth, Leicestershire, UK). Heptane 
was from Rathburn (Walkerburn, UK). Pyridine, acetic anhydride, glucose, 
glycerol, 13C6-glucose and butanetriol were from Sigma Aldrich (Dorset, UK). 
d2-Glucose and d5-glycerol were from Cambridge Isotope Laboratories, Inc. 
(Andover, USA).   
 
All solutions for standard and enrichment curves were prepared in HPLC 
grade water and stored at 4 °C (for a maximum of 2 weeks) until use. Internal 
standard solution contained 13C6-glucose (5 mg/mL) and butanetriol (0.25 
mg/mL). Standard solutions prepared were glucose (5 mg/mL), glycerol 
(0.025 mg/mL), d2-glucose (0.1 mg/mL) and d5-glycerol (0.025 mg/mL).  
Derivatising solution of pyridine:acetic anhydride (1:1 v/v) and the 
reconstitution solvent (5% acetic anhydride in heptane) were prepared fresh 
on day of analysis.  
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2.11.2 Instrumentation 
The gas chromatograph mass spectrometer (GC-MS) consisted of a Finnigan 
GC8000TOP GC, a AS800 autosampler, a single quadropole Voyager mass 
spectrometer, operated via Xcalibur software version 1.2 (Finnigan, now 
Thermo Scientific, Manchester, UK).  The analytical column was a HP-
Innowax column (30 m x 0.32 mm x 0.25 µm; Agilent Technologies Ltd., 
Stockport, UK). The sample was injected (1 µL) by splitless injection, with 
injector temperature set to 260 °C. The column oven temperature was 60 °C 
at injection, programmed to reach 150 °C at a rate of 30 °C/minute, and then 
further programmed to reach 260 °C at a rate of 10 °C, with a final hold time 
of 3 minutes. Interface and source temperatures were 240 °C and 175 °C 
respectively. Helium gas was used as the mobile phase, at a flow rate of 2.5 
mL/min. Mass spectra were recorded using negative ion chemical ionisation 
with methane (research grade, BOC, Edinburgh, UK) as reagent gas at an 
electron energy of 70 eV. Selected ion monitoring was used with a total run-
time of 18 minutes. Derivatives of glycerol, d5-glycerol and butanetriol were 
monitored from 0 - 10 minutes, and those of glucose, d2-glucose and 13C6-
glucose monitored from 10 - 18 minutes. Monitored ions were: glycerol 
triacetate m/z 217, d5-glycerol triacetate m/z 222, butanetriol triacete m/z 231 
(internal standard), glucose pentacetate m/z 287, d2-glucose pentacetate m/z 
289, 13C6-glucose pentacetate m/z 293 (internal standard). Typical retention 
times for derivatives of glycerol and d5-glycerol were 7.15 and 7.12 minutes 
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respectively, and butanetriol 8.16 minutes. Glucose, d2-glucose and 13C6-
glucose derivatives were detected as isomers with typical retention times of 
15.06 and 15.38 minutes (glucose derivative) and 15.05 and 15.37 minutes 
(d2-glucose and IS derivatives).  
 
2.11.3 Sample preparation 
A standard curve was prepared in expected concentration ranges of glucose 
(0 - 9.25 mmol/L), glycerol (0 – 90.5 µmol/L), d2-glucose (0 - 0.18 mmol/L) 
and d5-glycerol (0 – 90.5 µmol/L) in plasma. An enrichment curve was 
prepared representing 0 - 12% enrichment for both glucose and glycerol, 
with d2-glucose and d5-glycerol respectively.   
 
Acetonitrile (1 mL) was added to extraction wells (96-well Strata Impact™ 
protein precipitation plate, Phenomenex, Macclesfield, Cheshire, UK). 
Standards, enrichment standards and samples (200 µL) were added. Internal 
standard solution (25 µL) was added to standard curve and samples. Internal 
standard was not added to enrichment samples. After a 20 minute incubation 
(RT), vacuum was applied (0.3 bar) and extracts collected. Eluates were 
reduced to dryness under oxygen-free nitrogen (OFN; 37 °C). Acetate 
derivatives were formed (Figure 2.1, Figure 2.2); to the dry residue pyridine: 
acetic anhydride (200 µL, 1:1, v/v) was added and this was allowed to stand 
(RT, 15 minutes). Derivatised samples were dried under OFN (37 °C) and 
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reconstituted in 5% acetic anhydride in heptane. 1 µL of sample was injected 










































anhydride (1:1, v/v) 
Room temperature 
Figure 2.1 Derivatisation of glycerol (left; MW 92.09) with pyridine:acetic 













anhydride (1:1, v/v) 
Room temperature 
Figure 2.2 Derivatisation of glucose (left; MW 180.16) with pyridine:acetic 
anhydride to form glucose pentacetate (right; MW 390.34) 
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2.12 Quantitation of urinary steroids by gas-
chromatography tandem mass spectrometry (GC-
MS/MS)  
 
2.12.1 Reagents and standards 
Unless stated otherwise, all reagents and standards were from Sigma Aldrich 
(Dorset, UK).  F, E, THF, αTHF, THE, epi-F and epi-THF were from 
Steraloids (Newport, USA). HPLC grade water was from Fisher Scientific 
(Loughborough, UK). HPLC grade methanol was from VWR (Lutterworth, 
Leicestershire, UK). Ethyl acetate was from Rathburn (Walkerburn, UK).  
 
Lipidex™-5000 (PerkinElmer, Waltham, USA) was passed through a sintered 
glass filter funnel to remove methanol. It was then washed with cyclohexane 
(200 mL) and mobile phase (98:1:1 
cyclohexane:hexamethyldisilazane:pyridine; 200 mL). Solid product was 
returned to original bottle and prepared into a slurry by addition of mobile 
phase (approximately 200 mL).  
 
2.12.2 Instrumentation 
Samples were analysed by gas chromatography tandem mass spectrometry 
(GC-MS/MS).  The system consisted of a Trace GC Ultra gas chromatograph, 
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TriPlus Autosampler (room temperature), TSQ Quantum XLS mass 
spectrometer, operated via Xcalibur software, version 2.1.0 (Thermo Fisher 
Scientific, Hemel Hempstead, UK).  
 
The analytical column was a DB-17MS column (30 m x 0.25 mm x 0.25 µm; 
Agilent Technologies Ltd., Stockport, UK).  The mobile phase was helium gas 
at a flow rate of 2 mL/minute. The sample was injected (1 µL) by 
Programmed Temperature Vaporising (PTV) injection. The column oven 
temperature was 120 °C initially, and then increased (30 °C/minute) to 200 
°C, held for 1 minute, then increased (5 °C/minute) to a final temperature of 
300 °C where it was held for 1 minute.  The mass spectrometer was operated 
in positive selected reaction monitoring mode. Auxiliary line and mass 
spectrometer source temperatures were both 280 °C. Collision gas was argon. 
Emission current was 50 µA, and electron energy 70 eV. Transitions 
monitored for quantitation are summarised in Table 2-4. Total run-time was 
25.67 minutes.  
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Cortisol (F) 605.4 515.4 20 22.98 
Cortisone (E) 531.4 441.4 15 23.73, 23.95 
α-THF  652.6 562.4 15 17.6 
β-THF 652.6 562.4 15 17.83 
THE 578.4 488.3 15 18.67 
IS
s 
Epi-F 605.4 515.4 20 22.2 
d8-E 539.4 449.4 15 23.62, 23.84 















Androsterone 360.2 270.2 15 14.71 
Epi-androsterone 360.2 270.2 15 16.14 





331.2 241.2 15 11.51 
Table 2-4 Transitions monitored for quantitation. CE, collision energy; V, volts; Rt, 
retention time; min, minutes; F, cortisol; E, cortisone; TH, tetrahydro-; IS, internal 
standard. Where 2 isomers were detected (indicated by two Rt), these were 
combined for quantitation.  
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2.12.3 Sample preparation 
Standards of analytes were prepared in methanol (1 mg/mL). Aliquots 
(detailed below) were added to water (20 mL) to prepare a series of aqueous 
standards:  
0.05 - 150 µg (epiandrosterone, androsterone and aetiocholanolone; 
quantified with 5α-androstane-3α, 17α-diol); 0.01 - 300 µg (THF, αTHF, THE; 
quantified with Epi-THF) and 0.005 - 300 µg (cortisol, cortisone,; quantified 
with Epi-F and d8-E respectively). 
 
Internal standards (Epi-THF, 30 µg; Epi-F, 5 µg; d8E, 5 µg; 5α-androstane-3α, 
17α-diol, 25 µg; total volume 75 µL in acetonitrile) were added to all samples 
(20 mL) and aqueous standards (20 mL), which were then extracted using 
conditioned Sep-Pak® C18 cartridges (300 mg, Waters Millipore, Watford, 
UK).  Methanol (5 mL) was added to condition the cartridge and water (5 
mL) equilibrate. Blank, standards and samples were added to the cartridges 
and allowed to elute through with gravity. Cartridges were washed with 
water (5 mL) and steroids were then eluted with methanol (2 mL).  Eluates 
were reduced to dryness under OFN (60°C). 
 
Steroid conjugates were hydrolysed with β-glucuronidase (Helix pomatia, 
Type H-2, 85000 units/mL; 100 µL; 37 °C for 48 hours) in sodium acetate 
buffer (2 mL; 0.2 M; adjusted to pH 4.6 with formic acid). Hydrolysates were 
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passed through reconditioned Sep-Pak® C18 columns (methanol 5 mL; water 
5 mL), eluted with methanol (2 mL). The eluate was dried under OFN (60 
°C), reconstituted in water (200 µL) and steroids extracted in ethyl acetate (3 
mL).   
 
The supernatant was dried and remaining steroids were derivatised to form 
methoxime-trimethylsilyl (MO-TMS) derivatives. Fifty µL of methoxyamine 
hydrochloride in dry pyridine (2% w/v) was incubated in capped Reactivial 
(60 °C; 30 minutes) and then evaporated under OFN (60 °C). 1-
(Trimethylsilyl)imidazole (TMSI, 50 µL) was added to the dried residue and 
incubated (100 °C; 2 hours) in capped Reactivial.  
 
Lipidex 5000 columns were then prepared by the addition of pre-prepared 
Lipidex 5000 (1 mL in mobile phase) to a Pasteur pipette with silanised glass 
wool, creating a column depth of ~1 inch. Mobile phase (98:1:1 
cyclohexane:hexamethyldisilazane:pyridine) was added (3 x 1 mL).  
 
Mobile phase (1 mL) was added to reaction solution in the Reactivial and 
then collected and passed through the prepared Lipidex column. The 
Reactivial was washed with mobile phase (2 x 0.5 mL) and washes were also 
passed through the Lipidex column. Mobile phase (1 mL) was added directly 
into Lipidex column. All eluates were collected and evaporated to dryness 
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under nitrogen (60 °C). Dried samples were reconstituted in 200 L decane 
and transferred to GC-MS vials, and stored at -20 °C prior to analysis.  
 
2.13 Quantitation of plasma dexamethasone by liquid 
chromatography tandem mass spectrometry (LC-
MS/MS) 
 
2.13.1 Reagents and standards 
HPLC grade water and formic acid were from Fisher Scientific 
(Loughborough, UK). HPLC grade methanol was from VWR (Lutterworth, 
Leicestershire, UK). Acetonitrile and ethyl acetate were from Rathburn 
Chemical Ltd. (Walkerburn, UK). Dexamethasone was from Alfa Aesar 
(Haysham, UK), 11-dehydrodexamethasone and d4-dexamethasone were 
from Steraloids (Newport, USA). 6-hydroxy dexamethasone had been 
synthesised in house (kind gift, Dr G Naredo, Mass Spectrometry Core, 
University of Edinburgh). Stock solutions of analytes and internal standard 
were prepared (10 µg/mL in methanol) and stored at -20 °C. Standards were 
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2.13.2 Instrumentation 
Analysis was performed on a Waters Acquity™ UPLC with autosampler (10 
°C), coupled to an ABSciex QTRAP® 5500 mass spectrometer, and operated 
with Analyst Software version 1.5.1. Separation was achieved on a SunFire™ 
C18 column (150 x 4.6 mm, 5 µm) at 20 °C, with a linear gradient from 60:40 
to 45:55 (acetonitrile with 0.1% FA: water with 0.1% FA) at a flow rate of 1.5 
mL/min with a total run-time of 6 minutes. Ionisation was performed in 
positive electrospray mode with curtain gas 20 psi, collision gas medium, 
spray voltage 5500 V, source temperature 500 °C, source gases 40 psi. Mass 
transitions of protonated ions monitored were (Declustering Potential, DP; 
Collision Energy, CE; Cell Exit Potential, CXP): dexamethasone  m/z 393 → 
373 (DP 71; CE 11; CXP 16); 11-dehydro dexamethasone m/z 391 → 253 (DP 
71; CE 27; CXP 12); 6-hydroxy dexamethasone m/z 409 → 227 (DP 61; CE 23; 
CXP 10); d4-dexamethasone m/z 397 → 377 (DP 51; CE 11; CXP 16).   
 
2.13.3 Sample preparation 
A standard curve was prepared representing a concentration range of 0 – 300 
ng/mL for all analytes. Standard curves were prepared in plasma (pooled 
human plasma collected from men and women ages 16 – 45 years on no 
medications; TCS Biosciences, Buckingham, UK). d4-Dexamethasone 
(internal standard, 15 ng) was added to plasma (200 µL) and standard curve, 
and all samples were extracted with solid-phase and then liquid-liquid 
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extraction. Initially samples were extracted with Sep-Pak® C18, 200 mg 
cartridges. Following conditioning (methanol 5 mL) and equilibration (water 
5 mL), samples were loaded and then analytes eluted with methanol (2 mL). 
Eluates were dried under nitrogen (60 °C), resuspended in water (200 µL) 
and then extracted with ethyl acetate (2 mL). The supernatant was dried and 
resuspended in mobile phase. Injection volume was 10 µL.  
 
2.14 Routine laboratory tests 
Routine laboratory blood tests were sent (on the day of sampling) for 
processing by the NHS Lothian clinical biochemistry and haematology 
laboratories at the Western General Hospital (Edinburgh, UK). The 
laboratory participates in the UK National External Quality Assessment 
Service to ensure quality control. Sample collection is described in Chapters 
5.3.4.3 and 5.3.4.4.       
 
Full blood count was measured by a XE-5000 automated flow cytometer 
(Sysmex UK, Milton Keyes, UK). HbA1c was measured by reverse-phase 
HPLC on a Menarini HA8160 HbA1c analyser (Menarini, Wooburn Green, 
UK). All other analytes were measured on an Architect c16000 analyser 
(Abbott Diagnostics Ltd., Maidenhead, UK) using manufacturer's kit 
materials according to laboratory protocols. Low density lipoprotein (LDL) 
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cholesterol was a calculated parameter, using the equation: LDL cholesterol = 
total cholesterol – HDL cholesterol – (triglyceride/2.2).   
 
In a single batch at the end of the study, sex hormone binding globulin 
(SHBG) and oestradiol (E2) were measured by the clinical biochemistry 
laboratory at the Royal Infirmary of Edinburgh (Edinburgh, UK). SHBG from 
serum was measured by an automated chemiluminescent based assay 
according to protocol for, and performed on, an Immulite® 2000 system 
(Siemens, Surrey, UK). Lower limit of sensitivity was 0.2 nmol/L and intra-
assay error ≤ 5.3%. Oestradiol was measured from serum by a 
Chemiluminescent Microparticle Immunoassay according to protocols from 
Abbott Diagnostics (Illinois, USA) using an Architect c16000 analyser. The 
functional sensitivity (minimum concentration quantified with < 20% 
coefficient of variation) was 50 pmol/ L. Cross-reactivity with 17β-oestradiol 
3-sulfate was 0.1% and with oestrone 0.7%, and intra-assay error ≤  7%.   
 
2.15 Statistics and calculations 
All statistical calculations were performed using SPSS for Windows software 
package, version 19 (IBM, Portsmouth, UK). Statistical significance was taken 
at the 5% level. Area under the curve calculations were performed with 
Kinetica, version 5.0 (Thermo Fisher Scientific, Loughborough, UK).  
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The interpretation of the clinical study described in Chapters 5 and 6 can be 
enhanced by the measurement of dutasteride, finasteride and androgen 
concentrations in the serum of participants. Measurement of serum 
dutasteride and finasteride concentrations can complement assessment of 
compliance in study volunteers. Measurement of androgen concentrations 
(testosterone, dihydrotestosterone, androstenedione) is a key component of 
evaluating pharmacodynamic effects of 5αR inhibitors on androgen 
metabolism and their possible effects on adrenal and gonadal 
steroidogenesis. There are no published methods for simultaneous 
measurement of this combination of analytes from human serum; therefore a 
novel assay was developed.  
 
Historically androgens such as testosterone have been quantified by 
radioimmunoassay (RIA), which offers distinct advantages as an analytical 
method as samples do not require extraction, and methods are fast and cost-
effective. However RIAs do also have several important limitations which 
have seen their use in androgen measurement decline (Soldin and Soldin, 
2009). They can be affected by binding proteins e.g. albumin and SHBG 
(present in unextracted samples) and other structurally related compounds 
(Tate and Ward, 2004). Accordingly, immunoassays lack precision and 
accuracy at lower concentrations (Wang et al., 2004a), and this may be 
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particularly relevant to analytes such as dihydrotestosterone (DHT) which 
are present in low circulating concentrations (Shiraishi et al., 2008). 
Furthermore the antibodies for some selected androgens are not specific, 
giving rise to interference in assays by other hormones (Taieb et al., 2002). 
Direct comparisons of DHT measurement by immunoassay and liquid 
chromatography mass spectrometry (LC-MS) show that RIA overestimates 
DHT concentrations especially at low concentrations, likely a  reflection of 
the lack of analyte specificity with RIA (Shiraishi et al., 2008). For these 
reasons, the field of Clinical Biochemistry has moved towards the use of LC-
MS/MS in assessment of testosterone, particularly in patients with lower 
concentrations, including women, older men, and patients with type 2 
diabetes (Kushnir et al., 2010b). In the study of 5R inhibitors, the 
concentration of DHT was anticipated to be suppressed, presenting an 
analytical challenge. 
 
As banned substances in professional sport, both finasteride and dutasteride 
are sometimes measured in doping control, as well as in clinical studies, 
although not routinely in the hospital environment. While the measurement 
of 5αR inhibitors is usually via chromatography based analytical techniques, 
two enzyme-linked immunosorbent assays (ELISA) have been developed for 
the measurement of dutasteride, finasteride and a metabolite of finasteride in 
human urine (Brun et al., 2010). While potentially promising, at this stage 
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these assays are still limited in their utility as they have only been validated 
in urine and are heavily dependent on measurement of 5αR inhibitor 
metabolites. They have potential issues with cross-reactivity between 
finasteride and dutasteride (3.7%), although these drugs are unlikely to be 
co-prescribed. Immunoassay approaches were not suitable for use in the 
study described, due to the need to separate and quantify multiple steroid 
and drug compounds in a single assay, both for efficient throughput and 
limited sample volumes. 
 
The analytical approach selected for this thesis was liquid chromatography 
tandem mass spectrometry (LC-MS/MS), which largely overcomes many 
limitations of other analytical methods and allows precise, accurate, and 
simultaneous determination of multiple analytes present at low 
concentrations. Gas chromatography mass spectrometry (GC-MS) methods 
(Legrand et al., 1995, Wudy et al., 1992) may have been possible but requires 
the additional step of derivatisation which adds to sample handling and 
preparation time, while also adding potential issues with stability of 
derivatives. GC-MS methods also tend to have longer run times. The use of 
high pressure liquid chromatography (HPLC) alone to determine finasteride 
levels (Ptacek et al., 2000) was not suitable for our purposes as the detection 
limits offered by HPLC were inadequate to detect analytes present in low 
concentration. In the absence of  mass separation and detection, it may have 
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been difficult to differentiate compounds which may be co-eluting, for 
example drug metabolites and isomeric androgens.  
 
An LC-MS approach has previously been used successfully in the 
quantitation of dutasteride (Gomes et al., 2009, Ramakrishna et al., 2004) and 
finasteride (Chen et al., 2008, Constanzer et al., 1994, de Menezes et al., 2001, 
Guo et al., 2007, Matuszewski et al., 1998, Phapale et al., 2010), however these 
methods have always been for one drug or the other. Measurement of 
androgens via mass spectrometry has been described by several groups, and 
of particular interest are those where DHT has been measured via LC-
MS/MS and applied to adult male and female (Shiraishi et al., 2008), as well 
as paediatric populations (Kulle et al., 2010). These assays use small sample 
volumes (100 µL) with extraction approaches including liquid-liquid 
(Shiraishi et al., 2008) and solid-phase  (Kulle et al., 2010) techniques.  
 
To allow efficient processing of study samples it was desirable to quantify all 
analytes in a single assay, and no such method has been reported. An 
extraction method suitable for all analytes was necessary, and especially 
given the differences in circulating concentrations of the androgenic steroids 
(e.g. much higher concentration of testosterone than DHT) adequate 
separation was essential. Expected concentrations of analytes are 
summarised in Table 3-1. DHT concentrations are decreased with dutasteride 
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and finasteride therapy by approximately 95% and 70% respectively (Clark et 
al., 2004, GlaxoSmithKline, 2008, Merck, 1998). In addition, testosterone 
increases by approximately 10-20% with both 5αR inhibitors, though (unlike 
DHT) testosterone concentrations generally stay within the normal reference 
range.  
 
 Analyte Expected circulating concentrations 





Androstenedione 0.23 – 1.34  
0.37 – 2.41 
0.8 – 4.68  
1.3 – 8.4 





2.65 – 9.71 9.2 – 33.7  (Shiraishi et al., 2008) 
DHT 
 
0.14 - 0.77 0.47 – 2.65  (Shiraishi et al., 2008) 
DHT post  
finasteride (↓~70%) 
 




0.007 - 0.0385 0.02 - 0.13 (Clark et al., 2004) 
Finasteride  1.8 - 49; mean 
trough at steady 
state 9.4 
 (Merck, 1998) 
Dutasteride Mean 36 after 3 
months treatment  
 (GlaxoSmithKline, 
2008) 
Table 3-1 Approximate reference ranges for expected concentrations in serum 
of androstenedione, testosterone, dihydrotestosterone (DHT) in adult men. Also 
shown are concentrations of DHT predicted post-treatment with 5αR inhibitors 
finasteride and dutasteride.  
 




To develop, optimise and validate a sensitive, precise and accurate LC-
MS/MS method for simultaneous quantitation of testosterone, 
dihydrotestosterone, androstenedione, finasteride and dutasteride extracted 
from human serum, with validation based on standards deemed acceptable 
by the U.S. Food and Drug Administration (USFDA, 2001).  
 
3.3 Method development 
3.3.1 Reagents and Standards 
Unless stated otherwise, all solvents were from Rathburn Chemical Ltd. 
(Walkerburn, UK). Water and ammonium hydroxide (35%, v/v) solution 
(both HPLC gradient grade), glacial acetic acid (99.79%, v/v) and formic acid 
were from Fisher Scientific (Loughborough, UK). Methanol and 
dichloromethane (HPLC gradient grade) were from VWR (Lutterworth, 
Leicestershire, UK). o-Phosphoric acid (85% v/v) was from BDH Laboratory 
Supplies (Poole, UK). Ammonium acetate and ammonium formate were 
from Sigma-Aldrich (Dorset, UK).  
 
Androstenedione, testosterone, epitestosterone, DHT, 
dehydroepiandrosterone, 2,3,4-[13C3]-androstenedione, 2,3,4-[13C3]-
testosterone and 2,3,4-[13C3]-5-DHT, were from Sigma-Aldrich (Dorset, UK). 
 




[2H3]-testosterone, 2,2,4,4-[2H4]-5-DHT and 16,16,17-[2H3]-5-DHT were  
from CDN Isotopes, QMX laboratories (Essex, UK). Finasteride was from 
Steraloids (Rhode Island, USA) and dutasteride was from AK Scientific 
(Mountain View, USA). d9-Finasteride was synthesised in-house (kind gift, 
Dr G Naredo). Stock solutions were prepared at 1 mg/mL and 10 µg/mL in 
methanol, and stored at -20 ºC. Working solutions were prepared on the day 
of analysis.  
 
3.3.2 Biological samples 
For method optimisation and validation, pooled male human serum 
(collected from healthy men aged 17-45 years on no medications), and  
steroid-stripped serum were purchased (TCS Biosciences, Buckingham, UK). 
Due to residual androstenedione and testosterone detectable in the steroid-
stripped serum, it was re-stripped before use. Dextran-coated charcoal 
(Sigma Aldrich, Dorset, UK) was added to steroid-stripped serum (0.1 g/ 10 
mL), stirred (~24 hours, 4 °C) and centrifuged (1811 g, 4 °C, 30 minutes). 
Stripped serum was decanted and then sequentially filtered through 1.20 µm 
(Sartorius minisart, Sartorius AG, Göttingen, Germany) and 0.22 µm filters 
(Millex® GP filter unit, Millipore Ireland Ltd., Carrigtwohill, Ireland) until 
clear serum was obtained. Aliquots were frozen (-20 °C) until further use.  
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For method application, serum was collected from male subjects 
participating in the clinical study described in Chapters 5 and 6 prior to and  
following 90 days of treatment with either dutasteride (n = 16), finasteride (n 
= 16) or tamsulosin (n = 14). Appropriate ethical approval was obtained prior 
to sample collection and is described further in Chapter 5.3.3.  
 
3.3.3 LC-MS/MS Instrumentation 
Initial method development was performed on a Thermo Electron Surveyor 
MS Pump and a Thermo Surveyor HPLC autosampler, interfaced with a 
Thermo Electron TSQ Quantum Discovery triple quadrupole mass 
spectrometer and operated with Xcalibur Version 2.0.6 software (Thermo 
Electron, Hemel Hempstead, UK). The method was transferred and 
developed further on a Waters Acquity™ UPLC (Manchester, UK) with 
autosampler, coupled to an ABSciex QTRAP® 5500 mass spectrometer 
(Warrington, UK), operated with Analyst® Software version 1.5.1. Nitrogen 
was used as source, curtain and collision gas. All subsequent method 
development and validation steps described were completed on the latter 
instrument (referred to as ‘QTRAP’), which afforded greater sensitivity.  
  
3.3.4 Tuning of standards for ion selection 
Solutions (in methanol) of dutasteride (1 µg/mL), finasteride (10 ng/mL), 
testosterone (100 ng/mL), dihydrotestosterone (100 ng/mL), 
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androstenedione (200 ng/mL), 13C3 testosterone (100 ng/mL), 13C3 
dihydrotestosterone (200 ng/mL) and 13C3 androstenedione (100 ng/mL), 
d9-finasteride (10 µg/mL) were prepared separately and infused (10 
µL/min) into the QTRAP source operating in positive atmospheric pressure 
chemical ionisation (APCI) mode. Protonated ions were exposed to a range 
of variables of collision energy, cell exit potential and declustering potential 
in order to ascertain ideal ionisation conditions. The mass of ions formed was 
determined and the mass transitions selected were those with the most 
abundant product ions, from the eight most abundant transitions screened. 
Mass spectrometric source conditions (curtain gas, collision gas, spray 
voltage, source temperature, and source gases) were then optimised for 
DHT, the least abundant analyte. For comparison, the same tuning steps 
were repeated in electrospray ionisation (ESI) mode.  
 
3.3.5 Chromatographic method development 
Using unextracted mixes of analytes in aqueous solution, optimum LC-
MS/MS conditions were established. The following parameters were 
manipulated with variables tested listed: 
 Column 
o Kinetex C18 100 x 3 mm, 2.6 µm (Phenomenex®, Macclesfield, 
UK); Kinetex C18 150 x 3 mm, 2.6 µm (Phenomenex®, 
Macclesfield, UK); Ascentis express 100 x 3 mm, 2.7 µm 
 
Chapter 3: Measurement of androgens and 5αR inhibitors by LC-MS/MS  
125 
 
(Supelco, Bellefonte, USA); Kinetex PFP 100 x 3 mm, 2.6 µm 
(Phenomenex®, Macclesfield, UK); Poroshell C18 100 x 2.1 mm, 
2.7 µm (Agilent, Santa Clara, USA) 
 Column temperature 
o Ranging from 25 ºC to 50 ºC 
 Mobile phase 
o Acetonitrile: water; acetonitrile: water with 0.1% formic acid 
(FA); methanol: water; methanol: water with FA (0.01%); 
methanol: water with FA (0.1%); methanol: water with FA 
(0.2%); methanol: ammonium acetate (AmAc, 5 mM); methanol: 
AmAc (1mM) with FA (0.1%); methanol: AmAc (2.5 mM) with 
FA (0.1%); methanol: AmAc (5 mM) with FA (0.1%); methanol: 
ammonium formate (5 mM). 
 Gradient  
o A range of gradients were tried with variations on the initial, 
peak and interval ratios between the mobile phases. Length of 
time at each isocratic stage, length of time to peak gradient and 
length of time returning from gradient were all manipulated. 
 Flow rate  
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3.3.6 Optimisation of analyte extraction method from human 
serum 
Types of extraction methods tested included protein crash (Impact™ protein 
precipitation plate, Phenomenex®, UK), phospholipid crash (Ostro™, 
Waters, UK), solid phase (Oasis® HLB, 10 mg/ 1 mL, 30 µm, and 30 mg/ 1 
mL, 30 µm, both from Waters, UK; Strata-X-Drug B™, 33 µm, cation mixed 
mode polymer sorbet, 30 mg/ 1 mL, Phenomenex®, UK), supported liquid 
(Isolute® Array SLE+, 200 µL; Isolute® SLE+ columns, 1 mL, both from 
Biotage, Uppsala, Sweden) and liquid-liquid extraction. We were unable to 
replicate the liquid-liquid extraction approach described previously 
(Shiraishi et al., 2008), with endogenous DHT not detected.  
 
The extraction solvent tested in protein and phospholipid crash methods was 
acetonitrile, with sample:solvent ratios tested of 1:3, 1:6, and 1:9. In 
supported liquid extractions, pre-extraction mixing was tested with: formic 
acid (1%, 0.1%), water, NH4OH (0.1 M), and acetic acid (0.1%). Extracting 
solvents tested were: dichloromethane, diethyl ether, ethyl acetate, hexane, 
methanol, acetonitrile. In liquid-liquid extractions, samples were tested neat 
or mixed (1:1, v/v) with water, or formic acid (0.1%), ammonia (5%). Samples 
were extracted with a sample:solvent ratio of 1:20 and 1:40. Solvents tested 
were ethyl acetate:hexane (3:2, v/v, with and without NaOH (0.1 M)) and 
ethyl acetate (with and without saturated NaCl).  
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The method selected and optimised further was the Oasis® HLB (30 mg/ 30 
µm) solid phase extraction method. In an effort to aid deproteination and 
improve sample flow through the extraction column, mixing of sample was 
tried with the following: formic acid (2%, 1%, 0.1%), phosphoric acid (4%), 
water, NH4OH (0.1 M). The proportion of methanol (in water) in the wash 
step was optimised, with the following tried: 5%, 15%, 25%, 50%. A second 
wash/ elution step was also tested consisting of methanol:water (50:50, v/v) 
with either formic acid (2%) or NH4OH (5%). Elution was tested with 
methanol, acetonitrile, isopropanol and ethyl acetate.  
 
Matrices tested for standard curve were water, stripped serum, male serum 
and female serum.  
 
3.3.7 Assay validation 
3.3.7.1 Recovery 
Recovery was calculated by expressing the mean of the integrated peak areas 
from extracted standards, as a percentage of the mean integrated peak area 
from unextracted standards. This was performed in replicates (n=6) using 
stripped serum as matrix and enriched with: androstenedione (1 ng), 
testosterone (1 ng), finasteride (1 ng), DHT (10 ng) and dutasteride (10 ng). 
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3.3.7.2 Assessment of ion suppression by serum 
The effect of the biological matrix (human serum) on ionisation efficiency 
was assessed in replicates of 6 by post-spiking extracted blank serum with all 
analytes amounts corresponding to the midpoint of the standard curve 
(standard 5, Table 3-2), and response compared to standards with the same 
amounts of analyte dissolved in mobile phase. Blank serum sample were also 
run so endogenous analyte amounts could be subtracted from peak areas 
detected in post-spiked samples.  
 
3.3.7.3 Analyte specificity 
Analyte specificity was ensured to avoid potential interferences by other 
endogenous components in serum. Extracted blank stripped serum analysed 
with the described method was checked for interferences at or close to the 
expected retention times for all analytes and internal standards, and this was 
repeated with unstripped serum for finasteride and dutasteride.    
 
Additional analyte and internal standard specificity was ensured with 
measurement of two (quantifier and qualifier) mass transitions for all except 
DHT, where the qualifier transition was not detected in normal serum. 
Acceptable quantifier: qualifier ratios in biological samples were those within 
20% of the mean ratio seen in standards. 
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3.3.7.4 Limits of Detection (LOD) 
LOD were determined by analysing solutions prepared by serial dilution of 
analyte and internal standard stock solutions, with the LOD corresponding 
to a peak area where signal: noise ratio (SNR) was  3. 
 
3.3.7.5 Lower Limits of Quantitation (LLOQ) 
LLOQ following extraction was determined by extracting analyte and 
internal standard from serum at amounts corresponding to 0.2 x LOD, 0.5 x 
LOD, LOD and 5/3 x LOD. Amounts lower than the LOD were tested in case 
of ion enhancement effects. The LLOQ was defined as the amount where 
variance in replicates of 6 was  20%. 
 
3.3.7.6 Linearity 
Two standard curves were generated, one in water (for quantitation of 
androgens) and one in serum (for quantitation of dutasteride and 
finasteride). A standard curve was generated with each analyte and internal 
standard by adding internal standards (1 ng each) to blank serum or water, 
and increasing amounts of analytes. Standard curves represented 
concentration ranges: testosterone (1, 2, 3, 5, 7.5, 10, 12.5, 15 ng/mL), DHT 
(0.1, 0.2, 0.5, 1, 2, 3, 4, 5 ng/mL), androstenedione (0.1, 0.2, 0.5, 1, 2, 3, 4, 5 
ng/mL), finasteride (1, 2, 5, 10, 25, 50, 75, 100 ng/mL) and dutasteride (1, 2, 
5, 10, 25, 50, 75, 100 ng/mL), and are summarised in Table 3-2. Peak areas of 
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each analyte and internal standard were integrated and a calibration curve 
constructed (peak area ratio of analyte/ internal standard versus 
concentration of analyte). Regression lines of best fit were constructed and 
deemed acceptable if the regression coefficient, r, was greater than > 0.99. 
Weightings compared were none, 1/x and 1/x2 to improve accuracy and 

















0 0 (0) 0 (0) 0 (0) 0 0 
1 0.1 (0.4) 1 (3.5) 0.1 (0.3) 1 1 
2 0.2 (0.7) 2 (6.9) 0.2 (0.7) 2 2 
3 0.5 (1.8) 3 (10.4) 0.5 (1.7) 5 5 
4 1 (3.5) 5 (17.4) 1 (3.4) 10 10 
5 2 (7.0) 7.5 (26.0) 2 (6.9) 25 25 
6 3 (10.5) 10 (34.7) 3 (10.3) 50 50 
7 4 (14.0) 12.5 (43.4) 4 (13.8) 75 75 
8 5 (17.5) 15 (52.1) 5 (17.2) 100 100 
Table 3-2 Points of standard curves; standard curve for androgens prepared in 
water, standard curves for finasteride and dutasteride prepared in pooled male 
serum. Std., standard; AND, androstenedione; DHT, dihydrotestosterone.  
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3.3.7.7 Precision and accuracy 
The intra-assay accuracy and precision were determined in a standard curve 
with 3 points of the standard curve prepared in replicates of 6 (standard 
points 2, 5, 8). The inter-assay accuracy and precision were determined from 
four standard curves prepared on different days. The precision was 
calculated as the relative standard deviation of the mean (RSD) with RSD (%) 
= standard deviation/ mean x 100. The % accuracy was calculated as the 
concentration/ theoretical concentration x 100. 
 
3.3.7.8 Stability 
Stability was assessed by reinjection of a single calibration curve and patient 
sample after 24 hours in the auto-sampler (10 °C), and then again following 
28 day storage (-20 °C). Storage conditions giving no greater that 10% change 
in response were accepted.   
 
3.3.7.9 Injector reproducibility 
Injector variability was assessed by injecting 6 times the standards 1, 2, 3, 5, 8 
(as per Table 3-2), and a pooled male serum sample enriched with both 








3.4.1 Mass spectrometric conditions of analytes 
All analytes and internal standards (structures shown in Table 3-3) ionised 
efficiently in both positive electrospray ionisation (ESI) and positive 
atmospheric pressure chemical ionisation (APCI) conditions. APCI was 
selected for use due to increased peak areas measured for endogenous DHT 
from serum. Source conditions were optimised to DHT and found acceptable 
for all other analytes and internal standards. Both quantifier and qualifier 
transitions of analyte and internal standard were subsequently monitored, 
with the exception of DHT for which the qualifier ion was not visible in 
serum therefore was not monitored.  
 
In the final mass spectrometric method, the QTRAP was optimised to, and 
operated in, positive APCI mode, with curtain gas 25 psi, collision gas low, 
spray voltage 5 kV, nebuliser current 3.5 µA, source temperature 500 °C, ion 
source gas 55 psi. Multiple reaction monitoring of the analyte quantifier and 
qualifier transitions were performed as summarised in Table 3-4.               
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Analyte structure IS structure 




































































































Table 3-3 Analyte and internal standard (IS) chemical structures. MW, 
molecular weight. *d9-Finasteride was used as IS for both 5αR inhibitor drugs. 
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Table 3-4 Mass spectral conditions for analysis of analytes and internal standards utilising atmospheric pressure chemical 
























Androstenedione 286.4 287 97; 109 56 29; 27 18; 12 
Testosterone 288.4 289 97; 109 16 27; 31 14; 16 
Dihydrotestosterone 290.4 291 255 16 21 28 
Finasteride 372.5 373 317; 305 26 27; 41 14; 28 
Dutasteride 528.5 529 461; 264 161 45; 55 48; 32 
INTERNAL STANDARDS 
13C3-Androstenedione 289.4 290 100; 112 31 27; 39 12; 16 
13C3-Testosterone 291.4 292 100; 112 1 27; 35 4; 8 
13C3-Dihydrotestosterone 293.4 294 258 61 21 12 
d9-Finasteride 381.6 382 318; 314 41 33; 41 34; 36 
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3.4.2 Selection of internal standards 
Stable isotope labelled internal standards were selected. d9-Finasteride was 
synthesised in house for use as internal standard for both finasteride and 
dutasteride. d9-Finasteride had an approximately two-fold increase in 
response in serum compared to water or stripped serum. This was however 
able to be used in a serum standard curve, as the drugs were not 
endogenous.  
 
d5-Testosterone and d4-DHT were unsuitable for use as internal standards 
due to loss of A-ring deuteriums during sample processing. d3-Testosterone 
was unsuitable for use due to a very high background present in the 
testosterone transition. d3-DHT and d7-androstenedione were unsuitable for 
use due to varying response in different matrices; with decreased or 
increased response respectively in stripped serum and water compared to 
serum samples. Therefore 13C rather than deuterium labelled standards were 
selected for use in final method. Suitability and stability of selected internal 
standards, 13C3-androstenedione, 13C3-testosterone, 13C3-DHT and d9-
finasteride was demonstrated, with no significant interference between 
analytes and internal standards. Stability of all selected internal standards 
was demonstrated with samples enriched only with internal standard 
showing acceptable response over time and a lack of analyte seen at amounts 
of internal standard used. Fragmentation patterns between analytes and 
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internal standards were essentially identical and their relationship was 
demonstrated to be linear (Section 3.4.6.5).  
 
3.4.3 Chromatographic conditions 
Given the potential for interference between analytes, and also mass + 2 
isomers from analytes, it was necessary to develop chromatographic 
conditions capable of adequately separating all analytes within a single run.  
 
Findings from the parameters assessed during method development were:   
 Column 
 A peak for dutasteride was not seen with the Kinetex PFP 
column, suggesting retention was either too great or too little. 
Responses for all analytes were seen with the Ascentis express 
and Poroshell C18 columns, however the peak areas were 
significantly smaller than seen with the Kinetex C18 columns. 
At higher concentrations, the 150 mm Kinetex C18 was similar 
to its 100 mm counterpart, however was superior at lower 
concentrations with improved signal to noise ratio.  
 Column temperature  
 Optimum temperature was found to be 35 ºC, as assessed by 
peak symmetry and resolution.  
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 Mobile phase  
 Methanol gave greater peak area than acetonitrile for all 
analytes. The use of formic acid as a modifier enhanced peak 
areas achieved with water. A concentration of 0.1% formic acid 
resulted in larger peak areas than 0.01% or 0.2%. Ammonium 
acetate (5 mM) with and without formic acid, and ammonium 
formate did not give significant improvements over formic 
acid.  
 Gradient  
 A gradient was necessary for optimum resolution. The 
extension of time to reach peak gradient was a the key factor 
allowing adequate separation of all peaks. This was initially 
optimised as a 12 minute gradient in aqueous standards, 
however was later shortened to 9 minutes to allow separation 
of androstenedione from an interfering peak in serum. This 
adaptation meant that while testosterone was adequately 
resolved from DHEA and epitestosterone, the latter two 
steroids were not clearly resolved from each other. However 
this was accepted since these steroids were not quantified; the 
important factor was to ensure they were separated from 
analytes of interest. The lengthening of the isocratic period 
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following the gradient resolved issues with DHT giving split 
peaks.  
 Flow rate  
 Optimum flow rate, as judged by peak shape and areas, was 
250 µL/min.  
 
A representative chromatogram is shown in Figure 3.1.  
 





Figure 3.1 Representative chromatogram of quantifier mass transitions for 
analytes in unextracted standard mix with androstenedione (2 ng/mL), 
testosterone (7.5 ng/mL), dihydrotestosterone (2 ng/mL), finasteride (25 ng/mL) 
and dutasteride (25 ng/mL), together with internal standards. Cps, counts per 















While spiked aqueous and stripped serum extracts demonstrated acceptable 
recoveries from most extraction methods tested, the key challenge in 
optimising an extraction method was extracting endogenous DHT from 
serum, and developing one method suitable for extraction of both androgens 
and 5αR inhibitors.  
 
None of the liquid-liquid extractions tested were able to recover endogenous 
DHT, and the poor extraction efficiency of the 5αR inhibitors meant they 
would not have been detected at expected concentrations. Supported liquid-
liquid extractions proved the least time-consuming extraction approach, 
however recoveries and peak areas achieved for 5αR inhibitors were 
insufficient for expected concentrations, and there were problems with the 
reproducibility of androgen recovery, therefore this approach was not 
pursued further. Protein precipitation and phospholipid crash methods gave 
poorer recoveries and lower peak areas than solid phase extractions, 
however the main problem was that endogenous DHT was not detected 
following these extraction methods.   
 
The extraction method which was suitable for all analytes and thus taken 
forward for further development and validation was a solid phase extraction 
with Oasis® HLB cartridges. Pre-extraction mixing with water gave the best 
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response, seen as larger peak areas for DHT. When using only 5% methanol 
in the wash step there were several large peaks eluting close to the retention 
time of DHT; optimisation of this step showed 50% methanol in water to 
retain response of DHT, while acting to wash off the other analytes that were 
previously detected. Representative chromatograms are shown in Figure 3.2.   
 
Methanol was the best eluting solvent, giving clean extracts and adequate 
response for all analytes. Isopropanol gave similar responses in all analytes 
but extracts were visually more opaque. Acetonitrile gave visually more 
opaque extracts than all other solvents and no improvement in response. 
Ethyl acetate did improve the peak areas for androstenedione and 
testosterone by approximately 25%, however did not improve DHT and 
decreased peak areas for dutasteride by approximately 50%. Given that DHT 
and dutasteride were the more challenging analytes in this assay, extraction 
with ethyl acetate was not pursued.  
 
 






Figure 3.2 Representative chromatograms of wash step optimisation in normal 
male serum. A. Wash step of 5% methanol in water. B. Wash step of 50% 
methanol in water, with clearer DHT peak without decrease in size of peak area. 
DHT, dihydrotestosterone; cps, counts per second.   
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Significant difficulties were encountered with determining the best matrix 
for standard curves due to differing responses of both analytes and internal 
standards in the different matrices tested. During early method development 
it was noted that analytes responded differently in aqueous versus serum 
standards in protein crash extraction methods. Following this, stripped 
serum was used for standard curves. However, several deuterated internal 
standards differed in their behaviour when extracted from aqueous solution 
compared to when extracted from serum. Increases in response were seen 
with d7-androstenedione and d9-finasteride, and a decrease in response was 
seen with d3-DHT. Female plasma was not suitable for use due to a high 
concentration of androstenedione. When tested in aqueous extracts, all 
androgens were able to be accurately quantified in the optimised extraction 
method. While finasteride was able to be quantified accurately in standards 
prepared in water, stripped serum or serum, only serum provided accurate 
dutasteride quantitation. Therefore two standard curves were used – one for 
androgens and another for the 5αR inhibitor drugs.  
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3.4.5 Final extraction and chromatographic method taken 
forward for validation 
Samples were extracted via solid-phase extraction (Oasis® HLB). Extraction 
cartridges were primed with methanol (1 mL) then water (1 mL). Samples 
(500 µL) were enriched with internal standard (1 ng); water (500 µL) was 
added. Samples were then mixed with a pipette and loaded onto primed 
extraction cartridges. After a wash step (50% methanol in water, 1 mL), 
analytes were eluted with methanol (1 mL). Eluates were dried under 
oxygen-free nitrogen (37 °C) and reconstituted in mobile phase (100 µL). 
Injection volume was 10 µL.   
 
Analytes were separated at 35 ºC on Kinetex C18 column (150 x 3 mm, 2.6 
µm). Elution was achieved with a 9 minute linear gradient from 30:70 to 
80:20 (methanol: water with 0.1% FA) at a flow rate of 250 µL/min. Initial 
hold was 1 minute with a linear gradient applied until 10 minutes, hold until 
16 minutes, with a total run-time of 19 minutes.  
 
3.4.6 Assay validation 
3.4.6.1 Recovery 
The recoveries (RSD) were: androstenedione 88.7% (15.4%), testosterone 
84.6% (13.4%), DHT 85.5% (14.7%), finasteride 89.6% (14.3%), dutasteride 
94.5% (10.4%).  
 




3.4.6.2 Ion suppression 
There was no ion suppression noted for any analytes, though a small amount 
of ion enhancement with some. Mean (RSD) relative responses in post-spiked 
serum compared to unextracted serum were: androstenedione 110.8% (1.7%); 
testosterone 115.3% (2.1%); DHT 109.2% (2.4%); finasteride 111.0% (0.9%); 
dutasteride 97.2% (3.0%).   
 
3.4.6.3 Analyte specificity 
With the measurement of multiple analytes in a complicated biological 
matrix such as serum, analyte specificity was an essential developmental 
aim. All analytes and internal standards were adequately resolved from 
potential interferences. Of note, testosterone and its biologically inert epi-
isomer, epitestosterone, were separated chromatographically, as seen in 
Figure 3.3. In addition, its isobaric steroid DHEA was not detected in the 
mass transitions (both quantifier and qualifier) monitored for testosterone. In 
mass transitions when all three (testosterone, epitestosterone and DHEA) 
were seen, DHEA co-eluted with epitestosterone, however did not co-elute 









Figure 3.3 Representative chromatograms demonstrating separation of 
testosterone from epitestosterone and dehydroepiandrosterone (DHEA). A. m/z 
289→97 had adequate baseline separation of testosterone and epitestosterone; 
DHEA was not seen in this transition. B. m/z 289 → 271 showing adequate 
baseline separation of testosterone from both DHEA and epitestosterone. While 
DHEA and epitestosterone were co-eluting, they were separate from 
testosterone, and DHEA was detected in a different mass transition from 
testosterone, the analyte of interest. Cps, counts per second; Rt, retention time.  
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3.4.6.4 LOD and LLOQ  
Analyte limits of detection and lower limits of quantitation are summarised 
in Table 3-5.  
Table 3-5 Limits of detection (LOD) and lower limits of quantitation (LLOQ) 




Standard curves were demonstrated to be linear in the range required for all 
analytes; intercept, r values and weightings are summarised in Table 3-6.  
Representative standard curves for each analyte are shown in Figure 3.4 
(androstenedione), Figure 3.5 (testosterone), Figure 3.6 (DHT), Figure 3.7 
(finasteride) and Figure 3.8 (dutasteride).  
 
 Standard 










Androstenedione 0-5 0.08 0.26 0.125 0.44 
Testosterone 0-15 0.003 0.01 0.005 0.02 
DHT 0-5 0.13 0.43 0.21 0.72 
Finasteride 0-100 0.02  0.003  
Dutasteride 0-100 0.2  0.1  
 




Figure 3.4 Representative standard curve, prepared in aqueous solution, for 





Figure 3.5 Representative standard curve, prepared in aqueous solution, for 








Figure 3.6 Representative standard curve, prepared in aqueous solution, for 










Figure 3.7 Representative standard curve, prepared in serum, for finasteride, 
with 1/x weighting applied. IS, internal standard, d9-finasteride.  
 
Figure 3.8 Representative standard curve, prepared in serum, for dutasteride, 
with 1/x weighting applied. IS, internal standard, d9-finasteride.  
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 Mean intercept 
(SD) 
Mean r value 
(SD) 
Weightings 
Androstenedione -0.00674 (0.02) 0.996 (0.002) None and 1/x 
Testosterone 0.084 (0.31) 0.993 (0.004) None 
Dihydrotestosterone -0.01097 (0.02) 0.995 (0.003) 1/x 
Finasteride 0.044624 (0.06) 0.997 (0.003) 1/x and 1/x2 
Dutasteride 8.13E-08 (2.42E-07) 0.993 (0.003) 1/x and 1/x2 
Table 3-6 Average intercept and r values from standard curves (n=4) for each 
analyte. Weighting used listed in final column. SD, standard deviation.  
 
3.4.6.6 Precision and accuracy 
Intra- and inter-assay precision and accuracy are summarised in Table 3-7 
and Table 3-8, demonstrating acceptable results for most analytes. The main 
issues remaining are in the accurate quantitation of low concentrations of 
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Table 3-7 Intra- and inter-assay precision and accuracy data for androstenedione (AND), testosterone and dihydrotestosterone 
(DHT) quantified from aqueous standard curve.  
  Intra-assay (n=6 ) Inter-assay (n=3-4) 
Concentration 











AND Low (Std 2) 0.18 (0.01) 5.4 87.6 0.19 (0.02) 19.3 93.6 
Mid (Std 5) 1.65 (0.12) 7.2 101 1.75 (0.16) 8.9 92.3 
High (Std 8) 4.22 (0.27) 6.5 98.3 5.01 (0.59) 11.9 103.4 
Sample 0.16 (0.02) 9.9  0.20 (0.04) 20.1  
Testosterone Low (Std 2) 1.80 (0.07) 2.8 94.4 1.88 (0.19) 10.0 94.9 
Mid (Std 5) 6.50 (0.42) 5.8 117 7.29 (0.83) 11.3 100.6 
High (Std 8) 14.40 (0.75) 4.9 100 15.28 (0.65) 4.2 103.3 
Sample 9.40 (0.61) 6.0  4.22 (0.21) 5.0  
DHT Low (Std 2) 0.26 (0.02) 9.1 137 0.23 (0.04) 15.5 119.5 
Mid (Std 5) 1.70 (0.11) 6.4 119 1.83 (0.14) 7.4 100.0 
High (Std 8) 4.11 (0.20) 4.9 103 5.00 (0.60) 12.1 105 
Sample 1.39 (0.19) 12.8  1.13 (0.31) 27.3  
 





  Intra-assay (n=6 ) Inter-assay (n=3-4) 
Concentration 











Finasteride Low (Std 2) 2.18 (0.24) 10 101 1.87 (0.30) 16.2 92.7 
Mid (Std 5) 24.68 (1.34) 5.5 104 24.51 (2.08) 8.5 100.9 
High (Std 8) 95.69 (6.23) 6.5 101 99.17 (4.35) 4.4 102.3 
Sample 8.45 (0.35) 4.1 84.5 8.96 (0.69) 7.8 89.6 
Dutasteride Low (Std 2) 1.67 (0.37) 22 88.2 1.86 (0.16) 8.8 94.5 
Mid (Std 5) 25.07 (2.40) 9.6 110 26.00 (2.60) 10.0 107.4 
High (Std 8)^    86.5 (4.40) 5.1 105 
Sample 16.25 (1.83) 11.2 81.3 15.05 (1.26) 8.4 75.3 
Table 3-8 Intra- and inter-assay precision and accuracy data for finasteride and dutasteride quantified from standard curve 
prepared in serum. ^ Intra-assay data  for dutasteride at high standard are incomplete due to a technical failure.    
 




Acceptable autosampler and extract storage stability were demonstrated for 
a calibration curve and patient sample, as shown in Table 3-9.  
 
 Relative response after 
24 hours in autosampler 
(10 °C) 
Relative response after 28 
days in freezer 
(-20 °C) 
Androstenedione 102.7% 98.3% 
Testosterone 99.7% 101.0% 
DHT 90.0% 97.5% 
Finasteride 95.3% 103.4% 
Dutasteride 92.0% 92.0% 
Table 3-9 Relative response for calculated concentrations for all analytes in a 
single patient sample after 24 hours in the autosampler (10 °C) and after 28 
days in the freezer (-20 °C).  
 
3.4.6.8 Injector reproducibility 
Reproducibility upon repeat injections (n=6) of standards and sample is 
summarised in Table 3-10 and demonstrated a reasonable contribution of the 
injector to inter-assay variability. Reproducibility was not improved with 
repeat injections from vials (instead of plates), therefore for ease of method 
application, plates continued to be used.  
 
 
Chapter 3: Measurement of androgens and 5αR inhibitors by LC-MS/MS  
155 
 
 Std 1 Std 2 Std 3 Std 5 Std 8 Sample 
Androstenedione 6.1% 4.5% 7.8% 5.5% 1.8% 6.8% 
Testosterone 5.9% 3.6% 1.9% 3.8% 4.2% 2.7% 
DHT 116.4% 4.7% 5.2% 8.6% 4.9% 5.7% 
Finasteride 4.6% 4.6% 3.4% 5.0% 7.2% 4.5% 
Dutasteride 9.7% 5.1% 9.3% 3.1% 6.8% 8.0% 
Table 3-10 Injector reproducibility – relative standard deviations (RSD) for 
each analyte at 5 different extracted standards and a sample spiked with 
finasteride (10 ng/mL) and dutasteride (20 ng/mL). Of note, dihydrotestosterone 
(DHT) at standard 1 is below the lower limit of quantitation, and was detected 
on 4 of the 6 injections only, hence such a high RSD value. Std, standard.  
 
3.5 Application 
The assay described was applied to clinical samples, and results are 
described in Chapter 5.4.3.2.   
 
In addition, a series of 6 male and 6 female serum samples (kindly gifted by 
Dr Geoff Beckett, Royal Infirmary of Edinburgh (RIE)) which had been 
analysed by LC-MS/MS were analysed by the described method for 
comparison. One patient was on testosterone replacement therapy; no 
patients were on 5αR inhibitor treatment. As androstenedione and DHT are 
not routinely measured in Dr Beckett's laboratory, these results were unable 
to be compared. Results are demonstrated in Figure 3.9.  
 














































Figure 3.9 Bland-Altman plot demonstrating comparison of serum testosterone 
concentrations measured by assay presented in this chapter (“Assay 
developed”) with concentrations measured by Dr Beckett’s assay (“NHS 
assay”). Results show that, overall, the assay presented in this chapter gives 
slightly higher results for serum testosterone.  
 




The purpose of the work presented in this chapter was to develop a method 
which allowed simultaneous analysis of androgenic steroids and the 5αR 
inhibitors dutasteride and finasteride from human serum. This approach was 
applied as a measure of compliance with, and biochemical effects of, 5αR 
inhibitors (Chapter 5 and 6).   
 
The ionisation methods evaluated for use were electrospray ionisation (ESI) 
and atmospheric pressure chemical ionisation (APCI). All analytes and 
internal standards ionised in both ionisation modes, and for most ESI was 
superior in terms of peak area response. However, the main challenge in this 
assay was the detection of DHT at the low concentrations present in serum. 
As APCI gave a better response for DHT in terms of greater peak area seen 
from the same extract, this ionisation mode was selected for further use. For 
purposes of this assay, this was sufficient for detecting all other analytes, 
however if the method were to be applied to other applications where DHT 
was not needing to be measured, then it would be appropriate to use ESI.  In 
addition, if derivatisation was to be used to introduce a permanent positive 
charge, then ESI would be the appropriate ionisation method for most 
derivatives. The reason that APCI gave an improved DHT response may be 
due to its advantage in measurement of small non-polar compounds such as 
steroids, and particularly due its reduced ionisation of phospholipids and 
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overall reduced predisposition towards matrix effects (Ismaiel et al., 2008).  
As seen in the present method also, there was no evidence of matrix ion 
suppression in APCI.  
 
Method development initially focussed on optimising chromatography, in 
order to gain adequate separation of peaks and achieve optimal peak areas 
for each analyte and internal standard. In particular, the potential 
interference from mass + 2 isomers needed to be avoided through adequate 
chromatography. Reported methods for detection of individual analytes 
predominantly use C18 columns, though these vary in length from 50 mm 
(Chen et al., 2008, Gomes et al., 2009, Ramakrishna et al., 2004)  to 150 mm 
(de Menezes et al., 2001, Guo et al., 2007). Initial attempts were with a 
pentafluorophenyl (PFP) column, however while adequate peak areas were 
seen with most analytes of interest, dutasteride was not detected. A possible 
reason for the poor separation of dutasteride is the 6 fluorine atoms in the 
dutasteride molecule, which may have a much greater affinity for the column 
making elution difficult. Rather than improving detection and resolution, the 
use of a column with a reduced particle size, the Poroshell C18 (particle size 
2.1 µm), led to consistently reduced peak areas for all analytes. The best 
response was with the Kinetex C18 column which allowed all analytes and 
internal standards to be detected, and resulted in larger peak areas than any 
other column tested. The 150 mm column provided better peak resolution at 
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low concentrations than the 100 mm column, and was therefore selected for 
use.  
 
The mobile phase has a hydrophobic and hydrophilic component, with or 
without the addition of modifiers. The hydrophobic component in published 
literature includes acetonitrile (Constanzer et al., 1994, de Menezes et al., 
2001, Guo et al., 2007) and methanol (Harwood and Handelsman, 2009, 
Shiraishi et al., 2008).  However the use of acetonitrile suppressed ionisation 
resulting in smaller peak areas for all analytes. As the hydrophilic mobile 
phase, water alone can be used (Harwood and Handelsman, 2009), however 
ionisation was improved when formic acid was added as a modifier. The use 
of formic acid in conjunction with ammonium acetate has been reported 
(Chen et al., 2008, Macdonald et al., 2010); this was attempted early in 
method development with mobile phase switching partway through the run. 
However, on transfer to the new instrument the mobile phase system went 
from a quaternary to a binary system which did not allow mobile phase 
switching in the manner required, though ammonium acetate also no longer 
significantly improved response from DHT therefore was not pursued 
further. Gradient was optimised, with extension of the time taken to reach 
the peak gradient being the key component allowing optimal baseline 
separation (particularly of testosterone and epitestosterone), while extension 
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of the isocratic time after the initial gradient resolved issues with peaks 
splitting.    
 
UPLC was tested briefly, however attempts with both 50 mm and 100 mm 
C18 UPLC columns showed poorer peak shape and resolution, with no 
significant increase in sensitivity. This approach was not pursued following 
initial testing, though it is likely that with further development work this 
may have yielded superior results and/ or a shortened run-time.   
  
Ideally an internal standard is physically and chemically similar to the 
analyte of interest, while not being present in the sample being analysed. 
Deuterium or stable isotope labelled internal standards lend themselves to 
this application, and being commercially available these are used in many 
reported androgen assays (Harwood and Handelsman, 2009, Janzen et al., 
2008, Shiraishi et al., 2008). While often considered to be the ideal internal 
standard, deuterated internal standards do have potential problems (Stokvis 
et al., 2005). During sample processing e.g. in an acidic environment, 
deuterium may be lost from the steroid structure resulting in unlabelled or 
partially labelled analyte (Chavez-Eng et al., 2002). With deuterated DHT, 
instability of deuteriums attached to the steroidal A-ring compared to D-ring 
has been reported (Boudreau et al., 2009) and in this method authors went on 
to successfully utilise d3-DHT rather than d4-DHT for DHT quantitation. In 
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the method presented here this problem was encountered with both d4-DHT 
and d5-testosterone. Problems with a very high background peak with d3-
testosterone (D-ring labelled) meant this was not suitable for use for 
testosterone quantitation, and instead 13C3-testosterone was found to be an 
appropriate alternative. While d3-DHT did not demonstrate the same 
instability of deuterium as d4-DHT, it did behave differently in different 
matrices, making it unsuitable for quantitation, and instead 13C3-DHT was 
successfully employed. Similar problems were found with d7-
androstenedione with relative response differing by matrix, therefore this 
was also replaced with its 13C3 labelled counterpart, 13C3-androstenedione.  
Similar fragmentation patterns between analytes and internal standards also 
provided additional selectivity.  
 
In reported analytical methods for finasteride, a GC-MS technique described 
by Guarna et al. (Guarna et al., 1995) is notable for the synthesis and use of 
d3-finasteride as the internal standard. In all other reports of finasteride and 
dutasteride analysis, non-deuterated internal standards are used, with 
finasteride used as the internal standard for plasma dutasteride 
measurement in both published methods (Gomes et al., 2009, Ramakrishna et 
al., 2004). In-house synthesis of d9-finasteride permitted use of a structurally 
similar compound as internal standard for both 5αR inhibitors, while the 
method could be applied to samples without knowledge of a volunteer’s 
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drug assignment. While d9-finasteride gave an exaggerated response in 
serum, this was not an issue as both dutasteride and finasteride were 
quantified from a standard curve prepared in serum. The accuracy for 
dutasteride quantitation was not as high as desired, at 75% (inter-assay) and 
81% (intra-assay). This was sufficient for the application in this study, as 
detection and not accurate quantitation was the principal purpose. It may be 
that another internal standard (such as a stable-isotope labelled dutasteride) 
might provide more accurate quantitation, however the assay would need to 
be developed further to try and improve this.  
 
There are several extraction methods reported for the analytes of interest in 
the presented assay. The majority of publications report a liquid-liquid 
extraction (Guo et al., 2007, Harwood and Handelsman, 2009, Janzen et al., 
2008, Ptacek et al., 2000, Ramakrishna et al., 2004, Shiraishi et al., 2008), 
however endogenous DHT was not seen in any of the liquid-liquid extraction 
methods tested during assay development. Supported liquid extraction 
initially provided encouraging results for the measurement of androgens, 
with particularly good response for endogenous DHT. However SLE did not 
extract 5αR inhibitors with efficiency suitable for clinically expected 
concentrations. Further problems were encountered when assay validation 
was attempted with significant intra- and inter-assay variability in response. 
This was the case for all analytes, however was particularly marked with 
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androstenedione and DHT, with RSDs in the order of 150%. Attempts were 
made to troubleshoot this problem, together with input from the 
manufacturer, however the problem continued therefore SLE could not be 
pursued further. Success has also been reported with solid-phase extractions 
for 5αR inhibitors (Constanzer et al., 1994, Gomes et al., 2009) and androgens 
(Kulle et al., 2010, Mitamura et al., 2005). Waters Oasis® Hydrophilic 
Lipophilic Balanced (HLB) reversed phase HLB cartridges provided the most 
reproducible extractions and were effective for all analytes. While the 
method developed is similar to the extraction method described by Kulle et 
al. (Kulle et al., 2010), with different instrumentation the same sensitivity was 
not able to be reproduced. However the extraction method described was 
simple, and with transfer to 96-well plate format was suitable for processing 
of large numbers of samples.  
 
A key consideration in this assay was the specificity of the assay. Indeed, this 
was the principle reason for selection of LC-MS/MS as the analytical 
method. Androgens were chromatographically well separated, ensuring that 
isomeric and isobaric species did not affect quantitation. Of note, 
epitestosterone and DHEA were chromatographically separated from 
testosterone, and all three androgens being quantified (androstenedione, 
testosterone and DHT) were chromatographically separated from each other 
and mass + 2 isomers from analytes or internal standards would not have co-
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eluted. In addition, at amounts used, internal standards used did not give 
any detectable interference in the analyte transitions.  
 
An additional consideration in this assay is the potential presence of 5αR 
inhibitor drug metabolites in serum. As well as unchanged drug, dutasteride 
is known to have 3 major (4′-hydroxydutasteride, 1,2-dihydrodutasteride, 
and 6-hydroxydutasteride) and 2 minor (6,4′-dihydroxydutasteride and 15-
hydroxydutasteride) metabolites detected in human serum following dosing 
to steady state (GlaxoSmithKline, 2008). Finasteride has two main in vivo 
metabolites detected in serum (Merck, 1998). With different molecular 
weights to their parent drug, metabolites of both finasteride and dutasteride 
would be anticipated to give rise to different precursor ions and mass 
transitions and hence not be detected in the current assay. 
 
A crucial consideration is the validity of this assay with respect to expected 
circulating androgen and drug concentrations (Table 3-1). The main analyte 
potentially out of range for this assay was DHT, particularly after treatment 
with 5αR inhibitors, where a dramatic decrease in DHT concentrations is 
expected. Measurement of DHT via LC-MS/MS is difficult due to its low 
circulating concentration, poor ionisation and lack of product ions present in 
high abundance (Kushnir et al., 2011). For these reasons, the majority of 
approaches in LC-MS have required derivatisation, targeting either the 
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hydroxyl group at carbon 17 (Licea-Perez et al., 2008, Yamashita et al., 2009), 
or keto group at carbon 3 (Kalhorn et al., 2007) (Table 3-3). While instrument 
sensitivity allowed quantitation of normal DHT concentrations in men, in 
order to quantify DHT post 5αR inhibitor treatment, the method described 
would need to be developed further and DHT quantified following 
derivatisation.  In addition, for application to other samples where DHT 
concentrations would be expected to be low and/ or sample volume would 
be limited (e.g. women, children, small animal models), then derivatisation 
would also be required. However the method could potentially be applied to 
studies in female disorders characterised by hyperandrogenism, such as 
polycystic ovarian syndrome, as circulating testosterone and 
androstenedione in women would be able to be quantified using this 
method. For the purposes of application to the clinical study in Chapters 5 
and 6, this method was applicable to all samples; however derivatisation 
would be required if needing to quantify DHT following inhibition of 5αR. 
The extraction method developed would however still be applicable in this 
case.  
 
Samples previously assayed for testosterone by Dr G. Beckett (Clinical 
Biochemstry, RIE) were analysed with the method presented in this chapter. 
There was overall very good agreement between the assays over a wide 
concentration range, with a slight positive bias towards towards the assay 
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presented here. This difference may be related to differences in extraction 
method; for reasons of economy and speed the RIE laboratory use a protein 
crash extraction method, which could result in greater ion suppression 
giving slightly lower calculated concentrations for testosterone.   
 
Measuring 5αR inhibitor concentrations in serum in this study were 
primarily to act as a supporting assessment of compliance with prescribed 
study interventions. Detailed pharmacokinetic studies were not the purpose 
of this assay; however it could be applied to such an application. It was noted 
throughout assay development that extraction, chromatography and 
detection of finasteride was achieved with ease in almost every method 
development test. In contrast, dutasteride was much more difficult to find a 
suitable extraction and chromatography method for. The assay described is 
ideal for this setting where measurement of androgens is also desired, and 
sample volume, handling and analysis time are reduced, however if only 
5αR inhibitor drug concentrations are required then an alternate (simpler 
and shorter) method could be utilised.  
 
The method developed was suitable for measurement of androgens, 
dutasteride and finasteride from human serum. The assay is notable for the 
ability to measure these five analytes simultaneously despite significant 
challenges in chromatographic and extraction method development. The 
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assay requires relatively little sample volume (500 µL), has a simple 
extraction method in 96-well format, and is able to quantify DHT without 
derivatisation. However in order to reliably detect DHT following 5αR 
inhibition, further method development would be required, including 
derivatisation. Expected concentrations of all analytes fell within the linear 
range of the standard curve, other than DHT once its synthesis was inhibited 
by 5αR inhibitors. Intra- and inter-day precision and accuracy were 
acceptable, though improvement in accuracy of quantitation of dutasteride 
and also DHT (at low concentrations) would be desirable. Stability testing 
demonstrated the assay to be applicable to normal laboratory practice. The 
described assay was successfully applied to samples taken from research 
volunteers taking dutasteride, finasteride and control (tamsulosin), as 
described in Chapters 5 and 6. Attempts to simultaneously measure 
tamsulosin in this assay were unsuccessful, therefore an additional assay was 
developed to assess compliance with tamsulosin; this assay is presented in 
the next chapter.  
 
 
Chapter 4: Measurement of tamsulosin via LC-MS/MS  168 
 
 






Chapter 4: Measurement of tamsulosin from 
human serum by liquid chromatography 
tandem mass spectrometry  
 5β DHE 3α, 5β THE 
 
 




Tamsulosin, an α blocker, is often used as the first-line medical treatment of 
benign prostatic hyperplasia (BPH) (discussed in Chapter 1.3.2). In clinical 
studies such as that described in Chapters 5 and 6 where response to 
pharmacological intervention is studied, establishing compliance with study 
medication is important. Traditional methods of establishing compliance 
such as a ‘pill count’ at the end of the study can be complemented by 
measurement of presence of drug in serum. The method described in 
Chapter 3 was not suitable for quantitation of tamsulosin, therefore a 
separate assay was developed.  
 
Tamsulosin concentrations in those treated with the 0.4 mg modified release 
formulation are reported to be between 11.8 ng/mL (Ramakrishna et al., 
2005a) and 16.1 ng/mL (Taguchi et al., 1998) after a single dose, and 10 
ng/mL after 21 days dosing (Wolzt et al., 1998). Measurement of tamsulosin 
levels has been reported from human plasma by HPLC (Macek et al., 2004, 
Soeishi et al., 1990), LC-MS (Ding et al., 2002) and LC-MS/MS (Qi et al., 2004, 
Ramakrishna et al., 2005a, Matsushima et al., 1997, Choi et al., 2012), with key 
features of these methods described in Table 4-1. HPLC alone precludes 
additional specificity and sensitivity afforded by its use in conjunction with 
mass spectrometry, and in all assays described requires undesirably large (1-
1.5 mL) sample volumes. While LC-MS methods have been described, it is 
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now increasingly recognised that tandem mass spectrometry (such as LC-
MS/MS) with the monitoring of 2 mass transitions is the gold standard of 
analyte measurement.  As summarised in  Table 4-1, the combination of an 
LC-MS/MS approach, minimal sample volume, simple extraction method 
and excellent analyte recovery has not been achieved with any published 
method. Despite relatively low analyte recovery, other features of the 
method by Ramakrishna et al. (Ramakrishna et al., 2005a) were acceptable 
with a straightforward and validated method, however this approach was 
not able to be reproduced on our system, both in terms of chromatography 














(Soeishi et al., 1990) HPLC >1 step incl. S.NaHCO3; EA 1.5 mL 0.5 – 15  70% 
(Matsushima et al., 1997) LC-MS/MS S. NaHCO3; H:EA 200 µL 0.5 – 50 >80%  
(Taguchi et al., 1998) HPLC+ Details NR NR 0.5 – 50  NR 
(Ding et al., 2002) LC-MS/MS S. NaHCO3; EA 1 mL 0.2 – 30  84.2-94.5% 
(Macek et al., 2004) HPLC Na2CO3; BA 1 mL 0.4 – 40 NR 
(Ramakrishna et al., 2005a) LC-MS/MS NaOH; DEE:DCM 100 µL 0.1 – 50  59.3% 
(Keski-Rahkonen et al., 2007) LC-MS/MS S. NaHCO3; EA 1 mL 0.1 – 19.3 66-77% 
(Choi et al., 2012) LC-MS/MS None; MTBE 500 µL 0.01 - 20 77.8% 
 
Table 4-1 Summary of key characteristics of published assays to quantify tamsulosin from plasma or serum. LLE, liquid-
liquid extraction; HPLC, high performance liquid chromatography; LC-MS/MS, liquid chromatography tandem mass 
spectrometry; S., saturated; H, hexane; EA, ethyl acetate; NR, not reported; BA, butyl acetate; DEE, diethyl ether; DCM, 
dichloromethane; MTBE, methyl tert-butyl ether. 
+
 This method principally describes a radioreceptor assay which is not 
included in this table.  
 
 




To develop, optimise and validate a sensitive, precise and accurate LC-
MS/MS method for the measurement of tamsulosin from human serum, 
with validation based on standards deemed acceptable by the U.S. Food and 
Drug Administration (USFDA, 2001).  
 
4.3 Method development 
4.3.1 Reagents and Standards 
Unless stated otherwise, all chemicals were from Sigma Aldrich (Dorset, UK) 
and solvents from Rathburn Chemical Ltd. (Walkerburn, UK).  Tamsulosin 
hydrochloride was from AK Scientific (Mountain View, USA).  The internal 
standard, d9-finasteride had been synthesised in house. Water and 
ammonium hydroxide (35%, v/v) solution (both HPLC gradient grade), and 
glacial acetic acid (99.79%, v/v) were from Fisher Scientific (Loughborough, 
UK). Methanol and dichloromethane (HPLC gradient grade) were from 
VWR (Lutterworth, Leicestershire, UK). o-Phosphoric acid (85% v/v) was 
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4.3.2 Biological samples 
Pooled male human serum (collected from healthy men aged 17-45 years on 
no medications) was purchased (TCS Biosciences, Buckingham, UK) for use 
as blank matrix in method development, validation and standard curves. For 
method application, serum was collected from male subjects (age range 21-73 
years, n=14) participating in the clinical study described in Chapters 5 and 6. 
Serum was also analysed from subjects within the study not receiving 
tamsulosin (age range 20-85 years, n=33). All biological samples were 
collected with informed consent with local regulatory and ethical approval.   
 
4.3.3 Selection of internal standard 
In the absence of a commercially available stable isotope labeled internal 
standard, compounds tested as potential internal standards were 
trichlormethiazide, ketoconazole, phthalylsulfathiazole (QMX Laboratories, 
Essex, UK) and d9-finasteride (in-house synthesis, discussed in Chapter 3). 
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Table 4-2 Structural formulae and molecular weights (MW) of tamsulosin and 
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4.3.4 LC-MS/MS Instrumentation 
Initial method development was performed on a Thermo Electron Surveyor 
MS Pump and a Thermo Surveyor HPLC autosampler, interfaced with a 
Thermo Electron TSQ Quantum Discovery triple quadrople mass 
spectrometer and operated with Xcalibur Version 2.0.6 software (Thermo 
Electron, Hemel Hempstead, UK). The method was transferred and 
developed further on a Waters Acquity™ UPLC (Manchester, UK) with 
autosampler, coupled to an ABSciex QTRAP® 5500 mass spectrometer 
(Warrington, UK), operated with Analyst® Software version 1.5.1. All 
subsequent method development and validation steps described were 
completed on the latter instrument, which offered greater sensitivity.  
 
4.3.5 Tuning of standards for ion selection 
Solutions of tamsulosin hydrochloride and d9-finasteride were prepared 
separately (1 ng/mL in 5:95 methanol: 2 mM ammonium acetate), following 
dilution of stock solution (1 mg/mL in methanol), and infused (7 µL/min) 
into the LC-MS/MS source operating in positive electrospray ionisation 
mode. Protonated ions were exposed to a range of variables of collision 
energy, cell exit potential and declustering potential in order to ascertain 
ideal ionisation conditions. The mass of ions formed was determined and the 
most abundant ions, out of the eight most abundant transitions screened, 
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undergoing predictable transitions to form abundant product ions were 
selected for use in subsequent analysis. Both quantifier and qualifier 
transitions of analyte and internal standard were subsequently monitored. 
Mass spectrometric source conditions (curtain gas, collision gas, spray 
voltage, source temperature, source gases) were then optimised for 
tamsulosin.  
 
4.3.6 Fourier Transform Ion Cyclotron Resonance Mass 
Spectrometry (FTICRMS)  
Accurate mass confirmation for tamsulosin and d9-finasteride were 
confirmed by FTICRMS. Analyte and internal standard were dissolved 
separately (20 ng/µL) in acetonitrile: 0.1% trifluoroacetic acid in water (60:40, 
v/v). ESI-FTICRMS was performed by direct infusion into a 12 T SolariX dual 
source (ESI/MALDI) FTICRMS (Bruker Daltonics, MA, US). The instrument 
was operated with SolariX control v1.5.0 (build 42.8) software. Ions were 
detected between m/z 250 and 1500, yielding a 1 Mword time-domain 
transient. Ions of interest were isolated for 20 seconds prior to collision-
induced dissociation (CID) experiments. CID was carried out using 35 eV as 
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4.3.7 Chromatographic method development 
Using unextracted mixes of analyte and internal standard in aqueous 
solution, optimal chromatographic conditions were determined. The 
following parameters were manipulated, with variables tested listed: 
 Column:  
 Variations of stationary phase (C18, PFP), particle size (1.7 µm-
5 µm), column dimensions (50-250 mm x 2.1-4.6 mm) and 
nature (conventional reverse phase, fused core).  
 Columns tested: Ascentis® Express C18 100 x 3 mm, 2.7 µm 
(Supelco, Sigma-Aldrich, Dorset, UK); Poroshell 120 EC-C18 
100 x 2.1 mm, 2.7 µm (Agilent, Wokingham, UK); BDS Hypersil 
C18, 50 x 2.1 mm, 5 µm (Thermo Scientific, Welwyn Garden 
City, UK); Hypersil Gold 150 x 2.1 mm, 3 µm (Thermo 
Scientific, Welwyn Garden City, UK); Atlantis® T3 100 x 2.1 
mm, 3 µm (Waters, Elstree, UK); Sunfire™ 250 x 4.6 mm, 5 µm 
(Waters, Elstree, UK); Sunfire™ 100 x 4.6 mm, 5 µm (Waters, 
Elstree, UK); Acquity UPLC® BEH C18, 50 x 2.1 mm, 1.7 µm 
(Waters, Elstree, UK); Kinetex C18 150 x 3mm, 2.6 µm 
(Phenomenex, Macclesfield, UK); Kinetex PFP 100 x 3mm, 2.6 
µm (Phenomenex, Macclesfield, UK).   
 Column temperature 
 Ranging from 25 °C to 50 °C 
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 Mobile phases 
 Methanol: water; Methanol: aqueous ammonium acetate (10 
mM, 5 mM, 2 mM, 1 mM, 0.5 mM); Methanol with acetic acid 
(2%, 1% v/v): water; Methanol with acetic acid (2%, 1% v/v): 
aqueous ammonium acetate (5 mM); Methanol: water with 
formic acid (1%, 0.1%, 0.03% v/v); Acetonitrile: water; 
Acetonitrile: formic acid (1%, 0.1%, 0.03% v/v).  
 Gradient 
 Isocratic and gradient methods were tested. A range of 
gradients were tried with variations on the initial, peak and 
interval ratios between the mobile phases. Length of time at 
each isocratic stage, length of time to peak gradient and length 
of time returning from gradient were all manipulated. 
 Flow rates 
 Several flow rates were tested ranging from 0.1 – 0.5 mL/min.  
 
4.3.8 Optimisation of extraction method from human serum 
Tamsulosin (1 mg) and d9-finasteride (1 mg) were dissolved separately in 
methanol and stored at -20 °C. Stock solutions (10 µg/mL in methanol) of 
tamsulosin and d9-finasteride (internal standard) were then prepared and 
stored at -20 °C. Standards of lower concentration were prepared on the day 
of analysis by serial dilution of stock solutions.   
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As tamsulosin is not present endogenously, it was appropriate to optimise 
this assay in the biological matrix, serum. Efficiency of extraction was 
compared between the different extraction methods attempted, the most 
effective selected and repetitions (n=6) performed to ensure reproducibility 
and robustness.    
 
Types of extraction methods tested included solid phase (Oasis® HLB, 10 
mg/1 mL, Waters, UK; Strata-X-Drug B™, 33 µm, cation mixed mode 
polymer sorbet, 30 mg/ 1 mL, Phenomenex, UK), supported liquid extraction 
(Isolute® Array SLE+, 200 µL, Biotage, Uppsala, Sweden) and liquid-liquid 
extraction. In liquid-liquid extractions pre-extraction pH modification was 
attempted with sodium bicarbonate (saturated, pH 9.55), sodium hydroxide 
(1 M, pH 13.71; 0.1 M, pH 13.17), ammonium acetate (50 mM, pH 6.65; 10 
mM, pH 6.76) and ammonium hydroxide (0.1 M, pH 10.9). Eluting/ 
extraction solvents of different polarities and lipophilicity were tested with a 
sample: solvent ratio of 1:20 in all cases, with any additional proportions 
tested indicated: chloroform, dichloromethane, dichloromethane: diethyl 
ether (30:70, v/v, 1:35), methyl tert-butyl ether (MTBE), diethylether, ethyl 
acetate:hexane (3:2, v/v), ethyl acetate, methanol.  
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4.3.9 Assay validation 
4.3.9.1 Recovery 
Recovery was calculated by expressing the mean of the integrated peak areas 
from extracted standards, as a percentage of the mean integrated peak area 
from unextracted standards. This was performed in 6 replicates with blank 
serum samples enriched with both analyte (1 ng) and internal standard (1 
ng). 
 
4.3.9.2 Assessment of ion suppression 
Effect of the biological matrix (human serum) on ionisation efficiency was 
assessed in replicates of 6 by post-spiking extracted blank serum with 




Analyte specificity was ensured to avoid potential interferences by other 
endogenous components in serum. Extracted blank serum analysed with the 
described method was checked for inteferences at or close to the expected 
retention times for tamsulosin and d9-finasteride.  Additional analyte and 
internal standard specificity was ensured with measurement of two 
(quantifier and qualifier) mass transitions. Acceptable quantifier: qualifier 
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ratios in biological samples were those within 20% of the mean ratio seen in 
standards.  
 
4.3.9.4 Limit of detection (LOD) 
Limits of detection (LOD) were determined by analysing solutions prepared 
by serial dilution of analyte and internal standard stock solutions, with the 
LOD corresponding to a peak area where signal: noise ratio (SNR) was  3.   
 
4.3.9.5 Limit of quantitation (LOQ) 
Limit of quantitation (LOQ) following extraction was determined by 
extracting analyte and internal standard from serum at amounts 
corresponding to LOD, 2 x LOD, and 4 x LOD. The LOQ was defined as the 
amount where variance in replicates of 6 was 20%.  
 
4.3.9.6 Linearity 
A standard curve was generated by adding d9-finasteride (1 ng) to blank 
serum and increasing amounts (0.02, 0.1, 0.2, 0.5, 1, 2, 3, 4, 5 ng) of tamsulosin 
(corresponding to a concentration range of 0-50 ng/mL). Peak areas of 
tamsulosin and d9-finasteride were integrated and a calibration curve 
constructed (peak area ratio of tamsulosin/ d9-finasteride versus amount of 
tamsulosin). Regression lines of best fit were constructed and deemed 
acceptable if the regression coefficient, r, was greater than >0.99. Weightings 
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compared were none, 1/x and 1/x2 to improve accuracy and precision at the 
lowest concentrations and to afford intercepts as close to zero as possible. 
 
4.3.9.7 Accuracy and precision 
The intra-assay accuracy and precision were determined in a standard curve 
with 4 points of the standard curve prepared in replicates of 6 (standard 
concentration: 0.2, 1, 20, 50 ng/mL). The inter-assay accuracy and precision 
were determined from six standard curves prepared on six independent 
occasions. Injector variability was assessed by injecting the same samples 
(0.2, 1, 20, 50 ng/mL). six times on the same day. Precision and injector 
variability were also assessed in a sample of serum from a patient on 
tamsulosin treatment. The precision was calculated as the relative standard 
deviation of the mean (RSD) with RSD (%) = standard deviation/ mean x 
100. The % accuracy was calculated as the concentration/ theoretical 
concentration x 100.  
 
4.3.9.8 Stability 
Stability was assessed by reinjection of a single calibration curve and patient 
sample after 24 hours in the auto-sampler (10 °C), and then again following 
28 day storage (-20 °C). Storage conditions giving no greater that 10% change 
in response were accepted.  
 
 




4.4.1 Mass spectrometric conditions of analytes 
Tamsulosin and d9-finasteride were both ionised efficiently under positive 
electrospray ionisation conditions, yielding the mono-protonated molecular 
ions with m/z 409.1 and m/z 382.4 respectively. The mass spectrometer was 
optimised to, and operated in, positive electrospray ionisation mode, with 
curtain gas 25 psi, collision gas medium, spray voltage of 5 kV, source 
temperature of 550 °C, source gases both 55 psi. Source conditions optimised 
to tamsulosin were found acceptable for the internal standard. Selected 
ionisation was reassessed using the final mobile phase and optimal 
conditions for analyte and internal standard, and final mass spectrometric 
conditions are summarised in Table 4-3. Proposed analyte and internal 
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Table 4-3 Mass spectral conditions for analysis of tamsulosin (analyte) and d9-
finasteride (internal standard) utilising positive electrospray ionisation. amu, 






















408.5 409 228 33 20 141 
Tamsulosin 
(qualifier) 








381.6 382 314 39 14 96 
 
 




Figure 4.1 Chemical structures and proposed fragmentation patterns for 
tamuslosin and d9-finasteride. Accurate masses shown for quantifier and 
qualifier ions were confirmed to within 10 ppm of their theoretical 
monoisotopic mass by Fourier Transform Ion Cyclotron Resonance Mass 
Spectrometry. A. Structure and proposed fragmentation pattern for 
tamsulosin. B. Structure and proposed fragmentation for d9-finasteride. C. 
Proposed mechanism for fragmentation of d9-finasteride into quantifier 
ion.   
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4.4.2 Selection of internal standard 
The internal standard selected for use was d9-finasteride due to similar 
behaviour to tamsulosin in all stages of extraction, chromatography and 
ionisation. Other internal standards screened were selected from the 
literature (Ramakrishna et al., 2005b) or by inference of similar structure but 
were not suitable for use as they ionised very poorly in positive electrospray 
mode, and required different extraction methods from tamsulosin to ensure 
reproducible recovery.  
 
4.4.3 Chromatographic conditions 
The addition of ammonium acetate to the aqueous mobile phase consistently 
resulted in increased peak areas for tamsulosin than acidic modifiers, and 
tamsulosin was not detected with water alone. Mobile phases containing 
methanol yielded better peak shape than acetonitrile and methanol was 
therefore selected as non-aqueous mobile phase. Flow rate and column 
temperature were optimised to enhance peak shape and area for tamsulosin.  
 
4.4.4 Extraction 
While a proportion of the analyte added was recovered following extraction 
by most methods tested (based on methods summarised in Table 4-1), the 
key developmental difficulties were maximising recoveries and ensuring 
 
 
Chapter 4: Measurement of tamsulosin via LC-MS/MS  187 
 
 
reproducibility in recovery. Reproducible recovery could not be obtained by 
any method tested without pre-extraction pH modification. Upon initial 
screening, liquid-liquid extraction (LLE) methods were taken forward with 
pre-extraction pH modification.  
 
4.4.5 Final extraction and chromatographic method taken 
forward for validation 
Serum (100 µL) was dispensed into a glass tube, and d9-finasteride (1 ng) 
added (as 10 µL of 100 ng/mL solution). NH4OH (0.1 M, 100 µL) was added 
and samples mixed (5 minutes, 100 rpm, KS 260 Basic shaker, IKA®, Staufen, 
Germany). Analyte and IS were extracted via a liquid-liquid extraction with 
MTBE (2 mL). Following mixing (5 minutes, 100 rpm), and centrifugation 
(1791g, 4 °C, 10 minutes), the supernatant was transferred to another glass 
vial. Extracted samples were dried under oxygen free nitrogen (40 °C) and 
the residue reconstituted in mobile phase (100 µL, methanol: 2 mM 
ammonium acetate, 5:95, v/v). Injection volume was 10 µL.    
 
Compounds were separated at 40 °C on an Ascentis® Express C18 column 
(100 x 3 mm, 2.7 µm, Sigma Aldrich, Dorset, UK), protected by a Hypersil 
C18 guard cartridge (10 x 3 mm, 3 µm, Thermo Electron, Hemel Hempstead, 
UK). Elution with excellent peak shape was achieved with a flow rate of 0.35 
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mL/min, using a gradient from 5:95 (methanol: aqueous ammonium acetate 
(2 mM)), with an initial hold of 0.5 minutes then a linear increase in organic 
mobile phase to 95:5 at 2.5 minutes and held until 3.5 minutes before re-
equilibration, with a total run-time of 6 minutes.  
 
Extraction method and chromatographic conditions optimised for tamsulosin 
were suitable for extraction, elution and detection of d9-finasteride. 
Representative chromatograms show tamsulosin and d9-finasteride from 
standard solutions (Figure 4.2) and from a patient sample enriched with only 
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Figure 4.2 Representative mass chromatograms of quantifier mass transitions 
for analyte, tamsulosin, 20 ng/ mL (upper panel) and internal standard, d9-
finasteride, 10 ng/ mL (lower panel) from spiked extracted serum.     
 
Figure 4.3 Representative mass chromatograms of tamsulosin (quantified as 
17.1 ng/ mL) extracted from a patient sample enriched with internal standard, 
d9-finasteride (10 ng/ mL).The patient had received tamsulosin (0.4 mg daily) 
for 90 days.   
Tamsulosin  
m/z 409 → 228  
d9-Finasteride  
m/z 382 → 318 
Tamsulosin  
m/z 409 → 228  
d9-Finasteride  
m/z 382 → 318 
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4.4.6 Assay validation 
Results from assay validation of LLE are summarised in Table 4-4.  
 
4.4.6.1 Recovery 
Analyte recovery was 99.9% (RSD 10.5%) and internal standard recovery was 
106.9% (RSD 13.3%).  
 
4.4.6.2 Ion suppression 
The presence of matrix did not significantly affect the intensity of response of 
tamsulosin (94.7% response, RSD 7.8%).  
 
4.4.6.3 Specificity 
Extracted blank matrix had no interfering peaks at, or close to, the retention 
times of tamsulosin or d9-finasteride. 
 
4.4.6.4 Limits of detection (LOD) 
Corresponding to a signal: noise ratio of 3, the LOD of tamsulosin was 1.28 
pg on column (0.13 ng/mL) and that of d9-finasteride was 1.46 pg (0.15 




Chapter 4: Measurement of tamsulosin via LC-MS/MS  191 
 
 
4.4.6.5 Limit of quantitation (LOQ) 
The intra-assay LOQ following extraction for tamsulosin was 2 pg on column 
(0.2 ng/mL, RSD 11.1%). 
 
4.4.6.6 Linearity  
The standard curve was demonstrated to be linear in the range 0.2-50 ng/mL 
with an average r value of 0.9952 (n=6) with 1/x weighting applied, and 
average intercept of 0.001 (n=6). A representative standard curve is shown in 
Figure 4.4.   
 
Figure 4.4 Representative standard curve with 1/x weighting applied. IS, 
internal standard.  
 
4.4.6.7 Precision and Accuracy 
Intra and inter-assay accuracy and intra-assay precision were acceptable 
(<20% RSD for precision and 80-120% accuracy) at the LOQ, and inter-assay 
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precision was acceptable from the low point (1 ng/mL) of the standard curve 
(RSD 7.9%). Above these values, variability relating to precision (RSD) and 
accuracy was <15% and were therefore acceptable. Results are summarised 
in Table 4-4.  
 
4.4.6.8 Stability 
Acceptable autosampler and extract storage stability were demonstrated 
(Table 4-5). Data collated from a single standard curve and patient sample 
reinjected following 24 hours in the autosampler (10 °C) were unchanged, 
with a relative response (stored/original) of 100.3%. Extracts reinjected 
following storage at -20 °C for 28 days had 93.9% response compared to the 
original run.  
 
4.4.6.9 Injector reproducibility 
Acceptable reproducibility upon repeat (n=6) injections of standards and 
sample was demonstrated with RSDs of: LOQ (0.2 ng/mL) 6%, low (1 
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LLOQ (0.2 ng/mL) 0.18 (0.02) 11.1 89.4 0.21 (0.07) 36.1 103.3 
Low (1 ng/mL) 1.1 (0.09) 7.9 111.4 1.1 (0.08) 7.4 100.5 
Mid (20 ng/mL) 22.8 (2.9) 12.9 114.1 23.2 (2.7) 11.8 104.3 
High (50 ng/mL) 45.7 (3.8) 8.3 91.5 49.0 (1.8) 3.8 96.8 
Patient sample 17.8 (0.97) 5.5  18.1 (1.0) 5.6  
 
Table 4-4 Summary table of precision and accuracy data, demonstrating acceptable intra-assay precision and accuracy to limits 
of 0.2 ng/mL. Inter-assay precision became acceptable at low point (1 ng/ mL) as defined U.S. FDA guidance (USFDA, 2001). 
SD, standard deviation; R, relative; LLOQ, lower limit of quantitation.  
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Initial run After 24 hours in 
autosampler 
After 28 days 
stored at -20 °C 
Relative 
response 
17.1 ng/mL 17.2 ng/mL  100.3% 
17.9 ng/mL  16.8 ng/mL 93.9% 
Table 4-5 Calculated concentration of tamsulosin in patient sample, 
demonstrating acceptable stability at 10 °C for 24 hours (in the autosampler) 
and at -20 °C for 28 days (in the freezer).  
 
4.5 Method application 
Analysis was performed as per the method described. For validation 
purposes the method was applied to samples from men who had received 
treatment (n=3), where concentrations of 16.7 – 36.1 ng/mL were quantified 
using 100 µL serum. These were within the quantitation limits of the assay. 
In serum obtained from men who had not received tamsulosin treatment 
(n=3), analyte was not detected (Figure 4.5). Results from clinical samples are 








Figure 4.5 Application of method to serum from patient enriched with internal 
standard, d9-finasteride (10 ng/mL). For validation, method was applied to 
serum from patients on tamsulosin (n=3), and patients not on tamsulosin (n=3) 
with representative chromatograms shown. A. Demonstrates tamsulosin was not 
detected in serum from a patient not receiving tamsulosin. B. Demonstrates 
tamsulosin was detected in serum from a patient on treatment with 0.4 mg 
monitored released tamsulosin daily for 90 days, corresponding to a 
concentration of 26.2 ng/mL. cps, counts per second.     
Tamsulosin  
m/z 409 → 228  
d9-Finasteride  
m/z 382 → 318 
 
 




The method developed is suitable for use for measurement of tamsulosin 
from human serum, and, in comparison to many other described methods, 
offers distinct advantages in terms of sample volume required (100 µL), limit 
of detection (0.13 ng/mL), ease of sample preparation and excellent analyte 
recovery (99.9%), a combination that has been missing from previous 
methods (Table 4-1). 
 
One of the challenges faced during development was achieving symmetrical 
chromatographic peaks, a common problem with basic analytes such as 
tamsulosin, which interact by ion-exchange with unprotected silanol groups. 
Tamsulosin has a secondary amine group with a pKa of 8.4 and problems 
with peak tailing has been encountered by other researchers (Ding et al., 
2002), typically requiring modification of the pH or buffering of the mobile 
phase. The addition of FA as a mobile phase modifier has been reported to be 
helpful (Ramakrishna et al., 2005a), aimed at reducing the pH less than 3 to 
ensure protonation of the silanol groups. However on our system basic 
rather than acidic modifiers were found to give a larger peak area for 
tamsulosin, while acidic modifiers yielded poor peak shape and impeded 
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Before optimising the mobile phase, stationary phases with differing 
selectivity were compared, including PFP and C18 phase columns. PFP 
stationary phase can be useful with analytes containing aromatic rings, such 
as tamsulosin, given their ability to interact by π-π or dipole-dipole 
interactions. However with tamsulosin, the C18 phase provided the most 
consistent intensity of peak area and the most symmetrical peak shape when 
compared to other columns. A consistent finding was that alteration of 
gradient did not significantly improve the extent of peak tailing but, rather it 
was selection of the column that made the greatest difference. Overall, of the 
columns tested, the Ascentis Express demonstrated the best peak shapes and 
resolution, possibly reflecting the nature of its end-capping and was taken 
forward for further method development. Column temperature was 
optimised to 40 °C, seen as an improvement in peak shape.    
 
Using the Ascentis column, trials of several aqueous mobile phases 
demonstrated the superiority of buffering with ammonium acetate in peak 
shape and area of both analyte and internal standard. This achieved a pH of 
7.38 at which approx. 90% of tamsulosin would be ionised, enhancing the 
intensity of mass spectrometric response. Varying concentrations of 
ammonium acetate showed 2 mM (pH 7.38) to be the optimum in terms of 
analyte peak area, while still retaining consistency in chromatographic 
response. Higher concentrations of ammonium acetate (achieving a pH of  
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6.6-6.9 at which tamsulosin would be expected to be close to 100% ionised) 
instead worsened peak areas, possibly due to the formation of ammonium 
adducts and associated ion suppression. Inconsistency in retention time was 
seen with lower (1 mM, 0.5 mM) concentrations, suggesting this was 
insufficient buffering capacity to overcome the silanol interactions. The 
addition of the stronger base triethylamine (TEA) has been reported to 
reduce peak tailing (Ding et al., 2002), the principle for this approach being 
that the strong base competes with the more weakly basic analyte for 
interactions with silanols. However when it was tested as a modifier on our 
system this did not improve peak tailing.  
 
Under the final conditions selected, a total run-time of 6 minutes allowed 
high sample throughput. While shorter run-times of 2-3 minutes are 
described with isocratic methods (Matsushima et al., 1997, Ramakrishna et 
al., 2005a, Qi et al., 2004), when attempted on our system, these isocratic 
methods resulted in broad and tailing peaks, with decreased selectivity these 
(Schellinger and Carr, 2006). A shorter run time with gradient elution was 
not possible due to incomplete column re-equilibration.  
 
Extraction methods published largely utilise traditional solid-phase (SPE) 
and liquid-liquid extraction (LLE) processes. Several extraction methods 
were compared during method development including LLE, supported 
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liquid, and SPE. Without modifying the pH of samples prior to extraction 
there was unacceptably high variability in replicate sample response with all 
approaches, probably a reflection of tamsulosin being partially ionised at 
neutral pH. As in other publications, a notable feature is the need for pre-
extraction pH modification with basic modifiers such as NaHCO3 (Ding et 
al., 2002, Matsushima et al., 1997), Na2CO3 (Qi et al., 2004, Macek et al., 2004) 
or NaOH (Ramakrishna et al., 2005a). LLE was taken forward with pH 
modification. A number of basic (ammonium acetate, ammonium hydroxide, 
sodium bicarbonate, sodium hydroxide) modifiers were tested in order to 
stabilise analyte extraction efficiency via LLE; the strongest base tested, with 
a pH of 10.9, ammonium hydroxide provided the best response in terms of 
peak areas and most consistent response with acceptable RSDs between 
replicate samples for both analyte and internal standard. Several extracting 
solvents were compared including ethyl acetate and hexane which gave poor 
and inconsistent recovery, diethyl ether and dichloromethane which gave 
consistent but very poor recovery. Following method optimisation (solvent 
type, proportions, multiples of extraction), excellent recovery and consistent 
responses were achieved with a liquid-liquid extraction with 20 volumes 
MTBE, to 1 volume sample, following mixing with 0.1 M ammonium 
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The ideal internal standard behaves in a similar fashion to the analyte 
throughout the extraction and analytical process. In the absence of a 
commercially available deuterated internal standard, structurally similar 
compounds (trichlormethiazide, ketoconazole and phthalylsulfathiazole) 
were explored as potential internal standards. Trichlormethiazide 
quantitation has been described with tamsulosin as internal standard due to 
structural similarities (Ramakrishna et al., 2005b), and both ketoconazole and 
phthalylsulfathiazole also share structural similarities with tamsulosin. 
However, while extraction efficiency of trichlormethiazide was reproducible, 
extraction of ketoconazole and phthalylsulfathiazole required pre-extraction 
pH modification that differed to conditions suitable for tamsulosin. In 
addition, none of these compounds behaved in a manner similar to 
tamsulosin in the mass spectrometer with very poor ionisation efficiency in 
positive ESI mode. Indeed most potential internal standards tested were well 
suited to ionisation in negative mode; however negative ionisation efficiency 
of tamsulosin was unsuitable for expected clinically-relevant concentrations. 
While switching between positive and negative ionisation modes is possible, 
this approach was not pursued. The internal standard ultimately selected 
was deuterated finasteride, which had been synthesised for use in the assay 
described in Chapter 3. While lacking in structural similarities to tamsulosin, 
d9-finasteride was well suited as an internal standard due to its very similar 
behaviour throughout the analytical process including extraction, ionisation 
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and detection. As tamsulosin is primarily used in treatment of BPH, where it 
is frequently co-prescribed with finasteride, it was important not to use 
unlabelled finasteride as internal standard. Analyte and internal standard are 
well resolved by chromatography, separated by mass, and the use of both 
quantifier and qualifier ions added further confirmation of specificity. While 
not optimised in the method described, due to its suitability for use with d9-
finasteride, results suggest this method may be easily adapted to also 
measure finasteride. This would be particularly useful in other clinical 
studies in BPH where finasteride and tamsulosin are often used in different 
treatment groups, or administered as combination therapy. 
  
Analyte specificity was ensured through use of LC-MS/MS analytical 
technique, together with monitoring of both quantifier and qualifier mass 
transitions. Metabolites of tamsulosin have different molecular weights to 
tamsulosin (Taguchi et al., 1997), and would therefore generate different 
precursor ions and mass transitions from their parent drug. 
 
The method developed was suitable for measurement of tamsulosin from 
human serum, and, in comparison to many other described methods, offers 
distinct advantages in terms of sample volume required (100 µL), limit of 
detection (0.13 ng/mL), ease of sample preparation and excellent analyte 
recovery (99.9%), a combination that has been missing from previous 
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methods. The method was validated and conformed to internationally 
accepted standards. Expected concentration of tamsulosin fell within the 
linear range of the standard curve. Intra- and inter-day precision and 
accuracy were acceptable and stability testing demonstrated the assay to be 
applicable to normal laboratory practice. The described assay was 
successfully applied to samples taken from research volunteers taking 


















Chapter 5: The effects of inhibition of 5-
reductases on metabolic health in men 
 
 




5αRs catalyse reduction of a range of steroid hormones, including androgens, 
glucocorticoids, progesterones and mineralocorticoids (Russell and Wilson, 
1994). Metabolites are either more or less active than their parent steroid, and 
in some cases the activity of the metabolite remains uncertain. The best 
understood pathway of 5αR metabolism is the conversion of the androgen 
testosterone to its more potent metabolite, DHT. Inhibition of this pathway 
with 5αR inhibitors could conceivably have detrimental effects due to a 
decrease in DHT in tissues such as liver and adipose. A decrease in androgen 
action in liver, modeled through liver-specific genetic disruption of  AR in 
male mice, results in hepatic steatosis and insulin resistance following a high-
fat diet (Lin et al., 2008). Similarly, in adipose, male mice with fat-specific AR 
knockdown develop insulin resistance and later insulin deficiency and, when 
high-fat fed, this is further compounded by a susceptibility to increased 
visceral adiposity (McInnes et al., 2012).   
 
In addition to effects on androgen metabolism, 5αR inhibition may also 
adversely affect metabolic health by alterations in glucocorticoid metabolism. 
Global attenuation of tissue glucocorticoid regeneration is protective to 
metabolic health, as demonstrated following transgenic disruption of 
11HSD1 in murine models (Kotelevtsev et al., 1997, Morton et al., 2004) and 
use of 11HSD1 inhibitors in humans (Rosenstock et al., 2010). In addition, 
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tissue specific elevation in glucocorticoid concentrations in liver and adipose 
tissue are associated with features of the metabolic syndrome (Paterson et al., 
2004, Masuzaki et al., 2001). One of the cortisol inactivating enzymes, 
11βHSD2, when absent or deficient (Wilson et al., 2001), when inhibited  by 
liquorice (Stewart et al., 1987), or in knockout mouse models (Kotelevtsev et 
al., 1999) shows predisposition to cortisol-induced hypertension. 
Overexpression of adipose 11βHSD2 in a murine model is protective against 
the metabolic syndrome (Kershaw et al., 2005). Upon this background, it 
follows therefore that other enzymes, such as 5Rs, regulating glucocorticoid 
concentrations in tissues including liver or adipose may also influence 
metabolic health. Specifically, impaired inactivation of glucocorticoids by 
5αRs may induce accumulation of glucocorticoids in tissues with adverse 
metabolic consequences. 
 
Preclinical data support this concept. In contrast to humans where both 
isozymes are expressed in liver, rats have only 5αR1 expressed in hepatic 
tissues, and mice express predominantly 5R1 (Table 1-1). Male mice null for 
5αR1 (5αR -/-; (Mahendroo et al., 1996)), when fed a ‘western’ (high fat, high 
sugar) diet developed obesity and hepatic steatosis, in addition to both 
fasting and post-glucose hyperinsulinaemia (Livingstone et al., 2008). A 
study in obese Zucker rats treated with finasteride (which, in contrast to 
humans, inhibits both 5αR isozymes in the rat (Azzolina et al., 1997)) 
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demonstrated a propensity towards fatty liver and impaired glucose 
tolerance (Livingstone et al., 2009a). However there is a dearth of studies of 
metabolism in man following 5R inhibition, with existing reports restricted 
to measures of fasting glucose (Amory et al., 2007). A key limitation in 
literature to date was the lack of a randomised trial in humans with detailed 
dynamic assessment of insulin sensitivity in response to 5αR inhibition.  
 
Inhibitors of 5αR have been developed for the treatment of disorders such as 
benign prostatic hyperplasia, where reduced conversion from testosterone to 
the more potent androgen DHT reduces prostate size and thus improves 
obstructive urinary symptoms. Finasteride inhibits 5αR2 alone, while 
dutasteride is a dual isozyme inhibitor. While not their therapeutic intent, 
drugs inhibiting 5αR could also have consequences for other steroid 
metabolic pathways, including glucocorticoids. Slower glucocorticoid 
metabolism could, in theory, lead to an elevation in intra-tissue cortisol 
concentrations at sites where these enzymes are expressed, and importantly 
for this thesis liver and adipose. Since elevation of intra-tissue cortisol 
concentrations in other contexts is associated with features of the metabolic 
syndrome, particularly dyslipidaemia, obesity and insulin resistance, it 
follows that pharmacological inhibition of 5αR in man may lead to clinically 
significant adverse metabolic effects.  
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Isozymes of 5αR differ in their tissue distribution and this also varies 
between species; broadly 5αR1 is primarily expressed in metabolic tissues 
such as liver and 5αR2 is primarily expressed in reproductive tissues such as 
prostate (Table 1-1), with some 5R2 also expressed in human liver. Given 
the observed differences in tissue distribution, it was hypothesised that 
metabolic dysfunction would be observed to a greater degree following 
inhibition of 5αR1 rather than 5αR2. In practice, since sole 5R1 inhibitors are 
not available, the adverse effects might be manifest to a greater degree when 
both isozymes of 5αR are inhibited (with dutasteride), compared to 
inhibition of 5αR2 alone (with finasteride). Human 5αR2 deficiency is not 
described to have associated adverse metabolic consequences, however in 
the rare cases where a decrease in 5α reduction of cortisol was noted (Fisher 
et al., 1978), the metabolic consequences are not described. While a mouse 
model with genetic disruption of 5αR1 is widely used (Mahendroo et al., 
1996), 5αR1 deficiency is not a known clinical entity in humans. Therefore 
pharmacological inhibition with dutasteride is currently the only means of 
investigating the consequences of 5αR1 inhibition in humans.   
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5.2 Hypothesis and Aims 
5.2.1 Hypothesis 
The principal hypothesis investigated was: 
Inhibition of 5-reductases causes, or exacerbates, features of the 
metabolic syndrome, particularly insulin resistance. This effect may be 
mediated by increased glucocorticoid action in metabolic tissues.  
An additional arm of the study investigated the effects of inhibition of 5Rs 
on HPA axis function. The background and hypothesis for this further work 




The aims of the study were to:  
a) Establish whether pharmacological inhibition of 5αR in humans 
has an adverse effect on insulin sensitivity, resulting in alterations 
of glucose and lipid homeostasis.  
b) Establish whether metabolic sequelae of 5αR inhibition are more 
pronounced with inhibition of 5αR1 and 5αR2 (with dutasteride), 
compared to inhibition of 5αR2 alone (with finasteride).  
 
 




This section details the clinical methods used, initially describing the study 
design (Sections 5.3.1, 5.3.2, and 5.3.3), followed by each stage of the clinical 
study protocol (Section 5.3.4) and finally detailing clinical and analytical 
methods utilised in the study (Sections 5.3.5 to 5.3.8). Laboratory methods 
developed in support of this study are described in Chapters 3 and 4, and 
general laboratory methods used are described in Chapter 2.   
 
5.3.1 Study design  
Study design was that of a prospective, double-blind, randomised controlled 
study, with three treatment arms (dutasteride, finasteride, tamsulosin).   
 
The study protocol included an initial screening visit (study day ‘A’), an 
assessment of metabolism (study day ‘B1’) and an assessment of HPA axis 
function (study day ‘C1’). Volunteers were then randomised to treatment 
with one of three arms – dutasteride (a dual 5αR1 and 5αR2 inhibitor), 
finasteride (a 5αR2 inhibitor) and tamsulosin (an α1 adrenergic antagonist, 
used as control group). Treatment was for 3 months, with standard doses 
used in therapy of benign prostatic hyperplasia, after which volunteers 
returned for a repeat assessment of metabolism (study day ‘B2’) and HPA 
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axis function (study day ‘C2’), as well as an MRI scan for assessment of 
abdominal and hepatic fat.   
 
An overview of the initial study design is presented in Figure 5.1. 
 
 













Patients recruited from nurse Urology clinics 
Day ‘A’: Screening Visit 
Day ‘B1’: Pre-treatment metabolic assessment 
(including adipose biopsy and clamp) 
24 hour urine and saliva collections 
Three months of treatment (double blind, randomised) with: 
Tamsulosin 0.4 mg daily (control), Dutasteride 0.5 mg daily, or 
Finasteride 5 mg daily. 
24 hour urine and saliva collections 
Day ‘B2’: Post-treatment metabolic assessment 
Urology clinic follow up 
Day ‘C1’: Pre-treatment testing of HPA axis           
(low dose dexamethasone and short Synacthen tests) 
 
Day ‘C2’: Post-treatment testing of HPA axis 
and MRI scan 
MRI liver/ abdominal fat  
 
Figure 5.1 Summary of initial study protocol. HPA, hypothalamic 
pituitary adrenal; MRI, magnetic resonance imaging 
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5.3.2 Power calculations, sample size and interim analysis 
This study was designed to enrol 99 men (33 in each arm of the study). 
Sample size calculations were performed using PS Power and Sample Size 
Program, version 3.0.14 (Dupont and Plummer, 1990). Ideally power 
calculations would be based on pilot data from a related study. However, a 
directly comparable study with paired population mean and variance data 
was unavailable at the time of planning, therefore calculations were based on 
mean (SD) glucose disposal rates during hyperinsulinaemia of 3.85 (0.88) 
mg/kg/min in a study 6 obese men treated with 7 days of carbenoxolone (a 
non-selective 11βHSD1 inhibitor) (Sandeep et al., 2005). The use of 
carbenoxolone did not alter insulin sensitivity in obese men studied. It was 
felt appropriate to use this study of obese men (rather than lean men) in the 
power calculations as the phenotype observed in animal models was in male 
mice on a high-fat diet with associated weight gain, therefore this was 
thought to be more comparable to the study planned. Using these data, to 
achieve 90% power to detect a 15% difference in glucose disposal rates to 
statistical significance (defined as p<0.05), a calculated sample size of 26 per 
group was required. A final group size of 33 per group was chosen, allowing 
for a > 20% dropout rate.   
 
A single planned interim analysis was conducted when approximately half 
of the planned volunteers had completed participation (n=38), as the initial 
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power calculations had not been based on paired data and therefore had 
possibly over-estimated the sample size required. Data analysed at the 
interim analysis were M values during hyperinsulinaemia in baseline and 
post-treatment clamps, with a p value of <0.016 (p<0.05/ 3 groups) deemed 
in advance to be sufficient for stopping the study early. Interim results 
demonstrated a decrease in insulin sensitivity with dutasteride treatment 
compared to both finasteride and tamsulosin treated groups, with p values of 
0.002 and 0.003 respectively. Based on these interim data, all volunteers 
enrolled in the study completed their participation, however no further 
recruitment took place and the study was stopped early. Data presented in 
this thesis are results from the final analysis only. There was no statistical 
adjustment made for the repeat assessment of the M value in the final 
analysis.  
 
5.3.3 Ethical and Service Approvals for Study 
The study was subject to peer review and supported by the Chief Scientist 
Office (CZB/4/642). Approvals from the Lothian Research Ethics Committee 
(09/S1101/33) and Research and Development (2009/W/END/01) office 
were obtained. Research support arrangements through the Western General 
Hospital (WGH) Urology service, Wellcome Trust Clinical Research Facility 
(E09732), laboratories at the WGH and the Royal Infirmary of Edinburgh 
(RIE), Scottish Brain Research Imaging Centre, RIE Radiopharmacy, WGH 
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Pharmacy, Tayside Pharmaceuticals (Dundee, UK) and the Scottish Primary 
Care Research Network (SPCRN) were obtained. The Medicines and 
Healthcare products Regulatory Agency (MHRA) confirmed that the study 
was not a Clinical Trial of an Investigational Medicinal Product, and 
therefore the study was conducted as a research study rather than a clinical 
trial, and did not have an assigned clinical trials number or a data 
monitoring committee. An internal independent advisor, Professor Jane E 
Norman (Centre for Reproductive Health, University of Edinburgh), 
provided informal advice during the implementation of the study. Dr 
Rebecca Reynolds (Endocrinology Unit, University of Edinburgh) was the 
internal independent contact for potential volunteers.  
 
5.3.4 Study protocol 
5.3.4.1 Inclusion and Exclusion Criteria 
Inclusion criteria were men aged 50 - 80 years with symptomatic BPH 
requiring medical therapy. This was later widened to include all men aged ≥ 
20 years (Study design and key amendments, Section 5.3.1), with healthy 
volunteers comprising the majority of participants studied, as presented in 
Section 5.4.4. Exclusion criteria were 5αR inhibitor use in previous 3 months, 
glucocorticoid use in previous 3 months, diabetes mellitus, impaired glucose 
tolerance, significant hepatic, renal or thyroid disease, hypogonadism, 
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In the initial study protocol, patients with diagnosed BPH were recruited 
from Urology clinics at the Western General Hospital, Edinburgh. Eligible 
and interested patients were given a patient information sheet to read, then 
phoned at a convenient time. If interested, they were invited to attend a 
screening visit.  
 
Due to difficulties with recruitment, the final study protocol was modified 
(Section 5.4.1) with the following key differences:  
 Recruitment was extended to also include both primary care patients 
and healthy volunteers.  
 Primary care recruitment was conducted with the assistance of the 
Scottish Primary Care Research Network (SPCRN). SPCRN 
identified and recruited practices, and if consenting, searched 
primary care databases and generated a list of potential 
participants whose names were reviewed by the GP before 
invitations were sent out. The candidate was responsible for 
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gaining appropriate approvals, compiling recruitment packs and 
all follow up of patients who responded.  
 Healthy volunteers were recruited by advertising in newspapers, 
online and on poster boards around Edinburgh (principally at 
University of Edinburgh sites) and participation followed the 
same study protocol, though without any urological assessment or 
follow up. 
 Age of eligibility was widened to include those ≥ 20 years. 
 Study days C1 and C2 were made optional.  
 Volunteer payments (in addition to travel expenses) were introduced 
from subject 6 onwards.   
 
5.3.4.3 Study day A 
Study day A, the screening visit, was scheduled at a convenient time of day 
and involved discussion of the study and review of the inclusion and 
exclusion criteria to ensure eligibility. If informed consent was obtained, 
participants were included in the study and a subject number was assigned 
at this stage. Clinical records were reviewed and, if not performed 
previously, a digital rectal examination was done (or organised through the 
patient’s general practitioner). Height (Section 5.3.5.2), weight (Section 
5.3.5.3), blood pressure and pulse (Section 5.3.5.1) were taken, along with 
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screening blood tests (full blood count, liver, kidney and thyroid function 
and random glucose, analysed as described in Chapter 2.14) collected by 
venepuncture from the antecubital fossa. Patients were asked to complete a 
24 hour urine collection (Section 5.3.5.8) and saliva samples (waking, 30 
minutes after waking, noon, 4pm, and bedtime) (Section 5.3.5.9) prior to the 
next study day.  
 
5.3.4.4 Study day B 
Study day B was designed to assess metabolism. Patients were asked to 
attend at 7:30 am, fasted from 10 pm the previous evening. Measurements for 
height, weight, systolic and diastolic blood pressure and pulse rate were 
repeated as per study day A. Hip and waist circumference were measured 
(Section 5.3.5.4) and bioimpedance measurements performed (Section 
5.3.5.5). Basal fasting blood samples were taken (Section 5.3.5.6.1). Biopsies of 
subcutaneous abdominal adipose were taken (Section 5.3.5.10). A 
euglycaemic hyperinsulinaemic clamp was then carried out (Section 5.3.5.6).  
 
5.3.4.5 Study day C 
Study day C was designed to assess the HPA axis. The evening prior to the 
visit, patients were asked to take 250 µg (EC50 dose; (Reynolds et al., 2001)) 
dexamethasone (Essential Generics, Surrey, UK) orally at 10 pm and then 
remain fasted and attend at 7:30 am the following morning. A 20 gauge 
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cannula was inserted in the antecubital fossa and half an hour later a blood 
sample was taken. All sampling was from the inserted cannula (with the 
initial 2 mL of blood discarded) and blood was collected in lithium heparin 
tubes. Synacthen (1 µg; EC50 dose; (Daidoh et al., 1995)) was administered IV, 
and flushed with normal saline (0.9%, 10 mL). Further sampling was 
performed at 20, 30, 40 and 60 minutes. All samples were used for 
measurement of plasma cortisol (Chapter 2.6) and in addition baseline 
samples were also used for measurement of dexamethasone and 
dexamethasone metabolites (Chapter 2.13).  
 
5.3.4.6 Treatment  
Volunteers were randomised to double-blind once-daily treatment with one 
of tamsulosin MR (0.4 mg daily), dutasteride (0.5 mg daily) or finasteride (5 
mg daily) for a period of 3 months (Section 5.3.6.1).  
 
5.3.4.7 Reassessment post treatment including repeat study days B 
and C 
At the end of the three month treatment period, participants were asked to 
return with a repeat 24 hour urine and saliva collection. Study days B and C 
were repeated in the same manner as pre-treatment tests. An MRI scan 
(Section 5.3.5.7) was performed in those without contra-indications to 
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scanning. Measurements were for intra-abdominal fat volume and proton  
spectroscopy to assess liver fat content. 
 
5.3.4.8 Assessment of compliance with treatment allocation 
Adequate compliance was deemed to be presence of drug in serum, 
measured by LC-MS/MS (Chapters 3 and 4). In addition, pills remaining 
were counted at the end of the study, and suppression of concentrations of 
5-reduced steroids in serum and urine (for the 5R inhibitors) was assessed, 
however these were not regarded as defining compliance.  
 
5.3.5 Clinical methods 
5.3.5.1 Measurement of systolic and diastolic blood pressure and pulse 
rate 
Systolic and diastolic blood pressure and pulse rate were measured after 
sitting for at least 10 minutes using a 705IT automatic blood pressure monitor 
(OMRON Healthcare, Hoofddorp, The Netherlands).   
 
5.3.5.2 Measurement of standing height 
Volunteers stood, without shoes, with feet parallel and head, shoulder blades 
and heels against the back of the wall mounted ruler. Measurement at the top 
of the head was recorded to the nearest 0.1 cm.  
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5.3.5.3 Measurement of weight 
With outdoor clothing, shoes and heavy items from pockets removed, 
volunteer weight was measured in kilograms on an electronic scale (Seca, 
Birmingham, UK) after the instrument was calibrated.  
 
5.3.5.4 Measurement of hip and waist circumference 
Waist circumference was measured in a horizontal line, level with the 
umbilicus, with the volunteer standing with their hands by their sides, using 
a non-extensible measuring tape (Lufkin executive W606P). In the same 
standing position, hip circumference was measured by wrapping the tape 
measure around the buttocks and measurement taken at the point of 
maximum circumference. Measurements were made to the nearest 0.1 cm. 
Waist: hip ratio (WHR) was calculated as the waist circumference divided by 
the hip circumference.  
 
5.3.5.5 Assessment of body fat  
Body fat in mass and percentage was measured by electrical bioimpedance 
using an OMRON BF306 Body Fat Monitor (OMRON Healthcare (UK) Ltd, 
Henfield, UK) All measurements were conducted in the morning and 
following an overnight fast, though water intake was not regulated or 
recorded. The monitor was pre-set with the volunteer’s height, weight, age 
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and gender. Manufacturer reported detectable range for body fat was 5 – 
50%, and validated for use in ages 10 – 80 years. If aged > 80 years, 
bioimpedance was performed with age entered as 80 years and no 
adjustment to data was made for this. Electrodes were hand-to-hand, with 
weak alternating current (50 kHz, 0.5 mA) applied. Volunteers stood with 
their feet apart and arms held out at 90º, with the palm of each hand placed 
firmly on both electrode handles with fingers wrapped around the handles.  
Readings for body fat in kg and % were given by the monitor and results 
were taken as the average of three consecutive readings.  
 
5.3.5.6 Hyperinsulinaemic euglycaemic clamp with deuterated glucose 
and glycerol tracers 
A hyperinsulinaemic euglycaemic clamp was conducted for assessment of 
insulin sensitivity (method summarised in Figure 5.2). Three cannulae were 
inserted – two for venous infusions and one contra-lateral hand vein cannula 
inserted retrogradely for sampling arterialised blood during the clamp. The 
hand veins were 'arterialised' by external heating (Dreamland, Wirral, UK) 
throughout the clamp. The initial phase of the clamp was administration 
(Braun Infusomat® Space pump) of stable isotope tracers (Section 5.3.6.3). An 
initial priming bolus (over 1 minute) was administered (d2-glucose 17 
µmol/kg; d5-glycerol 1.6 µmol/kg) to decrease time required to reach steady 
state. A tracer infusion was then commenced (d2-glucose 0.22 µmol/kg/min; 
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d5-glycerol 0.11 µmol/kg/min) and continued throughout the clamp. The 
second phase (90 - 180 minutes) consisted of low-dose Actrapid® insulin 
infusion (10 mU/m2/min - for inhibition of lipolysis and assessment of 
hepatic glucose output), with parallel 20% dextrose infusion adjusted to 
maintain euglycaemia. The third phase (180 - 270 minutes) consisted of high-
dose Actrapid® insulin infusion (40 mU/m2/min – for assessment of 
peripheral glucose uptake), again with 20% dextrose infusion adjusted to 
maintain euglycaemia.  Four steady state plasma samples were taken over a 
20 minute period at the end of each phase. Glucose levels were clamped 
throughout at 4.5 - 5.5 mmol/L, as measured in whole blood from 
arterialised sample by glucometer (Accu-Check® Advantage, Roche, 
Germany). 
 
5.3.5.6.1 Blood sampling during study day B 
Sampling of fasting baseline blood was immediately following insertion of a 
20 gauge anterograde intravenous cannula, subsequently used for infusions. 
Samples were used for measurement of: glucose (Chapter 2.14), insulin 
(Chapter 2.14), C-peptide (Chapter 2.14), androgens and 5αR inhibitor drugs 
(Chapter 3), tamsulosin (Chapter 4), DHEAS (Chapter 2.5), cortisol (Chapter 
2.6), CBG (Chapter 2.7), adipokines (Chapter 2.9), SHBG (Chapter 2.14), and 
oestradiol (Chapter 2.14).  
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To obtain samples from arterialised hand vein cannula during clamps, the 
saline infusion keeping the cannula patent was discontinued, approximately 
2 mL of blood/saline was removed and discarded, and the sample was then 
taken before the infusion of saline was resumed. Arterialised plasma samples 
were used for measurement of: glucose levels by glucometer during clamp 
(Section 5.3.5.6), and for later measurement of d2-glucose, glycerol and d5-
glycerol (Chapter 2.11), insulin (Chapter 2.3) and NEFAs (Chapter 2.8).  
 
 
Figure 5.2 Schematic of hyperinsulinaemic euglycaemic clamp, consisting of 
three 90 minute phases. Deuterated tracers were given throughout clamp, with 
insulin administered in second (low dose insulin) and third (high dose insulin) 
phases of the clamp. 20% Dextrose was co-administered with insulin to 
maintain euglycaemia. Arrows represent sampling timepoints. BGL, blood 
glucose level.  
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5.3.5.7 Magnetic resonance imaging  
Volunteers without contra-indications to scanning underwent magnetic 
resonance imaging (MRI) for intra-abdominal visceral and subcutaneous fat 
volumes, proton spectroscopy for liver fat measurements and structural 
images for clinical reporting. Scans were performed on a GE Signa Horizon 
1.5T HDxt clinical scanner (General Electric, Milwaukee, USA) equipped 
with a self-shielding gradient set (33 mT m-1 maximum gradient strength) 
and manufacturer supplied Torso Array coil.  
 
5.3.5.7.1 Visceral and subcutaneous abdominal adipose 
Images for abdominal visceral and subcutaneous fat volumes were acquired 
in 10 mm slices with Iterative Decomposition of water and fat with Echo 
Asymmetry and Least-squares estimation (IDEAL) sequence, an imaging 
application designed for optimised fat quantitation.  
 
Acquired samples were anonymised prior to interpretation. Measurements 
for abdominal fat were made with sliceOmatic version 4.3 (TomoVision, 
Magog, Quebec, Canada) software. Areas identified as either subcutaneous 
or visceral were identified by colour coding, and quantified with the 
programme software. All scans were analysed in 5 slices, with the central 
slice located at the L4/5 level. For comparison, data were analysed as both 
single slices at L4/5 and in 5-slice groups centred at L4/5. There was a 
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maximum difference of 2.7% in measured fat content and the two measures 
did not differ significantly, therefore single slice measures were utilised in 
data analysis.   
 
Volume of adipose was expressed as estimated mass by taking into account 
the density of adipose tissue. The density assumed for results presented was 
0.92 g/mL.  
 
Intra-rater reproducibility was assessed by repeated (n=2, different days) 
measurement of all parameters on 6 scans, independently anonymised and 
randomly selected.  Average coefficient of variation was calculated (standard 
deviation /mean * 100), and accepted if < 10% for each of visceral fat, 
subcutaneous fat, or abdominal volume. Acceptable results were obtained 
with mean CV of 6.9% for visceral fat, 2.2% for subcutaneous fat and 0.3% for 
abdominal volume.  
 
5.3.5.7.2 Liver 1H magnetic resonance spectroscopy  
Single voxel proton MR spectroscopy was performed for assessment of 
hepatic fat, using the body coil of the same scanner, using a point-resolved 
spectroscopy sequence (PRESS), with water suppression. The voxel was 
positioned using structural T2 images obtained during breath hold 
(inspiration). Voxel size was 10 mm3 and was demarcated by 6 saturation 
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bands (anterior, posterior, superior, inferior, left and right) reviewed in axial, 
coronal and sagittal planes. The voxel was positioned within the liver, 
avoiding the edge of the liver and major vessels. An example of voxel 
placement is shown in Figure 5.3. Spectra were acquired during free 
breathing, with echo time (TE) 40 ms and relaxation time (TR) 5000 ms.   
 
 
Figure 5.3 Representative axial image of voxel placement for MR spectroscopy, 
utilised for quantitation of fat in human liver. The voxel was 10 mm
3
 in size and 
was demarcated by saturation bands reviewed in axial, coronal and sagittal 
planes. The voxel was positioned over the liver in an area as devoid of vascular 
structures as possible.  
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Post-processing and quantification of MRS data was performed in jMRUI  
(Naressi et al., 2001a, Naressi et al., 2001b) using a nonlinear least-squares 
algorithm (AMARES, (Vanhamme et al., 1997)) with Gaussian line shapes to 
model each spectral peak of interest (e.g., water at 4.7 ppm, methylene fat at 
1.3 ppm). Fat fraction was subsequently defined as the ratio of the area under 
the fat peak to the combined areas under the water and fat peaks: 
 
 
Scans with a large fat fraction (> 20%) had all data manually reviewed and 
confirmed as technically reliable prior to inclusion.  
 
5.3.5.7.3 Images for clinical reporting 
To comply with ethical requirements, additional structural images (T2 liver) 
were acquired for clinical reporting by a radiologist checking for incidental 
findings, and all results were conveyed to the patient’s general practitioner.  
These images were not analysed as part of the study.  
 
5.3.5.8 Urine collection 
Volunteers were asked to collect 24 hour urine collections at home. Urine 
was collected from the second void after waking for a 24 hour period in a 
non-acidified collection bottle. Total volume was recorded and samples were 
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processed and stored as described in Section 5.3.7. Samples were used for 
measurement of urinary androgens and glucocorticoids, as described in 
Chapter 2.12.  
 
5.3.5.9 Saliva collection 
Volunteers were asked to complete a collection of 5 saliva samples during the 
day (waking, 30 minutes after waking, noon, 4 pm, and bedtime) using 
Salivette® collection tubes (Sarstedt, Sarstedt, Germany). Collections were 
separated from meals and other potential contaminants (e.g. toothpaste, 
cigarettes). Samples were processed and stored as described in Section 5.3.7. 
Samples were used for measurement of salivary cortisol, as described in 
Chapter  2.4.  
 
5.3.5.10 Biopsy of subcutaneous abdominal fat 
Local anaesthetic (2% Lignocaine, Hameln Pharmaceuticals, Gloucester, UK) 
was injected subcutaneously at a site lateral to, and directed towards, the 
umbilicus. A 14 gauge needle attached to a 30 mL syringe was inserted into 
subcutaneous adipose, the plunger of the syringe withdrawn to create a 
vacuum then held in place with a test tube (12 x 75 mm, Fisherbrand®, Fisher 
Scientific, Loughborough, UK) while a sample of adipose was obtained. 
Samples were washed (through Isopon™ aluminium mesh, DF Wishart, 
Edinburgh, UK) with DEPC water, then frozen immediately on dry ice before 
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storage (-80 ºC) for future analysis.  Three samples were obtained in the same 
manner. Fat biopsies were not collected if felt to be unsafe (due to very low 
amounts of subcutaneous abdominal fat). Samples were used for analysis of 
mRNA abundance of genes of interest (Chapter 2.10).  
 
5.3.6 Study medication and intravenous drug preparations 
5.3.6.1 Study medication randomisation and dispensing 
Volunteers were randomised to double-blind once-daily treatment with one 
of tamsulosin MR (0.4 mg daily, Synthon Hispania, Sant Boi de Llobregat, 
Spain), dutasteride (0.5 mg daily; Glaxo Smith Kline Pharmaceuticals 
(Poznań, Poland)) or finasteride (5 mg daily; Gedeon Richter (Budapest, 
Hungary)). Medication was dispensed in one bottle containing 100 capsules. 
 
Randomisation was performed independently of the investigation team, by 
Tayside Pharmaceuticals (Dundee, UK) through a computerised random 
number generator (http://www.randomization.com; reference seed 25371; 
created 09 December 2009). Randomisation method was fixed–size block 
randomisation (n=18 per block). No stratification or minimisation was used 
in the randomisation process. Allocation concealment was ensured by 
appropriate storage of the randomisation code (sealed envelope in locked 
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storage) so neither study personnel conducting study visits, nor study 
participants, could predict group assignment prior to study enrolment. 
 
The study was double-blind, with both investigator and participant blinded 
to treatment allocation throughout the study period. All medications were 
blinded (by enclosing in a hard gelatin capsule and packing with Lactose Ph 
Eur) and stored in numbered but otherwise identical bottles. Monthly contact 
was made with volunteers, and they were given a wallet-sized card with 
routine contact details for the candidate and emergency contact details for 
on-call pharmacy.  
 
Patient volunteers were unblinded at the end of the study period (at the 
earliest this was after the clamp on visit ‘B2’) to allow decisions regarding 
ongoing care. Healthy volunteers were unblinded at either the interim or 
final analysis.  
 
5.3.6.2 Sodium chloride (0.9%) 
Sodium chloride (0.9%) (Baxter, Thetford, Norfolk, UK) was used as a diluent 
for infusions and flush for cannulae.  
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5.3.6.3 Stable isotope tracers: d2-glucose and d5-glycerol 
Deuterated tracers were from Cambridge Isotope Laboratories, Inc. 
(Andover, USA). Chemical and isotopic purity were assessed by the 
manufacturer, and tracers were certified to be manufactured via a chemical 
route and therefore without risk of Transmissible Spongiform 
Encephalopathies.  
 
a) 6, 6- [2H]2-glucose (d2-glucose): ≥ 98% purity as determined by HPLC 
and ≥ 99% isotopic enrichment as determined by GC-MS. 
b) 1, 1, 2, 3, 3 – [2H]5-glycerol (d5-glycerol): ≥ 98% purity as determined 
by HPLC and ≥ 99% isotopic enrichment as determined by GC-MS. 
 
Tracers were prepared in sterile solutions by the Radiopharmacy (Royal 
Infirmary of Edinburgh, Edinburgh, UK), as follows: 
 
a) d2-glucose: 2.11 g / 6 mL, to give concentration of 350 mg/mL 
b) d5-glycerol: 380 mg/ 9.5 mL, to give concentration of 40 mg/mL 
Solutions were stored (-40 °C) for a maximum of 8 weeks.  
 
Solutions were defrosted and infusions prepared in the clinical research 
facility on the morning of each study.  
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Drug for infusion: 
d5-Glycerol (7.5 mL, 300 mg) was added to sodium chloride (0.9%, 489.3 mL) 
to give a volume of 496.8 mL. d2-Glucose (3.2 mL, 1.12 g) was added to make 
up to total of 500 mL. Final concentrations were: d5-glycerol 300 mg/ 500 mL 
and d2-glucose 1.12 g/ 500 mL. Infusion was administered as described in 
Section 5.3.5.6 .  
 
Drug for bolus: 
d5-Glycerol (0.5 mL, 20 mg) was added to sodium chloride (0.9%, 19.5 mL) to 
give a concentration of 1 mg/mL. d2-Glucose (1 mL, 350 mg) was added to 
sodium chloride (0.9%, 19 mL) to give a concentration of 17.5 mg/mL. 
Boluses were administered prior to infusion as described in Section 5.3.5.6.   
 
5.3.6.4 Insulin 
The infusion was prepared from 100 IU/ mL vial of Actrapid® insulin 
(Actrapid®, Novo Nordisk, West Sussex, UK). Actrapid (0.3 mL, 30 IU) was 
added to 0.9% sodium chloride (100 mL) to give a final concentration of 0.3 
IU/mL, and was then infused as described in Section 5.3.5.6.    
  
5.3.6.5 20% Dextrose 
Dextrose infusion was dextrose (20%, w/v) (Baxter, Thetford, Norfolk, UK) 
containing 200 g anhydrous dextrose per 1000 mL water.  
 




Bolus for intravenous administration was prepared from 250 µg/mL vial of 
Tetracosactide (Alliance Pharmaceuticals Ltd., Chippenham, Wiltshire, UK; 
Tetracosactide is referred to as Synacthen throughout this thesis,). Synacthen 
(1 mL) was added to 0.9% sodium chloride (49 mL) to give a concentration of 
5 µg/mL.  Synacthen (1 µg as 0.2 mL of 5 µg/mL) was added to 0.9% sodium 
chloride (0.8 mL) to give a final concentration of 1 µg/mL, and was 
administered immediately, as described in Section 5.3.4.5.  
 
5.3.7 Sample collection tubes and sample processing 
All blood tubes used were S-Monovette® tubes (serum gel 7.5 mL or 4.9 mL 
to collect serum, lithium heparin 5.5 mL or 2.7 mL to collect plasma, EDTA 
2.7 mL to collect whole blood, fluoride gel 2.7 mL for glucose) from Sarstedt 
(Sarstedt, Germany).  
 
Samples not sent directly to NHS Lothian laboratories were processed on-site 
at the WTCRF following collection as follows, and stored for future analysis.  
 
Equipment used was: 
a) Sigma 4K15 Centrifuge (Münich, Germany) 
b) Micromail II scales (Salter Brecknell, Smethwick, UK) 
 




All blood samples collected were prepared by centrifugation (1912 g, 10 
minutes, 4 ºC) and collected plasma/ serum frozen (-80 ºC) for later analysis.  
 
The volumes of the 24 hour urine collections were measured, and 6 aliquots 
(~20 mL each) frozen and stored (-40 ºC) for later measurement of 
glucocorticoid and androgen metabolites (Chapter 2.12).   
 
Saliva was collected by centrifugation of the collection tubes (1912 g, 5 
minutes, 4 ºC) and frozen (-40 ºC) until analysis at a later date for salivary 
glucocorticoid concentrations (Chapter 2.4).  
 
Chapter 5: The effects of inhibition of 5α-reductases on metabolic health 
235 
 
5.3.8 Data analysis 
5.3.8.1 Body mass index 
Body mass index (BMI) was calculated as: 
 
 
5.3.8.2 Body surface area 
Body surface area (BSA) was calculated according to the Mosteller method 
(Mosteller, 1987) with the equation: 
 
 
5.3.8.3 Homeostatic model assessment of insulin resistance (HOMA-IR) 
HOMA-IR was calculated based on the original description (Matthews et al., 
1985) with the equation: 
 
where a higher value is indicative of lower insulin sensitivity. 
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5.3.8.4 Quantitative insulin sensitivity check index (QUICKI) 
QUICKI was calculated as originally described (Katz et al., 2000) with the 
equation: 
 
where a higher value is indicative of greater insulin sensitivity.  
 
5.3.8.5 M value 
In relation to the hyperinsulinaemic euglycaemic clamp, the mean steady 
state infusion rate of glucose (‘M value’) was calculated as the average 
infusion rate during the sampling period of 15 minutes at the end of the high 
dose insulin phase (+255 to +270 minutes) of the clamp.  
 
5.3.8.6 Glucose and glycerol tracer kinetics 
In order to calculate tracer kinetics during the hyperinsulinaemic 
euglycaemic clamp the following equations were used:  
 

















This equation was used to calculate the endogenous production of glucose at 
baseline (without insulin infusion) during the first phase of the clamp.  
 
However, during the next two phases of the clamp (low dose insulin, high 
dose insulin) glucose was also administered IV as part of the clamp (to 






Chapter 5: The effects of inhibition of 5α-reductases on metabolic health 
238 
 




This was equivalent to the rate of disposal of glucose.  
 





For both glucose and d2 glucose, the contribution of the mass + 0 isotope to 
the total amount is 92.5%, and the contribution of the mass + 2 isotope is 
1.1%. Appropriate corrections were applied to adjust both the infused 
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To calculate the rate of appearance of glycerol the following equations were 
used: 
 













For both glucose and glycerol kinetics, equivalent ionisation of both tracer 
and tracee was ensured by monitoring of enrichment curves, therefore the 
ratio of peak areas was deemed a robust assessment.  
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5.3.8.7 Statistical methods 
Statistical analysis was performed using SPSS for Windows software 
package, version 19 (IBM, Portsmouth, UK). Data analysed were of the 46 
volunteers who completed and were deemed compliant with the study 
treatment protocol (as defined in Section 5.3.4.8). Data are presented as mean 
(standard deviation, SD) unless otherwise stated. Comparisons are presented 
as mean (95% confidence interval), together with test of statistical 
significance. ANalysis of COVAriance (ANCOVA) is usually considered the 
ideal statistical method for randomised studies with pre- and post- 
intervention measures (Vickers and Altman, 2001). In order to use an 
ANCOVA as the statistical approach, it is important that the ANCOVA 
model fits the data. The key assumptions which need to be met are: a normal 
distribution, linear regression (a linear relationship between the post-
treatment and pre-treatment values), homogeneity of variance (similar 
scatter of individual data points around regression lines for each treatment 
group) and homogeneity of regression lines (similar, parallel, regression 
slopes for each treatment group). The latter (homogeneity of regression lines) 
is a key assumption in this model. In the present study while the ANCOVA 
was explored, it was not suitable for use, as the primary and many secondary 
endpoints in the study did not meet necessary assumptions, in particular 
regression lines were not parallel between treatment groups, invalidating 
this model. Expert statistical advice was received from Professor Gordon D 
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Murray (Centre for Population Health Sciences, University of Edinburgh) 
who advised that it would be inappropriate to pursue using an ANCOVA 
when the analytical assumptions are not met, and suggested changing of the 
statistical methodology to the simpler but still valid and robust method using 
analysis of change from baseline. While a repeated-measures ANOVA is 
used by some in such study designs, this was not felt to be appropriate as 
assumptions for this were not met including differences in group sizes, as 
well as a lack of sphericity (equal variance in the differences between 
treatment groups) in some endpoints. Analysis as change from baseline with 
post-hoc testing takes into account repeated measures and allows pairwise 
comparisons between groups.  
 
The final statistical method selected for use and presented in this thesis was 
comparison between treatment groups by ANalysis Of VAriance (ANOVA) 
on the change from baseline in each treatment group, unless stated otherwise 
in the text. Where ANOVA was significant (p < 0.05), further post-hoc testing 
was performed with a Least Significant Difference (LSD) test to allow 
pairwise comparisons. Data was tested for normality of distribution by visual 
assessment of histograms. Homogeneity of variance was tested by Levene’s 
test, and accepted if result was non-significant (p > 0.05). If needed and if 
appropriate, data transformation was tested by log, square root, square, and 
reciprocal, and the method selected was that which resulted in a normal 
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distribution. If assumptions were not met then non-parametric testing was 
used (Kruskal-Wallis test). For MRI scans, results were analysed as above 
though only for the post-treatment measure as there was no baseline 
measure. 
 
Statistical significance was taken at the 5% level. Where values are missing 
these are indicated and not imputed. Nor was there additional adjustment 
made for multiple comparisons. For statistical analysis, values below the 








5.4.1 Study design and key amendments 
In the first 9 months recruitment into the study from Urology clinics was 
poor, with only 2 patients enrolled (plus two withdrawals on medical 
grounds, Section 5.4.3.3). Review of recruitment revealed this was largely 
due to low numbers of patients seen in clinic, and also the majority of 
patients being ineligible for, or declining participation for reasons including 
the time commitment involved in the study or a reluctance to change 
medication.  
 
In order to address poor recruitment rates, during the next 7 months, a series 
of changes were made to the original protocol. Attempts were made to 
address concerns expressed by some patients with respect to time 
commitments required by making study day C optional, and potential loss of 
income due to attendance at study visits by introducing volunteer payments. 
Further efforts were made to improve access to Urology patients seen in 
clinics, and also extend recruitment to patients seen in primary care. Due to 
ongoing poor recruitment, recruitment of healthy volunteers was 
commenced.    
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5.4.2 Recruitment rates  
Recruitment improved with the implementation of changes described above, 
though still lagged significantly behind the original targets. Recruitment 
from the Urology Clinic slowed further after 1 year when other avenues of 
recruitment were prioritised. In total, 39 primary care practices were invited, 
3 practices agreed to assist, and a total of 37 patients were invited, of which 
30 were suitable for inclusion, and 7 agreed to participate. Healthy volunteer 
recruitment was primarily via advertising and later also by word of mouth. 
Overall response and recruitment rates are summarised in Figure 5.4.   
 
 



















255 Information sheets requested or sent 
95 Yes 160 No  
58 Attend 
screening 
7 Not consented/ 
Ineligible 
51 Consented 
44 Ineligible / 
Unable to participate 




46 Included in final analysis 
Figure 5.4 CONSORT diagram of overall recruitment rates. ‘Yes’ indicates an 
interest in participation, ‘No’ indicates either an unfavourable response or no 
response.  Two of the 4 volunteers who did not complete the study were 
assigned a study number following informed consent but did not participate 
further. CONSORT, consolidated standards of reporting trials (Moher et al., 
2012). 
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5.4.3 Compliance and study participation 
5.4.3.1 Pill count 
Pills missed (by pill count) were, on average, 4.1% (dutasteride), 3.7% 
(finasteride), and 3.2% (tamsulosin).  
 
5.4.3.2 Serum drug concentrations   
Dutasteride and finasteride were only detected in volunteers prescribed the 
medication, and neither was detected in those in the tamsulosin group. 
Dutasteride was not detected in serum of one subject in the dutasteride 
group, suggesting non-compliance with his assigned medication. In addition 
his serum DHT was not suppressed, nor his urinary steroids ratios 
(described for compliant subjects in Section 5.4.5) altered as expected with 
5αR inhibitor treatment. This volunteer was therefore excluded from 
subsequent study analyses.  Amongst other volunteers in the dutasteride 
group, serum levels detected were between 3.0 – 28.5 ng/mL, in line with 
expected concentrations (Chapter 3).  
 
All subjects in the finasteride group had detectable drug in serum, in the 
range 2.0 – 64.0 ng/mL, in line with expected concentrations (Chapter 3).  
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Tamsulosin was not detected in any volunteers who were not prescribed the 
drug in the study but was detected in serum from the six patients who were 
receiving this drug prior to randomisation into the study (range 2.8 – 12.9 
ng/mL). In samples taken at the end of the study, tamsulosin was detected in 
all patients who were in the tamsulosin group, and also the patient requiring 
rescue tamsulosin treatment (Section 5.4.3.3), with an average serum drug 
level of 8.3 ng/mL (range 1.7 – 15.2 ng/mL), in line with expected 
concentrations (Chapter 4).    
 
5.4.3.3 Study participation 
Of the 51 men who consented to participation, 4 did not complete the study. 
One volunteer was taken out of the study due to persistent subclinical 
hypothyroidism on biochemical screening, due to concerns this may impact 
on study outcomes. One volunteer receiving finasteride withdrew from the 
study due to the development of urinary retention and impotence early in 
the study period. A further two volunteers did not return for study visits 
following screening due to the development of unrelated illness  and 
subsequent inability to negotiate further time away from study and 
employment. Of the 47 volunteers who completed the study, 46 were 
included in the final analysis. As detailed above (Section 5.4.3.2) one 
volunteer (in the dutasteride group) had no detectable dutasteride in serum, 
therefore was excluded from the analysis. Measurement of body fat was not 
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possible in one volunteer (in the dutasteride group), due to amount of body 
fat being below the sensitivity of the bioimpedance instrument (< 5% body 
fat).  
 
One volunteer (from the finasteride group) did not attend for visits C1 or C2, 
therefore analysis of dynamic testing of the HPA axis was performed with 45 
volunteers (Chapter 6).  
 
One BPH patient developed intolerable symptoms upon cessation of his 
usual tamsulosin at the start of the study period; he was able to complete the 
study with partial unblinding and administration of unblinded tamsulosin 
MR 0.4 mg daily along with the blinded study medication (which was 
confirmed by the independent study advisor not to be tamsulosin in order to 
prevent over-medication). Adverse effects and outcomes are summarised in 
Table 5-1.  
 
 





Nature of adverse event 
(severity) 
Outcome 
Patient Subclinical hypothyroidism on 
biochemical screening  
Withdrawn  
Patient Urinary retention and 
impotence (severe) 
Withdrew  
Healthy Dizziness and diarrhoea (mild) Continued 
Healthy Diarrhoea (mild) Discontinued tablets for 3 
weeks, then recommenced 
with no further problems 
Healthy Impotence (mild) Continued 
Patient Worsening of BPH symptoms 
(moderate) 
Continued 
Patient Worsening of BPH symptoms 
(severe) 
Continued with rescue 
tamsulosin 
Patient Recurrence of chronic leg pain 
(mild) 
Discontinued tablets for 2 
weeks, then recommenced 
with no further problems 
Table 5-1 Summary of reported adverse events during study. The two subjects who 
temporarily discontinued tablets went on to complete at least 90 days of treatment 
before follow up visits were completed.  Severity of symptoms is as reported by the 
volunteer, not as defined by the Good Clinical Practice International Clinical Trial 
Harmonisation directives.    
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The study protocol specified 3 months of medication prior to follow-up 
visits. The average and range of days in the study is summarised by group in 
Table 5-2. The individual in the dutasteride group who had 111 and 112 days 
at visits B2 and C2 respectively had intermittently missed pills through the 
study therefore leaving him with additional days on medication past the 100 




Dutasteride Finasteride Tamsulosin 
N 16 16 14 
Days at 
visit B2 
Average 94.8 91.6 92.2 
Range 91 - 111 86 - 99 87 - 97 
N 16 15 14 
Days at 
Visit C2 
Average 97.6 93.5 95.1 
Range 93 - 112 87 - 101 89 - 100 
Table 5-2 Length of time participants were on prescribed study medication, 
indicating average, minimum and maximum by group. N, number.  
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5.4.4 Volunteer characteristics at baseline 
Volunteers were randomised to one of three treatment groups. Key 
characteristics of participants at baseline are summarised in Table 5-3.  
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 Dutasteride Finasteride Tamsulosin Difference 
N  16 16 14  
Age 35.3 (14.6) 40.3 (19.2) 49.4 (18.4) p=0.12 
BPH patients (N) 2 4 5 N/A 
BMI (kg/m2) 25.3 (4.41) 26.8 (3.82) 25.5 (2.76) p=0.49 
WHR 0.90 (0.08) 0.89 (0.07) 0.93 (0.06) p=0.39 
SBP (mmHg) 131.0 (11.43) 136.4 (14.91) 138.8 (18.26) p=0.35 
DBP (mmHg) 77.6 (9.96) 78.4 (11.19) 81.3 (8.85) p=0.58 
Body fat (kg) 16.5 (8.70)   (N=15) 18.9 (6.97) 20.1 (5.94) p=0.40 
Body fat (%) 19.8 (8.49)   (N=15) 22.1 (6.62) 24.7 (5.99) p=0.19 
Glucose (mmol/ L) 4.96 (0.49) 4.98 (0.50) 5.14 (0.37) p=0.54 
Insulin (pmol/L) 58.8 (23.79)  54.1 (17.85) 63.2 (32.97)  p=0.62 
C-peptide 
(pmol/L) 
539 (156.9) (N=15) 539.4 (172.9) 612.9 (295.7) p=0.57 
HOMA-IR 1.89 (0.79) 1.73 (0.63) 2.19 (1.14) p=0.54 
Total C (mmol/L) 4.41 (0.64) 4.87 (1.01) 5.20 (0.95) p=0.06 
TG+ (mmol/L) 1.25 (0.6) 1.21 (0.7) 1.35 (0.7) p=0.83+ 
Table 5-3 Key characteristics of study participants at baseline. Data are mean (SD). 
Blood tests presented were all fasting samples. In a randomised study any differences 
at baseline are recognised to occur by chance. When assessed by one-way ANOVA 
there were no differences between groups at baseline. 
+
Raw data is presented, 
however was log transformed for statistical analysis. N, number; BMI, body mass 
index; WHR, waist: hip ratio; S, systolic; D, diastolic; BP, blood pressure; HOMA-
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With the inclusion of healthy volunteers all groups were, on average, 
younger than most BPH patients, however as an indicator of whole body 5αR 
activity at baseline, the serum DHT: T ratio did not correlate with age, as 
seen in Figure 5.5.  
 
 
Figure 5.5 No correlation was observed between baseline serum DHT 
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In addition to the study drug, several volunteers were receiving other 
prescribed medications prior to commencing participation in the study. 
These are summarised in Table 5-4. There were no alterations to medications 
or medication doses during the study period. Of note, the volunteer on 
thyroxine was clinically and biochemically euthyroid for several years, and 
thyroid function was normal on biochemical testing at the screening visit.  
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α Blocker Tamsulosin A D F, G, H, I 
α Blocker Indoramin  E  
Anti-muscarinic Tolterodine   F 
Anti-muscarinic Solifenacin A   
Dyslipidaemia Lipid lowering drug Simvastatin B E J, K 
Hypertension Thiazide diuretic Bendroflumethiazide B   
ARB Losartan   J 
Primary MI prevention Anti-platelet  Aspirin C  J 
Dyspepsia PPI Lansoprazole   L 
Hypothyroidism Thyroid hormone Thyroxine   I 
Chronic back pain µ Opiod receptor 
agonist 
Tramadol (prn)   K 
Mild COPD β agonist inhaler 
(short-acting) 
Salbutamol (prn)   K 
Table 5-4 Medications at baseline, taken by participants in each group, with matching letters representing the same participant. 
ARB, angiotensin II receptor blocker; MI, myocardial infarction; PPI, proton pump inhibitor; prn, pro re nata (as needed); 
COPD, chronic obstructive pulmonary disease.  
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5.4.5 Pharmacodynamic responses to 5αR inhibitors 
5.4.5.1 Circulating steroids 
Serum androgen concentrations before and after drug treatment are 
summarised in Table 5-5.   
 
There was a decrease from baseline in serum DHT concentrations, to 
approximately the same degree with both dutasteride and finasteride, and in 
many volunteers DHT was still quantifiable post treatment. There were 5 
volunteers in the dutasteride group and 3 volunteers in the finasteride group 
in whom DHT was not detectable post treatment. As expected, DHT 
concentrations did not change with tamsulosin treatment. There was no 
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∆ Dutasteride   
vs. ∆ Tamsulosin 
Mean (95% CI) 
∆ Finasteride    
vs. ∆ Tamsulosin 
Mean (95% CI) 
∆ Dutasteride     
vs. ∆ Finasteride 
Mean (95% CI) 
N 16 16 14    
T 
nmol/L 
Pre  25.4 (8.91) 20.7 (8.81) 21.2 (8.48) Difference between groups: p=0.22  
Post  30.4 (12.80) 23.9 (7.93) 22.9 (9.48) 
Change  + 5.1 + 3.7 + 1.7 
DHT 
nmol/L 
Pre  2.9 (1.56) 2.1 (1.20) 2.0 (1.27) Difference between groups: p=0.02 
Post  1.8 (1.65) 1.0 (0.64) 1.7 (1.07) -0.9 (-1.5; -0.2) 
p=0.01 
-0.8 (-1.5; -0.2) 
p=0.01 
-0.0 (-0.6; 0.6) 
p=0.99 Change  - 1.2 -1.1 -0.3 
Table 5-5 Serum testosterone (T) concentrations were unchanged, however serum dihydrotestosterone (DHT) was significantly 
decreased following three months of dutasteride or finasteride. Data are mean (SD). Change from baseline compared between 
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5.4.5.2 Urinary steroids 
Changes in urinary steroids, pertinent to pharmacodynamic responses to the 
drugs, are shown in Table 5-6 and Table 5-7. Other urinary steroid results, 
relating to HPA axis responses, are shown and discussed further in Chapter 
6. Urinary 5α-reduced metabolites of both cortisol and androstenedione were 
significantly decreased following treatment with both dutasteride and 
finasteride. The decrease in αTHF with dutasteride and finasteride was also 
reflected in associated changes in the βTHF/αTHF and F/αTHF ratios. 
Androgen metabolites changed with both 5αR inhibitors. Compared to 
baseline, there was an expected decrease in androsterone (α) and there was a 
significant increase in the aetiocholanolone (β)/androsterone (α) ratio. There 
were not marked differences in extent of change in 5-reduced metabolites 
between the dutasteride and finasteride groups, except in the increase in the 
aetiocholanolone/ androsterone ratio which was greater with dutasteride 
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 Dutasteride Finasteride Tamsulosin 
∆ D vs. ∆ T 
Mean (95% CI)  
∆ F vs. ∆ T 
Mean (95% CI)  
∆ D vs. ∆ F 
Mean (95% CI) 




Pre  1806 (699.2) 2373 (1737.1) 2116 (1297.1) Difference between groups: p<0.001 




291 (-1113; 531) 




Pre  817 (403.4) 805 (604.5) 861 (484.6) Difference between groups: p<0.001† 
Post  2461 (1350.5) 1710 (1002.9) 1029 (658.8) p<0.001 p=0.01 p=0.28 
Change  +1643 +905 +168 
5αTHF 
µg/day 
Pre  1664 (1006.9) 1858 (1424.3) 1786 (1123.3) Difference between groups: p<0.001 
Post  32 (36.2) 51 (53.6) 1773 (1153.9) -1620 (-2422; -817) 
p<0.001 
-1794 (-2597; -992) 
p<0.001 
174 (-601; 950) 
p=0.65 Change  -1633 -1807 -13 
5βTHF 
µg/day 
Pre  1724 (511.5) 1670 (649.2) 1793 (508.3)  
Difference between groups: p=0.96 Post  1718 (521.3) 1683 (506.9) 1742 (615.9) 
Change  -6 +14 -52 
Table 5-6 Urinary androgen and glucocorticoid metabolites. There was a significant decrease in 5αTHF and androsterone 
following 5αR inhibition, together with a significant increase in aetiocholanolone (Aetio). Data are mean (SD). Change from 
baseline compared between groups by one-way ANOVA, with LSD post-hoc tests where significant, or †Kruskal Wallis test with 
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 Dutasteride Finasteride Tamsulosin 
∆ D vs. ∆ T 
Mean (95% CI)  
∆ F vs. ∆ T 
Mean (95% CI)  
∆ D vs. ∆ F 
Mean (95% CI) 












Pre  1.39 (0.78) 1.21 (0.73) 1.30 (0.67) Difference between groups: p<0.001† 
Post  96.20 (66.72) 55.69 (33.36) 1.37 (0.90) p<0.001 p<0.001 p=0.65 
Change  +94.81 +54.48 +0.07 
F/ αTHF Pre  0.10 (0.10) 0.10 (0.05) 0.12 (0.11) Difference between groups: p<0.001† 
Post  6.12 (3.68) 4.22 (2.33) 0.13 (0.12) p<0.001 p<0.001 p=0.88 
Change  +6.01 +4.11 +0.01 
F/ βTHF Pre  0.08 (0.05) 0.09 (0.04) 0.09 (0.05)  
Difference between groups: p=0.67 Post  0.08 (0.04) 0.08 (0.04) 0.09 (0.04) 








s Aetio (β) / 
Andro (α) 
 
Pre  0.45 (0.18) 0.36 (0.20) 0.43 (0.14) Difference between groups: p<0.001†  
Post  21.82 (9.73) 8.26 (15.55) 0.85 (1.43) p<0.001 p=0.01 p=0.01 
Change  +21.37 +7.89 +0.43 
Table 5-7 Indices of pathways of A-ring reduction of glucocorticoids and androgens by 5αR were decreased relative to 5βR 
following three months of either dutasteride or finasteride. Data are mean (SD). Change from baseline compared between 
groups by one-way ANOVA (F/βTHF), or 
†
Kruskal Wallis test with pairwise comparisons. D, dutasteride; F, finasteride; T, 
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5.4.6 Effects of 5αR inhibition on insulin sensitivity 
5.4.6.1 Insulin sensitivity in the fasted state 
Under fasting conditions, glucose was unchanged by treatment; however 
there was a trend towards an increase in insulin, and a significant increase in 
C-peptide in the dutasteride group (Table 5-8). HbA1c was not different. 
Measures calculated from glucose and insulin are summarised in Table 5-9. 
Here it is seen that HOMA-IR increased significantly from baseline with 





Chapter 5: The effects of inhibition of 5α-reductases on metabolic health 
  262 
 
 
 Dutasteride Finasteride Tamsulosin ∆ D  vs. ∆ T 
Mean (95% CI) 
∆ F vs. ∆ T 
Mean (95% CI) 
∆ D vs. ∆ F 
Mean (95% CI) 
N 16 16 14  
Glucose 
mmol/L 
Pre  4.96 (0.49) 4.98 (0.50) 5.14 (0.37) Difference between groups: p=0.34 
Post  5.09 (0.53) 4.93 (0.38) 5.06 (0.38) 
Change  + 0.13 - 0.05 - 0.08 
HbA1c 
nmol/mol 
Pre  35.2 (4.18) 35.1 (2.64) 36.2 (3.07) Difference between groups: p=0.62† 
Post  35.6 (4.00) 35.9 (2.29) 36.6 (3.32) 
Change  + 0.4 + 0.9 + 0.4 
Insulin 
pmol/L 
Pre  58.8 (23.80) 54.1 (17.85) 63.1 (33.01) Difference between groups: p=0.07 
Post  68.8 (30.01) 57.7 (19.13) 59.3 (33.06) 
Change  + 10.0 +0.6 -3.9 
 N 15 16 14 Difference between groups: p=0.04 
C-peptide 
pmol/L 
Pre  539 (156.9) 539 (172.9) 613 (295.7) 100 (14; 187) 
p=0.02 
11 (-74; 97) 
p=0.79 
89 (5; 173) 
p=0.04 Post  615 (171.2) 526 (165.6) 588 (269.5) 
Change  + 76 - 13 - 25 
Table 5-8 Three months of treatment with dutasteride (D) significantly increased fasting C-peptide, with a trend towards an 
increase in fasting insulin. There was no difference in fasting glucose or haemoglobin A1c (HbA1c) between groups. Data are 
mean (SD), change from baseline compared between groups by one way ANOVA, with LSD post-hoc tests where significant, 
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∆ Dutasteride   
vs. ∆ Tamsulosin 
Mean (95% CI) 
∆ Finasteride    
vs. ∆ Tamsulosin 
Mean (95% CI) 
∆ Dutasteride     
vs. ∆ Finasteride 
Mean (95% CI) 
N 16 16 14    
HOMA-IR 
 
Pre  1.89 (0.79) 1.73 (0.63) 2.09 (1.17) Difference between groups: p=0.03 
Post  2.28 (1.06) 1.83 (0.65) 1.95 (1.19) 0.53 (0.13; 0.93) 
p=0.01 
0.24 (-0.16; 0.63) 
p=0.23 
0.29 (-0.09; 0.68) 
p=0.13 Change  + 0.39 + 0.10 - 0.14 
QUICKI Pre  0.36 (0.03) 0.36 (0.02) 0.35 (0.03)  
Difference between groups: p=0.11 Post  0.35 (0.04) 0.35 (0.02) 0.35 (0.03) 
Change  - 0.007 - 0.003 - 0.004 
Table 5-9 HOMA-IR (Homeostatic model assessment of insulin resistance) increased significantly following three months of 
treatment with dutasteride. QUICKI (Quantitative insulin sensitivity check index) was unaltered. Data are mean (SD). Change 
from baseline compared between groups by one-way ANOVA, followed by LSD post-hoc tests where significant. N, number; ,
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5.4.6.2 Glucose disposal, glucose production and lipolysis during a 
hyperinsulinaemic euglycaemic clamp 
5.4.6.2.1 Glucose concentrations during clamp 
The clamp glucose target of 4.5 – 5.5 mmol/L was successfully achieved, as 
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Figure 5.6 Plasma glucose concentrations (mmol/L) during hyperinsulinaemic phases of clamps conducted before (B1) or after 
(B2) three months of treatment with dutasteride, finasteride or tamsulosin; target was 4.5-5.5 mmol/L and this was successfully 
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5.4.6.2.2 Tracer: tracee ratios (TTRs) for d2-glucose: glucose  
TTRs are shown in Figure 5.7. d2-Glucose: glucose ratios achieved steady 
state in each phase of the clamp. Relative standard deviations between 
samples in each phase ranged from 0.4 – 3.8%. TTR increased between 
baseline and the end of the tracer only infusion period. There was no 
difference in TTR at the end of low dose insulin. TTR decreased with high 
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Figure 5.7 d2-Glucose: glucose tracer: tracee ratios during hyperinsulinaemic euglycaemic clamps, before (B1) and after (B2) 
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5.4.6.2.3 Insulin concentrations during clamp 
Insulin concentrations at baseline were presented in Section 5.4.6.1. Insulin 
concentrations during the clamp are summarised in Table 5-10.  
 
During the first phase of the clamp when d2-glucose and d5-glycerol were 
administered, insulin concentrations were increased post-treatment in the 
dutasteride group only, compared to control.  
 
Differences in insulin concentrations following both low-dose and high-dose 
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∆ Dutasteride   
vs. ∆ Tamsulosin 
Mean (95% CI) 
∆ Finasteride    
vs. ∆ Tamsulosin 
Mean (95% CI) 
∆ Dutasteride     
vs. ∆ Finasteride 
Mean (95% CI)  
N 16 16 14    
Tracer only  
(pre-insulin 
infusion) 
Pre  31.5 (13.11) 35.6 (12.39) 36.9 (19.74) Difference between groups: p=0.03 
Post  37.1 (18.11) 34.6 (11.10) 30.8 (11.18) 11.7 (3.2; 20.3) 
p=0.008 
5.1 (-3.5; 13.6) 
p=0.24 
6.6 (-1.6; 14.9) 




Pre  85.8 (35.00) 83.8 (23.24) 82.1 (25.89)  
Difference between groups: p=0.84 Post  91.1 (39.49) 83.1 (23.25) 81.5 (22.71) 
Change  + 5.4 - 0.8 - 0.6 




Pre  306.7 (72.73) 295.3 (53.34) 258.7 (57.55)  
Difference between groups: p=0.51 Post  326.2 (56.08) 303.3 (76.24) 291.8 (56.59) 
Change  + 20.3 + 8.0 + 33.0 
Table 5-10 Plasma insulin concentrations (pmol/L) following tracer (d2-glucose and d5-glycerol) only phase of clamp increased 
following 3 months of treatment with dutasteride. Insulin concentrations following low dose (10 mU/m
2
/min) or high dose (40 
mU/m
2
/min) phases of the clamp did not differ between groups. Data are mean (SD), and comparisons by one-way ANOVA of 
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5.4.6.2.4 Endogenous glucose production  
There were no differences in fasting plasma glucose concentrations, and 
these data were presented in Section 5.4.6.1.  Endogenous glucose production 
(EGP) at baseline and with low-dose insulin is summarised in Table 5-11, 




 Dutasteride Finasteride Tamsulosin Difference 




Pre  7.24 (1.50) 7.91 (1.11) 7.38 (1.66) p=0.10 
Post  7.13 (1.26) 7.71 (0.97) 7.74 (1.34) 




Pre  3.95 (3.32) 4.47 (2.22) 5.02 (1.90) p=0.77 
Post  4.24 (2.16) 4.23 (2.47) 4.93 (2.25) 




Pre  9.03 (2.06) 10.23 (1.78) 9.83 (2.17) p=0.24 
Post  9.10 (2.20) 10.02 (1.82) 10.21 (1.76) 





Pre  5.10 (3.95) 5.80 (3.10) 6.67 (2.39) p=0.72 
Post  5.54 (3.08) 5.54 (3.44) 6.56 (2.96) 
Change  +0.44 -0.25 -0.11 
Table 5-11 Endogenous glucose production (EGP) during first two phases of 
hyperinsulinaemic euglycaemic clamp did not change with three months of 
dutasteride, finasteride or tamsulosin. EGP presented were calculated following 90 
minutes of tracer infusion (d2-glucose and d5-glycerol), and following low-dose (10 
mU/m
2
/min) insulin infusion; effect of tracers was evident with p<0.001 for change 
in d2-glucose:glucose ratio from baseline to low-dose insulin, and effect of insulin 
was evident with p<0.001 for change in insulin concentration from pre-insulin to 
low-dose insulin. Data are mean (SD). Change from baseline compared between 
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High dose insulin was administered to assess peripheral glucose uptake. 
There may be, however, some remaining hepatic glucose output during this 
phase. Although d2-glucose could be detected in all subjects, in 36/92 clamps 
apparent negative values were obtained for EGP at high dose insulin, 
confirming suppression of hepatic glucose output particularly in very insulin 
sensitive volunteers. This did however mean calculations to quantify EGP 
during high dose insulin were unreliable, and only peripheral glucose 
uptake was formally measured and these results are shown below in Sections 
5.4.6.2.5 and 5.4.6.2.6.  
 
5.4.6.2.5 Glucose infusion rates during high dose insulin (M value) 
There was a decrease from baseline in the M value in the dutasteride group 
compared to both the finasteride and tamsulosin groups. There was no 
difference between the finasteride and tamsulosin groups.  
 
M values are shown in Table 5-12, demonstrating that the inferred decrease 
in insulin sensitivity with dutasteride compared to the other two groups 
persists when calculated by weight or by fat-free mass, which is important 
given the increase in fat mass seen in this group (Section 5.4.8.2). Individual 
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on dutasteride require less glucose to maintain euglycaemia, whereas those 
on finasteride and tamsulosin require more.  
 
Subtle variations in glucose concentrations achieved during clamps are 
inevitable, as shown in Section 5.4.6.2.1. The values included in the final 
analysis are those without adjustment for glucose concentration, however 
when data were adjusted to allow for slight variations in glucose 
concentrations during clamp (by using the ratio of glucose infusion rate/ 
glucose concentration, rather than the infusion rate alone), changes 
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∆ Dutasteride   
vs. ∆ Tamsulosin 
Mean (95% CI) 
∆ Finasteride    
vs. ∆ Tamsulosin 
Mean (95% CI) 
∆ Dutasteride     
vs. ∆ Finasteride 
Mean (95% CI) 
N 15 16 14    
mL/hr Pre  151.6 (50.5) 142.1 (62.8) 97.6 (43.2) Difference between groups: p=0.003 
Post  130.6 (60.0) 167.9 (80.4) 123.3 (52.0) -46.7 (-77.1; -16.3) 
p=0.003 
+ 0.1 (-29.8; 30.1) 
p=0.99 
-46.8 (-76.2;-17.4) 
p=0.003 Change  - 21.00 + 25.83 + 25.71 
µmol/kg/ 
min 
Pre  37.7 (14.8) 31.6 (14.0) 23.3 (12.8) Difference between groups: p=0.003 
Post  32.4 (17.1) 37.5 (16.6) 29.7 (15.8) -11.6 (-18.9; -4.3) 
p=0.003 
-0.5 (-7.7; 6.6) 
p=0.88 
-11.1 (-18.2; -4.0) 
p=0.003 Change  - 5.27 + 5.83 + 6.36 
µmol/ 
kgFFM/min 
Pre  45.2 (15.3) 40.0 (16.3) 30.7 (15.7) Difference between groups: p=0.002 
Post  39.0 (18.5) 47.8 (20.5) 38.3 (17.7) -13.8 (-22.6; -4.9) 
p=0.002 
0.2 (-8.5; 8.9) 
p=0.96 
-14.0 (-22.5; -5.5) 
p=0.002 Change  - 6.17 + 7.82 + 7.59 
Table 5-12 M value (mean steady state glucose infusion rate) during high-dose (40 mU/m
2
/min) insulin infusion phase of the clamp, 
significantly decreased after 3 months of treatment with dutasteride, compared to both finasteride and tamsulosin. M value shown in 
mL/hr (infusion as given), as µmol/kg/min (adjusted for body weight), and as µmol/kgFFM/min (adjusted for fat mass). Data are 
mean (SD) and change from baseline is compared between groups by one-way ANOVA followed by LSD post-hoc tests. N, number; 
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Figure 5.8 M values (mean steady state glucose infusion rate) during high dose insulin infusion (40 mU/ m
2
/ minute), with value 
calculated as average glucose infusion rate between timepoints +255 to +270 minutes. Results presented from before and after 
three months of dutasteride, finasteride or tamsulosin. Increased (or unchanged) and decreased glucose infusion rates required 
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5.4.6.2.6 Glucose rate of disposal (Rd glucose) during high dose insulin  
 
Rd glucose can be derived from the M value and TTR, allowing for the rate 
of glucose infusion and any residual hepatic glucose output remaining. As 
shown in Table 5-13, results were essentially identical to the M value, with a 
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∆ Dutasteride   
vs. ∆ Tamsulosin 
Mean (95% CI) 
∆ Finasteride    
vs. ∆ Tamsulosin 
Mean (95% CI) 
∆ Dutasteride     
vs. ∆ Finasteride 
Mean (95% CI) 
N 15 16 14    
µmol/ 
kg/min 
Pre  34.8 (13.3) 29.3 (13.0) 21.6 (11.9) Difference between groups: p=0.003 
Post  30.0 (4.1) 34.7 (3.8) 27.5 (14.6) -10.7 (-17.5; -4.0) 
p=0.003 
-0.5 (-7.2; 6.2) 
p=0.88 
-10.2 (-16.8; -3.7) 
p=0.003 Change  - 4.9 + 5.4 + 5.9 
µmol/ 
kgFFM/min 
Pre  41.9 (13.7) 37.0 (15.1) 28.4 (14.5) Difference between groups: p=0.002 
Post  36.1 (17.1) 44.2 (19.0) 35.4 (16.4) -12.7 (-20.9; -4.5) 
p=0.003 
0.2 (-7.8; 8.3) 
p=0.95 
-12.9 (-20.8; -5.0) 
p=0.002 Change  - 5.7 + 7.2 + 7.0 
Table 5-13 Rate of disposal (Rd) of glucose during high dose insulin decreased significantly following three months of dutasteride, 
compared to both finasteride and tamsulosin. Results were the same when expressed per kg fat-free mass (FFM). Effect of tracers was 
evident with p<0.001 for decrease in d2-glucose:glucose ratio from low to high dose insulin, and effect of insulin was evident with 
p<0.001 for change in insulin concentration from low to high dose insulin. Data are mean (SD), and change from baseline compared 
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5.4.6.2.7 Tracer: Tracee Ratios (TTRs) for d5-glycerol: glycerol 
d5-Glycerol: glycerol TTRs are demonstrated in Figure 5.9.  In comparison to 
glucose tracer kinetics there was increased variability in d5-glycerol: glycerol 
TTRs, largely due to difficulty in accurately quantifying d5-glycerol at low 
concentrations. Despite these analytical issues however, relative standard 
deviation at each steady state phase ranged from 1.2 – 11.7%, and the 
majority were below 5%.  
 
TTRs increased from zero at baseline, following commencement of tracer 
infusion.  There was an increase in TTR between baseline and the end of low 
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Figure 5.9 d5-Glycerol: glycerol tracer: tracee ratios during hyperinsulinaemic euglycaemic clamp, before (B1) and after (B2) 




Chapter 5: The effects of inhibition of 5α-reductases on metabolic health 
  279 
 
 
5.4.6.2.8 Glycerol concentrations during clamp 
Glycerol concentrations were suppressed in response to low-dose insulin  
and further in response to high dose insulin, reflecting inhibition of lipolysis 
by insulin, as shown in Figure 5.10. However the changes in glycerol 
concentration following treatment were not different between groups, as 




Chapter 5: The effects of inhibition of 5α-reductases on metabolic health 




Figure 5.10 Plasma glycerol concentrations were suppressed during hyperinsulinaemic euglycaemic clamps. Bars and p values 
indicate difference between phases of the clamp, calculated for each group by paired t-tests comparing mean values for each 
phase. Data are mean; error bars indicate 95% confidence interval. B1, before treatment; B2, after treatment.  
p < 0.001 
p < 0.05 
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N 16 16 14  
Fasting Pre  48.4 (21.11) 50.4 (28.98) 53.6 (35.55) p=0.10 
Post  67.9 (73.44) 47.7 (27.94) 42.3 (20.1) 
Change  +19.5 -2.7 -11.3 
Post-tracer Pre  41.2 (20.12) 42.8 (18.95) 42.3 (23.66) p=0.28 
Post  45.7 (25.27) 38.4 (18.72) 38.2 (16.00) 
Change  +4.5 -4.4 -4.0 
Low dose 
insulin 
Pre  18.0 (10.48) 17.4 (12.27) 22.6 (24.93) p=0.17 
Post  22.4 (15.85) 16.0 (11.95) 16.0 (9.64) 
Change  +4.4 -1.5 -6.7 
 N 15 16 14  
High dose 
insulin 
Pre  14.7 (10.68) 10.6 (9.57) 15.0 (20.81) p=0.21 
Post  13.1 (11.13) 8.9 (8.54) 6.9 (7.40) 
Change  -1.8 -1.7 -8.1 
Table 5-14 Plasma glycerol concentrations (µmol/L) during hyperinsulinaemic 
euglycaemic clamps did not differ following three months of either dutasteride, 
finasteride or tamsulosin. Glycerol concentrations are from fasting samples, 
following tracer infusion only (average of +75 to +90 minutes), following low 
dose insulin (average of +165 to +180 minutes) and following high dose insulin 
(average of +255 to +270 minutes). Data are mean (SD) and change from 
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5.4.6.2.9 Glycerol kinetics 
There were no differences between treatment groups in the rate of 
appearance (Ra) of glycerol, either at baseline following infusion of tracer 
only, or following low dose insulin infusion intended for suppression of 
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N 16 16 14  
Post-tracer 
µmol/kg/min 
Pre  2.02 (1.04) 1.80 (0.87) 2.35 (1.12) p=0.78 
Post  2.14 (1.08) 1.76 (0.44) 2.29 (1.07) 




Pre  1.00 (0.56) 1.02 (0.54) 1.49 (1.03) p=0.27 
Post  1.07 (0.47) 1.00 (0.51) 1.21 (0.31) 




Pre  2.54 (1.35) 2.32 (1.11) 3.14 (1.46) p=0.60 
Post  2.78 (1.66) 2.27 (0.64) 3.04 (1.47) 





Pre  1.23 (0.60) 1.32 (0.72) 1.99 (1.33) p=0.16 
Post  1.39 (0.69) 1.30 (0.67) 1.60 (0.41) 
Change  + 0.16 - 0.02 - 0.39 
Table 5-15 Rate of appearance (Ra) of glycerol during hyperinsulinaemic 
euglycaemic clamps did not change after three months of dutasteride, finasteride or 
tamsulosin. Ra glycerol calculated following 90 minutes of tracer infusion (d2-
glucose and d5-glycerol), and following low-dose (10 mU/m
2
/min) insulin infusion. 
Effect of tracers was evident with p<0.001 for change in d5-glycerol:glycerol ratio 
from baseline to low-dose insulin, and effect of insulin was evident with p<0.001 for 
change in insulin concentration from pre-insulin to low-dose insulin. Results 
presented both per kg and per kg fat-free mass (FFM). Data are mean (SD); change 
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5.4.6.2.10 Non-esterified fatty acids (NEFAs) 
NEFAs were suppressed with low-dose insulin infusion in all groups, with 
results shown in Figure 5.11. However, there was less suppression of NEFAs 
with low-dose insulin infusion following three months of dutasteride 
treatment. Changes in fasting NEFAs and at the end of the tracer only 
infusion period were not significantly different. Results are summarised in 
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Figure 5.11 Plasma non-esterified fatty acid (NEFA) concentrations at baseline, following infusion of deuterated (d2-glucose and 
d5-glycerol) tracers, and following low dose (10 mU/m
2
/min) insulin infusion. NEFA concentrations suppressed with insulin 
infusion compared to pre-insulin concentrations (p<0.001 by paired t-tests).  
d2-Glucose and d5-glycerol 
(Pre-insulin) 
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∆ Dutasteride   
vs. ∆ Tamsulosin 
Mean (95% CI) 
∆ Finasteride    
vs. ∆ Tamsulosin 
Mean (95% CI) 
∆ Dutasteride     
vs. ∆ Finasteride 
Mean (95% CI)  
N 16 16 14    
Fasting 
µM 
Pre  485.1 (212.59) 443.9 (219.10) 649.4 (267.30)  
Difference between groups: p=0.37 Post  523.8 (278.72) 493.1 (175.35) 580.2 (382.73) 




Pre  484.2 (209.82) 479.6 (233.41) 628.9 (223.76)  
Difference between groups: p=0.46 Post  520.1 (206.62) 497.5 (253.38) 577.2 (199.31) 





Pre  184.9 (111.62) 193.4 (131.70) 295.1 (210.35) Difference between groups: p=0.041 
Post  245.2 (146.37) 189.7(134.22) 214.1 (82.83) 141.4 (32.7; 250.1) 
p=0.01 
77.3 (-31.4; 186.0) 
p=0.16 
64.0 (-41.0; 169.0) 
p=0.23 Change  +60.3 -3.7 -81.0 
Table 5-16 Plasma non-esterified fatty acids (NEFAs) were significantly less suppressed with low-dose insulin infusion following 
3 months of dutasteride versus tamsulosin. Concentrations were measured prior to the clamp (“fasting”), at the end of the tracer 
(d2-glucose and d5-glycerol, “post-tracer”) infusion, and at the end of 90 minutes of low-dose insulin infusion. Data are mean 
(SD) and change from baseline compared between groups by one-way ANOVA with LSD posthoc tests where significant. N, 
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5.4.7 Effect of 5αR inhibition on blood pressure and heart 
rate  
Following three months of treatment, there were no differences in blood 
pressure or heart rate, as shown in Table 5-17. Of note, the control group 
















Pre  131.0 (11.43) 136.4 (14.91) 138.8 (18.26) p=0.56 
Post  134.6 (15.98) 140.4 (9.77) 137.6 (15.22) 
Change  + 3.6 + 4 - 1.2  
DBP 
mmHg 
Pre  77.6 (9.96) 78.4 (11.19) 81.3 (8.85) p=0.60 
Post  81.5 (10.03) 80.4 (6.24) 82.2 (9.17) 
Change  + 3.9 + 2 + 0.9 
HR 
bpm 
Pre  72 (11.3) 65 (9.4) 74 (16.5) p=0.70 
Post  70 (11.1) 66 (6.1) 73 (14.9) 
Change  - 2 + 0.9 - 0.3  
Table 5-17 Three months of either dutasteride, finasteride or tamsulosin did not 
change systolic blood pressure (SBP), diastolic blood pressure (DBP) or heart 
rate (HR). Data are mean (SD), and change from baseline is compared between 
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5.4.8 Effect of 5αR inhibition on anthropometric 
measurements and body composition  
5.4.8.1 Weight, BMI and WHR 
There were no significant differences in body weight, BMI or WHR, as 











N 16 16 14  
Weight 
kg 
Pre  77.4 (13.18) 83.8 (14.10) 80.5 (10.41) p=0.17 
Post  78.3 (12.32) 83.2 (13.49) 80.5 (11.03) 
Change  + 0.9 - 0.6 0 
BMI 
kg/m2 
Pre  25.3 (4.41) 26.8 (3.82) 25.5 (2.76) p=0.14 
Post  25.6 (4.30) 26.6 (3.47) 25.6 (3.19) 
Change  + 0.3 - 0.2 + 0.1 
WHR Pre  0.90 (0.08) 0.89 (0.07) 0.93 (0.06) p=0.96 
Post  0.90 (0.06) 0.90 (0.06) 0.93 (0.05) 
Change  0 + 0.1 0 
Table 5-18 There was no change in weight, body mass index (BMI) or waist: hip 
ratio (WHR) following three months of dutasteride, finasteride or tamsulosin. 
Data are mean (SD), and change from baseline is compared between groups by 
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5.4.8.2 Body fat 
Results demonstrate an increase in body fat with dutasteride treatment, 
compared to tamsulosin, and a trend towards an increase when compared to 
finasteride. These changes were seen with both absolute (kg) measurements, 
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∆ Dutasteride   
vs. ∆ Tamsulosin 
Mean (95% CI) 
∆ Finasteride    
vs. ∆ Tamsulosin 
Mean (95% CI) 
∆ Dutasteride     
vs. ∆ Finasteride 
Mean (95% CI)  
N 16 16 14    
Body fat 
kg 
Pre  16.5 (8.70) 18.9 (6.97) 20.1 (5.94) Difference between groups: p=0.048 
Post  17.8 (8.52) 18.7 (6.39) 19.6 (6.82) 1.7 (0.3; 3.2) 
p=0.02 
0.4 (-1.1; 1.8) 
p=0.63 
1.4 (-0.04; 2.8) 
p=0.06 Change  + 1.3 - 0.2 - 0.5 
Body fat 
% 
Pre  19.8 (8.49) 22.1 (6.62) 24.7 (5.99) Difference between groups: p=0.02 
Post  21.5 (8.36) 22.3 (6.79) 24.0 (6.87) 2.4 (0.7; 4.0) 
p=0.006 
0.9 (-0.7; 2.6) 
p=0.27 
1.4 (-0.2; 3.0) 
p=0.08 Change  + 1.7 + 0.2 - 0.8 
Table 5-19 Body fat (assessed by electrical bioimpedance) increased following three months of treatment with dutasteride. Data 
are mean (SD). Change from baseline compared between groups by LSD post-hoc tests following a statistically significant one-
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5.4.8.3 Fat distribution 
5.4.8.3.1 Abdominal visceral and subcutaneous adipose quantified by MRI 
Results from the 40 structural scans performed are summarised in Table 5-20. 
The increase in body fat with dutasteride treatment (Section 5.4.8.2) was not 
accompanied by an increase in either visceral or subcutaneous abdominal 
adipose on MRI. There was also no change in the ratio of visceral to 
subcutaneous fat. In the absence of a baseline measure, relationships between 
abdominal fat and other potentially relevant covariates (including weight, 
BMI, body fat, WHR) were explored, with no significant differences in any 
measure. 
 Dutasteride Finasteride Tamsulosin Difference 
between groups 
N 13 16 11  
VF (kg) 0.09 (0.04) 0.07 (0.04) 0.10 (0.05) p=0.16 
SCF (kg) 0.22 (0.10) 0.21 (0.10) 0.20 (0.08) p=0.85 
AV (kg) 0.56 (0.15) 0.55 (0.12) 0.55 (0.12) p=0.98 
VF (%) 15.9 (4.4)  12.3 (5.8) 17.0 (7.0) p=0.09 
SCF (%) 37.8 (9.9) 35.9 (11.4) 35.4 (7.9) p=0.81 
VF:SCF 0.45 (0.18) 0.39 (0.22) 0.50 (0.21) p=0.40 
Table 5-20 The amounts of visceral fat (VF), subcutaneous fat (SCF) and 
abdominal volume (AV) measured by magnetic resonance imaging at L4/5 level 
after three months of treatment with dutasteride, finasteride or tamsulosin were 
not different between groups. The ratio of VF:SCF also did not differ between 
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5.4.8.3.2 Hepatic fat content quantified by 1H Spectroscopy 
Hepatic fat measurement by proton spectroscopy was limited by technical 
problems in 3 scans where data were unable to be processed, therefore a total 
of 37 scans were included in spectroscopy analysis (dutasteride, N=13; 
finasteride, N=15; tamsulosin N=9). Representative spectra demonstrating 
low fat fraction and high fat fraction are shown in Figure 5.12 and Figure 5.13 
respectively.  
 
Liver spectroscopy results were not normally distributed. Log 
transformation normalised data however failed on homogeneity of variance, 
and other transformations tested did not normalise data. Therefore results 
were analysed by Kruskal-Wallis test. Median (inter-quartile ranges) values 
were:  dutasteride 9.4% (3.59; 23.57), finasteride 4.7% (1.31; 43.20) and 
tamsulosin 3.4% (1.78; 9.16), and the wide variation in fat fraction results are 
evident in Figure 5.14. There were no statistically significant differences 
between treatment groups (p=0.22). There was no baseline measure and 
relationships between fat fraction, and other potentially relevant covariates 
(including weight, BMI, body fat, waist circumference, WHR, triglycerides) 
were not linear, therefore an ANCOVA was not appropriate. Adjustment for 
these variables by using the fat fraction divided by the variable showed that 
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Figure 5.12 Magnetic resonance spectroscopy spectra from subject with low fat 




Figure 5.13 Magnetic resonance spectroscopy spectra from subject with high fat 
fraction, calculated as 27%. ppm, parts per million. 
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Figure 5.14 Box plot of hepatic fat fractions measured by 
1
H spectroscopy 
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5.4.9 Effect of 5αR inhibition on serum adipokine and 
cytokine concentrations  
The increase in body fat with dutasteride (Section 5.4.8.2) was not associated 
with an increase in serum adipokines (leptin, adiponectin or resistin), or 
cytokines (MCP-1 or IL-8), as summarised in Table 5-21. Results adjusted for 
fat mass did not alter these findings (data not shown).   
 
There was marked variation both within and between groups in leptin 
concentrations; therefore although leptin appears to increase from baseline 
with dutasteride, this was not statistically significant. Technical difficulties 
with the adiponectin and resistin assay and instrument led to many results 
(especially for adiponectin) having RSDs which were greater than the 
manufacturer recommended cut-off of 22%. Findings were not altered when 
data were considered with and without samples with high RSDs (data not 
shown). MCP-1 did not change with any treatment, although there was a 
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Table 5-21 Serum leptin, adiponectin, resistin, MCP-1, and IL-8 concentrations 
did not change following three months of either dutasteride, finasteride or 
tamsulosin. Data are mean (SD). Change from baseline was compared between 
groups; leptin by 
†
Kruskal-Wallis test and all others by one-way ANOVA. N, 
number; , treatment; Adipo, adiponectin; MCP-1, monocyte chemoattractant 














Pre  5865 (6990) 3459 (1844) 6106 (7107) p=0.32† 
Post  6921 (6259) 3487 (2015) 6398 (7677) 




Pre  13.4 (8.0) 13.7 (5.8) 16.4 (16.2) p=0.93 
Post  14.7 (6.4) 14.6 (7.5) 16.7 (9.6) 
Change  + 1.3  + 0.9  + 0.3  




Pre  23.7 (10.7) 23.3 (11.4) 27.0 (11.4) p=0.50 
Post  24.0 (9.6) 23.6 (7.0) 29.9 (13.2) 




Pre  237 (72.4) 189 (69.6) 274 (110.0) p=0.33 
Post  238 (83.3) 197 (85.9) 249 (106.9) 
Change  +1 +8 -25 
IL-8 
pg/mL 
Pre  5.6 (3.5) 6.0 (4.7) 7.3 (1.7) p=0.08 
Post  5.6 (3.6) 6.3 (3.8) 6.2 (1.7) 
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5.4.10 Effect of 5αR inhibition on metabolic and 
inflammatory gene transcription in subcutaneous 
adipose   
39 of the 46 volunteers had fat biopsies taken before and after treatment, and 
these were all included in the analysis. All samples had acceptable RNA 
quality following electrophoretic analysis and were taken forward to reverse 
transcription and quantitative RT-PCR.  
 
Of the genes tested, only SRD5A2 and AKR1C2 were unable to be reliably 
measured by RTPCR and were therefore not included in the analysis. Error 
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Gene Error Eff. 
ACACA: Acetyl-Coenzyme A carboxylase α isoform 1 0.0138 1.974 
PLIN2: Adipocyte differentiation-related protein (Perilipin 2) 0.0250 1.987 
ADIPOQ: Adiponectin 0.0315 1.987 
AR: Androgen receptor 0.0226 1.725 
CYP19A1: Aromatase 0.0759 1.938 
DGAT2: Diacylglycerol O-acyltransferase homolog 2      0.0249 1.952 
ESR1: Estrogen receptor α 0.0253 1.781 
ESR2: Estrogen receptor β 0.0178 1.941 
FASN: Fatty acid synthase  0.0176 1.932 
GPD2: Glycerol-3-phosphate dehydrogenase 2 (mitochondrial) 0.0375 1.939 
GR: Glucorticoid receptor 0.0170 1.794 
LIPE: Hormone sensitive lipase  0.0299 1.865 
LEP: Leptin 0.0418 2.001 
LPL: Lipoprotein lipase  0.0125 1.906 
HSD11B1: 11β-Hydroxysteroid dehydrogenase type 1 (11βHSD1) 0.0132 1.882 
GPAM: Glycerol-3-phosphate acyltransferase 1 (mitochondrial) 0.0120 1.782 
MCP1: Monocyte chemotactic protein 1  0.0113 1.894 
PPARG: Peroxisome proliferator-activated receptor γ (PPARγ) 0.0163 1.701 
PPARGC1A: PPARγ coactivator 1α 0.0411 2.025 
SRD5A1: 5α-Reductase type 1 (5αR1) 0.0139 1.965 
SREBF1: Sterol regulatory element binding transcription factor 1  0.0236 2.201 
SREBF2: Sterol regulatory element-binding transcription factor 2 0.0287 1.823 
UCP 2: Uncoupling protein 2  0.0237 1.858 
PPIA: Peptidylprolyl isomerase A (cyclophilin A) 0.0093 1.856 
RPL32: Ribosomal protein L32 0.0177 2.084 
TBP: TATA-binding protein  0.0091 1.845 
GAPDH: Glyceraldehyde-3-phosphate dehydrogenase 0.0242 1.922 
Table 5-22 Error and efficiency (Eff.) results from all genes tested. Error was 
acceptable if <0.05, and efficiency if between 1.7 – 2.2; all genes except 
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It was noted that all housekeeping genes tested, and indeed most genes 
tested, increased in abundance following tamsulosin treatment. The 
explanation for this finding is unclear. Although not ideal, given this was a 
consistent finding, it was felt appropriate to combine the best three 
housekeeping genes (PPIA, TBP, GAPDH), as the use of these would 
normalise gene results from transcripts of interest and still allow 
comparisons to be made.  
 
Results are summarised in Table 5-23, Table 5-24 and Table 5-25. AR was the 
only gene to change significantly upon treatment, with mRNA abundance 
decreased from baseline in both dutasteride and finasteride treated groups, 
compared to tamsulosin, demonstrated in Figure 5.15. As seen, abundance of 
AR transcript in dutasteride and finasteride treated groups did not differ 
from each other. While abundance of other transcripts did not change with 
treatment, it is recognised that many genes quantified are not solely 
transcriptionally regulated, therefore non-transcriptional changes would not 
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 Dutasteride Finasteride Tamsulosin Difference 
N 13 14 12  
Genes transcribing enzymes for steroid hormone synthesis and metabolism 
SRD5A1 
(5αR1) 
Pre  0.28 (0.09) 0.28 (0.09) 0.30 (0.11) p=0.47 
Post  0.29 (0.08) 0.24 (0.10) 0.31 (0.11) 
Change  + 0.01 - 0.04 + 0.01 
HSD11B1 
(11βHSD1) 
Pre  0.44 (0.29) 0.35 (0.22) 0.52 (0.55) p=0.58† 
Post  0.28 (0.25) 0.23 (0.12) 0.27 (0.31) 
Change  - 0.16 - 0.12 - 0.25 
CYP19A1* 
(Aromatase) 
Pre  0.26 (0.25) 0.33 (0.25) 0.24 (0.19) p=0.998 
Post  0.22 (0.21) 0.29 (0.24) 0.21 (0.13) 
Change  - 0.04 - 0.03 - 0.04 
Genes transcribing steroid hormone receptors 
AR Pre  0.34 (0.19) 0.31 (0.12) 0.22 (0.11) p=0.045 
Post  0.22 (0.13) 0.23 (0.11) 0.26 (0.17) 
Change  - 0.12 - 0.08 + 0.04 
GR Pre  0.35 (0.17) 0.34 (0.18) 0.26 (0.12) p=0.62 
Post  0.34 (0.11) 0.31 (0.14) 0.27 (0.11) 




Pre  0.32 (0.13) 0.40 (0.23) 0.32 (0.12) p=0.40 
 Post  0.26 (0.15) 0.32 (0.19) 0.32 (0.15) 




Pre  0.32 (0.14) 0.35 (0.13) 0.32 (0.14) p=0.86 
Post  0.32 (0.22) 0.31 (0.16) 0.29 (0.12) 
Change  - 0.01 - 0.03 - 0.04 
Table 5-23 Androgen receptor (AR) transcript decreased in abundance following 
5αR inhibition (details in text and in Figure 5.15). There were no other differences 
in transcript ratios shown from subcutaneous abdominal adipose biopsies before 
and after three months of dutasteride, finasteride or tamsulosin. Change from 
baseline compared between groups by one-way ANOVA. *Standard curve for 
CYP19A1 had high error (0.0759). 
† 
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 Dutasteride Finasteride Tamsulosin Difference  
N 13 14 12  




Pre  0.20 (0.11) 0.27 (0.16) 0.21 (0.08) p=0.28† 
Post  0.25 (0.20) 0.24 (0.16) 0.26 (0.16) 




Pre  0.25 (0.17) 0.24 (0.13) 0.24 (0.14) p=0.65 
Post  0.29 (0.28) 0.27 (0.14) 0.23 (0.09) 




Pre  0.29 (0.15) 0.39 (0.28) 0.25 (0.17) p=0.17† 
Post  0.30 (0.23) 0.28 (0.22) 0.43 (0.47) 




Pre  0.36 (0.37) 0.44 (0.31) 0.33 (0.18) p=0.62† 
Post  0.24 (0.15) 0.34 (0.13) 0.32 (0.20) 
Change  - 0.12 - 0.10 - 0.02 
PLIN2 
(Perilipin) 
Pre  0.30 (0.16) 0.32 (0.16) 0.33 (0.17) p=0.97 
Post  0.22 (0.13) 0.25 (0.11) 0.26 (0.13) 
Change  - 0.08 - 0.07 - 0.07 
PPARG 
(PPARγ) 
Pre  0.46 (0.21) 0.49 (0.17) 0.45 (0.18) p=0.61 
Post  0.40 (0.20) 0.46 (0.16) 0.48 (0.31) 




Pre  0.43 (0.46) 0.38 (0.20) 0.26 (0.09) p=0.33† 
Post  0.19 (0.08) 0.34 (0.19) 0.25 (0.18) 




Pre  0.33 (0.12) 0.30 (0.11) 0.31 (0.09) p=0.36 
Post  0.38 (0.13) 0.28 (0.09) 0.35 (0.11) 
Change  + 0.04 - 0.02 + 0.03 
Table 5-24 There were no differences in transcript levels shown, from 
subcutaneous abdominal adipose biopsies before and after three months of 
dutasteride, finasteride or tamsulosin. Change from baseline compared between 
groups by one-way ANOVA. 
† 
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 Dutasteride Finasteride Tamsulosin Difference  
N 13 14 12  
Genes transcribing adipokines 
LEP 
(Leptin) 
Pre  0.19 (0.13) 0.19 (0.07) 0.18 (0.14) p=0.37 
Post  0.17 (0.12) 0.12 (0.07) 0.17 (0.15) 
Change  - 0.03 - 0.07 - 0.01 
ADIPOQ 
(Adiponectin) 
Pre  0.35 (0.12) 0.40 (0.16) 0.26 (0.12) p=0.10 
Post  0.32 (0.23) 0.30 (0.16) 0.34 (0.22) 
Change  - 0.03 - 0.10 + 0.08 
MCP1 Pre  0.39 (0.20) 0.40 (0.27) 0.48 (0.07) p=0.47 
Post  0.29 (0.14) 0.39 (0.30) 0.34 (0.22) 
Change  - 0.10 - 0.01 - 0.14 
Genes transcribing proteins involved in lipid and sterol homeostasis 
DGAT2 Pre  0.22 (0.20) 0.31 (0.20) 0.18 (0.08) p=0.12 
Post  0.29 (0.23) 0.24 (0.24) 0.32 (0.32) 
Change  + 0.07 - 0.07 0.14  
SREBF1 Pre  0.16 (0.14) 0.18 (0.12) 0.13 (0.06) p=0.28† 
Post  0.17 (0.21) 0.26 (0.29) 0.24 (0.21) 
Change  + 0.01 + 0.08 + 0.11 
SREBF2 Pre  0.37 (0.15) 0.44 (0.21) 0.36 (0.15) p=0.27 
Post  0.44 (0.17) 0.40 (0.31) 0.44 (0.27) 




Pre  0.32 (0.16) 0.30 (0.10) 0.30 (0.11) p=0.39 
Post  0.25 (0.15) 0.23 (0.11) 0.31 (0.19) 




Pre  0.33 (0.20) 0.28 (0.13) 0.25 (0.13) p=0.62† 
Post  0.32 (0.22) 0.22 (0.11) 0.27 (0.24) 
Change  - 0.01 - 0.05 + 0.02 
Table 5-25 There were no differences in transcript levels shown, from 
subcutaneous abdominal adipose biopsies before and after three months of 
dutasteride, finasteride or tamsulosin. Change from baseline compared between 
groups by one-way ANOVA. 
† 
Analysed by Kruskal-Wallis test. N, number; ,
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Figure 5.15 Abundance of transcript of gene encoding the androgen receptor 
(AR) in subcutaneous abdominal adipose before (B1) and after (B2) three 
months of dutasteride, finasteride or tamsulosin. Abundance decreased 
following 5αR inhibition. Shown are B1 and B2 means, as well as the change 
from baseline. Error bars indicate 95% confidence intervals (CI). Pairwise 
comparisons by one-way ANOVA with LSD post-hoc show mean (95% CI) 
changes of: dutasteride versus tamsulosin -0.15 (-0.28; -0.03), p=0.02; finasteride 
versus tamsulosin -0.12 (-0.25; 0.00), p=0.06 and dutasteride versus finasteride -
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5.4.11 Effect of 5αR inhibition on circulating lipids 
Other than a trend (p=0.08) towards an increase in fasting total cholesterol 
with finasteride, there were no significant differences between groups. 
Results are summarised in Table 5-26.  
 Dutasteride Finasteride Tamsulosin Difference 
between 
groups 
N 16 16 14  
Total C 
mmol/L 
Pre  4.41 (0.64) 4.87 (1.01) 5.20 (0.95) p=0.08 
Post  4.34 (0.78) 4.98 (1.04) 4.93 (1.03) 
Change  - 0.07 + 0.11 - 0.27 
HDL-C 
mmol/L 
Pre  1.29 (0.36) 1.28 (0.27) 1.38 (0.65) p=0.47 
Post  1.27 (0.29) 1.28 (0.24) 1.25 (0.34) 
Change  - 0.02 0 - 0.13 
LDL-C 
mmol/L 
Pre  2.55 (0.64) 3.03 (1.05) 3.21 (0.76) p=0.43 
Post  2.57 (0.73) 3.14 (1.02) 3.12 (0.93) 
Change  + 0.02 + 0.11 - 0.09 
TG 
mmol/L 
Pre  1.25 (0.55) 1.21 (0.69) 1.35 (0.74) p=0.38 
Post  1.10 (0.70) 1.24 (0.65) 1.23 (0.65) 




Pre  3.69 (1.17) 3.98 (1.31) 4.25 (1.29) p=0.69 
Post  3.67 (1.20) 4.08 (1.25) 4.19 (1.36) 
Change  - 0.02 + 0.10 - 0.06 
Table 5-26 Fasting serum lipids did not change following three months of 
dutasteride, finasteride or tamsulosin. Data are mean (SD), and change from 
baseline is compared between groups by one way ANOVA. N, number; ,
treatment; C, cholesterol; HDL, high density lipoprotein; LDL, low density 
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5.4.12 Effect of 5αR inhibition on serum liver function 
tests (LFTs) 
Results from  LFTs are summarised in Table 5-27. Alkaline phosphatase 
(ALP) increased from baseline with finasteride and this was statistically 
significant versus tamsulosin only, with a mean difference of 6.8 U/L (1.58; 
12.04), p=0.01. There were no other differences between groups. Albumin 
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N 16 16 14  
Bilirubin 
µmol/L 
(3 – 16) 
Pre  13.1 (6.77) 12.7 (5.55) 13.2 (10.47) p=0.63 
Post  10.4 (3.98) 12.4 (5.11) 11.9 (5.79) 
Change  - 2.7 - 0.3 - 1.3 
ALT 
U/L 
(10 – 50) 
Pre  30.0 (13.72) 28.4 (13.05) 28.6 (16.41) p=0.66 
Post  25.8 (8.72) 28.3 (17.28) 25.4 (10.65) 
Change  - 4.2 - 0.1 - 3.2 
ALP 
U/L 
(40 – 125) 
Pre  60.9 (16.81) 72.8 (9.97) 79.3 (20.36) p=0.04 
Post  58.5 (15.25) 74.1 (12.23) 73.8 (20.51) 
Change  - 2.4 + 1.6 - 5.5 
N 15 16 12  
AST 
U/L 
(10 – 45) 
Pre  26.9 (7.11) 25.6 (4.72) 28.4 (12.77) p=0.07 
Post  21.9 (6.49) 27.9 (12.80) 20.6 (5.45) 
Change  - 5.0 + 2.3 - 7.8 
GGT 
U/L 
(5 – 55) 
Pre  22.9 (15.17) 20.1 (11.56) 29.3 (26.23) p=0.30 
Post  27.2 (15.64) 24.3 (12.39) 26.8 (23.46) 
Change  + 4.3 + 4.2 - 2.5 
AST: ALT 
ratio 
Pre  1.0 (0.36) 1.0 (0.32) 1.1 (0.32) p=0.73† 
Post  0.9 (0.27) 1.2 (0.99) 1.0 (0.32) 
Change  - 0.1 + 0.2 - 0.10 
Table 5-27 Other than alkaline phosphatase (ALP, details in text), serum liver 
function tests did not change following three months of dutasteride, finasteride or 
tamsulosin. Data are mean (SD), and change from baseline is compared between 
groups by one way ANOVA, except AST/ALT ratio compared by 
†
Kruskal Wallis 
test. N, number; , treatment; ALT, alanine transaminase; AST, aspartate 
transaminase; GGT, γ glutamyl transpeptidase. Laboratory normal ranges are 
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5.4.13 Effect of 5αR inhibition on circulating oestradiol, 
cortisol and steroid hormone binding proteins  
There was a trend (p=0.07) towards an increase in serum oestradiol following 
5αR inhibition. There was no change in plasma cortisol concentrations, or in 
the serum binding proteins, albumin, sex hormone binding globulin (SHBG) 
or corticosteroid binding globulin (CBG). Results are summarised below in 
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Pre  788.5 (236.68) 768.7 (203.49) 817.9 (201.33) p=0.88 
Post  692.1 (186.20) 688.8 (172.89) 757.3 (157.28) 
Change  - 96.4 - 79.9 - 60.6 
E2 
pmol/L 
Pre  81.8 (31.51) 69.2 (29.76) 73.4 (35.17) p=0.07† 
Post  126.7 (67.79) 94.0 (32.01) 80.8 (40.75) 




Pre  27.9 (9.01) 24.4 (8.74) 31.1 (11.23) p=0.25 
Post  27.1 (10.37) 25.1 (9.06) 33.4 (16.02) 
Change  - 0.8 + 0.7 + 2.3 
CBG 
nmol/L 
Pre  988 (172.2) 936 (126.0) 959 (127.4) p=0.75† 
Post  966 (168.2) 905 (211.6) 929 (156.5) 
Change  -22 -31 -31 
N 15 16 12  
Alb 
g/L 
Pre  41.6 (3.07) 43.2 (3.78) 41.2 (4.08) p=0.26  
Post  38.8 (3.41) 39.9 (2.17) 39.7 (2.46) 
Change  - 2.8 - 3.3 - 1.5 
Table 5-28 There was a trend towards an increase in oestradiol (E2) following 
5αR inhibition. Plasma cortisol concentrations did not change, nor did sex 
hormone binding globulin (SHBG), corticosteroid binding globulin or albumin 
(Alb). Data are mean (SD) before and after three months of dutasteride, 
finasteride or tamsulosin. Change in baseline compared between groups by one-
way ANOVA, other than E2 and CBG compared by 
†
Kruskal-Wallis test. N, 
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This chapter has presented a double blind randomised controlled study 
designed to investigate the metabolic consequences of 5αR inhibition in a 
population of adult men; an area largely neglected in published literature. 
The principal hypotheses related to the concept that by inhibiting 5αR1 in 
metabolic tissues, a resulting elevation in local cortisol concentrations would 
be adverse for metabolic health. Dynamic tests of insulin and glucose 
homeostasis showed a clear decrease in insulin sensitivity following three 
months of treatment with the dual 5αR1 and 5αR2 inhibitor dutasteride, 
versus both the 5αR2 selective inhibitor finasteride and the control group 
tamsulosin, with data suggestive of impaired peripheral glucose uptake. In 
addition, body composition was altered with an increase in body fat in the 
dutasteride group only.  
 
A key objective in this study was to utilise an appropriately powered 
randomised study design in order to establish causality (Roberts and 
Torgerson, 1998). In the context of 5αR inhibitors there have been studies 
investigating some aspects of metabolism (Andriole and Kirby, 2003, Hong et 
al., 2010), however there was a lack of a well-designed randomised study, 
including both finasteride and dutasteride, that incorporated sensitive 
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weeks, (Gravas and Oelke, 2010)), a cross-over study was not possible, and 
so a parallel group randomised controlled design was selected. The block 
randomisation method had 18 subjects per block; an adequate block size to 
prevent allocations being deciphered, whilst also used to ensure an even 
number of participants in each treatment arm. However, as the study was 
stopped early treatment groups were slightly unequal in size, though within 
the recommended acceptable difference of less than half the block size (in 
this case, 9) (Altman and Dore, 1990). Every effort was made to ensure that 
potentially important variables (e.g. using the same glucometer) were kept 
consistent throughout the study. An additional positive feature of the study 
design was conducting pre- and post-drug study visits in parallel, so factors 
such as season or medication batches would not differentially affect study 
groups.   
 
By chance, the three groups in this study appeared to differ at baseline in 
several measures including age, body fat and insulin sensitivity, with the 
tamsulosin group in poorer health. In order to ensure that age and metabolic 
characteristics were approximately equal at baseline, an alternate 
randomisation method which may have been considered would be 
‘minimisation’ (Treasure and MacRae, 1998), with volunteers randomised 
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entailed determination of the baseline clamp M value (or a surrogate 
measure such as fasting glucose) and randomisation performed at that stage. 
Minimisation may have been particularly advantageous in interpretation of 
post-study MRI results. As the original study protocol included people in a 
narrower age range (presumably with less heterogeneity in insulin 
sensitivity), this was not predicted to be an issue at the time of study 
planning, however in future studies this approach should be considered.  
 
Recruitment was one of the main challenges encountered and necessitated 
review of study design. Temporarily pursued in parallel was a cross-
sectional study with metabolic measures conducted with patients already on 
5αR inhibitors; an important consideration given 34% of patients reviewed in 
BPH clinics were already on 5αR inhibitors. However cross-sectional studies 
do not minimise confounders by randomisation and are unable to establish 
causation; given the aims of the study this was not ideal.   
 
Instead several steps were taken to improve recruitment rates and retain the 
randomised study protocol. Key factors contributing to poor recruitment 
were the small number of eligible patients attending urology clinics and most 
eligible participants declining participation. Attempts to widen recruitment 
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Livingston due to reluctance from clinic staff, and the Borders General 
Hospital in Melrose due to distance from Edinburgh and low numbers of 
BPH patients seen. BPH is a chronic disease with the vast majority of patients 
cared for by GPs; therefore recruitment was widened to include primary 
care. Patients approached were those with diagnosed BPH on alpha blockers, 
who did not meet any of the exclusion criteria. While ~400,000 prescriptions 
for tamsulosin are dispensed in Scotland annually (Scotland, 2011), regional 
information is not publicly available. In addition, details of co-prescribing or 
presence of co-morbidities are not collated on a community basis. The nature 
of this study (i.e. a lack of immediate results pertaining to targets disorders 
in primary care) meant it proved less attractive for GP practices to invest 
time and resource, and recruitment of both practices and patients was 
difficult. However, despite multiple issues, primary care proved a valuable 
recruitment avenue, providing 15% of volunteers who completed the study. 
The need for study volunteers to be BPH patients was not an absolute 
requirement, but the study was initially designed in this manner as it was 
seen as potentially more acceptable to volunteers to take medication for a 
disease requiring treatment. However, in the end recruitment of healthy 
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A single interim analysis was conducted to ensure the initial sample size 
calculation was not an over-estimation, and the study was stopped early 
based on these results. The M value was chosen as a surrogate for the 
primary endpoint, glucose disposal, as results from tracer kinetics were not 
available at the time. At the final analysis it was seen that results from the M 
value were almost identical to those of Rd glucose, confirming that this was 
an appropriate selection. The statistical approach to dealing with the interim 
analysis was to stop the study with p<0.016 (taken from 0.05/3 groups) at 
interim analysis, and to make no further adjustment at the final analysis. 
Interim data was analysed by the study team, as the study was conducted 
without an independent data monitoring committee (DMC), a practice 
recommended for studies with the described endpoints and duration (Grant 
et al., 2005). While there would be an argument for independent 
investigators to conduct an interim data analysis even in small studies such 
as this, final results were in keeping with interim data, alleviating any 
concerns about a potential “regression to the truth” with attenuation of 
treatment effect that can be seen following some interim analyses (Pocock 
and White, 1999).  
 
Recruitment of healthy volunteers resulted in the inclusion of many 




Chapter 5: The effects of inhibition of 5α-reductases on metabolic health 
  314 
 
 
importantly a great proportion of leaner subjects. Arguably this could 
influence the physiological effects of the medications, and hence diminish the 
power of the study. β Cell function declines with age (Ma et al., 2009, Fritsche 
et al., 2002), however age-related decline in insulin sensitivity may largely be 
due to changes in body composition, in particular an increase in body fat, 
rather than age per se (Basu et al., 2003, Boden et al., 1993, Ferrannini et al., 
1996). In rodent models, animals with increased body weight were more 
susceptible to the metabolic effects of 5αR disruption or inhibition 
(Livingstone et al., 2008, Livingstone et al., 2009a); making the results for 
dutasteride in this human study perhaps even more striking.  In addition to 
metabolism, it was important to establish whether 5αR abundance changes 
with age. On a population basis, the serum DHT: testosterone (T) ratio 
remains steady from age 20 onwards (Starka et al., 2009), and indeed in the 
present study also there was no significant correlation between age and the 
DHT:T ratio.  
 
One participant, a BPH patient previously on tamsulosin, required rescue 
medication due to intolerable symptoms upon cessation of tamsulosin at the 
commencement of the study. Although there are several potential statistical 
methods for dealing with this (White et al., 2001), no statistical adjustment 
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intended therapeutic effects, symptoms were not related to any study 
endpoints, and tamsulosin was the control group and therefore assumed not 
to affect study endpoints.   
 
An important consideration in this study was selection of the control group. 
An active treatment was selected rather than placebo, as the original study 
design included only BPH patients requiring medical therapy. With the 
inclusion of healthy volunteers, the study was kept as the original design 
randomising participants to one of tamsulosin, dutasteride or finasteride. 
Although utilised as a control, tamsulosin, a selective α1A and α1D 
antagonist, could potentially act at extra-prostatic α1 receptors, with 
principal considerations in this study being the potential effects of 
tamsulosin on metabolism.  
 
Effects of tamsulosin on insulin sensitivity are not well described. In the 
present study peripheral insulin sensitivity improved in the tamsulosin 
group, so while in vitro α1 activation increases glucose uptake in muscle cells 
(Hutchinson and Bengtsson, 2005), the lack of reports on in vivo effects of 
tamsulosin on muscle insulin sensitivity mean it is uncertain but unlikely 
that tamsulosin would have directly impacted on muscle metabolism and 
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(Kershaw and Flier, 2004), in vivo microdialysis studies in healthy men 
suggest sympathetic effects on adipose are primarily mediated via β rather 
than α receptors (Boschmann et al., 2002). While slight improvements in 
insulin sensitivity may result from α blockade in diabetic patients (Pasanisi et 
al., 1999, McCarty, 2004), studies use α blockers other than tamsulosin so are 
not directly comparable. Conversely, there are three case reports in known 
type 2 diabetics of hyperglycaemia upon commencement of  tamsulosin 
treatment (Borgsteede et al., 2010), however there are many potential 
confounders in these cases, and certainly in our (non-diabetic) volunteers 
there was no evidence of hyperglycaemia. In the present study most 
transcripts quantified from subcutaneous adipose biopsies increased with 
tamsulosin. The reason for this is not clear. It may reflect an interaction of 
tamsulosin with RNA stability or the function of other aspects of the assay; 
without formal assessment it is not possible to confirm the reason.   
 
Tamsulosin is unlikely to have affected hepatic physiology in this study as its 
effects are not mediated through α1B receptors (Lepor, 2007), which are the 
α1 receptors present in rat liver (Piascik and Perez, 2001), though expression 
of α1 receptor isozymes in human liver is not described. Tamsulosin did not 
affect blood pressure or heart rate; an important observation as α1A and α1D 
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respectively (Jensen et al., 2009), and are also expressed in large and medium 
size arteries (in rat) (Piascik and Perez, 2001).  
 
Knowing that 5αR inhibitors take several (usually up to 6) months to give 
clinically noticeable effects, an alternative study design may have been 
considered, with the use of open-label tamsulosin where necessary, and the 
randomisation to one of placebo, dutasteride, or finasteride.  This would 
have reflected clinical practice as usually 5αR inhibitors are not given as first 
line treatment, not just due to their relatively high cost, but also because most 
patients require immediate therapeutic benefit from α blockade before 
combination with 5αR if symptoms persist. In hindsight, especially given 
that 35 out of the 46 volunteers included in the final analysis were healthy 
volunteers, the ideal study design would have utilised a placebo as control 
rather than tamsulosin.  
 
In this study there was an observed improvement in insulin sensitivity with 
both tamsulosin and finasteride. This was possibly due to the ‘Hawthorne 
effect’ (Sedgwick, 2012), a component of the classically described placebo 
effect, and describes the beneficial response which may occur as a result of 
participation in research. This is distinct from any effect from the actual drug 
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in behaviour as a result of being observed or assessed. Anecdotally from 
participants this appeared to be the case for most and this remains a possible 
explanation. However, within group changes were not addressed in this 
study, as the study question was not whether groups changed from baseline, 
but rather the comparative change between groups.  
 
With improved recruitment the study was able to progress and go on to 
address its aims. Insulin sensitivity was the primary endpoint assessed using 
the gold standard measure, a hyperinsulinaemic euglycaemic clamp 
(Defronzo et al., 1979). Additional measures included fasting plasma glucose, 
insulin and C-peptide concentrations.  
 
Fasting glucose did not differ following treatment, and this was in keeping 
with previous literature (Amory et al., 2007). However it is well recognised 
that a fasting glucose alone is a very crude index of insulin sensitivity, and 
indeed this was seen in this study also. The use of a hyperinsulinaemic 
euglycaemic clamp (Defronzo et al., 1979) allowed detailed assessment of 
insulin sensitivity and, through combination with deuterated glucose and 
glycerol tracers, allowed investigation of hepatic and peripheral insulin 
sensitivity. Deuterated glucose was selected as the tracer, as it cannot be 
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lactate can be reintroduced into glucose synthesis, resulting in an 
underestimation of glucose turnover (Choukem and Gautier, 2008). The 
addition of deuteriums at carbon 6 of the glucose molecule ensured non-
recycling, thus providing the most accurate estimation of endogenous 
glucose production (Coggan, 1999). Deuterated glycerol was used to 
establish insulin sensitivity of adipose tissue. With no re-uptake of glycerol 
into adipocytes, this was selected as an appropriate marker of lipolysis. The 
choice and position of label is not thought to be important with glycerol as it 
is with glucose, and as d5-glycerol does not influence glycerol physiology 
(Matthews et al., 1991), it was an appropriate choice for tracer molecule.  
 
Compared to both finasteride and tamsulosin, results from 
hyperinsulinaemic euglycaemic clamps demonstrate a clear decrease in 
insulin sensitivity with dutasteride.  Glucose disposal was ~14% lower after 
three months of dutasteride. Research into clinically significant changes in 
glucose disposal has primarily been conducted in trials of oral anti-diabetic 
agents. Glucose disposal is increased by 13% with metformin (Inzucchi et al., 
1998), 35% by the sulphonylurea gliclazide (Vestergaard et al., 1995) and 20-
32% with pioglitazone (Miyazaki et al., 2002). There were no diabetic subjects 
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lower. However results suggest the decrease in glucose disposal with 
dutasteride treatment may be clinically relevant. 
 
While there was an overall decrease in insulin sensitivity with dutasteride, 
the absence of any significant change in EGP during low dose insulin 
suggests that hepatic insulin sensitivity was preserved following 5αR 
inhibition. Human liver expresses both 5αR1 and 5αR2 (Russell and Wilson, 
1994), and is thought to be the main site of cortisol metabolism by 5αR. 5αR 
mRNA abundance in liver is increased in morbidly obese patients and shows 
a positive correlation with fasting serum insulin concentrations (Baudrand et 
al., 2011). Unfortunately (and surprisingly) Baudrand et al. (Baudrand et al., 
2011) made no mention of which 5αR isozyme was quantified. The relative 
importance of 5αR1 and 5αR2 in human liver is not described. As seen, 5αR 
inhibition led to a convincing alteration of THF/αTHF ratios; however this 
change was seen in both dutasteride and finasteride. While the decrease in 
αTHF was greater with dutasteride, the marked change with finasteride 
implies that if liver is the main contributor to cortisol 5α reduction, both 
5αR1 and 5αR2 must play important roles in this process. It is then perhaps 
not surprising that the reduction in insulin sensitivity seen with dutasteride 
only was not able to be localised to the liver as one would have expected 




Chapter 5: The effects of inhibition of 5α-reductases on metabolic health 
  321 
 
 
reaches a “threshold” of intra-tissue cortisol after which metabolic effects are 
seen, but there is no evidence to support this at this stage. Alternatively 5R1 
and 5R2 may be expressed in different cell-types within the liver, but as yet 
that is unknown. A further possibility is that there may be a non-linear 
relationship between hepatic 5αR inhibition and urinary αTHF excretion, 
with a greater accumulation of cortisol in liver with dutasteride treatment 
compared to finasteride which is not apparent in urinary ratios. There is no 
evidence for this in the present context, however proof-of-principle has been 
demonstrated previously when the decrease in hepatic conversion of 
cortisone to cortisol with increasing doses of 11βHSD1 inhibitor often does 
not have a linear relationship with urinary THF concentrations (unpublished 
data, Professor Brian R Walker).  
 
Hepatic insulin sensitivity was preserved when assessed by glucose kinetics, 
however hepatic steatosis was also investigated as this was a pathological 
feature in 5αR1 -/- mice (Livingstone et al., 2009a, Livingstone et al., 2008).  
Subtle and early changes in liver fat content are difficult to assess in humans, 
however the use of 1H spectroscopy (Qayyum, 2009) offered the most 
sensitive investigative tool. Results demonstrate marked heterogeneity in 
liver fat fraction and no significant differences between treatment groups. In 
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ALP with finasteride would not be considered clinically significant. While an 
isolated increase in ALP can be seen in fatty liver (Pantsari and Harrison, 
2006) ALP levels were much higher (~ 140 U/L vs. ~ 70 U/L) than in the 
present study, and incremental change in response to any intervention was 
not examined, therefore their findings cannot be extrapolated to this study. 
Transaminases are potential markers of fatty liver disease (Paschos and 
Paletas, 2009) but similarly to ALP they do not appear to be useful in 
examination of a small incremental change in healthy volunteers, and indeed 
no changes were seen in this study. 
 
Body fat increased with dutasteride treatment, though this was not 
accompanied by measurable changes in either abdominal fat distribution or 
glycerol tracer kinetics. There was however a decrease in insulin-mediated 
lipolysis suppression seen as a decrease in NEFA suppression with low-dose 
insulin infusion during the clamp. The lack of significant change in Ra 
glycerol and glycerol concentrations may simply reflect difficulties with 
variability in the analytical method, or biological variability between 
volunteers. A potential limitation in assessment of transcript abundance in 
adipose was that adipose sampled was subcutaneous not visceral. With 
evidence of whole body alterations in adipose insulin sensitivity 
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of alterations in subcutaneous adipose physiology, it may be that effects of 
5αR1 inhibition have greater consequence in visceral rather than 
subcutaneous adipose. 
 
Subcutaneous and visceral abdominal fat mass did not differ between 
groups. While MRI scanning with the IDEAL sequence (optimised for water 
and fat separation) (Costa et al., 2008) was utilised, this may still have 
limitations in detecting small changes in abdominal fat content, particularly 
if there was not a disproportionate increase in one depot (subcutaneous or 
visceral) over another. Results were not different whether assessed by single 
slice at L4/5, or via 5 slices centred on L4/5. Single slice scanning has 
important resource implications and L4/5 is traditionally considered the 
landmark of choice (Ross et al., 1992). However several studies suggest 
scanning at L2/3 or L3 may show greater correlation with total abdominal fat 
content (Demerath et al., 2007, Han et al., 1997, Abate et al., 1997); the use of a 
more cranial level in future studies may result in more accurate quantitation 
and a reduction in sample size required (Demerath et al., 2007). An 
additional limitation in this study was MRI scanning post-treatment only 
due to financial and service constraints; attempts to co-vary for the lack of a 
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Abundance of transcripts of genes regulating lipid metabolism in 
subcutaneous adipose did not differ. While studies with paired visceral and 
subcutaneous adipose sampling demonstrate subcutaneous samples to 
provide a reliable indicator of metabolic disease (Klimcakova et al., 2011), 
this may not be the case in studies such as this where a relatively small 
number of transcripts were measured. Factors influencing depot-specific 
adipose deposition are complex, however subcutaneous transcripts including 
DGAT and SREBP1c increase in men with the greatest accumulation of 
visceral fat following 56 days of overfeeding (Alligier et al., 2013). These 
transcripts were not different in the present study, however while Alligier et 
al. only saw a 0.7% increase in body fat %, they did see a significant increase 
in waist circumference, so perhaps overfeeding leads to a different pattern of 
fat distribution than 5αR1 inhibition.   
 
Although body fat was increased with dutasteride, food intake and activity 
levels were not assessed, therefore it is unknown whether these factors were 
altered. A question that was addressed was whether, either as cause or effect, 
adipokines were altered in subcutaneous adipose and in serum. Associations 
with metabolic disease have been described with several adipokines, 
including leptin (Galletti et al., 2007, Galletti et al., 2012), adiponectin (Arita 




Chapter 5: The effects of inhibition of 5α-reductases on metabolic health 
  325 
 
 
2008), MCP-1 (Kim et al., 2006) and IL-8 (Kim et al., 2006), hence these were 
selected for quantitation in serum.  
 
There was no change in serum leptin concentrations nor any change in leptin 
mRNA abundance in subcutaneous adipose; indicating leptin is unlikely to 
be mediating the increase in body fat. Adiponectin has an inverse association 
with obesity and metabolic disease, however no such change was seen in this 
study, suggesting changes are not mediated by changes in adiponectin. The 
lack of change in serum resistin, MCP-1 and IL-8, and unaltered MCP-1 
mRNA abundance in subcutaneous adipose again suggest that metabolic 
changes following dutasteride treatment are likely not associated with 
inflammatory changes in adipose tissue.  
 
Glucose disposal at high dose insulin reflects both any residual hepatic 
glucose production as well as disposal into peripheral tissues.  In this study 
36/92 (39%) of clamps had a negative calculated endogenous glucose 
production during high-dose insulin infusion; a result seen when high rates 
of glucose infusion are required to maintain euglycaemia and likely reflects 
complete suppression of EGP. The negative values may arise due to 
incomplete equilibration between the rapidly infused dextrose and the pre-
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the addition of d2-glucose to the 20% dextrose infused during 
hyperinsulinaemia (Finegood et al., 1987); an approach which should be 
considered in future studies particularly where healthy (often very insulin 
sensitive) volunteers are studied.   
 
The decrease in glucose disposal during high dose insulin was entirely 
reminiscent of changes in the M value, indicating that hepatic glucose output 
was adequately suppressed and glucose disposal was matched by the 
infusion rates given. This is indicative of predominantly peripheral insulin 
resistance. Adding further weight to this finding was that in order to 
maintain euglycaemia following tracer only infusion, those on dutasteride 
were hyperinsulinaemic and skeletal muscle is known to be the primary 
insulin-sensitive site of post-prandial glucose uptake (DeFronzo and 
Tripathy, 2009). The weight-adjusted doses were between 32-59 g d2-glucose 
during the 90 minute period; amounts approximately equivalent to the 0.5 
g/kg dose administered in an IV glucose tolerance test (IVGTT) (Bingley et 
al., 1992), though given continuously rather than as a bolus. A maximum 
IVGTT dose is usually 35 g, however effects on insulin concentrations 
plateau at ~ 20 g of glucose (Bingley et al., 1992) therefore variations in 
amount in the current study would be unlikely to have a material difference 
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the expected pancreatic response with increases in fasting C-peptide, 
HOMA-IR and a trend towards an increase in insulin concentrations.    
 
The finding of a predominantly muscle rather than hepatic phenotype was 
unexpected given the background animal data which demonstrated hepatic 
insulin resistance and fatty liver in 5αR1 knockout mice and 
pharmacologically treated Zucker rats (Livingstone et al., 2008, Livingstone 
et al., 2009a). Skeletal muscle biopsies were therefore not included in the 
study design, nor was skeletal muscle 1H spectroscopy, so it is unknown 
whether direct indicators of aberrant glucose physiology or lipid 
accumulation within skeletal muscle may be present in those treated with 
dutasteride. 
 
Skeletal muscle insulin resistance is thought to be the initial pathology 
preceding the development of type 2 diabetes (DeFronzo and Tripathy, 
2009). In response to high carbohydrate meals, young insulin resistant 
compared to insulin sensitive men (matched for age, weight, BMI and 
activity levels) demonstrate significantly impaired muscle glycogen synthesis 
and divergence of carbohydrate substrate towards hepatic lipogenesis and 
triglyceride synthesis (Petersen et al., 2007). This was in the absence of 
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2007). Their findings suggested impaired muscle insulin sensitivity preceded 
hepatic and visceral adipose insulin resistance, and increased susceptibility 
has been demonstrated in the elderly (Flannery et al., 2012). Furthermore, the 
effects of skeletal muscle insulin resistance on hepatic lipogenesis are, at least 
in part, reversed with exercise (Rabol et al., 2011). In the present study there 
was no change in fasting triglycerides, and muscle glycogen synthesis was 
not assessed. It is possible however that the skeletal muscle insulin resistance 
demonstrated may have preceded changes in hepatic insulin sensitivity with 
a longer duration of dutasteride treatment.  
 
Muscle insulin sensitivity has not been reported in 5αR models, though it is 
possible that this was also present but not studied. An alternate possibility is 
that there may be important inter-species differences in the early 
pathophysiology and development of the metabolic syndrome. In rats, 
hepatic insulin resistance is seen prior to muscle insulin resistance in 
response to high fat feeding (Kraegen et al., 1991).  The sequence of tissue-
specific effects in the development of insulin resistance in response to 5αR 
genetic manipulation or pharmacological inhibition is not understood at 
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Determining the mechanism behind the decrease in skeletal muscle insulin 
sensitivity with dutasteride treatment principally involves determining the 
site of pathology (whether localised within muscle or a paracrine effect), and 
determining which steroid hormone(s) may be mediating these effects.  
Expression and importance of 5αR in skeletal muscle is not as well studied as 
other tissue types. 5αR1 mRNA and protein (Pollanen et al., 2011, Yarrow et 
al., 2012) are present in human skeletal muscle, though in vitro activity was 
not detected (Thigpen et al., 1993). There are low levels of 5αR2 mRNA 
expression (Pollanen et al., 2011) but not protein or activity (Thigpen et al., 
1993). 5αR3 protein is also present in human skeletal muscle (Godoy et al., 
2011, Yarrow et al., 2012).  
 
The presence of 5αR protein in muscle does not necessarily mean it plays an 
important role in normal physiology. Muscle biopsies from people with 
neuromuscular disorders (n=24) and controls (n=7) had no detectable 5αR 
activity, though did have evidence of DHT metabolism by 3αHSD 
(Stuerenburg and Schoser, 1999). Others have reported detectable, but likely 
(in comparison to adipose) negligible conversion of testosterone to DHT in 
vivo (Longcope and Fineberg, 1985). Whether the post-exercise increase in 
muscle 5αR1 mRNA abundance in rats (Aizawa et al., 2010) is mirrored 
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The role of 5αR in muscle in the metabolism of other 5αR substrates, 
including glucocorticoids, is unknown, but these steroids play well 
established roles in regulating muscle insulin sensitivity. Given the lack of 
consistent evidence to date of the importance of 5αR in muscle with respect 
to androgen metabolism, it is possible that other substrates are of greater 
importance.  
 
With potentially little 5αR activity in skeletal muscle, effects seen may be 
paracrine due to signalling molecules, such as adipokines or changes in other 
steroid hormones. Skeletal muscle itself produces chemokines including 
MCP-1 and IL-8 (Wei et al., 2008, Pedersen and Akerstroem, 2007, Boyd et al., 
2006). While these were measured as ‘adipokines’ in the present study, of 
course circulating concentrations could reflect muscle synthesis as well. With 
no changes demonstrated, it is likely that chemokines and inflammatory 
changes within muscle are not mediating the effects seen, and rather steroid 
hormones may be playing a greater role, and this is discussed further below.  
 
Decreased adipose insulin sensitivity following dutasteride treatment, with 
an increase in circulating NEFAs, could itself result in a decrease in skeletal 
muscle insulin resistance. Insulin action in muscle is not impeded directly by 
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to increase on 1H spectroscopy) then to long chain acyl CoA which impairs 
insulin signaling (Boden et al., 2001). In addition, other triglyceride 
metabolites such as diacylglycerol and ceramide may also impair insulin 
sensitivity in skeletal muscle, through mechanisms which may include an 
increase in serine phosphorylation of IRS-1 (DeFronzo and Tripathy, 2009). 
Circulating NEFAs and intramyocellular ectopic fat accumulation have a 
strong negative correlation with peripheral glucose uptake in lean (Krssak et 
al., 1999) and obese (Sinha et al., 2002) non-diabetics. In addition, NEFAs are 
also associated with a decrease in muscle glycogen synthesis (Griffin et al., 
1999, Phillips et al., 1996). A seemingly paradoxical increase in 
intramyocellular lipid in athletes (Goodpaster et al., 2001) is thought to serve 
as an energy source for exercise, but in others excess free fatty acids in the 
circulation are stored as lipid in muscle and drive insulin resistance. While 
correlation of muscle lipid with insulin sensitivity is extensively described, 
causation is yet to be established, and while an interesting possible 
mechanism of action in the present study, it is unclear how likely this 
possibility may be.  
 
The primary site of the decrease in insulin sensitivity with dutasteride 
treatment appears to be peripheral, with evidence of impaired insulin 
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underpinning the changes seen are difficult (and likely impossible) to 
establish completely, however key likely mediators are glucocorticoids 
and/or sex hormones. In the study presented here, it is not possible to dissect 
these changes although this may be investigated further in animal models. In 
rodents gonadectomy may be utilised as a means of excluding (or at least 
diminishing) androgen-mediated effects, while adrenalectomy can be used to 
exclude effects of endogenous glucocorticoids. While very useful research 
tools, these approaches do have limitations: gonadectomy exposes the animal 
to less testosterone and not just less DHT (therefore cannot directly be 
extrapolated to studies of 5αR inhibition), and with adrenalectomy loss of 
mineralocorticoid and adrenal medullary hormones may confound 
interpretation. Despite these limitations however, results in castrated Zucker 
rats treated with 5aR inhibitors demonstrated persistence of the insulin 
resistance phenotype, along with steatosis even after gonadectomy; this 
suggested that effects were glucocorticoid mediated (Livingstone et al., 
2009a). Finasteride in rodents is a dual 5αR1 and 5αR2 inhibitor, and rat liver 
only expresses 5αR1 (Normington and Russell, 1992). Therefore hepatic 
effects of finasteride in rodents are likely to be the result of 5αR1 inhibition.  
 
In the present human study surrogate markers of androgen, glucocorticoid 
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mechanisms underpinning the metabolic effects seen. Measurement of 
steroid hormone concentrations and urinary metabolites demonstrated that 
both 5αR inhibitors had no effect on circulating cortisol, however did have 
similar effects in reducing serum DHT, as well as 5α glucocorticoid and 
androgen metabolites in urine. Testosterone did not increase significantly, 
however there was a trend towards an increase in oestradiol in the 
dutasteride group.   
 
The hormones mediating the metabolic effects seen with dutasteride 
treatment are likely to be either androgens or glucocorticoids. A decrease in 
serum DHT was seen with 5αR inhibition, and this may contribute to a 
phenotype of skeletal muscle insulin resistance. In cultured skeletal muscle 
cells from rat the addition of testosterone and DHEA increases GLUT4 
expression and translocation, and this process is inhibited with finasteride 
(Sato et al., 2008); demonstrating a DHT-dependent mechanism of action. As 
finasteride in rodents is a dual 5αR1 and 5αR2 inhibitor, this would be 
comparable to dutasteride in humans. In vivo, severe hypogonadism 
(testosterone  <8 nmol/L) is associated with insulin resistance (Tajar et al., 
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While decreased circulating DHT may contribute to the peripheral insulin 
resistance seen with dutasteride, the main difficulty with this concept is the 
similarity in degree of serum DHT inhibition with both 5αR inhibitors. 
Results demonstrated neither the extent of DHT suppression, nor the 
distinction between finasteride and dutasteride expected. DHT 
concentrations seen at baseline were within normal ranges described by LC-
MS/MS methods, and as expected lower than (relatively non-specific) RIA 
methods (Shiraishi et al., 2008), supporting the use of this analytical assay. 
DHT concentrations were expected to be suppressed by ~70% with 
finasteride and ~95% with dutasteride, by 4 weeks of treatment, analysed by 
GC-MS (Clark et al., 2004). In contrast to what was expected given the limits 
of quantitation in the present assay (Chapter 4), DHT was quantifiable in 
most volunteers even after 5αR inhibition, both dutasteride and finasteride 
suppressed DHT by approximately 50%, and perhaps more importantly, 
they did not differ from each other. While study tablets were blinded with an 
external coating, other studies use a similar approach. Extraction method and 
efficiency were not described by Clark et al. (Clark et al., 2004), and 95% 
confidence intervals were not able to be calculated from data presented. In 
another study (Wurzel et al., 2007), three months of dutasteride treatment 
decreased serum DHT concentrations  by 77.5% compared to placebo (95% 




Chapter 5: The effects of inhibition of 5α-reductases on metabolic health 
  335 
 
 
finasteride treatment, but this does demonstrate differences and variability in 
response to dutasteride, and results in the present study would be more 
comparable to these findings. It could perhaps be argued that Clark et al. 
(Clark et al., 2004) studied 5αR inhibition only in BPH patients, and although 
the prostate contributes little DHT to the circulation normally (Toorians et 
al., 2003), with larger prostates and potentially greater prostatic contribution 
to circulating DHT this may render BPH patients more sensitive to the effects 
of 5αR inhibition. It is difficult to pin down the exact reason for the 
unexpected similarity in androgen effects between dutasteride and 
finasteride seen in this study, though this implies that a reduction in 
circulating DHT was likely not the mechanism behind the marked 
differences in metabolic consequences.   
 
The decrease in AR transcript expression in subcutaneous adipose biopsies is 
likely a consequence of reduced signaling by DHT, and this supports the 
efficacy of the 5αR inhibitors administered and suggests they accessed 
adipose. DHT is known to upregulate adipose AR protein in vitro 
(Dieudonne et al., 1998), however down-regulation of AR in response to a 
decrease in DHT has not been described. While a decrease in androgen 
action in adipose is associated with insulin resistance (McInnes et al., 2012), 
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finasteride, suggesting that this is not related to which isozyme of 5αR is 
targeted and that down-regulation of androgen action in adipose is not 
mediating the metabolic differences seen. AR is present in skeletal muscle 
(Sinha-Hikim et al., 2004), however whether this is altered with 5αR 
inhibition is unknown.   
  
There was no change in SHBG concentrations seen as a result of 5αR 
inhibition with either dutasteride or finasteride, which might have led to 
different delivery of bioavailable steroid, and this is keeping with previous 
studies (Jaffe et al., 1994, Iranmanesh and Veldhuis, 2005). Together with an 
unchanged albumin, the lack of effect on SHBG suggests that androgen 
metabolic clearance was unaltered (Petra et al., 1985), and therefore unlikely 
to account for metabolic effects seen.  
 
There was no change in circulating cortisol concentrations following 
dutasteride treatment (due to adaptation by the HPA axis, Chapter 6), 
therefore any glucocorticoid mediated effect on muscle would need to be 
either via an increase in cortisol within muscle, or effects on other tissues 
which then signal to decrease muscle insulin sensitivity. Excess tissue 
glucocorticoids are recognised to affect muscle insulin sensitivity. In primary 
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uptake (Gathercole et al., 2007), whereas in rat skeletal muscle 
glucocorticoids do not affect insulin receptor number or function (Block and 
Buse, 1989) but do impede GLUT4 translocation (Dimitriadis et al., 1997). 
Increased GRα expression in human skeletal muscle cells is associated with 
the metabolic syndrome (Whorwood et al., 2002). GRα expression in 
subcutaneous adipose was unchanged in the present study, however any 
changes in transcript abundance in skeletal muscle are unknown. Urinary 
glucocorticoid metabolites following treatment suggest a reasonable degree 
of 5αR metabolism of cortisol is mediated by 5αR2, presumably hepatic 
5αR2. Therefore, if metabolic changes seen are related to cortisol metabolism, 
this is perhaps indicative of a ‘threshold’ of 5αR inhibition which goes on to 
cause metabolic derangement or alternatively cell-specific gene expression in 
the liver. It is otherwise difficult to explain why relatively small changes in 
glucocorticoid metabolite excretion between the two groups could account 
for such differing results in insulin sensitivity.  
 
Finally the possible consequences of 5αR1 inhibition on oestradiol signalling 
was considered. In the present study, there was a trend towards an increase 
in oestradiol with dutasteride, but not finasteride. This may reflect increased 
metabolism of testosterone by aromatase in the context of 5αR inhibition. 
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natural aromatase inhibitors (Iqbal et al., 1983), therefore the decrease seen in 
DHT with 5αR inhibition may increase aromatase activity. Previous literature 
is mixed in reports of effects of 5αR inhibition on oestradiol concentrations. 
Dutasteride in combination with testosterone increases oestradiol after both 3 
and 6 months of treatment (Page et al., 2011a), however a similar effect was 
seen with testosterone alone, therefore in this case may simply reflect 
additional aromatase substrate. After a year of either dutasteride or 
finasteride, there is no change in circulating oestradiol concentrations 
(Amory et al., 2007), so it is unclear whether the increase seen in the present 
study is perhaps a transient phenomenon.  
 
Increased oestradiol following dutasteride treatment may mediate some of 
the metabolic changes seen in this study. Higher endogenous oestradiol 
concentrations in men are associated with an increased risk of developing 
diabetes, independent of degree of adiposity (Vikan et al., 2010, Phillips et al., 
2003). Paradoxically, in hypogonadal obese patients with type 2 diabetes 
oestradiol concentrations are decreased (Dhindsa et al., 2011). As with 
glucocorticoids, it appears with oestradiol also that any aberration from the 
norm is associated with metabolic disease, rather than change in one 
direction only. While associations have been reported, causation between 
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possible role in this study remain unconfirmed. An important factor in 
interpretation of all oestradiol concentrations (including in the present study) 
is that the analytical method employed is almost always an immunoassay. 
There is some way to go before difficulties in measuring oestrogens via mass 
spectrometry are overcome, but perhaps this would aid in establishing the 
exact effects of 5αR inhibitors on circulating oestradiol concentrations.  
 
This chapter has focused on the roles of 5αR1 and 5αR2, and the 
consequences of inhibiting these isozymes. However these are not the only 
isozymes of 5αR; there is at least one other, identified as 5αR3 (Uemura et al., 
2008). At this stage, little is known about this isozyme and its importance in 
vivo. While the hypothesis in the present study was that the differential 
effects seen between dutasteride and finasteride therapy were mediated by 
their differential effects on 5αR1, it is also possible that changes seen are in 
fact (in part or wholly) mediated by 5αR3, or another as yet unidentified 
isozyme. With widespread distribution, particularly in liver, kidney, skeletal 
muscle, prostate and skin (Godoy et al., 2011), 5αR3 may play an important 
role in steroid hormone metabolism. The expression of 5αR3 in adipose is not 
known. Dutasteride is a known 5αR3 inhibitor (Mohler et al., 2011), though 
details of inhibition are not described. Finasteride is not thought to inhibit 
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presented would be an interesting avenue of further research, though 
considerable work is yet to be done to establish the importance of 5αR3, the 
role of 5αR3 in androgen and glucocorticoid metabolism (5αR3 metabolism 
of glucocorticoids has not yet been described), and the actions of the 5αR 
inhibitors (at clinical doses) against this isozyme.  
 
In conclusion, this chapter has described a double-blind randomised 
controlled study investigating the metabolic consequences of 5αR inhibition 
in men. Challenges, most notably poor recruitment, were overcome and the 
study was completed with 46 men included in the final analysis. Results 
demonstrate a clear decrease in insulin sensitivity and increase in body fat 
following three months of dutasteride treatment. The lack of such changes 
with finasteride implies that changes are likely mediated by 5αR1. The 
decrease in insulin sensitivity appeared most likely to be originating from 
skeletal muscle. Deciphering the exact mechanisms for these results are 
subject of ongoing work, however it has been clearly demonstrated for the 
first time in a human population that inhibition of 5αR with dutasteride 
increases body fat and impairs insulin sensitivity. These findings may have 
important implications for patients prescribed long-term dutasteride for 
benign prostatic hyperplasia.  
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The HPA axis regulates circulating cortisol concentrations, and adaptation of 
the axis in response to negative feedback allows an appropriate physiological 
response to stress. However, subtle alterations in the HPA axis, whether up-
regulation or down-regulation, have been associated with presence of, or 
predisposition to a number of disease processes. Dysregulation of the HPA 
axis is associated with stress and psychiatric disease (McEwen, 1998, Bradley 
and Dinan, 2010). Impaired glucocorticoid clearance is associated with down-
regulation of the HPA axis in chronic liver disease (McNeilly et al., 2010). 
Activation of the HPA axis may be insufficient for patient needs during 
critical illness (Arafah, 2006). The metabolic syndrome has been associated 
with relatively elevated circulating cortisol concentrations and potential HPA 
axis impairment (Phillips et al., 1998, Phillips et al., 2000, Bjorntorp et al., 
1999).   
 
Alterations in glucocorticoid regulation may influence the HPA axis 
peripherally, and also directly at sites of HPA axis feedback. Enzymes 
regulating tissue glucocorticoid concentrations include 11βHSDs (Walker 
and Andrew, 2006) and 5αRs (Russell and Wilson, 1994). Changes in 
glucocorticoid clearance by 5αR have been associated with HPA axis 
dysfunction in metabolic disease. Increased activity of 5αR is associated with 
obesity and polycystic ovarian syndrome (Vassiliadi et al., 2009, Andrew et 
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al., 1998, Reynolds et al., 2001, Rask et al., 2002). The increased 5αR activity 
seen in PCOS has been hypothesised to feedback and drive increased ACTH 
and subsequent normalisation of circulating cortisol, and an associated 
increase in adrenal androgen synthesis (Stewart et al., 1990, Vassiliadi et al., 
2009). In obesity increased 5αR activity may be a compensatory response 
which results in maintenance of hepatic insulin sensitivity.  
 
5αRs are widely distributed in sites which may directly or indirectly affect 
the HPA axis. In humans, 5αR1 mRNA and enzyme activity have been 
detected in hypothalamus (Thigpen et al., 1993), though not in pituitary 
(Russell and Wilson, 1994, Thigpen et al., 1993). In the human adrenal no 
5αR1 mRNA was detected, however in conditions optimised for 5αR1, low 
levels of activity were present (Thigpen et al., 1993). In contrast, 5αR2 is not 
known to be expressed in human hypothalamus, pituitary or adrenal 
(Thigpen et al., 1993). In addition, both 5αR1 and 5αR2 are widely expressed 
in metabolic and reproductive tissues respectively, and both isozymes are 
expressed in liver (Russell and Wilson, 1994). In rodents, which are often 
used as model systems, there is 5αR1 mRNA and protein in hypothalamus, 
pituitary and adrenal, while 5αR2 activity has been detected in 
hypothalamus and pituitary, both 5αR2 mRNA and activity are detected in 
the adrenal (summarised in Table 1-1).   
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In principle, a peripheral decrease in 5αR activity would decrease 
glucocorticoid clearance, however the tendency for cortisol to rise in the 
circulation would be fully compensated for by a functioning HPA axis. 
However, with 5αR also expressed in the brain, a decrease in 5αR activity in 
the brain could increase cortisol concentrations at HPA feedback sites, which 
may alter the set point of the HPA axis and hence cause a sustained 
reduction in plasma cortisol concentrations. As is seen with adrenocortical 
atrophy following pituitary disease (Reimondo et al., 2008), a compensatory 
downregulation of the HPA axis following 5αR inhibition, and associated 
decreased cortisol clearance, may lead to decreased adrenocortical 
responsiveness to ACTH and potentially hinder the stress response. Given 
the expression pattern of the 5αR isozymes it was hypothesised that 5αR2 
inhibition with finasteride may have some effect on the HPA axis, however 
dual 5αR1 and 5αR2 inhibition with dutasteride would likely have a greater 
effect. Findings in animal models support the hypothesis: in 
adrenalectomised 5αR1 -/- mice clearance of infused corticosterone is 
impaired and corticosterone responses to ACTH or to stress are reduced 
(unpublished).   
 
In humans, studies of the effects of finasteride on the HPA axis show no 
effect on basal cortisol concentrations (Rittmaster et al., 1994, Lewis et al., 
1997, Uygur et al., 1998), while response to ACTH (250 µg) has been shown 
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to be unaffected by some (Rittmaster et al., 1994), but decreased by others 
(Fruzzetti et al., 1994).  The effects of dutasteride on the HPA axis are 
unknown.  
 
Given the lack of randomised studies with dynamic testing of the HPA axis 
in response to both finasteride and dutasteride, this study was undertaken. 
The study described in Chapter 5 was designed principally to investigate the 
effect of 5αR inhibitors on metabolism and as a secondary endpoint, effects 
of 5αR inhibition on the HPA axis were also investigated.  
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6.1.1 Hypothesis and Aims 
6.1.1.1 Hypothesis 
Pharmacological inhibition of 5αRs in the periphery impairs glucocorticoid 
clearance, enhances negative feedback and hence causes relative adrenal 
insufficiency.  
 
Pharmacological inhibition of 5αRs in HPA negative feedback sites enhances 
negative feedback and lowers circulating cortisol concentrations.  
 
The extent of HPA axis dysfunction, both peripherally and centrally, is 
greater when both isozymes of 5R are inhibited than 5αR2 alone. 
  
6.1.1.2 Aims 
Establish whether pharmacological inhibition of 5αR leads to dysregulation 
of the HPA axis in men.  
 
Establish whether there are differing effects between the effects of finasteride 
(a 5αR2 inhibitor) and dutasteride (a dual 5αR1 and 5αR2 inhibitor).  
 




This study was conducted as per the methods described in Chapter 5.  
Aspects of the study relevant to the HPA axis will be briefly summarised 
here also.  
 
6.2.1 Study design 
Study design was a double-blind randomised controlled study, as described 
in Chapter 5.3.1.  
 
6.2.2 Study protocol 
The study protocol is described in detail in Chapter 5.3.4.   
 
6.2.2.1 Study day A  
This was the screening visit, as described in Chapter  5.3.4.3.  
 
6.2.2.2 Study day B  
Basal measures of the HPA axis were conducted on this visit.  
 
Volunteers returned 24 hour urine collections (described in Chapter 5.3.5.8, 
processing described in Chapter 5.3.7) and saliva collections (collection 
described in Chapter 5.3.5.9, processing described in Chapter 5.3.7).  
 




Fasting samples were taken at ~ 8 am; these were plasma for analysis of 
cortisol, and serum for analysis of DHEAS and androstenedione. Samples 
were collected as described in Chapter 5.3.5.6.1, and processed as described 
in Chapter 5.3.7.      
 
6.2.2.3 Study day C 
This study visit involved dynamic testing of the HPA axis.  
 
6.2.2.3.1 Low dose dexamethasone suppression test 
The evening prior to the visit, patients were asked to take dexamethasone 
(250 µg) orally at 10 pm and then remain fasted overnight and attend at 7:30 
am the following morning. A 20 gauge cannula was inserted in the 
antecubital fossa and half an hour later a blood sample was taken for 
measurement of plasma cortisol.   
 
6.2.2.3.2 Low dose short Synacthen test 
Following sampling for the dexamethasone suppression test, Synacthen (1 
µg, prepared as described in Chapter 5.3.6.6) was administered IV, and 
flushed with normal saline (0.9%, 10 mL). Sampling for plasma cortisol 
concentrations was performed at 20, 30, 40 and 60 minutes after Synacthen 
was given.  
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Samples during visit C were collected as described in Chapter 5.3.4.5. 
 
6.2.2.4 Treatment  
Volunteers were randomised to three months of dutasteride, finasteride or 
tamsulosin, as described in Chapter 5.3.4.6.  
 
6.2.2.5 Reassessment post treatment with repeat study days B and C 
Repeat visits B and C, including repeat urine and saliva collections, were 
conducted following the treatment phase of the study. 
 
6.2.3 Sample processing 
Samples were processed as described in Chapter 5.3.7 . 
 
6.2.4 Data analysis 
Statistical methods were as described in Chapter 5.3.8.7.  In addition, the Sign 
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Plasma free cortisol was calculated using Coolens’ equation (Coolens et al., 
1987): 
 
where U is unbound (free) cortisol (µmol/L); K is the affinity of CBG for 
cortisol at 37 °C; N is the ratio of albumin bound to free cortisol (the 
conventional value of 1.74 was used); G is plasma CBG level (µmol/L); and C 
is plasma cortisol level (µmol/L).  
 



















Ulick’s A ring reductase quotients (Ulick et al., 1992) (relative 5α- and 5β- 










Balance of 5αR and 5βR in androgen metabolism:   
Equation 1.2.4.7  
 




All 46 men included in the final analysis provided samples for measurement 
of hormones in urine, saliva, and morning plasma/serum. 45 Men 
participated in dynamic testing of the HPA axis.  
 
6.3.1 Effects of 5αR inhibition on daily production of 
glucocorticoids and androgens   
Daily production rates of glucocorticoids and androgens were assessed by 
their amounts in 24 hour urine collections.  
 
Changes in urinary glucocorticoids are shown in Table 6-1. There was a trend 
(p=0.06) towards a decrease from baseline in amounts of total glucocorticoids 
following 5αR inhibition. A decrease from baseline in the amount of αTHF 
with both dutasteride and finasteride was seen, without a compensatory 
increase in 5-reduced metabolites.  
 
Changes in urinary androgens are shown in Table 6-2. Both 5R inhibitors 
suppressed production of androsterone, the 5-reduced metabolite of 
androstenedione. In contrast to glucocorticoid metabolism, with 5αR 
inhibition there was a compensatory increase in androgen metabolites 
formed by 5β-reduction (measured as an increase in aetiocholanolone) with 
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both 5αR inhibitors. There was a significant decrease in total androgens with 
finasteride only.  
 
Urinary steroid ratios reflecting A ring metabolism are shown in Table 6-3. 
Both glucocorticoids and androgens show a decrease in 5α- compared to 5β- 
metabolism, following 5αR inhibition. There was no change in the F/βTHF 
ratio.  
 
Indices of 11βHSD activity are shown in Table 6-4. There was no evidence of 
change in 11βHSD2 activity (F/E ratio). There was however a decrease in the 
index of global metabolism of cortisol by 11βHSDs, seen as a decrease in the 
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 Dutasteride Finasteride Tamsulosin 
∆ Dutasteride  
vs. ∆ Tamsulosin 
Mean (95% CI)  
∆ Finasteride  
vs. ∆ Tamsulosin 
Mean (95% CI)  
∆ Dutasteride  
vs. ∆ Finasteride 
Mean (95% CI) 




Pre  9166 (2486.7) 9522 (4145.7) 9194 (3007.5)  
Difference between groups: p=0.06 Post  7147 (2500.0) 6998 (2460.4) 9228 (3590.4) 
Change  -2019 -2524 +34 
 F 
µg/day 
Pre  118.73 (44.76) 143.94 (52.62) 143.36 (45.44)  
Difference between groups: p=0.71 Post  123.19 (44.11) 135.01 (54.40) 136.74 (39.35) 
Change  +4.47 -8.93 -6.61 
5αTHF 
µg/day 
Pre  1664 (1006.9) 1858 (1424.3) 1786 (1123.3) Difference between groups: p<0.001 
Post  32 (36.2) 51 (53.6) 1773 (1153.9) -1620 (-2422; -817) 
p<0.001 
-1794 (-2597; -992) 
p<0.001 
174 (-601; 950) 
p=0.65 Change  -1633 -1807 -13.0 
5βTHF 
µg/day 
Pre  1724 (511.5) 1670 (649.2) 1793 (508.3)  
Difference between groups: p=0.96 Post  1718 (521.3) 1683 (506.9) 1742 (615.9) 
Change  -6 +14 -52 
Table 6-1 There was a significant decrease in 5αTHF, and a trend towards a decrease in total urinary glucocorticoids 
(αTHF+βTHF+THE) following 5αR inhibition. Dutasteride and finasteride did not differ from each other. Data are mean (SD). 
Change from baseline compared between groups by one-way ANOVA, with LSD post-hoc tests where significant. N, number; GC, 
glucocorticoids; , treatment; F, cortisol; THF, tetrahydrocortisol; THE, tetrahydrocortisone.   
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 Dutasteride Finasteride Tamsulosin 
∆ Dutasteride  
vs. ∆ Tamsulosin 
Mean (95% CI)  
∆ Finasteride  
vs. ∆ Tamsulosin 
Mean (95% CI)  
∆ Dutasteride  
vs. ∆ Finasteride 
Mean (95% CI) 




Pre  2623 (1029.9) 3178 (2168.8) 2977 (1731.0) Difference between groups: p=0.03  
Post  2582 (1388.3) 2107 (1263.5) 3065 (1649.5) -130 (-1085; 825) 
p=0.79 
-1159 (-2114; -204) 
p=0.02 
1029 (107; 1952) 
p=0.03 Change  -41 -1071 +89 
Aetio (β) 
µg/day 
Pre  817 (403.4) 805 (604.5) 861 (484.6) Difference between groups: p<0.001† 
Post  2461 (1350.5) 1710 (1002.9) 1029 (658.8) p<0.001 p=0.01 p=0.28 
Change  +1643 +905 +168 
Andro (α) 
µg/day 
Pre  1806 (699.2) 2373 (1737.1) 2116 (1297.1) Difference between groups: p<0.001 




291 (-1113; 531) 
p=0.48 Change  -1684 -1975 -79 
Table 6-2 Finasteride decreased total androgen metabolites after three months of treatment. Both dutasteride and finasteride caused 
a significant decrease in 5-reduced, and increase in 5β-reduced androgen metabolites. Data are mean (SD). Change from baseline 
compared between groups by one-way ANOVA, with LSD post-hoc tests where significant. N, number; , treatment; Aetio, 
Aetiocholanolone; Andro, androsterone.  
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 Dutasteride Finasteride Tamsulosin 
∆ D vs. ∆ T 
Mean (95% CI)  
∆ F vs. ∆ T 
Mean (95% CI)  
∆ D vs. ∆ F 
Mean (95% CI) 












Pre  1.39 (0.78) 1.21 (0.73) 1.30 (0.67) Difference between groups: p<0.001† 
Post  96.20 (66.72) 55.69 (33.36) 1.37 (0.90) p<0.001 p<0.001 p=0.65 
Change  +94.81 +54.48 +0.07 
F/ αTHF Pre  0.10 (0.10) 0.10 (0.05) 0.12 (0.11) Difference between groups: p<0.001† 
Post  6.12 (3.68) 4.22 (2.33) 0.13 (0.12) p<0.001 p<0.001 p=0.88 
Change  +6.01 +4.11 +0.01 
F/ βTHF Pre  0.08 (0.05) 0.09 (0.04) 0.09 (0.05)  
Difference between groups: p=0.67 Post  0.08 (0.04) 0.08 (0.04) 0.09 (0.04) 








s Aetio (β) / 
Andro (α) 
 
Pre  0.45 (0.18) 0.36 (0.20) 0.43 (0.14) Difference between groups: p<0.001†  
Post  21.82 (9.73) 8.26 (15.55) 0.85 (1.43) p<0.001 p=0.01 p=0.01 
Change  +21.37 +7.89 +0.43 
Table 6-3 Indices of pathways of A-ring reduction of glucocorticoids and androgens by 5αR decreased relative to 5βR following 
three months of either dutasteride (D) or finasteride (F). Data are mean (SD). Change from baseline compared between groups 
by one-way ANOVA (F/βTHF), or 
†
Kruskal Wallis test with pairwise comparisons. T, tamsulosin; N, number; THF, 
tetrahydrocortisol; , treatment; F, cortisol; Aetio, aetiocholanolone; Andro; androsterone.  
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 Dutasteride Finasteride Tamsulosin 
∆ Dutasteride  
vs. ∆ Tamsulosin 
Mean (95% CI)  
∆ Finasteride  
vs. ∆ Tamsulosin 
Mean (95% CI)  
∆ Dutasteride  
vs. ∆ Finasteride 
Mean (95% CI) 
N 16 16 14    
11β HSD activity measured as ratio of (βTHF + αTHF) / THE 
Pre  0.63 (0.27) 0.67 (0.38) 0.66 (0.23) Difference between groups: p=0.001 
Post  0.35 (0.10) 0.36 (0.16) 0.65 (0.26) -0.28 (-0.44; -0.11) 
p=0.001 
-0.30 (-0.47; 0.14) 
p=0.001 
0.02 (-0.14; 0.18) 
p=0.77 Change  -0.29 -0.31 -0.01 
11β HSD 2 activity measured as ratio of F/E 
Pre  1.18 (0.35) 1.50 (0.62) 1.37 (0.31)  
p=0.15 Post  1.37 (0.51) 1.30 (0.26) 1.34 (0.23) 
Change  +0.19 -0.19 -0.03 
Table 6-4 Urinary glucocorticoid metabolite ratios reflecting activity of 11β-hydroxysteroid dehydrogenase (HSD) enzymes, 
showing a significant decrease in the index of global 11βHSD activity ((βTHF + αTHF) / THE) following 5αR inhibition, but no 
change in the index of 11βHSD2 (F/E) activity. Data are mean (SD). Change from baseline compared between groups by one-
way ANOVA and LSD posthoc tests where significant. N, number; THF, tetrahydrocortisol; THE, tetrahydrocortisone; ,
treatment; F, cortisol; E, cortisone.   
 
Chapter 6: The effects of inhibition of 5αRs on the HPA axis  358 
 
 
6.3.2 Effects of 5αR inhibition on circulating concentrations 
of adrenal steroids  
Androstenedione concentrations in serum increased from baseline with 
dutasteride, compared to both finasteride and tamsulosin. There were no 
significant differences between treatment groups in DHEAS or basal cortisol 
concentrations. Results are summarised in Table 6-5.  
  
The pattern of salivary cortisol through the day also did not differ between 
treatment groups, as seen in Figure 6.1. CBG and calculated free plasma 
cortisol concentrations also did not change, as summarised in Table 6-6.   
 









∆ Dutasteride   
vs. ∆ Tamsulosin 
Mean (95% CI) 
∆ Finasteride    
vs. ∆ Tamsulosin 
Mean (95% CI) 
∆ Dutasteride     
vs. ∆ Finasteride 
Mean (95% CI) 
N 16 16 14    
AND 
nmol/L 
Pre  3.3 (1.07) 2.9 (1.07) 3.4 (1.78) Difference between groups: p=0.002 
Post  5.0 (1.72) 3.5 (1.25) 3.9 (2.02) 1.3 (0.5; 2.0) 
p=0.002 
0.0 (-0.8; 0.8) 
p=0.93 
1.2 (0.5; 2.0) 
p=0.002 Change  + 1.7 + 0.5 + 0.5 
DHEAS 
µmol/L 
Pre  0.9 (0.38) 0.8 (0.54) 0.7 (0.43)  
Difference between groups: p=0.20 Post  0.8 (0.33) 0.7 (0.47) 0.8 (0.57) 
Change  - 0.1 - 0.1 + 0.1 
Cortisol 
nmol/L 
Pre  788.5 (236.68) 768.7 (203.49) 817.9 (201.33)  
Difference between groups: p=0.88 Post  692.1 (186.20) 688.8 (172.89) 757.3 (157.28) 
Change  - 96.4 - 79.9 - 60.6 
Table 6-5 There was an increase in serum androstenedione (AND) with dutasteride treatment, but no change in serum 
dehydroepiandrosterone sulphate (DHEAS) or plasma cortisol. Samples are all fasting morning samples. Data are mean (SD). 
Change from baseline compared between groups by one-way ANOVA, followed by LSD post-hoc tests where significant. N, 
number; , treatment.  
 




Figure 6.1 Salivary cortisol levels through the day before (open shapes) and after (filled shapes) three months of dutasteride, 
finasteride or tamsulosin; levels and pattern through the day did not differ in response to treatment. Samples collected at 
waking, 30 minutes after waking (“30 min”), 12pm, 4pm, and bedtime. Data points are mean; error bars indicate 95% 













































































N 16 16 14  
CBG 
nmol/L 
Pre  988 (172.2) 936 (126.0) 959 (127.4) p=0.75† 
Post  966 (168.2) 905 (211.6) 929 (156.5) 





Pre  60.1 (23.19) 65.9 (33.18) 69.3 (24.47) p=0.41 
Post  49.4 (23.26) 57.7 (33.74) 65.9 (35.58) 
Change  -10.7 -8.2 -3.4 
Table 6-6 Plasma corticosteroid binding globulin (CBG) and plasma free 
cortisol (calculated by Coolens’ equation, details in text) did not differ following 
three months of dutasteride, finasteride or tamsulosin. Data are mean (SD) and 
change from baseline compared between groups by 
†
Kruskal Wallis test for 
CBG, and by one-way ANOVA for free cortisol. N, number; , treatment. 
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6.3.3 Effects of 5αR inhibition on HPA axis responses to 
suppression and stimulation 
Plasma dexamethasone and principal dexamethasone metabolite 
concentrations were quantified to ascertain whether drug treatment 
influenced dexamethasone metabolism, prior to interpretation of 
dexamethasone suppression testing. Changes from baseline did not differ  











N 16 15 14  
Dex 
ng/mL 
Pre  1.1 (0.60) 0.8 (0.23) 1.1 (0.30) p=0.39 
Post  0.9 (0.27) 0.9 (0.37) 1.0 (0.38) 
Change  -0.2 +0.1 -0.1 
6-OH Dex 
ng/mL 
Pre  1.3 (0.62) 1.0 (0.34) 1.1 (0.37) p=0.21 
Post  1.0 (0.31) 1.1 (0.55) 1.0 (0.36) 




Pre  0.3 (0.16) 0.2 (0.09) 0.2 (0.17) p=0.17 
Post  0.2 (0.12) 0.3 (0.31) 0.2 (0.13) 
Change  -0.0 +0.1 0 
Table 6-7 Dexamethasone metabolism was unaltered by drug treatment. Plasma 
dexamethasone (Dex), 6-hydroxy dexamethasone (6-OH Dex) and 11-dehydroxy 
dexamethasone (11-DH Dex) concentrations prior to and following three months 
of dutasteride, finasteride or tamsulosin. N, number; , treatment. 
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Dexamethasone suppression achieved ~ 45 – 48% suppression from morning 
cortisol concentrations. In response to dexamethasone suppression there was 
wide inter-individual variation in suppressed plasma cortisol concentrations 
and no statistically significant differences were seen, as summarised in Table 
6-8.  Expressing this data as a percentage of morning plasma cortisol 
concentrations (fasting samples without overnight dexamethasone 
suppression) also did not show any difference (data not shown).  
 
Peak cortisol concentrations following Synacthen (post-dexamethasone 
suppression test) were just in excess of values obtained for unstimulated 
morning cortisol concentrations, and area under the curve during short 
Synacthen test did not differ between groups, seen in Table 6-8. The pattern 
of response to Synacthen is demonstrated in Figure 6.2.   
 
Time to reach peak cortisol level following Synacthen administration was 
later following 5αR inhibition. As seen in Figure 6.3, most volunteers in the 
tamsulosin group reached peak plasma cortisol at the same time-point after 
three months of treatment. In contrast, those on 5αR inhibitors had a greater 
proportion of subjects who took longer to reach peak cortisol concentration. 
On Sign Test, the overall change between groups was p<0.001, with change 
from baseline by group: dutasteride p=0.02; finasteride p=0.13; tamsulosin 
p=0.25.   
 












N 16 15 14  
Cortisol following low dose dexamethasone suppression test 
Pre  356.6 (238.79) 383.6 (190.33) 368.7 (258.73) p=0.43 
Post  326.2 (260.94) 257.9 (154.10) 366.4 (205.00) 
Change  - 30.5 - 125.8 - 2.2 
Peak cortisol during low dose short Synacthen test 
Pre  868.1 (156.03) 889.9 (232.62) 852.4 (190.68) p=0.25 
Post  842.4 (160.00) 783.1 (110.75) 849.5 (204.47) 
Change  - 25.7 - 106.8 - 2.9 
Area under the curve during short Synacthen test 
Pre  42197 (9095.4) 42552 (10098.4) 42301 (10609.7) p=0.52 
Post  41840 (9048.0) 39906 (9874.9) 412623 (10564.0) 
Change  - 357 - 2646 - 1039 
Table 6-8 Circulating plasma cortisol concentrations (nmol/L) were not 
significantly different following dexamethasone suppression or Synacthen 
stimulation following three months of either dutasteride, finasteride or 
tamsulosin. Area under the curve (nM.minute) of cortisol concentrations during 
short Synacthen test also did not differ between treatment groups. Data are 
mean (SD). Change from baseline compared between groups by one-way 
ANOVA. N, number; , treatment.   
                    
 




Figure 6.2 Peak cortisol concentrations (p=0.25) and area under the curve (p=0.52) during low-dose (1 µg) short Synacthen test 
did not differ between groups. Time 0 minutes is the (dexamethasone suppressed) pre-Synacthen value, with Synacthen (IV, 1 
µg) administered immediately after. Plasma cortisol was then measured at 20, 30, 40 and 60 minutes post-dose. Open shapes 
with interrupted lines are before (study day C1) and filled shapes with solid lines are after (study day C2) three months of 
dutasteride, finasteride or tamsulosin. Data points are mean; error bars indicate 95% confidence intervals; change from 
baseline was compared between groups by one-way ANOVA.     
 




Figure 6.3 The time (minutes) to reach peak plasma cortisol following 
administration of Synacthen (1 µg, IV) was significantly later (p=0.02 on Sign 
test) in the dutasteride group. Data represent the change in time (post-treatment 
– pre-treatment), and each symbol represents a single volunteer.  
 




This chapter has presented investigation of the effects of 5αR inhibition on 
the HPA axis, studied as a secondary endpoint in a double-blind randomised 
controlled study, with 46 men. Both dual isozyme inhibition with dutasteride 
and 5αR2 inhibition with finasteride decreased 5αR metabolism of cortisol 
and the HPA axis was able to compensate for this decrease in cortisol 
clearance to maintain normal cortisol concentrations in plasma and saliva. 
No changes in response to suppression of the HPA axis by dexamethasone 
were seen, however subtle changes in response to stimulation were 
indicative of minor adrenal insufficiency. Serum androstenedione was 
increased with dutasteride only, and androgen metabolism by 5βR was 
increased as a compensatory response to 5αR inhibition with both 
dutasteride and finasteride.      
 
As anticipated, 5α-reduction of glucocorticoids was significantly inhibited by 
dutasteride and finasteride. It was possible that other metabolic routes may 
have compensated for inhibition of 5αR; however the products of 
metabolism of glucocorticoids by 5βR were unaltered, in line with a lack of 
change in cortisol as its substrate. In contrast, the conventional index of 
11βHSD activity was decreased, and in the absence of a change in 11βHSD2 
activity this implies a decrease in 11βHSD1 activity and is indicative of 
impaired cortisol regeneration. While this is plausible as a means to 
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compensate for impaired clearance, this index must be interpreted with 
caution. Given the equation for calculation of 11βHSD activity is highly 
dependent on 5αTHF, this may be influenced purely as a result of the 
decrease in 5αR activity, as has been suggested when a similar change was 
seen with finasteride treatment (Christakoudi et al., 2003). Indeed, if 11βHSD 
activity is inferred from βTHF/THE then there was no difference between 
groups (data not shown). However 11βHSD1 activity may indeed decrease 
with 5αR inhibition, perhaps as a compensatory protective down-regulation 
to attenuate the proposed increase in local glucocorticoid amounts upon 5R 
inhibition (Pelletier et al., 2007). While 5αR knockout mice had no change in 
liver 11βHSD1 transcript or protein (unpublished), there may be species 
differences between rodents and humans. End product inhibition due to 
cortisol accumulation is unlikely to be a contributing factor as 11βHSD1 in 
human liver microsomes is not thought subject to this (up to 20 x 
physiological concentrations) (Diederich et al., 2000).   
 
Overall, accompanying impaired metabolism by 5R, there was a trend to 
suppress total amounts of urinary glucocorticoids, indicative of a decrease in 
daily production rates, with both 5αR inhibitors. This finding supports the 
hypothesis that compensation by the HPA axis to down-regulate synthesis 
occurs in response to impaired clearance. The degree of decrease in urinary 
5αTHF and total glucocorticoids was not significantly different between 
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dutasteride and finasteride, and indeed inhibition of 5αR2 alone appeared to 
achieve ~97% suppression of 5αTHF. Finasteride in vivo is only thought to 
effectively inhibit 5αR2, not 5αR1, with Km values of <0.1 nM and 52 
respectively (Aggarwal et al., 2010), therefore these findings are believed 
reflective of 5αR2 inhibition. This suggests that 5αR2 makes a highly 
significant contribution to cortisol metabolism. Presumably this is reflective 
of 5αR2 in the liver which is the primary site of cortisol metabolism by 5-
reductase (Gold, 1961), although enzyme expressed in other peripheral sites 
may also be involved. Interestingly, in 2 patients with 5αR2 deficiency a 
similar decrease in cortisol 5α urinary metabolites has also been described, 
though a quantitative description was not published (Fisher et al., 1978).    
 
As with 5R1-/- mice under basal conditions, this suppression of 
glucocorticoid synthesis allowed the HPA axis to compensate for decreased 
5αR-mediated clearance and to maintain plasma cortisol concentrations 
within the normal range. Measures of basal, unstressed cortisol, obtained by 
sampling saliva across the day and specifically at the evening nadir, were 
unchanged. Cortisol circulates in blood bound to albumin and corticosteroid 
binding globulin (CBG) and measurements in saliva, a filtered fluid not 
allowing passage of proteins, allows for assessment of the free bioavailable 
portion. This was thought especially important at study planning, since with 
decreased hepatic clearance of cortisol, it was possible that hepatic CBG 
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synthesis could be decreased (Cole et al., 1999), making assessment of total 
circulating cortisol potentially misleading; circulating free cortisol may have 
increased, without affecting the total amount. Salivary cortisol levels did not 
differ between groups, indicating that (at least with this duration of 
treatment) CBG was unlikely to have been affected (Vining et al., 1983), and 
this was indeed corroborated by measurement of CBG and calculation of 
plasma free cortisol.  
 
Salivary cortisol also provides a complementary non-invasive measure of the 
diurnal profile of free cortisol (Kirschbaum and Hellhammer, 1994). The 
pattern of salivary cortisol did not differ between groups in this study, and in 
particular there was no ‘flattening’ of the saliva curve, as has been reported 
in obesity, suggesting morning cortisol concentrations were not lower and 
evening cortisol concentrations were not disproportionately higher 
(Rosmond et al., 1998) following 5αR inhibition, despite metabolic changes in 
the group receiving dutasteride. 
 
Differences in morning plasma cortisol concentrations were not seen between 
groups. In conjunction with this finding, there was also no difference in the 
so-called “cortisol awakening response” (Pruessner et al., 1997), measured as 
the increment rise between waking to 30 minutes after waking, a measure 
thought to reflect adrenal stimulation in which an increase has been 
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associated with the metabolic syndrome by some (Bengtsson et al., 2010) but 
not others (DeSantis et al., 2011). Notably the main difference seen here is in 
a lower morning cortisol level compared to healthy controls, and then a 
greater proportional rise after waking (Bengtsson et al., 2010).  
 
Dynamic testing of the HPA axis did not reveal marked differences between 
treatment groups, indicating that 5αR inhibition did not impair response to 
stimulation of the axis to any great degree. A short Synacthen (1 µg) test was 
executed at doses chosen to elicit EC50 responses, rather than maximal 
responses which would result from conventional doses (250 µg) (Reynolds et 
al., 2001, Daidoh et al., 1995, Dickstein et al., 1991). Despite only using a low 
dose, it can be seen that peak cortisol levels were ~850 nmol/L, which is 
considerably higher than peak concentrations of ~400 nmol/L reported 
elsewhere (Reynolds et al., 2001, Dickstein et al., 1991). However 
immunoassays differ considerably (Cohen et al., 2006), and a clearer picture 
is provided when interpreting these findings in conjunction with the basal 
morning cortisol levels; while cortisol levels following Synacthen look ‘high’, 
it can be seen that the basal morning cortisol levels are similar, supporting 
that the aim of the test in stimulating sub-maximal response was likely 
achieved. In addition, comparison to the dexamethasone suppressed plasma 
cortisol concentrations shows an approximately two-fold increase upon 
Synacthen stimulation, in keeping with others (Reynolds et al., 2001). The 
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time to peak cortisol during the short Synacthen test was delayed in those on 
dutasteride, with finasteride following a similar pattern, though this was not 
significant. This is reflective a delayed adrenal response to stimulation 
(Reynolds et al., 2001), and supports the hypothesis of a down-regulated 
HPA axis, though not to a great degree.  
 
The preservation of a relatively normal response following 5αR inhibition 
differed from the response seen in 5αR -/- mice, where the ability to mount a 
corticosterone response to restraint stress was substantially attenuated 
(Livingstone et al., 2010). The lack of difference seen in the present study 
may simply reflect an under-powered study, as assessment of the HPA axis 
was a secondary endpoint. However in the mice disruption of 5R1 slowed 
clearance by greater than 50% (unpublished), whereas in humans the effect 
of even dual 5R inhibition only attenuated glucocorticoid production by 
~20%. Therefore mice may be more dependent on this metabolic pathway, 
and in humans it may be necessary to inhibit either 5-reduction, both A-ring 
reductases or 11βHSD2 to induce adrenal insufficiency. In addition the 
treatment duration of 3 months may not have been sufficient to clearly 
demonstrate such a phenotype. The responses to dynamic testing in Zucker 
rats treated with finasteride for 1 month (where inhibition of 5αR1 would be 
less pronounced than in 5αR -/- mice) showed no change in response to 
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restraint, (unpublished), and this could perhaps be considered a more 
comparable model to the human study. 
 
With expression of 5αR in the brain (Table 1-1, Introduction) there is 
potential for 5αR inhibitors to have a central effect on the HPA axis, however 
there was no evidence for this in the present study. Had glucocorticoids 
accumulated centrally then cortisol concentrations would be expected to fall, 
however this was not seen. If GR levels had exhibited some degree of 
autoregulation (Rupprecht et al., 1991) to adjust to increased glucocorticoid 
concentrations, this would have manifest in the dexamethasone suppression 
test with decreased suppression of plasma cortisol, and once again there was 
no evidence for this.   
 
In contrast to normal circulating cortisol concentrations, serum 
androstenedione was increased with dutasteride only, likely a reflection of 
substrate accumulation following 5αR inhibition, which was more marked 
with the more efficacious drug. Androstenedione is a known substrate for 
5αR in both normal and BPH-affected human prostate (Weisser and Krieg, 
1997), with a Km value of 1.7 µM compared to 3.6 µM for testosterone 
(Andersson and Russell, 1990). Finasteride inhibits equally well the 5α-
reduction of both androstenedione and testosterone (Weisser and Krieg, 
1998); the activity of dutasteride in inhibiting androstenedione is not 
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described, though is likely to be equal if not more effective than finasteride. 
The post-treatment androstenedione concentrations in the dutasteride group 
were just slightly in excess of the reference range reported by some (Kushnir 
et al., 2010a), and well within those used in the NHS laboratories in 
Edinburgh (NHSLothian, 2011-2013). This finding is also in agreement with 
previous studies; one month of finasteride does not increase androstenedione 
(Rittmaster et al., 1994), and concentrations in two patients with 5αR2 
deficiency were surprisingly slightly lower than unaffected men (Fisher et al., 
1978). In contrast, as seen here, with 3-6 months of dutasteride treatment (co-
administered with testosterone) there is a significant increase in 
androstenedione, which was more marked than seen with testosterone 
administration alone (Page et al., 2011a). 
 
Dutasteride and finasteride both exhibited similar effects on urinary 
androgen metabolites, which are largely a reflection of adrenal androgen 
synthesis (Weykamp et al., 1989, Finken et al., 1999) and this corroborates 
less forward drive to synthesis by the HPA axis. An expected decline in the 
5α metabolite androsterone was seen with both dutasteride and finasteride 
and there was a compensatory increase in androgen metabolism by 5βR. 
Compensation was unable to compensate fully for those treated with 
dutasteride, leaving a residual increase in serum androstenedione. An 
additional contributing factor may be that while cortisol is closely regulated 
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by the HPA axis (Jacobson, 2005), regulation of androstenedione synthesis is 
not so tightly controlled (Takizawa et al., 2010), therefore rather than 
suppression of its synthesis, increased metabolism by 5βR may be the 
preferred clearance route. Androstenedione has a lower Km (4.85 µM) than 
cortisol (11 µM) for 5βR metabolism (Okuda and Okuda, 1984), and this may 
explain the increase in 5βR metabolism of androgens but not glucocorticoids. 
As NADPH is cofactor for both enzymes (Frederiksen and Wilson, 1971, 
Berseus and Bjorkhem, 1967, Kondo et al., 1994), with a decrease in 5αR 
activity there could in theory be an increase in cofactor availability for 5βR. 
This is unlikely however as 5αR is predominantly microsomal (Russell and 
Wilson, 1994) and 5βR is thought to be predominantly cytosolic, though has 
been reported in all sub-cellular fractions (Iyer et al., 1990).  
 
While total androgen urinary metabolites were decreased with finasteride, 
the decrease in 5αR metabolism was largely balanced by the increase in 5βR 
metabolism with dutasteride. This presumably reflects less need for 5βR 
compensation following finasteride treatment, however may also reflect a 
degree of 5βR inhibition with finasteride (Drury et al., 2009).  
 
The increase in serum androstenedione may reflect an increase in adrenal 
steroidogenesis, though notably an increase in DHEAS (which is not a 
known substrate of 5αR) was not seen. While modulated by the HPA axis, 
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adrenal androgens do not always show the same pattern of secretion (and 
therefore probably regulation) as cortisol (McKenna and Cunningham, 1991, 
Bornstein and Chrousos, 1999). Other effectors of adrenal androgen synthesis 
are, however, less well understood. Insulin in vitro (Kramer et al., 1990) and 
free fatty acids in vivo (Mai et al., 2006) have been reported to selectively 
stimulate adrenocortical androgen rather than glucocorticoid release; making 
it possible that the hyperinsulinaemia seen in the dutasteride group (Chapter 
5.4.6.1) may by contributing to the increased androstenedione concentrations. 
An increase in sensitivity to ACTH  in androgen synthesising cells has been 
reported in  PCOS patients (Azziz et al., 1998), though in contrast in men 
cortisol may be more sensitive than androstenedione to Synacthen infusion 
(Parker et al., 1996). Overall differing sensitivity of adrenocortical cells has 
not been studied in detail in men and at present it is unknown whether this 
played any role in the findings seen.  
 
While principal feedback to the HPA axis is from glucocorticoids (Jacobson, 
2005), androgens and oestrogens may also play a role; an important 
consideration given that following 5αR inhibition circulating 
androstenedione was increased, DHT decreased (Chapter 5.4.5.1), and there 
was a trend towards an increase in oestradiol (Chapter 5.4.13). Normally 
testosterone (Viau and Meaney, 1996) and DHT (Lund et al., 2006) both 
modulate the HPA axis, with a net effect to decrease circulating 
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glucocorticoids. Effects of DHT are also thought to be mediated by its (ERβ 
ligand) metabolite, 3β-diol, which also has an inhibitory effect (Handa et al., 
2011), and in theory would also decrease following 5αR inhibition. 
Androstenedione is not thought to play an important role in HPA feedback 
in men. Therefore the usual inhibitory effect exerted by DHT would be 
attenuated in the context of 5αR inhibition, and in turn increase adrenal 
steroidogenesis; the opposite of what was observed, and likely a reflection of 
the greater role of cortisol in HPA feedback than DHT.  Similarly oestradiol 
is thought to cause a hyper-responsive HPA axis (Kirschbaum et al., 1996), 
therefore in this setting the trend towards an increase in oestradiol is more 
likely to be an effect of 5αR inhibition, rather than a cause of HPA axis 
dysfunction. 
 
In conclusion, this chapter has described the effects of 5αR inhibition on the 
HPA axis in men. There was a significant decrease in cortisol metabolism by 
5αR with both dutasteride and finasteride. There were subtle signs of adrenal 
insufficiency following Synacthen stimulation, however there was 
preservation of normal circulating cortisol concentrations and the HPA axis 
was able to compensate for the effects of 5αR inhibition. A reduction in 5αR 
metabolism of androgens was compensated for by an increase in 5βR activity 
following both 5αR inhibitors, however incomplete compensation with 
dutasteride resulted in a residual increase in circulating androstenedione 
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concentrations. This study has demonstrated the first reported detailed 
measure in a human population of HPA axis function with both finasteride 
and dutasteride, and demonstrates differential adaptation of the HPA axis to 






















The aim of this thesis was to address the paucity of knowledge regarding the 
metabolic effects of 5αR inhibition in man. The central hypothesis was that, 
due to expression in metabolic tissues where androgen and glucocorticoid 
homeostasis are affected, inhibition of 5αR1 with dutasteride would be 
detrimental to metabolic health. A double-blind randomised controlled study 
was conducted, with 46 men studied prior to and following three months of 
treatment with dutasteride (dual inhibitor of 5αR1 and 5αR2), finasteride 
(5αR2 inhibitor) or tamsulosin (α blocker, control group). 5αR inhibition with 
dutasteride, but not finasteride, resulted in a significant decrease in 
peripheral insulin sensitivity and increase in body fat. In addition, there was 
evidence of subtle dysregulation of the HPA axis with both 5αR inhibitors.   
 
Excess tissue glucocorticoid is associated with features of the metabolic 
syndrome (Walker, 2001). One of the rate-limiting steps in glucocorticoid 
degradation is catalysed by 5αR (Shamim et al., 2000, Baudrand et al., 2011), 
therefore in theory, inhibition of 5αR1 may lead to an accumulation of 
cortisol in metabolic tissues. The two best characterised isozymes of 5αR 
differ in their tissue distribution: 5αR2 is predominantly expressed in the 
reproductive tract and liver (Russell and Wilson, 1994, Shirakawa et al., 
2004), while 5αR1 is expressed in metabolic tissues including liver and 
adipose (Russell and Wilson, 1994, Wake et al., 2007). Well known for 





dihydrotestosterone, 5αRs are inhibited in the treatment of androgen target 
tissue disorders, most notably benign prostatic hyperplasia (Aggarwal et al., 
2010). However, 5αR inhibition may also affect other substrates of 5αR, 
including glucocorticoids.  
 
Research in animal models has demonstrated that mice with genetic 
disruption of 5αR1 develop glucose intolerance and fatty liver, particularly 
when metabolically challenged with a high fat diet and female mice are more 
susceptible (Livingstone et al., 2008, Livingstone et al., 2009a). These results 
were recapitulated with pharmacological inhibition of 5αR1 and 5αR2 in 
obese Zucker rats (Livingstone et al., 2009a) and these findings are not 
androgen dependent, in that they persist in castrated animals. In humans, 
previous studies of metabolic effects of 5αR inhibition have been limited to 
measures of fasting glucose (Amory et al., 2007).  
 
This thesis has described the implementation of a double-blind randomised 
controlled clinical study, together with validation and application of novel 
supporting assays. Three months of treatment with dutasteride significantly 
impaired insulin sensitivity, decreasing glucose disposal by 5.7 
µmol/kgFFM/min (~14%) during high-dose insulin infusion. This was 





other surrogates of peripheral insulin sensitivity, skeletal muscle and adipose 
were implicated as the primary sites of impaired insulin action.  
 
Given the clear differences between dutasteride and both finasteride and 
control, steps to determine the mechanism were a key focus of the work 
presented; though as yet an exact mechanism remains elusive. It is implied in 
study findings that the metabolic effects of dutasteride must lie in the 
inhibition of 5αR1, as similar findings were not seen with finasteride. 
Circulating DHT and cortisol concentrations did not differ between groups, 
therefore could not account for this difference. Oestradiol had a trend 
towards increasing following 5αR inhibition, and rose more so with 
dutasteride. This remains a possible mediator, as both ERα and ERβ mRNA 
and protein are expressed in human skeletal muscle (Wiik et al., 2009). 
However, while oestrogens are associated with metabolic disease (Vikan et 
al., 2010, Phillips et al., 2003), the mechanism behind which they may impair 
skeletal muscle insulin sensitivity in men is not understood. Oestrogen 
effects on glucose homeostasis are thought to be mediated predominantly via 
ERα (Foryst-Ludwig and Kintscher, 2010), and if this is case then the 
probable decrease in the ERβ ligand 3β-diol (a DHT metabolite) with 5αR 
inhibition would likely not contribute to the phenotype seen. Future 
development of mass spectrometry based assays may provide a more reliable 





oestradiol concentrations following a year of treatment (Amory et al., 2007) 
the possibility remains that this was a transient feature. Inhibition of 5αR3 
(Godoy et al., 2011, Uemura et al., 2008) in this study was not specifically 
studied; however with increasing knowledge about this isozyme future 
studies may explore this possibility.  
 
Tissue accumulation of glucocorticoids was the underpinning mechanism 
thought responsible, however while liver is the primary site of glucocorticoid 
metabolism (Gold, 1961), there was no evidence of a hepatic insulin 
resistance phenotype with dutasteride. Indeed, the importance of both 5αR1 
and 5αR2 in hepatic glucocorticoid metabolism was demonstrated in this 
study with similar inhibition of 5αTHF seen with both inhibitor drugs. Tracer 
kinetics indicated hepatic insulin sensitivity was preserved, and there was no 
evidence of fatty liver on post-treatment 1H spectroscopy. There are of course 
inherent limitations in human studies, and it may be that fatty liver seen in 
animal models (Livingstone et al., 2008, Livingstone et al., 2009a) was not 
apparent with a short duration of treatment, that a post-study only measure 
of liver fat was not sufficiently sensitive to distinguish groups, or that 
impairment of hepatic insulin sensitivity is not a feature of human 5αR 
inhibition. It is also reasonable to consider that the early pathogenesis of the 






Body composition was altered with increased body fat in those on 
dutasteride only, and a degree of adipose insulin resistance was evident with 
less suppression of plasma NEFA levels following low-dose insulin infusion. 
However there was no change in the circulating adipokines or chemokines 
quantified, nor any alterations in gene transcript abundance to indicate 
metabolic or inflammatory changes in subcutaneous adipose. The increase in 
body fat was unable to be localised to a specific abdominal depot on MRI. In 
future studies, if resources permit and necessary technological advances are 
achieved, novel imaging techniques such as positron emission tomography 
(PET) scanning (Ng et al., 2012) may provide valuable non-invasive measures 
of glucose metabolism, enabling physiological assessment of both 
subcutaneous and visceral adipose.  
 
Local metabolism of steroids by 5αR1 within muscle, or the deposition of 
ectopic fat are possible mediators of metabolic effects seen in this study. 
Muscle biopsies and muscle spectroscopy were not performed in this study; 
therefore the deposition of fat or alteration in glucose metabolism post 
dutasteride treatment is unknown. Further ongoing work is in determination 
of relative expression of 5αR isozymes in metabolic tissues of interest in both 
rodent and human. However, as has been demonstrated previously 
(Stuerenburg and Schoser, 1999) 5αR mRNA and protein expression may not 





of arterio-venous sampling across a muscle bed may give some insight 
regarding muscle 5αR activity, in particular whether cortisol is metabolised 
by muscle 5αR. Muscle androgen metabolism could be further investigated 
with the use of deuterated testosterone tracers (Vierhapper et al., 1997, Wang 
et al., 2004b). In addition, a further valuable mechanistic investigation may 
be a cross-sectional clinical study with muscle spectroscopy performed in 
patients on dutasteride and finasteride compared to healthy controls, in 
particular looking for evidence of increased triglyceride in muscle, and/or 
muscle biopsies taken to assess for glycogen synthesis.  
 
Metabolic dysfunction is associated with impairments of the HPA axis 
(Pasquali et al., 2006), and vice versa (Rosmond et al., 1998). The clear 
metabolic changes induced by dutasteride treatment, together with 
expression of 5αR in sites potentially modulating the HPA axis (Thigpen et 
al., 1993, Russell and Wilson, 1994), may have altered function of the HPA 
axis. Investigated as a secondary endpoint in this study, there was a clear 
decrease in 5αR metabolism of both glucocorticoids and androgens, together 
with evidence of compensation. For glucocorticoids, compensation was by 
down-regulation of the HPA axis with decreased glucocorticoid production 
and maintenance of a normal circulating cortisol concentration. Androgens 
compensated largely by increasing metabolism by 5βR, with a residual 





accumulation. Pituitary response to dexamethasone suppression was normal; 
however there was evidence of a delayed peak cortisol response with adrenal 
Synacthen stimulation suggesting a degree of adrenal insufficiency. Overall, 
testing of the HPA axis revealed an ability to compensate for 5αR inhibition 
maintaining normal circulating cortisol concentrations. This observation 
naturally lends itself to the question of whether tissue glucocorticoid 
concentrations were also normalised. It is impossible to definitely establish 
this in this setting, however given ongoing metabolic abnormalities 
potentially driven by cortisol accumulation this is suggestive of a continuing 
elevation in tissue glucocorticoid concentrations. The use of deuterated 
cortisol tracers (Hughes et al., 2010) may in future provide more detailed 
information about peripheral tissue-specific glucocorticoid turnover 
following 5αR inhibition.  
 
The study presented sampled a subset of men, consisting mostly of healthy 
volunteers. As with all studies, sample groups cannot reflect the entire 
population and this must be considered before extrapolation of results to 
individual patients or communities. It could however be hypothesised that 
with declining β cell function (Ma et al., 2009) and increased body fat (Boden 
et al., 1993), older men would be more susceptible to metabolic consequences 
of 5αR inhibition than seen in the present study; rendering these results even 





with the metabolic syndrome (Moul and McVary, 2010, Parsons et al., 2006) 
and long-term prescription of 5αR inhibitors to patients with additional 
predispositions to metabolic disease can only make these data even more 
clinically relevant.  
 
The common usage of these medications also makes the work in this thesis 
potentially widely clinically applicable. Annually in Britain there are 
~500,000 dutasteride, ~2.3 million finasteride, ~4.7 million tamsulosin, and 
~70,000 combined dutasteride/ tamsulosin prescriptions dispensed (Wales, 
2011) (England, 2011) (Scotland, 2011). In men, finasteride is licensed for use 
in BPH and androgenic alopecia, and in women it is licensed for treatment of 
hirsutism. Dutasteride is licensed for use in BPH only, as are the combined 
dutasteride/ tamsulosin preparations. Given the adverse metabolic 
consequences of 5αR inhibition with dutasteride presented here, and the lack 
of evidence to suggest dutasteride is a more effective treatment (Andriole 
and Kirby, 2003, Nickel et al., 2011), it may be that finasteride should be the 
preferred drug in BPH. One consideration however is that finasteride is not 
available in a pre-prepared combination with an alpha blocker, meaning this 
approach may be less acceptable to patients needing combination treatment.  
 
Despite the demonstrated impairment of insulin sensitivity, there are select 





treatment of castration-resistant prostate cancer (CRPC), prostate cancer 
prevention, and prevention of complications from BPH. Dutasteride is 
possibly more effective than finasteride in lowering prostatic DHT 
concentrations (van der Sluis et al., 2012), but perhaps of greater importance 
the majority of prostate cancers express predominantly 5αR1 and the most 
commonly utilised prostate cancer cell line, LNCaP, expresses only 5αR1 and 
not 5αR2 (Negri-Cesi et al., 1998). Conversely, dutasteride may also have 
deleterious effects and in CRPC has been shown promote androstenedione 
metabolism to testosterone with its own AR agonist effects (Chang et al., 
2011). In addition, glucocorticoids (both endogenous and synthetic) are 
agonists for a mutated high-affinity cortisol-cortisone responsive AR seen in 
CRPC (Zhao et al., 2000, Chang et al., 2001). The balance between these 
factors, and the clinical importance and implications of dutasteride in these 
conditions are still being established, however if proven beneficial then a 
decrease in insulin sensitivity would clearly be of diminished relative 
importance in such patients.  
 
This thesis has focused on the effects of 5αR inhibition in men. Healthy 
women could not be studied in a similar manner as dutasteride is not 
licensed for use in women and risks to a male foetus if volunteers conceived 
during (or soon after) the study would be unacceptable. However, with high 





use of dutasteride in hirsutism treatment, for example in PCOS, may be 
affected by results in this thesis as PCOS itself is associated with insulin 
resistance (Amato et al., 2006). 5αR isozyme distribution is not thought to 
differ between men and women, therefore it could be expected that 
finasteride in women would not induce insulin resistance, though all that is 
known to date is that fasting glucose levels do not change (Moghetti et al., 
2000). The metabolic effects of sex steroids, and changes in sex steroids, are 
manifest in a gender-specific manner (Wu and von Eckardstein, 2003), and 
what effect dutasteride may have on sex steroids in women is unknown, 
though in 5αR -/- mice females were more susceptible to metabolic disease 
than males (Livingstone et al., 2008).   
 
Dutasteride induces peripheral insulin resistance, and insulin resistance is of 
key prognostic importance. As demonstrated in a landmark study in a Pima 
Indian population (Lillioja et al., 1993), insulin resistance (independently of 
obesity) was a significant risk factor for the development of type 2 diabetes 
after 5 years of follow-up. In addition, skeletal muscle insulin resistance, the 
primary feature seen with dutasteride treatment, is thought to be the key 
antecedent to future diabetes (DeFronzo and Tripathy, 2009). Therefore 
findings presented of increased insulin resistance with only 3 months of 
dutasteride therapy naturally beg the question of the potential long-term 





to conduct a retrospective analysis of the incidence of diabetes in patients 
taking dutasteride compared to finasteride or tamsulosin; data which (in 
contrast to detailed measures of insulin sensitivity) would be more readily 
available in population health databases. In addition, the progression or 
complications of metabolic disease may be more apparent in patients with 
diabetes treated with dutasteride. Both of these studies are now underway.  
 
In conclusion, this thesis has presented the first detailed study in humans 
comparing the metabolic effects of inhibiting 5αR2 with finasteride, to the 
effects of dual isozyme inhibition with dutasteride. There was a significant 
and likely clinically relevant decrease in peripheral insulin sensitivity and 
increase in body fat with dutasteride. In addition, testing of the HPA axis 
revealed subtle dysregulation with both 5αR inhibitors, though 
compensation for this was evident. The work presented in this thesis has 
highlighted a novel determinant of metabolic health with potentially 
important implications for BPH patients, and results lead now to further 
exciting avenues of potential research, particularly in exploring mechanisms 
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